1
|
Amelot A, Terrier LM, Mathon B, Joubert C, Picart T, Jecko V, Bauchet L, Benard F, Castel X, Chenin L, Cook AR, Emery E, Figarella-Branger D, Gauchotte G, Graillon T, Jouvet A, Kalamarides M, Knafo S, Lazard A, Lubrano V, Mokhtari K, Rigau V, Roualdes V, Rousseau A, Seizeur R, Uro-Coste E, Voirin J, Metellus P, Pallud J, Zemmoura I. Natural Course and Prognosis of Primary Spinal Glioblastoma: A Nationwide Study. Neurology 2023; 100:e1497-e1509. [PMID: 36690453 PMCID: PMC10104612 DOI: 10.1212/wnl.0000000000206834] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/30/2022] [Accepted: 12/05/2022] [Indexed: 01/24/2023] Open
Abstract
BACKGROUND AND OBJECTIVES Primary spinal glioblastoma is extremely rare. The dramatic neurological deterioration and unresectability of primary spinal glioblastoma makes it a particularly disabling malignant neoplasm. Since it is a rare and heterogeneous disease, the assessment of prognostic factors remains limited. METHODS Primary spinal glioblastomas were identified from The French Brain Tumor Database and the Club de Neuro-Oncologie of the Société Française de Neurochirurgie retrospectively. Inclusion criteria were age ≥ 18 years at diagnosis, spinal location, histopathological diagnosis of newly glioblastoma according to the 2016 World Health Organization classification, and surgical management between 2004 and 2016. Diagnosis was confirmed by a centralized neuropathological review. The primary outcome was overall survival. Therapeutic interventions and neurological outcomes were also collected. RESULTS Thirty-three patients with an histopathologically confirmed primary spinal glioblastoma (median age 50.9 years) were included (27 centers). The median overall survival (OS) was 13.1 months (range 2.5-23.7) and the median progression-free survival was 5.9 months (range 1.6-10.2). In multivariable analyses using Cox model, ECOG PS at 0-1 was the only independent predictor of longer OS [Hazard Ratio: 0.13, 95%CI 0.02-0.801; p=0.02], whereas a Karnofsky PS score <60 [Hazard Ratio: 2.89, 95%CI 1.05-7.92; p=0.03] and a cervical anatomical location [Hazard Ratio: 4.14, 95%CI 1.32-12.98; p=0.01] were independent predictors of shorter OS. The ambulatory status (Frankel D-E) [Hazard Ratio: 0.38, 95%CI 0.07-1.985; p=0.250] was not an independent prognostic factor while the concomitant standard radiochemotherapy with temozolomide (Stupp protocol) [Hazard Ratio: 0.35, 95%CI 0.118-1.05; p=0.06] was at the limit of significance. DISCUSSION Preoperative ECOG PS, Karnofsky PS score and the location are independent predictors of overall survival of primary spinal glioblastomas in adults. Further analyses are required to capture the survival benefit of concomitant standard radiochemotherapy with temozolomide.
Collapse
Affiliation(s)
- Aymeric Amelot
- Department of Neurosurgery, CHRU de Tours, Tours, France
| | - Louis-Marie Terrier
- Department of Neurosurgery, Clairval Private Hospital, Ramsay Generale de Sante, Marseille, France
| | - Bertrand Mathon
- Department of Neurosurgery, CHU Pitié-Salpêtrière, AP-HP, Sorbonne Université, Paris, France
| | | | - Thiebaud Picart
- Department of Neurosurgery, Hôpital Neurologique Pierre Wertheimer, Hospices Civils de Lyon, Bron, France
| | - Vincent Jecko
- Department of Neurosurgery A, CHU Pellegrin, Bordeaux, France
| | - Luc Bauchet
- Department of Neurosurgery, Hôpital Saint Eloi - Gui de Chauliac, Montpellier, France
| | - Florian Benard
- Department of Neurosurgery, CHU d'Angers, Angers, France
| | - Xavier Castel
- Department of Neurosurgery, CHU de St-Etienne, St Etienne, France
| | - Louis Chenin
- Department of Neurosurgery, CHU Amiens-Picardie, Amiens, France
| | - Ann-Rose Cook
- Department of Neurosurgery, CHRU de Tours, Tours, France
| | - Evelyne Emery
- Department of Neurosurgery, CHU de Caen, Caen, France
| | | | | | - Thomas Graillon
- Aix Marseille Univ, INSERM, APHM, MMG, UMR1251, Marmara Institute, La Timone Hospital, Neurosurgery departement, Marseille, France
| | - Anne Jouvet
- Department of Pathology, Cancer University Institute of Toulouse Oncopole, CHU Toulouse, Toulouse, France
| | - Michel Kalamarides
- Department of Neurosurgery, CHU Pitié-Salpêtrière, AP-HP, Sorbonne Université, Paris, France
| | - Steven Knafo
- Department of Neurosurgery, le Kremlin-Bicêtre, AP-HP, Kremlin-Bicêtre, France
| | - Arnaud Lazard
- Department of Neurosurgery, CHU Grenoble-Alpes, Grenoble, France
| | | | - Karima Mokhtari
- Department of Neuropathology, Pitié-Salpêtrière, AP-HP, Paris, France
| | - Valérie Rigau
- Department of Neuropathology, CHU Gui de Chauliac, Montpellier, France
| | | | | | - Romuald Seizeur
- Department of Neurosurgery, CHU de la Cavale Blanche, Brest, France
| | - Emmanuelle Uro-Coste
- Department of Pathology, Cancer University Institute of Toulouse Oncopole, CHU Toulouse, Toulouse, France
| | - Jimmy Voirin
- Department of Neurosurgery, Pasteur Hospital, HCC, Colmar, France
| | - Philippe Metellus
- Department of Neurosurgery, Clairval Private Hospital, Ramsay Generale de Sante, Marseille, France
| | - Johan Pallud
- Department of Neurosurgery, GHU-Paris Psychiatrie et Neurosciences, Hôpital Sainte Anne, Paris, France
| | | |
Collapse
|
2
|
Hendrikse LD, Haldipur P, Saulnier O, Millman J, Sjoboen AH, Erickson AW, Ong W, Gordon V, Coudière-Morrison L, Mercier AL, Shokouhian M, Suárez RA, Ly M, Borlase S, Scott DS, Vladoiu MC, Farooq H, Sirbu O, Nakashima T, Nambu S, Funakoshi Y, Bahcheli A, Diaz-Mejia JJ, Golser J, Bach K, Phuong-Bao T, Skowron P, Wang EY, Kumar SA, Balin P, Visvanathan A, Lee JJY, Ayoub R, Chen X, Chen X, Mungall KL, Luu B, Bérubé P, Wang YC, Pfister SM, Kim SK, Delattre O, Bourdeaut F, Doz F, Masliah-Planchon J, Grajkowska WA, Loukides J, Dirks P, Fèvre-Montange M, Jouvet A, French PJ, Kros JM, Zitterbart K, Bailey SD, Eberhart CG, Rao AAN, Giannini C, Olson JM, Garami M, Hauser P, Phillips JJ, Ra YS, de Torres C, Mora J, Li KKW, Ng HK, Poon WS, Pollack IF, López-Aguilar E, Gillespie GY, Van Meter TE, Shofuda T, Vibhakar R, Thompson RC, Cooper MK, Rubin JB, Kumabe T, Jung S, Lach B, Iolascon A, Ferrucci V, de Antonellis P, Zollo M, Cinalli G, Robinson S, Stearns DS, Van Meir EG, Porrati P, Finocchiaro G, Massimino M, Carlotti CG, Faria CC, Roussel MF, Boop F, Chan JA, Aldinger KA, Razavi F, Silvestri E, McLendon RE, Thompson EM, Ansari M, Garre ML, Chico F, Eguía P, Pérezpeña M, Morrissy AS, Cavalli FMG, Wu X, Daniels C, Rich JN, Jones SJM, Moore RA, Marra MA, Huang X, Reimand J, Sorensen PH, Wechsler-Reya RJ, Weiss WA, Pugh TJ, Garzia L, Kleinman CL, Stein LD, Jabado N, Malkin D, Ayrault O, Golden JA, Ellison DW, Doble B, Ramaswamy V, Werbowetski-Ogilvie TE, Suzuki H, Millen KJ, Taylor MD. Author Correction: Failure of human rhombic lip differentiation underlies medulloblastoma formation. Nature 2022; 612:E12. [PMID: 36446943 PMCID: PMC10729707 DOI: 10.1038/s41586-022-05578-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- Liam D Hendrikse
- The Arthur and Sonia Labatt Brain Tumor Research Centre, The Hospital for Sick Children, Toronto, Ontario, Canada
- Developmental and Stem Cell Biology Program, The Hospital for Sick Children, Toronto, Ontario, Canada
- Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada
| | - Parthiv Haldipur
- Center for Integrative Brain Research, Seattle Children's Research Institute, Seattle, WA, USA
| | - Olivier Saulnier
- The Arthur and Sonia Labatt Brain Tumor Research Centre, The Hospital for Sick Children, Toronto, Ontario, Canada
- Developmental and Stem Cell Biology Program, The Hospital for Sick Children, Toronto, Ontario, Canada
| | - Jake Millman
- Center for Integrative Brain Research, Seattle Children's Research Institute, Seattle, WA, USA
| | - Alexandria H Sjoboen
- Center for Integrative Brain Research, Seattle Children's Research Institute, Seattle, WA, USA
| | - Anders W Erickson
- The Arthur and Sonia Labatt Brain Tumor Research Centre, The Hospital for Sick Children, Toronto, Ontario, Canada
- Developmental and Stem Cell Biology Program, The Hospital for Sick Children, Toronto, Ontario, Canada
- Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada
| | - Winnie Ong
- The Arthur and Sonia Labatt Brain Tumor Research Centre, The Hospital for Sick Children, Toronto, Ontario, Canada
- Developmental and Stem Cell Biology Program, The Hospital for Sick Children, Toronto, Ontario, Canada
- Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada
| | - Victor Gordon
- Department of Biochemistry and Medical Genetics, University of Manitoba, Winnipeg, Manitoba, Canada
| | | | - Audrey L Mercier
- PSL Research University, Université Paris Sud, Université Paris-Saclay, CNRS UMR 3347, INSERM U1021, Institut Curie, Orsay, France
| | - Mohammad Shokouhian
- Department of Pediatrics and Child Health and Department of Biochemistry and Medical Genetics, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada
| | - Raúl A Suárez
- The Arthur and Sonia Labatt Brain Tumor Research Centre, The Hospital for Sick Children, Toronto, Ontario, Canada
- Developmental and Stem Cell Biology Program, The Hospital for Sick Children, Toronto, Ontario, Canada
| | - Michelle Ly
- The Arthur and Sonia Labatt Brain Tumor Research Centre, The Hospital for Sick Children, Toronto, Ontario, Canada
- Developmental and Stem Cell Biology Program, The Hospital for Sick Children, Toronto, Ontario, Canada
- Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada
| | - Stephanie Borlase
- Department of Biochemistry and Medical Genetics, University of Manitoba, Winnipeg, Manitoba, Canada
| | - David S Scott
- The Arthur and Sonia Labatt Brain Tumor Research Centre, The Hospital for Sick Children, Toronto, Ontario, Canada
- Developmental and Stem Cell Biology Program, The Hospital for Sick Children, Toronto, Ontario, Canada
| | - Maria C Vladoiu
- The Arthur and Sonia Labatt Brain Tumor Research Centre, The Hospital for Sick Children, Toronto, Ontario, Canada
- Developmental and Stem Cell Biology Program, The Hospital for Sick Children, Toronto, Ontario, Canada
- Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada
| | - Hamza Farooq
- The Arthur and Sonia Labatt Brain Tumor Research Centre, The Hospital for Sick Children, Toronto, Ontario, Canada
- Developmental and Stem Cell Biology Program, The Hospital for Sick Children, Toronto, Ontario, Canada
- Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada
| | - Olga Sirbu
- The Arthur and Sonia Labatt Brain Tumor Research Centre, The Hospital for Sick Children, Toronto, Ontario, Canada
- Developmental and Stem Cell Biology Program, The Hospital for Sick Children, Toronto, Ontario, Canada
- Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada
| | - Takuma Nakashima
- Division of Brain Tumor Translational Research, National Cancer Center Research Institute, Tokyo, Japan
| | - Shohei Nambu
- Division of Brain Tumor Translational Research, National Cancer Center Research Institute, Tokyo, Japan
| | - Yusuke Funakoshi
- Division of Brain Tumor Translational Research, National Cancer Center Research Institute, Tokyo, Japan
| | - Alec Bahcheli
- Department of Molecular Genetics, University of Toronto, Toronto, Ontario, Canada
- Computational Biology Program, Ontario Institute for Cancer Research, Toronto, Ontario, Canada
| | - J Javier Diaz-Mejia
- Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada
| | - Joseph Golser
- Center for Integrative Brain Research, Seattle Children's Research Institute, Seattle, WA, USA
| | - Kathleen Bach
- Center for Integrative Brain Research, Seattle Children's Research Institute, Seattle, WA, USA
| | - Tram Phuong-Bao
- Department of Pediatrics and Child Health and Department of Biochemistry and Medical Genetics, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada
| | - Patryk Skowron
- The Arthur and Sonia Labatt Brain Tumor Research Centre, The Hospital for Sick Children, Toronto, Ontario, Canada
- Developmental and Stem Cell Biology Program, The Hospital for Sick Children, Toronto, Ontario, Canada
- Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada
| | - Evan Y Wang
- The Arthur and Sonia Labatt Brain Tumor Research Centre, The Hospital for Sick Children, Toronto, Ontario, Canada
- Developmental and Stem Cell Biology Program, The Hospital for Sick Children, Toronto, Ontario, Canada
- Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada
| | - Sachin A Kumar
- The Arthur and Sonia Labatt Brain Tumor Research Centre, The Hospital for Sick Children, Toronto, Ontario, Canada
- Developmental and Stem Cell Biology Program, The Hospital for Sick Children, Toronto, Ontario, Canada
- Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada
| | - Polina Balin
- The Arthur and Sonia Labatt Brain Tumor Research Centre, The Hospital for Sick Children, Toronto, Ontario, Canada
- Developmental and Stem Cell Biology Program, The Hospital for Sick Children, Toronto, Ontario, Canada
- Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada
| | - Abhirami Visvanathan
- The Arthur and Sonia Labatt Brain Tumor Research Centre, The Hospital for Sick Children, Toronto, Ontario, Canada
- Developmental and Stem Cell Biology Program, The Hospital for Sick Children, Toronto, Ontario, Canada
| | - John J Y Lee
- The Arthur and Sonia Labatt Brain Tumor Research Centre, The Hospital for Sick Children, Toronto, Ontario, Canada
- Developmental and Stem Cell Biology Program, The Hospital for Sick Children, Toronto, Ontario, Canada
- Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada
| | - Ramy Ayoub
- Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada
| | - Xin Chen
- The Arthur and Sonia Labatt Brain Tumor Research Centre, The Hospital for Sick Children, Toronto, Ontario, Canada
- Developmental and Stem Cell Biology Program, The Hospital for Sick Children, Toronto, Ontario, Canada
| | - Xiaodi Chen
- The Arthur and Sonia Labatt Brain Tumor Research Centre, The Hospital for Sick Children, Toronto, Ontario, Canada
- Developmental and Stem Cell Biology Program, The Hospital for Sick Children, Toronto, Ontario, Canada
| | - Karen L Mungall
- Canada's Michael Smith Genome Sciences Centre, BC Cancer Agency, Vancouver, British Columbia, Canada
| | - Betty Luu
- The Arthur and Sonia Labatt Brain Tumor Research Centre, The Hospital for Sick Children, Toronto, Ontario, Canada
- Developmental and Stem Cell Biology Program, The Hospital for Sick Children, Toronto, Ontario, Canada
| | - Pierre Bérubé
- McGill University Genome Centre, McGill University, Montreal, Quebec, Canada
| | - Yu C Wang
- McGill University Genome Centre, McGill University, Montreal, Quebec, Canada
| | - Stefan M Pfister
- Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ), Heidelberg, Germany
- Department of Pediatric Oncology, Hematology, Immunology and Pulmonology, University Hospital Heidelberg, Heidelberg, Germany
| | - Seung-Ki Kim
- Department of Neurosurgery, Division of Pediatric Neurosurgery, Seoul National University Children's Hospital, Seoul, South Korea
| | - Olivier Delattre
- SIREDO Oncology Center (Pediatric, Adolescent and Young Adults Oncology), Institut Curie, Paris, France
- INSERM U830, Institut Curie, Paris, France
| | - Franck Bourdeaut
- SIREDO Oncology Center (Pediatric, Adolescent and Young Adults Oncology), Institut Curie, Paris, France
- INSERM U830, Institut Curie, Paris, France
| | - François Doz
- SIREDO Oncology Center (Pediatric, Adolescent and Young Adults Oncology), Institut Curie, Paris, France
- Université Paris Cité, Paris, France
| | | | | | - James Loukides
- The Arthur and Sonia Labatt Brain Tumor Research Centre, The Hospital for Sick Children, Toronto, Ontario, Canada
| | - Peter Dirks
- The Arthur and Sonia Labatt Brain Tumor Research Centre, The Hospital for Sick Children, Toronto, Ontario, Canada
- Developmental and Stem Cell Biology Program, The Hospital for Sick Children, Toronto, Ontario, Canada
- Department of Molecular Genetics, University of Toronto, Toronto, Ontario, Canada
- Division of Neurosurgery, The Hospital for Sick Children, Toronto, Ontario, Canada
| | - Michelle Fèvre-Montange
- INSERM U1028, CNRS UMR5292, Centre de Recherche en Neurosciences, Université de Lyon, Lyon, France
- Centre de Pathologie EST, Groupement Hospitalier EST, Université de Lyon, Bron, France
| | - Anne Jouvet
- Centre de Pathologie EST, Groupement Hospitalier EST, Université de Lyon, Bron, France
| | - Pim J French
- Department of Neurology, Erasmus University Medical Center, Rotterdam, Netherlands
| | - Johan M Kros
- Department of Pathology, Erasmus University Medical Center, Rotterdam, Netherlands
| | - Karel Zitterbart
- Department of Pediatric Oncology, Masaryk University School of Medicine, Brno, Czech Republic
| | - Swneke D Bailey
- Department of Surgery, Division of Thoracic and Upper Gastrointestinal Surgery, Faculty of Medicine, McGill University, Montreal, Quebec, Canada
- Cancer Research Program, Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada
| | - Charles G Eberhart
- Departments of Pathology, Ophthalmology and Oncology, John Hopkins University School of Medicine, Baltimore, MD, USA
| | - Amulya A N Rao
- Division of Pediatric Hematology/Oncology, Mayo Clinic, Rochester, MN, USA
| | - Caterina Giannini
- Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA
| | - James M Olson
- Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
| | - Miklós Garami
- 2nd Department of Pediatrics, Semmelweis University, Budapest, Hungary
| | - Peter Hauser
- 2nd Department of Pediatrics, Semmelweis University, Budapest, Hungary
| | - Joanna J Phillips
- Department of Neurological Surgery, University of California San Francisco, San Francisco, CA, USA
- Department of Pathology, University of California San Francisco, San Francisco, CA, USA
| | - Young S Ra
- Department of Neurosurgery, University of Ulsan, Asan Medical Center, Seoul, South Korea
| | - Carmen de Torres
- Developmental Tumor Biology Laboratory, Hospital Sant Joan de Déu, Esplugues de Llobregat, Barcelona, Spain
| | - Jaume Mora
- Developmental Tumor Biology Laboratory, Hospital Sant Joan de Déu, Esplugues de Llobregat, Barcelona, Spain
| | - Kay K W Li
- Department of Anatomical and Cellular Pathology, The Chinese University of Hong Kong, Shatin, Hong Kong
| | - Ho-Keung Ng
- Department of Anatomical and Cellular Pathology, The Chinese University of Hong Kong, Shatin, Hong Kong
| | - Wai S Poon
- Department of Surgery, The Chinese University of Hong Kong, Shatin, Hong Kong
| | - Ian F Pollack
- Department of Neurological Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
| | - Enrique López-Aguilar
- Division of Pediatric Hematology/Oncology, Hospital Pediatría Centro Médico Nacional century XXI, Mexico City, Mexico
| | - G Yancey Gillespie
- Department of Neurosurgery, University of Alabama at Birmingham, Birmingham, AL, USA
| | - Timothy E Van Meter
- Pediatrics, Virginia Commonwealthy University, School of Medicine, Richmond, VA, USA
| | - Tomoko Shofuda
- Division of Stem Cell Research, Institute for Clinical Research, Osaka National Hospital, Osaka, Japan
| | - Rajeev Vibhakar
- Department of Pediatrics, University of Colorado Denver, Aurora, CO, USA
| | - Reid C Thompson
- Department of Neurological Surgery, Vanderbilt Medical Center, Nashville, TN, USA
| | - Michael K Cooper
- Department of Neurology, Vanderbilt Medical Center, Nashville, TN, USA
| | - Joshua B Rubin
- Departments of Neuroscience, Washington University School of Medicine in St Louis, St Louis, MO, USA
| | - Toshihiro Kumabe
- Department of Neurosurgery, Kitasato University School of Medicine, Sagamihara, Japan
| | - Shin Jung
- Department of Neurosurgery, Chonnam National University Research Institute of Medical Sciences, Chonnam National University Hwasun Hospital and Medical School, Hwasun-gun, South Korea
| | - Boleslaw Lach
- Department of Pathology and Molecular Medicine, Division of Anatomical Pathology, McMaster University, Hamilton, Ontario, Canada
- Department of Pathology and Laboratory Medicine, Hamilton General Hospital, Hamilton, Ontario, Canada
| | - Achille Iolascon
- Dipartimento di Medicina Molecolare e Biotecnologie Mediche (DMMBM), University of Naples Federico II, Naples, Italy
- CEINGE Biotecnologie Avanzate, Naples, Italy
| | - Veronica Ferrucci
- Dipartimento di Medicina Molecolare e Biotecnologie Mediche (DMMBM), University of Naples Federico II, Naples, Italy
- CEINGE Biotecnologie Avanzate, Naples, Italy
| | - Pasqualino de Antonellis
- Dipartimento di Medicina Molecolare e Biotecnologie Mediche (DMMBM), University of Naples Federico II, Naples, Italy
- CEINGE Biotecnologie Avanzate, Naples, Italy
| | - Massimo Zollo
- Dipartimento di Medicina Molecolare e Biotecnologie Mediche (DMMBM), University of Naples Federico II, Naples, Italy
- CEINGE Biotecnologie Avanzate, Naples, Italy
| | - Giuseppe Cinalli
- Department of Pediatric Neurosurgery, Santobono-Pausilipon Children's Hospital, Naples, Italy
| | - Shenandoah Robinson
- Division of Pediatric Neurosurgery, Case Western Reserve, Cleveland, OH, USA
| | - Duncan S Stearns
- Department of Pediatrics-Hematology and Oncology, Case Western Reserve, Cleveland, OH, USA
| | - Erwin G Van Meir
- Department of Hematology and Medical Oncology, Emory University School of Medicine and Winship Cancer Institute, Atlanta, GA, USA
| | - Paola Porrati
- Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy
| | | | | | - Carlos G Carlotti
- Department of Surgery and Anatomy, Faculty of Medicine of Ribeirão Preto, University of São Paulo, São Paulo, Brazil
| | - Claudia C Faria
- Division of Neurosurgery, Centro Hospitalar Lisboa Norte (CHULN), Hospital de Santa Maria, Lisbon, Portugal
- Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal
| | - Martine F Roussel
- Department of Tumor Cell Biology, St Jude Children's Research Hospital, Memphis, TN, USA
| | - Frederick Boop
- Department of Tumor Cell Biology, St Jude Children's Research Hospital, Memphis, TN, USA
| | - Jennifer A Chan
- Charbonneau Cancer Institute, University of Calgary, Calgary, Alberta, Canada
| | - Kimberly A Aldinger
- Center for Integrative Brain Research, Seattle Children's Research Institute, Seattle, WA, USA
- Brotman Baty Institute for Precision Medicine, Seattle, WA, USA
| | - Ferechte Razavi
- Assistance Publique Hôpitaux de Paris, Hôpital Necker-Enfants Malades, Paris, France
| | - Evelina Silvestri
- Surgical Pathology Unit, San Camillo Forlanini Hospital, Rome, Italy
| | - Roger E McLendon
- Department of Pathology, Duke University, Durham, NC, USA
- Department of Neurosurgery, Duke University, Durham, NC, USA
| | - Eric M Thompson
- Department of Neurosurgery, Duke University, Durham, NC, USA
| | - Marc Ansari
- Cansearch Research Platform for Pediatric Oncology and Hematology, Faculty of Medicine, Department of Pediatrics, Gynecology and Obstetrics, University of Geneva, Geneva, Switzerland
- Division of Pediatric Oncology and Hematology, Department of Women, Child and Adolescent, University Geneva Hospitals, Geneva, Switzerland
| | - Maria L Garre
- U.O. Neurochirurgia, Istituto Giannina Gaslini, Genova, Italy
| | - Fernando Chico
- Department of Neurosurgery, Hospital Infantil de Mexico Federico Gomez, Mexico City, Mexico
| | - Pilar Eguía
- Department of Neurosurgery, Hospital Infantil de Mexico Federico Gomez, Mexico City, Mexico
| | - Mario Pérezpeña
- Instituto Nacional De Pediatría de México, Mexico City, Mexico
| | - A Sorana Morrissy
- Charbonneau Cancer Institute, University of Calgary, Calgary, Alberta, Canada
- Department of Biochemistry and Molecular Biology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada
- Alberta Children's Hospital Research Institute, Calgary, Alberta, Canada
| | - Florence M G Cavalli
- INSERM U900, Institut Curie, Paris, France
- PSL Research University, Institut Curie, Paris, France
- CBIO-Centre for Computational Biology, PSL Research University, MINES ParisTech, Paris, France
| | - Xiaochong Wu
- The Arthur and Sonia Labatt Brain Tumor Research Centre, The Hospital for Sick Children, Toronto, Ontario, Canada
- Developmental and Stem Cell Biology Program, The Hospital for Sick Children, Toronto, Ontario, Canada
| | - Craig Daniels
- The Arthur and Sonia Labatt Brain Tumor Research Centre, The Hospital for Sick Children, Toronto, Ontario, Canada
- Developmental and Stem Cell Biology Program, The Hospital for Sick Children, Toronto, Ontario, Canada
| | | | - Steven J M Jones
- Canada's Michael Smith Genome Sciences Centre, BC Cancer Agency, Vancouver, British Columbia, Canada
- Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia, Canada
- Department of Molecular Biology and Biochemistry, Simon Fraser University, Burnaby, British Columbia, Canada
| | - Richard A Moore
- Canada's Michael Smith Genome Sciences Centre, BC Cancer Agency, Vancouver, British Columbia, Canada
| | - Marco A Marra
- Canada's Michael Smith Genome Sciences Centre, BC Cancer Agency, Vancouver, British Columbia, Canada
- Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia, Canada
| | - Xi Huang
- The Arthur and Sonia Labatt Brain Tumor Research Centre, The Hospital for Sick Children, Toronto, Ontario, Canada
- Developmental and Stem Cell Biology Program, The Hospital for Sick Children, Toronto, Ontario, Canada
- Department of Molecular Genetics, University of Toronto, Toronto, Ontario, Canada
| | - Jüri Reimand
- Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada
- Department of Molecular Genetics, University of Toronto, Toronto, Ontario, Canada
- Computational Biology Program, Ontario Institute for Cancer Research, Toronto, Ontario, Canada
| | - Poul H Sorensen
- Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada
- Department of Molecular Oncology, BC Cancer Agency, Vancouver, British Columbia, Canada
| | - Robert J Wechsler-Reya
- Tumor Initiation and Maintenance Program, NCI-Designated Cancer Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA
| | - William A Weiss
- Department of Neurological Surgery, University of California San Francisco, San Francisco, CA, USA
- Department of Neurology, University of California San Francisco, San Francisco, CA, USA
- Department of Pediatrics, University of California San Francisco, San Francisco, CA, USA
| | - Trevor J Pugh
- Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada
- Computational Biology Program, Ontario Institute for Cancer Research, Toronto, Ontario, Canada
- Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada
| | - Livia Garzia
- Cancer Research Program, McGill University Health Centre Research Institute, Montreal, Quebec, Canada
| | - Claudia L Kleinman
- Department of Human Genetics, McGill University, Montreal, Quebec, Canada
- Lady Davis Research Institute, Jewish General Hospital, Montreal, Quebec, Canada
| | - Lincoln D Stein
- Department of Molecular Genetics, University of Toronto, Toronto, Ontario, Canada
- Adaptive Oncology, Ontario Institute for Cancer Research, Toronto, Ontario, Canada
| | - Nada Jabado
- Departments of Pediatrics and Human Genetics, McGill University, Montreal, Quebec, Canada
- The Research Institute of the McGill University Health Center, Montreal, Quebec, Canada
| | - David Malkin
- Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada
- Division of Haematology/Oncology, Department of Pediatrics, The Hospital for Sick Children, Toronto, Ontario, Canada
| | - Olivier Ayrault
- PSL Research University, Université Paris Sud, Université Paris-Saclay, CNRS UMR 3347, INSERM U1021, Institut Curie, Orsay, France
| | - Jeffrey A Golden
- Department of Pathology, Cedars-Sinai Medical Center, Los Angeles, CA, USA
| | - David W Ellison
- Department of Pathology, St Jude Children's Research Hospital, Memphis, TN, USA
| | - Brad Doble
- Department of Pediatrics and Child Health and Department of Biochemistry and Medical Genetics, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada
| | - Vijay Ramaswamy
- The Arthur and Sonia Labatt Brain Tumor Research Centre, The Hospital for Sick Children, Toronto, Ontario, Canada
- Developmental and Stem Cell Biology Program, The Hospital for Sick Children, Toronto, Ontario, Canada
- Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada
- Division of Haematology/Oncology, Department of Pediatrics, The Hospital for Sick Children, Toronto, Ontario, Canada
| | - Tamra E Werbowetski-Ogilvie
- Department of Biochemistry and Medical Genetics, University of Manitoba, Winnipeg, Manitoba, Canada
- CancerCare Manitoba Research Institute, Winnipeg, Manitoba, Canada
| | - Hiromichi Suzuki
- Division of Brain Tumor Translational Research, National Cancer Center Research Institute, Tokyo, Japan
| | - Kathleen J Millen
- Center for Integrative Brain Research, Seattle Children's Research Institute, Seattle, WA, USA
| | - Michael D Taylor
- The Arthur and Sonia Labatt Brain Tumor Research Centre, The Hospital for Sick Children, Toronto, Ontario, Canada.
- Developmental and Stem Cell Biology Program, The Hospital for Sick Children, Toronto, Ontario, Canada.
- Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada.
- Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada.
- Division of Neurosurgery, The Hospital for Sick Children, Toronto, Ontario, Canada.
| |
Collapse
|
3
|
Hendrikse LD, Haldipur P, Saulnier O, Millman J, Sjoboen AH, Erickson AW, Ong W, Gordon V, Coudière-Morrison L, Mercier AL, Shokouhian M, Suárez RA, Ly M, Borlase S, Scott DS, Vladoiu MC, Farooq H, Sirbu O, Nakashima T, Nambu S, Funakoshi Y, Bahcheli A, Diaz-Mejia JJ, Golser J, Bach K, Phuong-Bao T, Skowron P, Wang EY, Kumar SA, Balin P, Visvanathan A, Lee JJY, Ayoub R, Chen X, Chen X, Mungall KL, Luu B, Bérubé P, Wang YC, Pfister SM, Kim SK, Delattre O, Bourdeaut F, Doz F, Masliah-Planchon J, Grajkowska WA, Loukides J, Dirks P, Fèvre-Montange M, Jouvet A, French PJ, Kros JM, Zitterbart K, Bailey SD, Eberhart CG, Rao AAN, Giannini C, Olson JM, Garami M, Hauser P, Phillips JJ, Ra YS, de Torres C, Mora J, Li KKW, Ng HK, Poon WS, Pollack IF, López-Aguilar E, Gillespie GY, Van Meter TE, Shofuda T, Vibhakar R, Thompson RC, Cooper MK, Rubin JB, Kumabe T, Jung S, Lach B, Iolascon A, Ferrucci V, de Antonellis P, Zollo M, Cinalli G, Robinson S, Stearns DS, Van Meir EG, Porrati P, Finocchiaro G, Massimino M, Carlotti CG, Faria CC, Roussel MF, Boop F, Chan JA, Aldinger KA, Razavi F, Silvestri E, McLendon RE, Thompson EM, Ansari M, Garre ML, Chico F, Eguía P, Pérezpeña M, Morrissy AS, Cavalli FMG, Wu X, Daniels C, Rich JN, Jones SJM, Moore RA, Marra MA, Huang X, Reimand J, Sorensen PH, Wechsler-Reya RJ, Weiss WA, Pugh TJ, Garzia L, Kleinman CL, Stein LD, Jabado N, Malkin D, Ayrault O, Golden JA, Ellison DW, Doble B, Ramaswamy V, Werbowetski-Ogilvie TE, Suzuki H, Millen KJ, Taylor MD. Failure of human rhombic lip differentiation underlies medulloblastoma formation. Nature 2022; 609:1021-1028. [PMID: 36131014 PMCID: PMC10026724 DOI: 10.1038/s41586-022-05215-w] [Citation(s) in RCA: 41] [Impact Index Per Article: 20.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/08/2021] [Accepted: 08/09/2022] [Indexed: 02/08/2023]
Abstract
Medulloblastoma (MB) comprises a group of heterogeneous paediatric embryonal neoplasms of the hindbrain with strong links to early development of the hindbrain1-4. Mutations that activate Sonic hedgehog signalling lead to Sonic hedgehog MB in the upper rhombic lip (RL) granule cell lineage5-8. By contrast, mutations that activate WNT signalling lead to WNT MB in the lower RL9,10. However, little is known about the more commonly occurring group 4 (G4) MB, which is thought to arise in the unipolar brush cell lineage3,4. Here we demonstrate that somatic mutations that cause G4 MB converge on the core binding factor alpha (CBFA) complex and mutually exclusive alterations that affect CBFA2T2, CBFA2T3, PRDM6, UTX and OTX2. CBFA2T2 is expressed early in the progenitor cells of the cerebellar RL subventricular zone in Homo sapiens, and G4 MB transcriptionally resembles these progenitors but are stalled in developmental time. Knockdown of OTX2 in model systems relieves this differentiation blockade, which allows MB cells to spontaneously proceed along normal developmental differentiation trajectories. The specific nature of the split human RL, which is destined to generate most of the neurons in the human brain, and its high level of susceptible EOMES+KI67+ unipolar brush cell progenitor cells probably predisposes our species to the development of G4 MB.
Collapse
Affiliation(s)
- Liam D Hendrikse
- The Arthur and Sonia Labatt Brain Tumor Research Centre, The Hospital for Sick Children, Toronto, Ontario, Canada
- Developmental and Stem Cell Biology Program, The Hospital for Sick Children, Toronto, Ontario, Canada
- Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada
| | - Parthiv Haldipur
- Center for Integrative Brain Research, Seattle Children's Research Institute, Seattle, WA, USA
| | - Olivier Saulnier
- The Arthur and Sonia Labatt Brain Tumor Research Centre, The Hospital for Sick Children, Toronto, Ontario, Canada
- Developmental and Stem Cell Biology Program, The Hospital for Sick Children, Toronto, Ontario, Canada
| | - Jake Millman
- Center for Integrative Brain Research, Seattle Children's Research Institute, Seattle, WA, USA
| | - Alexandria H Sjoboen
- Center for Integrative Brain Research, Seattle Children's Research Institute, Seattle, WA, USA
| | - Anders W Erickson
- The Arthur and Sonia Labatt Brain Tumor Research Centre, The Hospital for Sick Children, Toronto, Ontario, Canada
- Developmental and Stem Cell Biology Program, The Hospital for Sick Children, Toronto, Ontario, Canada
- Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada
| | - Winnie Ong
- The Arthur and Sonia Labatt Brain Tumor Research Centre, The Hospital for Sick Children, Toronto, Ontario, Canada
- Developmental and Stem Cell Biology Program, The Hospital for Sick Children, Toronto, Ontario, Canada
- Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada
| | - Victor Gordon
- Department of Biochemistry and Medical Genetics, University of Manitoba, Winnipeg, Manitoba, Canada
| | | | - Audrey L Mercier
- PSL Research University, Université Paris Sud, Université Paris-Saclay, CNRS UMR 3347, INSERM U1021, Institut Curie, Orsay, France
| | - Mohammad Shokouhian
- Department of Pediatrics and Child Health and Department of Biochemistry and Medical Genetics, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada
| | - Raúl A Suárez
- The Arthur and Sonia Labatt Brain Tumor Research Centre, The Hospital for Sick Children, Toronto, Ontario, Canada
- Developmental and Stem Cell Biology Program, The Hospital for Sick Children, Toronto, Ontario, Canada
| | - Michelle Ly
- The Arthur and Sonia Labatt Brain Tumor Research Centre, The Hospital for Sick Children, Toronto, Ontario, Canada
- Developmental and Stem Cell Biology Program, The Hospital for Sick Children, Toronto, Ontario, Canada
- Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada
| | - Stephanie Borlase
- Department of Biochemistry and Medical Genetics, University of Manitoba, Winnipeg, Manitoba, Canada
| | - David S Scott
- The Arthur and Sonia Labatt Brain Tumor Research Centre, The Hospital for Sick Children, Toronto, Ontario, Canada
- Developmental and Stem Cell Biology Program, The Hospital for Sick Children, Toronto, Ontario, Canada
| | - Maria C Vladoiu
- The Arthur and Sonia Labatt Brain Tumor Research Centre, The Hospital for Sick Children, Toronto, Ontario, Canada
- Developmental and Stem Cell Biology Program, The Hospital for Sick Children, Toronto, Ontario, Canada
- Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada
| | - Hamza Farooq
- The Arthur and Sonia Labatt Brain Tumor Research Centre, The Hospital for Sick Children, Toronto, Ontario, Canada
- Developmental and Stem Cell Biology Program, The Hospital for Sick Children, Toronto, Ontario, Canada
- Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada
| | - Olga Sirbu
- The Arthur and Sonia Labatt Brain Tumor Research Centre, The Hospital for Sick Children, Toronto, Ontario, Canada
- Developmental and Stem Cell Biology Program, The Hospital for Sick Children, Toronto, Ontario, Canada
- Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada
| | - Takuma Nakashima
- Division of Brain Tumor Translational Research, National Cancer Center Research Institute, Tokyo, Japan
| | - Shohei Nambu
- Division of Brain Tumor Translational Research, National Cancer Center Research Institute, Tokyo, Japan
| | - Yusuke Funakoshi
- Division of Brain Tumor Translational Research, National Cancer Center Research Institute, Tokyo, Japan
| | - Alec Bahcheli
- Department of Molecular Genetics, University of Toronto, Toronto, Ontario, Canada
- Computational Biology Program, Ontario Institute for Cancer Research, Toronto, Ontario, Canada
| | - J Javier Diaz-Mejia
- Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada
| | - Joseph Golser
- Center for Integrative Brain Research, Seattle Children's Research Institute, Seattle, WA, USA
| | - Kathleen Bach
- Center for Integrative Brain Research, Seattle Children's Research Institute, Seattle, WA, USA
| | - Tram Phuong-Bao
- Department of Pediatrics and Child Health and Department of Biochemistry and Medical Genetics, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada
| | - Patryk Skowron
- The Arthur and Sonia Labatt Brain Tumor Research Centre, The Hospital for Sick Children, Toronto, Ontario, Canada
- Developmental and Stem Cell Biology Program, The Hospital for Sick Children, Toronto, Ontario, Canada
- Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada
| | - Evan Y Wang
- The Arthur and Sonia Labatt Brain Tumor Research Centre, The Hospital for Sick Children, Toronto, Ontario, Canada
- Developmental and Stem Cell Biology Program, The Hospital for Sick Children, Toronto, Ontario, Canada
- Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada
| | - Sachin A Kumar
- The Arthur and Sonia Labatt Brain Tumor Research Centre, The Hospital for Sick Children, Toronto, Ontario, Canada
- Developmental and Stem Cell Biology Program, The Hospital for Sick Children, Toronto, Ontario, Canada
- Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada
| | - Polina Balin
- The Arthur and Sonia Labatt Brain Tumor Research Centre, The Hospital for Sick Children, Toronto, Ontario, Canada
- Developmental and Stem Cell Biology Program, The Hospital for Sick Children, Toronto, Ontario, Canada
- Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada
| | - Abhirami Visvanathan
- The Arthur and Sonia Labatt Brain Tumor Research Centre, The Hospital for Sick Children, Toronto, Ontario, Canada
- Developmental and Stem Cell Biology Program, The Hospital for Sick Children, Toronto, Ontario, Canada
| | - John J Y Lee
- The Arthur and Sonia Labatt Brain Tumor Research Centre, The Hospital for Sick Children, Toronto, Ontario, Canada
- Developmental and Stem Cell Biology Program, The Hospital for Sick Children, Toronto, Ontario, Canada
- Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada
| | - Ramy Ayoub
- Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada
| | - Xin Chen
- The Arthur and Sonia Labatt Brain Tumor Research Centre, The Hospital for Sick Children, Toronto, Ontario, Canada
- Developmental and Stem Cell Biology Program, The Hospital for Sick Children, Toronto, Ontario, Canada
| | - Xiaodi Chen
- The Arthur and Sonia Labatt Brain Tumor Research Centre, The Hospital for Sick Children, Toronto, Ontario, Canada
- Developmental and Stem Cell Biology Program, The Hospital for Sick Children, Toronto, Ontario, Canada
| | - Karen L Mungall
- Canada's Michael Smith Genome Sciences Centre, BC Cancer Agency, Vancouver, British Columbia, Canada
| | - Betty Luu
- The Arthur and Sonia Labatt Brain Tumor Research Centre, The Hospital for Sick Children, Toronto, Ontario, Canada
- Developmental and Stem Cell Biology Program, The Hospital for Sick Children, Toronto, Ontario, Canada
| | - Pierre Bérubé
- McGill University Genome Centre, McGill University, Montreal, Quebec, Canada
| | - Yu C Wang
- McGill University Genome Centre, McGill University, Montreal, Quebec, Canada
| | - Stefan M Pfister
- Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ), Heidelberg, Germany
- Department of Pediatric Oncology, Hematology, Immunology and Pulmonology, University Hospital Heidelberg, Heidelberg, Germany
| | - Seung-Ki Kim
- Department of Neurosurgery, Division of Pediatric Neurosurgery, Seoul National University Children's Hospital, Seoul, South Korea
| | - Olivier Delattre
- SIREDO Oncology Center (Pediatric, Adolescent and Young Adults Oncology), Institut Curie, Paris, France
- INSERM U830, Institut Curie, Paris, France
| | - Franck Bourdeaut
- SIREDO Oncology Center (Pediatric, Adolescent and Young Adults Oncology), Institut Curie, Paris, France
- INSERM U830, Institut Curie, Paris, France
| | - François Doz
- SIREDO Oncology Center (Pediatric, Adolescent and Young Adults Oncology), Institut Curie, Paris, France
- Université Paris Cité, Paris, France
| | | | | | - James Loukides
- The Arthur and Sonia Labatt Brain Tumor Research Centre, The Hospital for Sick Children, Toronto, Ontario, Canada
| | - Peter Dirks
- The Arthur and Sonia Labatt Brain Tumor Research Centre, The Hospital for Sick Children, Toronto, Ontario, Canada
- Developmental and Stem Cell Biology Program, The Hospital for Sick Children, Toronto, Ontario, Canada
- Department of Molecular Genetics, University of Toronto, Toronto, Ontario, Canada
- Division of Neurosurgery, The Hospital for Sick Children, Toronto, Ontario, Canada
| | - Michelle Fèvre-Montange
- INSERM U1028, CNRS UMR5292, Centre de Recherche en Neurosciences, Université de Lyon, Lyon, France
- Centre de Pathologie EST, Groupement Hospitalier EST, Université de Lyon, Bron, France
| | - Anne Jouvet
- Centre de Pathologie EST, Groupement Hospitalier EST, Université de Lyon, Bron, France
| | - Pim J French
- Department of Neurology, Erasmus University Medical Center, Rotterdam, Netherlands
| | - Johan M Kros
- Department of Pathology, Erasmus University Medical Center, Rotterdam, Netherlands
| | - Karel Zitterbart
- Department of Pediatric Oncology, Masaryk University School of Medicine, Brno, Czech Republic
| | - Swneke D Bailey
- Department of Surgery, Division of Thoracic and Upper Gastrointestinal Surgery, Faculty of Medicine, McGill University, Montreal, Quebec, Canada
- Cancer Research Program, Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada
| | - Charles G Eberhart
- Departments of Pathology, Ophthalmology and Oncology, John Hopkins University School of Medicine, Baltimore, MD, USA
| | - Amulya A N Rao
- Division of Pediatric Hematology/Oncology, Mayo Clinic, Rochester, MN, USA
| | - Caterina Giannini
- Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA
| | - James M Olson
- Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
| | - Miklós Garami
- 2nd Department of Pediatrics, Semmelweis University, Budapest, Hungary
| | - Peter Hauser
- 2nd Department of Pediatrics, Semmelweis University, Budapest, Hungary
| | - Joanna J Phillips
- Department of Neurological Surgery, University of California San Francisco, San Francisco, CA, USA
- Department of Pathology, University of California San Francisco, San Francisco, CA, USA
| | - Young S Ra
- Department of Neurosurgery, University of Ulsan, Asan Medical Center, Seoul, South Korea
| | - Carmen de Torres
- Developmental Tumor Biology Laboratory, Hospital Sant Joan de Déu, Esplugues de Llobregat, Barcelona, Spain
| | - Jaume Mora
- Developmental Tumor Biology Laboratory, Hospital Sant Joan de Déu, Esplugues de Llobregat, Barcelona, Spain
| | - Kay K W Li
- Department of Anatomical and Cellular Pathology, The Chinese University of Hong Kong, Shatin, Hong Kong
| | - Ho-Keung Ng
- Department of Anatomical and Cellular Pathology, The Chinese University of Hong Kong, Shatin, Hong Kong
| | - Wai S Poon
- Department of Surgery, The Chinese University of Hong Kong, Shatin, Hong Kong
| | - Ian F Pollack
- Department of Neurological Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
| | - Enrique López-Aguilar
- Division of Pediatric Hematology/Oncology, Hospital Pediatría Centro Médico Nacional century XXI, Mexico City, Mexico
| | - G Yancey Gillespie
- Department of Neurosurgery, University of Alabama at Birmingham, Birmingham, AL, USA
| | - Timothy E Van Meter
- Pediatrics, Virginia Commonwealthy University, School of Medicine, Richmond, VA, USA
| | - Tomoko Shofuda
- Division of Stem Cell Research, Institute for Clinical Research, Osaka National Hospital, Osaka, Japan
| | - Rajeev Vibhakar
- Department of Pediatrics, University of Colorado Denver, Aurora, CO, USA
| | - Reid C Thompson
- Department of Neurological Surgery, Vanderbilt Medical Center, Nashville, TN, USA
| | - Michael K Cooper
- Department of Neurology, Vanderbilt Medical Center, Nashville, TN, USA
| | - Joshua B Rubin
- Departments of Neuroscience, Washington University School of Medicine in St Louis, St Louis, MO, USA
| | - Toshihiro Kumabe
- Department of Neurosurgery, Kitasato University School of Medicine, Sagamihara, Japan
| | - Shin Jung
- Department of Neurosurgery, Chonnam National University Research Institute of Medical Sciences, Chonnam National University Hwasun Hospital and Medical School, Hwasun-gun, South Korea
| | - Boleslaw Lach
- Department of Pathology and Molecular Medicine, Division of Anatomical Pathology, McMaster University, Hamilton, Ontario, Canada
- Department of Pathology and Laboratory Medicine, Hamilton General Hospital, Hamilton, Ontario, Canada
| | - Achille Iolascon
- Dipartimento di Medicina Molecolare e Biotecnologie Mediche (DMMBM), University of Naples Federico II, Naples, Italy
- CEINGE Biotecnologie Avanzate, Naples, Italy
| | - Veronica Ferrucci
- Dipartimento di Medicina Molecolare e Biotecnologie Mediche (DMMBM), University of Naples Federico II, Naples, Italy
- CEINGE Biotecnologie Avanzate, Naples, Italy
| | - Pasqualino de Antonellis
- Dipartimento di Medicina Molecolare e Biotecnologie Mediche (DMMBM), University of Naples Federico II, Naples, Italy
- CEINGE Biotecnologie Avanzate, Naples, Italy
| | - Massimo Zollo
- Dipartimento di Medicina Molecolare e Biotecnologie Mediche (DMMBM), University of Naples Federico II, Naples, Italy
- CEINGE Biotecnologie Avanzate, Naples, Italy
| | - Giuseppe Cinalli
- Department of Pediatric Neurosurgery, Santobono-Pausilipon Children's Hospital, Naples, Italy
| | - Shenandoah Robinson
- Division of Pediatric Neurosurgery, Case Western Reserve, Cleveland, OH, USA
| | - Duncan S Stearns
- Department of Pediatrics-Hematology and Oncology, Case Western Reserve, Cleveland, OH, USA
| | - Erwin G Van Meir
- Department of Hematology and Medical Oncology, Emory University School of Medicine and Winship Cancer Institute, Atlanta, GA, USA
| | - Paola Porrati
- Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy
| | | | | | - Carlos G Carlotti
- Department of Surgery and Anatomy, Faculty of Medicine of Ribeirão Preto, University of São Paulo, São Paulo, Brazil
| | - Claudia C Faria
- Division of Neurosurgery, Centro Hospitalar Lisboa Norte (CHULN), Hospital de Santa Maria, Lisbon, Portugal
- Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal
| | - Martine F Roussel
- Department of Tumor Cell Biology, St Jude Children's Research Hospital, Memphis, TN, USA
| | - Frederick Boop
- Department of Tumor Cell Biology, St Jude Children's Research Hospital, Memphis, TN, USA
| | - Jennifer A Chan
- Charbonneau Cancer Institute, University of Calgary, Calgary, Alberta, Canada
| | - Kimberly A Aldinger
- Center for Integrative Brain Research, Seattle Children's Research Institute, Seattle, WA, USA
- Brotman Baty Institute for Precision Medicine, Seattle, WA, USA
| | - Ferechte Razavi
- Assistance Publique Hôpitaux de Paris, Hôpital Necker-Enfants Malades, Paris, France
| | - Evelina Silvestri
- Surgical Pathology Unit, San Camillo Forlanini Hospital, Rome, Italy
| | - Roger E McLendon
- Department of Pathology, Duke University, Durham, NC, USA
- Department of Neurosurgery, Duke University, Durham, NC, USA
| | - Eric M Thompson
- Department of Neurosurgery, Duke University, Durham, NC, USA
| | - Marc Ansari
- Cansearch Research Platform for Pediatric Oncology and Hematology, Faculty of Medicine, Department of Pediatrics, Gynecology and Obstetrics, University of Geneva, Geneva, Switzerland
- Division of Pediatric Oncology and Hematology, Department of Women, Child and Adolescent, University Geneva Hospitals, Geneva, Switzerland
| | - Maria L Garre
- U.O. Neurochirurgia, Istituto Giannina Gaslini, Genova, Italy
| | - Fernando Chico
- Department of Neurosurgery, Hospital Infantil de Mexico Federico Gomez, Mexico City, Mexico
| | - Pilar Eguía
- Department of Neurosurgery, Hospital Infantil de Mexico Federico Gomez, Mexico City, Mexico
| | - Mario Pérezpeña
- Instituto Nacional De Pediatría de México, Mexico City, Mexico
| | - A Sorana Morrissy
- Charbonneau Cancer Institute, University of Calgary, Calgary, Alberta, Canada
- Department of Biochemistry and Molecular Biology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada
- Alberta Children's Hospital Research Institute, Calgary, Alberta, Canada
| | - Florence M G Cavalli
- INSERM U900, Institut Curie, Paris, France
- PSL Research University, Institut Curie, Paris, France
- CBIO-Centre for Computational Biology, PSL Research University, MINES ParisTech, Paris, France
| | - Xiaochong Wu
- The Arthur and Sonia Labatt Brain Tumor Research Centre, The Hospital for Sick Children, Toronto, Ontario, Canada
- Developmental and Stem Cell Biology Program, The Hospital for Sick Children, Toronto, Ontario, Canada
| | - Craig Daniels
- The Arthur and Sonia Labatt Brain Tumor Research Centre, The Hospital for Sick Children, Toronto, Ontario, Canada
- Developmental and Stem Cell Biology Program, The Hospital for Sick Children, Toronto, Ontario, Canada
| | | | - Steven J M Jones
- Canada's Michael Smith Genome Sciences Centre, BC Cancer Agency, Vancouver, British Columbia, Canada
- Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia, Canada
- Department of Molecular Biology and Biochemistry, Simon Fraser University, Burnaby, British Columbia, Canada
| | - Richard A Moore
- Canada's Michael Smith Genome Sciences Centre, BC Cancer Agency, Vancouver, British Columbia, Canada
| | - Marco A Marra
- Canada's Michael Smith Genome Sciences Centre, BC Cancer Agency, Vancouver, British Columbia, Canada
- Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia, Canada
| | - Xi Huang
- The Arthur and Sonia Labatt Brain Tumor Research Centre, The Hospital for Sick Children, Toronto, Ontario, Canada
- Developmental and Stem Cell Biology Program, The Hospital for Sick Children, Toronto, Ontario, Canada
- Department of Molecular Genetics, University of Toronto, Toronto, Ontario, Canada
| | - Jüri Reimand
- Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada
- Department of Molecular Genetics, University of Toronto, Toronto, Ontario, Canada
- Computational Biology Program, Ontario Institute for Cancer Research, Toronto, Ontario, Canada
| | - Poul H Sorensen
- Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada
- Department of Molecular Oncology, BC Cancer Agency, Vancouver, British Columbia, Canada
| | - Robert J Wechsler-Reya
- Tumor Initiation and Maintenance Program, NCI-Designated Cancer Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA
| | - William A Weiss
- Department of Neurological Surgery, University of California San Francisco, San Francisco, CA, USA
- Department of Neurology, University of California San Francisco, San Francisco, CA, USA
- Department of Pediatrics, University of California San Francisco, San Francisco, CA, USA
| | - Trevor J Pugh
- Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada
- Computational Biology Program, Ontario Institute for Cancer Research, Toronto, Ontario, Canada
- Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada
| | - Livia Garzia
- Cancer Research Program, McGill University Health Centre Research Institute, Montreal, Quebec, Canada
| | - Claudia L Kleinman
- Department of Human Genetics, McGill University, Montreal, Quebec, Canada
- Lady Davis Research Institute, Jewish General Hospital, Montreal, Quebec, Canada
| | - Lincoln D Stein
- Department of Molecular Genetics, University of Toronto, Toronto, Ontario, Canada
- Adaptive Oncology, Ontario Institute for Cancer Research, Toronto, Ontario, Canada
| | - Nada Jabado
- Departments of Pediatrics and Human Genetics, McGill University, Montreal, Quebec, Canada
- The Research Institute of the McGill University Health Center, Montreal, Quebec, Canada
| | - David Malkin
- Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada
- Division of Haematology/Oncology, Department of Pediatrics, The Hospital for Sick Children, Toronto, Ontario, Canada
| | - Olivier Ayrault
- PSL Research University, Université Paris Sud, Université Paris-Saclay, CNRS UMR 3347, INSERM U1021, Institut Curie, Orsay, France
| | - Jeffrey A Golden
- Department of Pathology, Cedars-Sinai Medical Center, Los Angeles, CA, USA
| | - David W Ellison
- Department of Pathology, St Jude Children's Research Hospital, Memphis, TN, USA
| | - Brad Doble
- Department of Pediatrics and Child Health and Department of Biochemistry and Medical Genetics, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada
| | - Vijay Ramaswamy
- The Arthur and Sonia Labatt Brain Tumor Research Centre, The Hospital for Sick Children, Toronto, Ontario, Canada
- Developmental and Stem Cell Biology Program, The Hospital for Sick Children, Toronto, Ontario, Canada
- Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada
- Division of Haematology/Oncology, Department of Pediatrics, The Hospital for Sick Children, Toronto, Ontario, Canada
| | - Tamra E Werbowetski-Ogilvie
- Department of Biochemistry and Medical Genetics, University of Manitoba, Winnipeg, Manitoba, Canada
- CancerCare Manitoba Research Institute, Winnipeg, Manitoba, Canada
| | - Hiromichi Suzuki
- Division of Brain Tumor Translational Research, National Cancer Center Research Institute, Tokyo, Japan
| | - Kathleen J Millen
- Center for Integrative Brain Research, Seattle Children's Research Institute, Seattle, WA, USA
| | - Michael D Taylor
- The Arthur and Sonia Labatt Brain Tumor Research Centre, The Hospital for Sick Children, Toronto, Ontario, Canada.
- Developmental and Stem Cell Biology Program, The Hospital for Sick Children, Toronto, Ontario, Canada.
- Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada.
- Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada.
- Division of Neurosurgery, The Hospital for Sick Children, Toronto, Ontario, Canada.
| |
Collapse
|
4
|
Li BK, Vasiljevic A, Dufour C, Yao F, Ho BLB, Lu M, Hwang EI, Gururangan S, Hansford JR, Fouladi M, Nobusawa S, Laquerriere A, Delisle MB, Fangusaro J, Forest F, Toledano H, Solano-Paez P, Leary S, Birks D, Hoffman LM, Szathmari A, Faure-Conter C, Fan X, Catchpoole D, Zhou L, Schultz KAP, Ichimura K, Gauchotte G, Jabado N, Jones C, Loussouarn D, Mokhtari K, Rousseau A, Ziegler DS, Tanaka S, Pomeroy SL, Gajjar A, Ramaswamy V, Hawkins C, Grundy RG, Hill DA, Bouffet E, Huang A, Jouvet A. Pineoblastoma segregates into molecular sub-groups with distinct clinico-pathologic features: a Rare Brain Tumor Consortium registry study. Acta Neuropathol 2020; 139:223-241. [PMID: 31820118 DOI: 10.1007/s00401-019-02111-y] [Citation(s) in RCA: 55] [Impact Index Per Article: 13.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/09/2019] [Revised: 11/13/2019] [Accepted: 11/14/2019] [Indexed: 12/22/2022]
Abstract
Pineoblastomas (PBs) are rare, aggressive pediatric brain tumors of the pineal gland with modest overall survival despite intensive therapy. We sought to define the clinical and molecular spectra of PB to inform new treatment approaches for this orphan cancer. Tumor, blood, and clinical data from 91 patients with PB or supratentorial primitive neuroectodermal tumor (sPNETs/CNS-PNETs), and 2 pineal parenchymal tumors of intermediate differentiation (PPTIDs) were collected from 29 centres in the Rare Brain Tumor Consortium. We used global DNA methylation profiling to define a core group of PB from 72/93 cases, which were delineated into five molecular sub-groups. Copy number, whole exome and targeted sequencing, and miRNA expression analyses were used to evaluate the clinico-pathologic significance of each sub-group. Tumors designated as group 1 and 2 almost exclusively exhibited deleterious homozygous loss-of-function alterations in miRNA biogenesis genes (DICER1, DROSHA, and DGCR8) in 62 and 100% of group 1 and 2 tumors, respectively. Recurrent alterations of the oncogenic MYC-miR-17/92-RB1 pathway were observed in the RB and MYC sub-group, respectively, characterized by RB1 loss with gain of miR-17/92, and recurrent gain or amplification of MYC. PB sub-groups exhibited distinct clinical features: group 1-3 arose in older children (median ages 5.2-14.0 years) and had intermediate to excellent survival (5-year OS of 68.0-100%), while Group RB and MYC PB patients were much younger (median age 1.3-1.4 years) with dismal survival (5-year OS 37.5% and 28.6%, respectively). We identified age < 3 years at diagnosis, metastatic disease, omission of upfront radiation, and chr 16q loss as significant negative prognostic factors across all PBs. Our findings demonstrate that PB exhibits substantial molecular heterogeneity with sub-group-associated clinical phenotypes and survival. In addition to revealing novel biology and therapeutics, molecular sub-grouping of PB can be exploited to reduce treatment intensity for patients with favorable biology tumors.
Collapse
Affiliation(s)
- Bryan K Li
- Division of Hematology/Oncology, Department of Pediatrics, The Hospital for Sick Children, University of Toronto, 555 University Ave., 10421B, Black, Toronto, ON, M5G 1X8, Canada
- Arthur and Sonia Labatt Brain Tumour Research Centre, Hospital for Sick Children, Toronto, ON, Canada
- Laboratory Medicine and Pathobiology, Faculty of Medicine, University of Toronto, Toronto, ON, Canada
| | - Alexandre Vasiljevic
- Faculté de Médecine, Université de Lyon, Lyon, France
- Service d'Anatomie et Cytologie Pathologiques, CHU de Lyon, Lyon, France
| | - Christelle Dufour
- Département de Cancérologie de l'Enfant et de l'Adolescent, Institut Gustave Roussy, Villejuif, Paris, France
| | - Fupan Yao
- Arthur and Sonia Labatt Brain Tumour Research Centre, Hospital for Sick Children, Toronto, ON, Canada
- Department of Medical Biophysics, Faculty of Medicine, University of Toronto, Toronto, ON, Canada
| | - Ben L B Ho
- Arthur and Sonia Labatt Brain Tumour Research Centre, Hospital for Sick Children, Toronto, ON, Canada
| | - Mei Lu
- Arthur and Sonia Labatt Brain Tumour Research Centre, Hospital for Sick Children, Toronto, ON, Canada
| | - Eugene I Hwang
- Department of Oncology, Children's National Medical Center, Washington, DC, USA
| | - Sridharan Gururangan
- Department of Pediatrics, Preston A. Wells Jr. Center for Brain Tumor Therapy, UF Health Shands Hospital, University of Florida, Gainesville, FL, USA
| | - Jordan R Hansford
- Children's Cancer Centre, Murdoch Children's Research Institute, Royal Children's Hospital, Melbourne, VIC, Australia
| | - Maryam Fouladi
- Division of Oncology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA
| | - Sumihito Nobusawa
- Department of Human Pathology, Gunma University Graduate School of Medicine, Maebashi, Japan
| | - Annie Laquerriere
- Department of Pathology, Normandy Center for Genomic and Personalized Medicine, Rouen University Hospital, Normandie University, UNIROUEN, Inserm U1245, F 76000, Rouen, France
| | | | - Jason Fangusaro
- Department of Pediatric Hematology and Oncology, Children's Healthcare of Atlanta and the Emory University School of Medicine, Atlanta, GA, USA
| | - Fabien Forest
- Department of Pathology, CHU St. Etienne, Saint-Étienne, France
| | - Helen Toledano
- Department of Pediatric Hematology Oncology, Schneider Children's Medical Center of Israel, Petah Tikva, Israel
| | - Palma Solano-Paez
- Arthur and Sonia Labatt Brain Tumour Research Centre, Hospital for Sick Children, Toronto, ON, Canada
- Hospital Infantil Virgen del Rocio, Seville, Spain
| | - Sarah Leary
- Cancer and Blood Disorders Center, Seattle Children's, Seattle, WA, USA
| | - Diane Birks
- Department of Pediatrics, University of Colorado Denver, Denver, CO, USA
| | - Lindsey M Hoffman
- Center for Cancer and Blood Disorders, Phoenix Children's Hospital, Phoenix, AZ, USA
| | - Alexandru Szathmari
- Département de Neurochirurgie Adulte et Pédiatrique, Hôpital Femme Mère Enfant, Hospices Civils de Lyon, Bron, France
| | | | - Xing Fan
- Department of Neurosurgery, University of Michigan, Ann Arbor, MI, USA
| | - Daniel Catchpoole
- Children's Cancer Research Unit, The Children's Hospital at Westmead, Westmead, NSW, Australia
| | - Li Zhou
- Children's Cancer Research Unit, The Children's Hospital at Westmead, Westmead, NSW, Australia
| | - Kris Ann P Schultz
- Cancer and Blood Disorder, Children's Hospitals and Clinics of Minnesota, Minneapolis, MN, USA
| | | | | | - Nada Jabado
- Departments of Pediatrics and Human Genetics, McGill University, Montreal, QC, Canada
| | - Chris Jones
- The Institute of Cancer Research, London, UK
| | - Delphine Loussouarn
- Service d'Anatomie et de Cytologie pathologiques, CHU Nantes, Nantes, France
| | - Karima Mokhtari
- Département de Neuropathologie, Hôpital Universitaire Pitie-Salpetriere, Paris, France
| | - Audrey Rousseau
- Département de Pathologie Cellulaire et Tissulaire, CHU d'Angers, Angers, France
| | - David S Ziegler
- Kids Cancer Centre, Sydney Children's Hospital, Sydney, NSW, Australia
- Children's Cancer Institute, Lowy Cancer Centre, University of New South Wales, Sydney, NSW, Australia
| | - Shinya Tanaka
- Department of Cancer Pathology, Faculty of Medicine, Hokkaido University, Hokkaido, Japan
| | - Scott L Pomeroy
- Department of Neurology, Harvard Medical School, Boston Children's Hospital, Boston, MA, USA
| | - Amar Gajjar
- Department of Oncology, Division of Neuro-Oncology, St. Jude Children's Research Hospital, Memphis, TN, USA
| | - Vijay Ramaswamy
- Division of Hematology/Oncology, Department of Pediatrics, The Hospital for Sick Children, University of Toronto, 555 University Ave., 10421B, Black, Toronto, ON, M5G 1X8, Canada
- Arthur and Sonia Labatt Brain Tumour Research Centre, Hospital for Sick Children, Toronto, ON, Canada
- Department of Medical Biophysics, Faculty of Medicine, University of Toronto, Toronto, ON, Canada
| | - Cynthia Hawkins
- Arthur and Sonia Labatt Brain Tumour Research Centre, Hospital for Sick Children, Toronto, ON, Canada
- Laboratory Medicine and Pathobiology, Faculty of Medicine, University of Toronto, Toronto, ON, Canada
- Division of Pathology, The Hospital for Sick Children, Toronto, ON, Canada
| | - Richard G Grundy
- Faculty of Medicine and Health Sciences, University of Nottingham, Nottingham, UK
| | - D Ashley Hill
- Division of Pathology, Center for Cancer and Immunology Research, Children's National Medical Center, Washington, DC, USA
| | - Eric Bouffet
- Division of Hematology/Oncology, Department of Pediatrics, The Hospital for Sick Children, University of Toronto, 555 University Ave., 10421B, Black, Toronto, ON, M5G 1X8, Canada
| | - Annie Huang
- Division of Hematology/Oncology, Department of Pediatrics, The Hospital for Sick Children, University of Toronto, 555 University Ave., 10421B, Black, Toronto, ON, M5G 1X8, Canada.
- Arthur and Sonia Labatt Brain Tumour Research Centre, Hospital for Sick Children, Toronto, ON, Canada.
- Laboratory Medicine and Pathobiology, Faculty of Medicine, University of Toronto, Toronto, ON, Canada.
- Department of Medical Biophysics, Faculty of Medicine, University of Toronto, Toronto, ON, Canada.
| | - Anne Jouvet
- Service d'Anatomie et Cytologie Pathologiques, CHU de Lyon, Lyon, France
- Pathology and Molecular Biology, SFCE, Bordeaux, France
| |
Collapse
|
5
|
Li B, Vasiljevic A, Dufour C, Ho B, Hwang E, Gururangan S, Hansford J, Laquerriere A, Delisle MB, Fangusaro J, Forest F, Sumihito N, Toledano H, Birks D, Fan X, Fouladi M, Gajjar A, Gauchotte G, Hoffman L, Jones C, Loussouarn D, Mokhtari K, Pomeroy S, Rousseau A, Somers G, Taylor M, Ziegler DS, Lu M, Hawkins C, Grundy R, Jouvet A, Bouffet E, Ashley Hill D, Huang A. PDTM-24. PINEOBLASTOMA SEGREGATES INTO MOLECULAR SUBTYPES WITH DISTINCT CLINICOPATHOLOGIC FEATURES: REPORT FROM THE RARE BRAIN TUMOUR CONSORTIUM. Neuro Oncol 2019. [DOI: 10.1093/neuonc/noz175.800] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
BACKGROUND
Pineoblastoma (PB) is a rare but aggressive pediatric brain tumour arising from the pineal gland. Overall survival rates are estimated at 50–70%, with younger patients (< 5 years old) faring much worse (15–40%) despite intensive treatment regimens. Although germline RB1 and DICER1 alterations have been reported in a small proportion of PB, the clinical significance of such alterations and the biology of sporadic cases remains unknown.
METHODS
We collected tumor tissue from 93 PB cases diagnosed at their referring centres. We undertook global DNA methylation profiling and performed multiple orthogonal consensus clustering analyses to elucidate PB subgroups. Chromosomal copy number alterations were determined using Conumee and GISTIC2, and whole exome or targeted sequencing was completed. Clinical data was analyzed with correlative statistical methods and outcomes were measured by Kaplan-Meier survival estimates.
RESULTS
PB comprise five epigenetic groups, designated 1, 2, 3, 4A, and 4B. Deleterious, mutually exclusive alterations affecting miRNA biogenesis pathway members (DICER1, DROSHA, and DGCR8) were observed in 12/21 group 1 and 11/11 group 2 samples. Group 4A was characterized by recurrent RB1 loss and gain of the oncogenic miR-17/92, and group 4B by recurrent gain or amplification of MYC. These groups also exhibit distinct clinical features. PB groups 1–3 arose in older children (median ages 5.2–14.0 years) and had intermediate to excellent outcome (5-year OS of 71.9–100%). Group 4A and 4B were restricted to much younger children (median age 1.3–1.4 years) and had dismal prognoses (5-year OS 37.5% and 28.6%, respectively).
CONCLUSIONS
PB divides into five groups with distinct genetic and clinical profiles. These findings will have important implications for precise patient stratification and form the foundation for preclinical studies of biology-informed therapies.
Collapse
Affiliation(s)
- Bryan Li
- Hospital for Sick Children, Toronto, ON, Canada
| | | | | | - Ben Ho
- Hospital for Sick Children, Toronto, ON, Canada
| | - Eugene Hwang
- Children’s National Medical Center, Washington, DC, USA
| | - Sridharan Gururangan
- Preston A. Wells Jr Center for Brain Tumor Therapy at the University of Florida, Gainesville, FL, USA
| | - Jordan Hansford
- Children’s Cancer Centre, Royal Children’s Hospital, Melbourne, Australia
| | | | | | - Jason Fangusaro
- Division of Pediatric Hematology-Oncology and Stem Cell Transplantation, Ann and Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL, USA
| | - Fabien Forest
- Department of Pathology, CHU St. Etienne, France, Saint-Étienne, France
| | - Nobusawa Sumihito
- Gunma University, Aramaki-machi, Maebashi City, Gunma Prefecture, Japan, Maebashi City, Japan
| | - Helen Toledano
- Department of Pediatric Hematology Oncology, Children’s Medical Center of Israel, Petach Tikva, Israel
| | - Diane Birks
- Department of Pediatrics, University of Colorado Denver, Denver, Colorado, USA
| | - Xing Fan
- Department of Neurosurgery, University of Michigan, Ann Arbor, MI, USA
| | | | - Amar Gajjar
- St. Jude Children’s Research Hospital, Memphis, TN, USA
| | | | | | | | | | - Karima Mokhtari
- Hôpital Universitaire Pitie-Salpetriere, France, Paris, France
| | | | | | - Gino Somers
- The Hospital for Sick Children, Toronto, ON, Canada
| | | | | | | | | | | | | | - Eric Bouffet
- The Hospital for Sick Children, Toronto, ON, Canada
| | - D Ashley Hill
- Division of Pathology, Children’s National Medical Center, Washington DC, USA
| | - Annie Huang
- The Hospital for Sick Children, Toronto, ON, Canada
| |
Collapse
|
6
|
Suzuki H, Kumar SA, Shuai S, Diaz-Navarro A, Gutierrez-Fernandez A, De Antonellis P, Cavalli FMG, Juraschka K, Farooq H, Shibahara I, Vladoiu MC, Zhang J, Abeysundara N, Przelicki D, Skowron P, Gauer N, Luu B, Daniels C, Wu X, Forget A, Momin A, Wang J, Dong W, Kim SK, Grajkowska WA, Jouvet A, Fèvre-Montange M, Garrè ML, Nageswara Rao AA, Giannini C, Kros JM, French PJ, Jabado N, Ng HK, Poon WS, Eberhart CG, Pollack IF, Olson JM, Weiss WA, Kumabe T, López-Aguilar E, Lach B, Massimino M, Van Meir EG, Rubin JB, Vibhakar R, Chambless LB, Kijima N, Klekner A, Bognár L, Chan JA, Faria CC, Ragoussis J, Pfister SM, Goldenberg A, Wechsler-Reya RJ, Bailey SD, Garzia L, Morrissy AS, Marra MA, Huang X, Malkin D, Ayrault O, Ramaswamy V, Puente XS, Calarco JA, Stein L, Taylor MD. Recurrent noncoding U1 snRNA mutations drive cryptic splicing in SHH medulloblastoma. Nature 2019; 574:707-711. [PMID: 31664194 PMCID: PMC7141958 DOI: 10.1038/s41586-019-1650-0] [Citation(s) in RCA: 93] [Impact Index Per Article: 18.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/13/2018] [Accepted: 09/03/2019] [Indexed: 11/30/2022]
Abstract
Recurrent somatic single nucleotide variants (SNVs) in cancer are largely confined to protein coding genes, and are rare in most pediatric cancers1–3. We report highly recurrent hotspot mutations of U1 spliceosomal small nuclear RNAs (snRNAs) in ~50% of Sonic Hedgehog medulloblastomas (Shh-MB), which were not present across other medulloblastoma subgroups. This U1-snRNA hotspot mutation (r.3a>g), was identified in <0.1% of 2,442 cancers across 36 other tumor types. Largely absent from infant Shh-MB, the mutation occurs in 97% of adults (Shhδ), and 25% of adolescents (Shhα). The U1-snRNA mutation occurs in the 5′ splice site binding region, and snRNA mutant tumors have significantly disrupted RNA splicing with an excess of 5′ cryptic splicing events. Mutant U1-snRNA mediated alternative splicing inactivates tumor suppressor genes (PTCH1), and activates oncogenes (GLI2, CCND2), represents a novel target for therapy, and constitutes a highly recurrent and tissue-specific mutation of a non-protein coding gene in cancer.
Collapse
Affiliation(s)
- Hiromichi Suzuki
- The Arthur and Sonia Labatt Brain Tumour Research Centre, The Hospital for Sick Children, Toronto, Ontario, Canada.,Developmental and Stem Cell Biology Program, The Hospital for Sick Children, Toronto, Ontario, Canada
| | - Sachin A Kumar
- The Arthur and Sonia Labatt Brain Tumour Research Centre, The Hospital for Sick Children, Toronto, Ontario, Canada.,Developmental and Stem Cell Biology Program, The Hospital for Sick Children, Toronto, Ontario, Canada.,Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada
| | - Shimin Shuai
- Informatics and Biocomputing, Ontario Institute for Cancer Research, Toronto, Ontario, Canada.,Department of Molecular Genetics, University of Toronto, Toronto, Ontario, Canada
| | - Ander Diaz-Navarro
- Departamento de Bioquímica y Biología Molecular, Instituto Universitario de Oncología, Universidad de Oviedo, Oviedo, Spain.,Centro de Investigación Biomédica en Red de Cáncer, Madrid, Spain
| | - Ana Gutierrez-Fernandez
- Departamento de Bioquímica y Biología Molecular, Instituto Universitario de Oncología, Universidad de Oviedo, Oviedo, Spain.,Centro de Investigación Biomédica en Red de Cáncer, Madrid, Spain
| | - Pasqualino De Antonellis
- The Arthur and Sonia Labatt Brain Tumour Research Centre, The Hospital for Sick Children, Toronto, Ontario, Canada.,Developmental and Stem Cell Biology Program, The Hospital for Sick Children, Toronto, Ontario, Canada
| | - Florence M G Cavalli
- The Arthur and Sonia Labatt Brain Tumour Research Centre, The Hospital for Sick Children, Toronto, Ontario, Canada.,Developmental and Stem Cell Biology Program, The Hospital for Sick Children, Toronto, Ontario, Canada
| | - Kyle Juraschka
- The Arthur and Sonia Labatt Brain Tumour Research Centre, The Hospital for Sick Children, Toronto, Ontario, Canada.,Developmental and Stem Cell Biology Program, The Hospital for Sick Children, Toronto, Ontario, Canada.,Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada
| | - Hamza Farooq
- The Arthur and Sonia Labatt Brain Tumour Research Centre, The Hospital for Sick Children, Toronto, Ontario, Canada.,Developmental and Stem Cell Biology Program, The Hospital for Sick Children, Toronto, Ontario, Canada.,Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada
| | - Ichiyo Shibahara
- The Arthur and Sonia Labatt Brain Tumour Research Centre, The Hospital for Sick Children, Toronto, Ontario, Canada.,Developmental and Stem Cell Biology Program, The Hospital for Sick Children, Toronto, Ontario, Canada
| | - Maria C Vladoiu
- The Arthur and Sonia Labatt Brain Tumour Research Centre, The Hospital for Sick Children, Toronto, Ontario, Canada.,Developmental and Stem Cell Biology Program, The Hospital for Sick Children, Toronto, Ontario, Canada.,Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada
| | - Jiao Zhang
- The Arthur and Sonia Labatt Brain Tumour Research Centre, The Hospital for Sick Children, Toronto, Ontario, Canada.,Developmental and Stem Cell Biology Program, The Hospital for Sick Children, Toronto, Ontario, Canada
| | - Namal Abeysundara
- The Arthur and Sonia Labatt Brain Tumour Research Centre, The Hospital for Sick Children, Toronto, Ontario, Canada.,Developmental and Stem Cell Biology Program, The Hospital for Sick Children, Toronto, Ontario, Canada
| | - David Przelicki
- The Arthur and Sonia Labatt Brain Tumour Research Centre, The Hospital for Sick Children, Toronto, Ontario, Canada.,Developmental and Stem Cell Biology Program, The Hospital for Sick Children, Toronto, Ontario, Canada.,Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada
| | - Patryk Skowron
- The Arthur and Sonia Labatt Brain Tumour Research Centre, The Hospital for Sick Children, Toronto, Ontario, Canada.,Developmental and Stem Cell Biology Program, The Hospital for Sick Children, Toronto, Ontario, Canada.,Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada
| | - Nicole Gauer
- The Arthur and Sonia Labatt Brain Tumour Research Centre, The Hospital for Sick Children, Toronto, Ontario, Canada.,Developmental and Stem Cell Biology Program, The Hospital for Sick Children, Toronto, Ontario, Canada
| | - Betty Luu
- The Arthur and Sonia Labatt Brain Tumour Research Centre, The Hospital for Sick Children, Toronto, Ontario, Canada.,Developmental and Stem Cell Biology Program, The Hospital for Sick Children, Toronto, Ontario, Canada
| | - Craig Daniels
- The Arthur and Sonia Labatt Brain Tumour Research Centre, The Hospital for Sick Children, Toronto, Ontario, Canada.,Developmental and Stem Cell Biology Program, The Hospital for Sick Children, Toronto, Ontario, Canada
| | - Xiaochong Wu
- The Arthur and Sonia Labatt Brain Tumour Research Centre, The Hospital for Sick Children, Toronto, Ontario, Canada.,Developmental and Stem Cell Biology Program, The Hospital for Sick Children, Toronto, Ontario, Canada
| | - Antoine Forget
- CNRS UMR, INSERM, Institut Curie, PSL Research University, Orsay, France.,CNRS UMR 3347, INSERM U1021, Université Paris Sud, Université Paris-Saclay, Orsay, France
| | - Ali Momin
- The Arthur and Sonia Labatt Brain Tumour Research Centre, The Hospital for Sick Children, Toronto, Ontario, Canada.,Developmental and Stem Cell Biology Program, The Hospital for Sick Children, Toronto, Ontario, Canada.,Department of Molecular Genetics, University of Toronto, Toronto, Ontario, Canada
| | - Jun Wang
- Tumor Initiation and Maintenance Program, NCI-Designated Cancer Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA
| | - Weifan Dong
- The Arthur and Sonia Labatt Brain Tumour Research Centre, The Hospital for Sick Children, Toronto, Ontario, Canada.,Developmental and Stem Cell Biology Program, The Hospital for Sick Children, Toronto, Ontario, Canada.,Department of Molecular Genetics, University of Toronto, Toronto, Ontario, Canada
| | - Seung-Ki Kim
- Department of Neurosurgery, Division of Pediatric Neurosurgery, Seoul National University Children's Hospital, Seoul, South Korea
| | | | - Anne Jouvet
- Centre de Pathologie EST, Groupement Hospitalier EST, Université de Lyon, Bron, France
| | - Michelle Fèvre-Montange
- CNRS UMR5292, INSERM U1028, Centre de Recherche en Neurosciences, Université de Lyon, Lyon, France
| | | | | | - Caterina Giannini
- Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA
| | - Johan M Kros
- Department of Pathology, Erasmus University Medical Center, Rotterdam, The Netherlands
| | - Pim J French
- Department of Neurology, Erasmus University Medical Center, Rotterdam, The Netherlands
| | - Nada Jabado
- Division of Experimental Medicine, McGill University, Montreal, Quebec, Canada
| | - Ho-Keung Ng
- Department of Anatomical and Cellular Pathology, The Chinese University of Hong Kong, Hong Kong, China
| | - Wai Sang Poon
- Department of Surgery, The Chinese University of Hong Kong, Hong Kong, China
| | - Charles G Eberhart
- Department of Pathology, John Hopkins University School of Medicine, Baltimore, MD, USA.,Department of Opthalmology, John Hopkins University School of Medicine, Baltimore, MD, USA.,Department of Oncology, John Hopkins University School of Medicine, Baltimore, MD, USA
| | - Ian F Pollack
- Department of Neurological Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
| | - James M Olson
- Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
| | - William A Weiss
- Department of Neurological Surgery, University of California San Francisco, San Francisco, CA, USA.,Department of Pediatrics, University of California San Francisco, San Francisco, CA, USA.,Department of Neurology, University of California San Francisco, San Francisco, CA, USA
| | - Toshihiro Kumabe
- Department of Neurosurgery, Kitasato University School of Medicine, Sagamihara, Japan
| | - Enrique López-Aguilar
- Division of Pediatric Hematology/Oncology, Hospital Pediatría Centro Médico Nacional Century XXI, Mexico City, Mexico
| | - Boleslaw Lach
- Department of Pathology and Molecular Medicine, Division of Anatomical Pathology, McMaster University, Hamilton, Ontario, Canada.,Department of Pathology and Laboratory Medicine, Hamilton General Hospital, Hamilton, Ontario, Canada
| | | | - Erwin G Van Meir
- Winship Cancer Institute, Emory University, Atlanta, GA, USA.,Laboratory of Molecular Neuro-Oncology, Department of Neurosurgery, School of Medicine, Emory University, Atlanta, GA, USA.,Department of Hematology and Medical Oncology, School of Medicine, Emory University, Atlanta, GA, USA
| | - Joshua B Rubin
- Department of Neuroscience, Washington University School of Medicine, St. Louis, MO, USA.,Department of Pediatrics, Washington University School of Medicine, St. Louis, MO, USA
| | - Rajeev Vibhakar
- Department of Pediatrics, University of Colorado Anschutz Medical Campus, Aurora, CO, USA
| | - Lola B Chambless
- Department of Neurological Surgery, Vanderbilt Medical Center, Nashville, TN, USA
| | - Noriyuki Kijima
- Department of Neurosurgery, Osaka National Hospital, Osaka, Japan
| | - Almos Klekner
- Department of Neurosurgery, Medical and Health Science Centre, University of Debrecen, Debrecen, Hungary
| | - László Bognár
- Department of Neurosurgery, Medical and Health Science Centre, University of Debrecen, Debrecen, Hungary
| | - Jennifer A Chan
- Charbonneau Cancer Institute, University of Calgary, Calgary, Alberta, Canada
| | - Claudia C Faria
- Division of Neurosurgery, Centro Hospitalar Lisboa Norte, Hospital de Santa Maria, Lisbon, Portugal.,Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal
| | - Jiannis Ragoussis
- McGill University and Genome Quebec Innovation Centre, Department of Human Genetics, McGill University, Montreal, Canada.,Department of Bioengineering, McGill University, Montreal, Canada
| | - Stefan M Pfister
- Hopp Children's Cancer Center Heidelberg (KiTZ), Heidelberg, Germany.,Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), Heidelberg, Germany.,Department of Pediatric Hematology and Oncology, Heidelberg University Hospital, Heidelberg, Germany
| | - Anna Goldenberg
- Department of Computer Science, University of Toronto, Toronto, Ontario, Canada.,Program in Genetics and Genome Biology, The Hospital for Sick Children, Toronto, Ontario, Canada
| | - Robert J Wechsler-Reya
- Tumor Initiation and Maintenance Program, NCI-Designated Cancer Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA.,Department of Pediatrics, University of California San Diego, San Diego, CA, USA
| | - Swneke D Bailey
- Department of Surgery, Division of Thoracic and Upper Gastrointestinal Surgery, Faculty of Medicine, McGill University, Montreal, Quebec, Canada.,Cancer Research Program, Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada
| | - Livia Garzia
- Cancer Research Program, Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada.,Department of Surgery, Division of Orthopedic Surgery, Faculty of Medicine, McGill University, Montreal, Quebec, Canada
| | - A Sorana Morrissy
- Charbonneau Cancer Institute, University of Calgary, Calgary, Alberta, Canada.,Department of Biochemistry and Molecular Biology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada
| | - Marco A Marra
- Canada's Michael Smith Genome Sciences Centre, BC Cancer Agency, Vancouver, British Columbia, Canada.,Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia, Canada
| | - Xi Huang
- The Arthur and Sonia Labatt Brain Tumour Research Centre, The Hospital for Sick Children, Toronto, Ontario, Canada.,Developmental and Stem Cell Biology Program, The Hospital for Sick Children, Toronto, Ontario, Canada
| | - David Malkin
- Division of Haematology/Oncology, Department of Pediatrics, The Hospital for Sick Children, Toronto, Ontario, Canada
| | - Olivier Ayrault
- CNRS UMR, INSERM, Institut Curie, PSL Research University, Orsay, France.,CNRS UMR 3347, INSERM U1021, Université Paris Sud, Université Paris-Saclay, Orsay, France
| | - Vijay Ramaswamy
- Developmental and Stem Cell Biology Program, The Hospital for Sick Children, Toronto, Ontario, Canada.,Division of Haematology/Oncology, Department of Pediatrics, The Hospital for Sick Children, Toronto, Ontario, Canada
| | - Xose S Puente
- Departamento de Bioquímica y Biología Molecular, Instituto Universitario de Oncología, Universidad de Oviedo, Oviedo, Spain.,Centro de Investigación Biomédica en Red de Cáncer, Madrid, Spain
| | - John A Calarco
- Department of Cell and Systems Biology, University of Toronto, Toronto, Canada
| | - Lincoln Stein
- Informatics and Biocomputing, Ontario Institute for Cancer Research, Toronto, Ontario, Canada
| | - Michael D Taylor
- The Arthur and Sonia Labatt Brain Tumour Research Centre, The Hospital for Sick Children, Toronto, Ontario, Canada. .,Developmental and Stem Cell Biology Program, The Hospital for Sick Children, Toronto, Ontario, Canada. .,Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada. .,Division of Neurosurgery, The Hospital for Sick Children, Toronto, Ontario, Canada.
| |
Collapse
|
7
|
Delteil C, Humez S, Boucekine M, Jouvet A, Hedouin V, Fanton L, Leonetti G, Tuchtan L, Piercecchi MD. Histological dating of subdural hematoma in infants. Int J Legal Med 2018; 133:539-546. [DOI: 10.1007/s00414-018-1980-8] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/21/2018] [Accepted: 12/05/2018] [Indexed: 12/01/2022]
|
8
|
Lin JS, Roussel B, Gaspar A, Zhao Y, Hou Y, Schmidt M, Jouvet A, Jouvet M. The unfinished journey with modafinil and discovery of a novel population of modafinil-immunoreactive neurons. Sleep Med 2018; 49:40-52. [DOI: 10.1016/j.sleep.2018.06.008] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
9
|
Li B, Vasiljevic A, Ho B, Norman J, Lu M, Hwang E, Hansford J, Jouvet A, Laquerriere A, Delisle MB, Gururangan S, Fangusaro J, Forest F, Sumihito N, Toledano H, Birks D, Fan X, Fouladi M, Gajjar A, Gauchotte G, Hoffman L, Jones C, Loussouarn D, Mokhtari K, Pomeroy S, Rousseau A, Somers G, Taylor M, Ziegler D, Hawkins C, Bouffet E, Grundy R, Dufour C, Huang A. EMBR-17. PINEOBLASTOMA SEGREGATES INTO MOLECULAR SUBTYPES WITH DISTINCT CLINICOPATHOLOGIC FEATURES: REPORT FROM THE RARE BRAIN TUMOR CONSORTIUM. Neuro Oncol 2018. [DOI: 10.1093/neuonc/noy059.201] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- Bryan Li
- Arthur and Sonia Labatt Brain Tumour Research Centre, Division of Hematology/Oncology, The Hospital for Sick Children, Toronto, ON, Canada
- Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada
| | | | - Ben Ho
- Arthur and Sonia Labatt Brain Tumour Research Centre, Division of Hematology/Oncology, The Hospital for Sick Children, Toronto, ON, Canada
| | - Joseph Norman
- Arthur and Sonia Labatt Brain Tumour Research Centre, Division of Hematology/Oncology, The Hospital for Sick Children, Toronto, ON, Canada
| | - Mei Lu
- Arthur and Sonia Labatt Brain Tumour Research Centre, Division of Hematology/Oncology, The Hospital for Sick Children, Toronto, ON, Canada
| | - Eugene Hwang
- Department of Oncology, Children’s National Medical Center, Washington, DC, USA
| | - Jordan Hansford
- Children’s Cancer Centre, Royal Children’s Hospital, Murdoch Children’s Research Institute, Melbourne, VIC, Australia
| | - Anne Jouvet
- CHU de Lyon, Lyon, France
- Pathology & Molecular Biology, SFCE,,, France
| | | | | | - Sridharan Gururangan
- Lillian S. Well Dept of Neurosurgery, University of Florida, Gainesville, FL, USA
| | - Jason Fangusaro
- Division of Pediatric Hematology-Oncology and Stem Cell Transplantation, Ann and Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL, USA
| | - Fabien Forest
- Department of Pathology, CHU St. Etienne, Saint-Étienne, France
| | - Nobusawa Sumihito
- Department of Human Pathology, Gunma University, Japan, Aramaki-machi, Maebashi City, Gunma Prefecture, Japan
| | - Helen Toledano
- Department of Pediatric Hematology Oncology, Children’s Medical Center of Israel, Petah Tikva, Israel
| | - Diane Birks
- Department of Pediatrics, University of Colorado Denver, Denver, CO, USA
| | - Xing Fan
- Department of Neurosurgery, University of Michigan, Ann Arbor, MI, USA
| | - Maryam Fouladi
- Division of Oncology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, USA
| | - Amar Gajjar
- Department of Oncology, Division of Neuro-Oncology, St. Jude Children’s Research Hospital, Memphis, TN, USA
| | | | - Lindsey Hoffman
- Department of Pediatrics, University of Colorado Denver, Denver, CO, USA
| | - Chris Jones
- The Institute of Cancer Research, London, UK
| | - Delphine Loussouarn
- Service d’Anatomie et de Cytologie pathologiques, CHU Nantes, Nantes, France
| | - Karima Mokhtari
- Département de Neuropathologie, Hôpital Universitaire Pitie-Salpetriere, Paris, France
| | - Scott Pomeroy
- F.M. Kirby Neurobiology Center, Boston Children’s Hospital, Boston, MA, USA
| | - Audrey Rousseau
- Département de Pathologie cellulaire et tissulaire, CHU d’Angers, Angers, France
| | - Gino Somers
- Arthur and Sonia Labatt Brain Tumour Research Centre, Division of Pathology, The Hospital for Sick Children, Toronto, ON, Canada
| | - Michael Taylor
- Arthur and Sonia Labatt Brain Tumour Research Centre, Division of Neurosurgery, The Hospital for Sick Children, Toronto, ON, Canada
| | - David Ziegler
- Kids Cancer Centre, Sydney Children’s Hospital, Sydney, NSW, Australia
| | - Cynthia Hawkins
- Arthur and Sonia Labatt Brain Tumour Research Centre, Division of Pathology, The Hospital for Sick Children, Toronto, ON, Canada
| | - Eric Bouffet
- Division of Hematology/Oncology, The Hospital for Sick Children, Toronto, ON, Canada
| | - Richard Grundy
- Faculty of Medicine & Health Sciences, University of Nottingham, Nottingham, UK
| | - Christelle Dufour
- Département de Cancérologie de l’Enfant et de l’Adolescent, Institut Gustave Roussy, Villejuif, Paris, France
| | - Annie Huang
- Arthur and Sonia Labatt Brain Tumour Research Centre, Division of Hematology/Oncology, The Hospital for Sick Children, Toronto, ON, Canada
- Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada
| |
Collapse
|
10
|
Meyronet D, Esteban-Mader M, Bonnet C, Joly MO, Uro-Coste E, Amiel-Benouaich A, Forest F, Rousselot-Denis C, Burel-Vandenbos F, Bourg V, Guyotat J, Fenouil T, Jouvet A, Honnorat J, Ducray F. Characteristics of H3 K27M-mutant gliomas in adults. Neuro Oncol 2018; 19:1127-1134. [PMID: 28201752 DOI: 10.1093/neuonc/now274] [Citation(s) in RCA: 187] [Impact Index Per Article: 31.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022] Open
Abstract
Background Diffuse H3 K27M-mutant gliomas occur primarily in children but can also be encountered in adults. The aim of this study was to describe the characteristics of H3 K27M-mutant gliomas in adults. Methods We analyzed the characteristics of 21 adult H3 K27M-mutant gliomas and compared them with those of 135 adult diffuse gliomas without histone H3 and without isocitrate dehydrogenase (IDH) mutation (IDH/H3 wild type). Results The median age at diagnosis in H3 K27M-mutant gliomas was 32 years (range: 18-82 y). All tumors had a midline location (spinal cord n = 6, thalamus n = 5, brainstem n = 5, cerebellum n = 3, hypothalamus n = 1, and pineal region n = 1) and were IDH and BRAF-V600E wild type. The identification of an H3 K27M mutation significantly impacted the diagnosis in 3 patients (14%) for whom the histological aspect initially suggested a diffuse low-grade glioma and in 7 patients (33%) for whom pathological analysis hesitated between a diffuse glioma, ganglioglioma, or pilocytic astrocytoma. Compared with IDH/H3 wild-type gliomas, H3 K27M-mutant gliomas were diagnosed at an earlier age (32 vs 64 y, P < .001), always had a midline location (21/21 vs 21/130, P < .001), less frequently had a methylated MGMT promoter (1/21 vs 52/129, P = .002), and lacked EGFR amplification (0/21 vs 26/128, P = .02). The median survival was 19.6 months in H3 K27M-mutant gliomas and 17 months in IDH/H3 wild-type gliomas (P = .3). Conclusion In adults, as in children, H3 K27M mutations define a distinct subgroup of IDH wild-type gliomas characterized by a constant midline location, low rate of MGMT promoter methylation, and poor prognosis.
Collapse
Affiliation(s)
- David Meyronet
- Hospices Civils de Lyon, Groupe Hospitalier Est, Service de Neuropathologie, Lyon, Cedex, France; Université Claude Bernard Lyon 1, Lyon, France; Department of Cancer Cell Plasticity, Cancer Research Centre of Lyon, INSERM U1052, CNRS UMR5286, Lyon, France; Hospices Civils de Lyon, Groupe Hospitalier Est, Service de Neuro-Oncologie, Lyon, Cedex, France; Hospices Civils de Lyon, Hôpital Edouard Herriot, Service d'Anatomie et Cytologie Pathologiques, Lyon, Cedex, France; CHU Toulouse, Hôpital de Rangueil, Service d'Anatomie et Cytologie Pathologique, Toulouse, France; CHU Toulouse, Hôpital Pierre-Paul Riquet, Service de Neurologie, Toulouse, France; CHU Saint-Etienne, Hôpital Nord, Service d'Anatomie et Cytologie Pathologique, Saint-Etienne, France; CHU de Tours, Hôpital Bretonneau, Service d'anatomie et cytologie pathologiques, Tours, Cedex, France; CHU de Nice, Hôpital Pasteur, Service d'anatomie et cytologie pathologiques, Nice, France; CHU de Nice, Hôpital Pasteur, Service de neurologie, Nice, France; Hospices Civils de Lyon, Groupe Hospitalier Est, Service de Neurochirurgie D, Lyon, Cedex, France; Institut NeuroMyoGene, INSERM 1217/CNRS 5310, Université de Lyon, Lyon, France
| | - Maud Esteban-Mader
- Hospices Civils de Lyon, Groupe Hospitalier Est, Service de Neuropathologie, Lyon, Cedex, France; Université Claude Bernard Lyon 1, Lyon, France; Department of Cancer Cell Plasticity, Cancer Research Centre of Lyon, INSERM U1052, CNRS UMR5286, Lyon, France; Hospices Civils de Lyon, Groupe Hospitalier Est, Service de Neuro-Oncologie, Lyon, Cedex, France; Hospices Civils de Lyon, Hôpital Edouard Herriot, Service d'Anatomie et Cytologie Pathologiques, Lyon, Cedex, France; CHU Toulouse, Hôpital de Rangueil, Service d'Anatomie et Cytologie Pathologique, Toulouse, France; CHU Toulouse, Hôpital Pierre-Paul Riquet, Service de Neurologie, Toulouse, France; CHU Saint-Etienne, Hôpital Nord, Service d'Anatomie et Cytologie Pathologique, Saint-Etienne, France; CHU de Tours, Hôpital Bretonneau, Service d'anatomie et cytologie pathologiques, Tours, Cedex, France; CHU de Nice, Hôpital Pasteur, Service d'anatomie et cytologie pathologiques, Nice, France; CHU de Nice, Hôpital Pasteur, Service de neurologie, Nice, France; Hospices Civils de Lyon, Groupe Hospitalier Est, Service de Neurochirurgie D, Lyon, Cedex, France; Institut NeuroMyoGene, INSERM 1217/CNRS 5310, Université de Lyon, Lyon, France
| | - Charlotte Bonnet
- Hospices Civils de Lyon, Groupe Hospitalier Est, Service de Neuropathologie, Lyon, Cedex, France; Université Claude Bernard Lyon 1, Lyon, France; Department of Cancer Cell Plasticity, Cancer Research Centre of Lyon, INSERM U1052, CNRS UMR5286, Lyon, France; Hospices Civils de Lyon, Groupe Hospitalier Est, Service de Neuro-Oncologie, Lyon, Cedex, France; Hospices Civils de Lyon, Hôpital Edouard Herriot, Service d'Anatomie et Cytologie Pathologiques, Lyon, Cedex, France; CHU Toulouse, Hôpital de Rangueil, Service d'Anatomie et Cytologie Pathologique, Toulouse, France; CHU Toulouse, Hôpital Pierre-Paul Riquet, Service de Neurologie, Toulouse, France; CHU Saint-Etienne, Hôpital Nord, Service d'Anatomie et Cytologie Pathologique, Saint-Etienne, France; CHU de Tours, Hôpital Bretonneau, Service d'anatomie et cytologie pathologiques, Tours, Cedex, France; CHU de Nice, Hôpital Pasteur, Service d'anatomie et cytologie pathologiques, Nice, France; CHU de Nice, Hôpital Pasteur, Service de neurologie, Nice, France; Hospices Civils de Lyon, Groupe Hospitalier Est, Service de Neurochirurgie D, Lyon, Cedex, France; Institut NeuroMyoGene, INSERM 1217/CNRS 5310, Université de Lyon, Lyon, France
| | - Marie-Odile Joly
- Hospices Civils de Lyon, Groupe Hospitalier Est, Service de Neuropathologie, Lyon, Cedex, France; Université Claude Bernard Lyon 1, Lyon, France; Department of Cancer Cell Plasticity, Cancer Research Centre of Lyon, INSERM U1052, CNRS UMR5286, Lyon, France; Hospices Civils de Lyon, Groupe Hospitalier Est, Service de Neuro-Oncologie, Lyon, Cedex, France; Hospices Civils de Lyon, Hôpital Edouard Herriot, Service d'Anatomie et Cytologie Pathologiques, Lyon, Cedex, France; CHU Toulouse, Hôpital de Rangueil, Service d'Anatomie et Cytologie Pathologique, Toulouse, France; CHU Toulouse, Hôpital Pierre-Paul Riquet, Service de Neurologie, Toulouse, France; CHU Saint-Etienne, Hôpital Nord, Service d'Anatomie et Cytologie Pathologique, Saint-Etienne, France; CHU de Tours, Hôpital Bretonneau, Service d'anatomie et cytologie pathologiques, Tours, Cedex, France; CHU de Nice, Hôpital Pasteur, Service d'anatomie et cytologie pathologiques, Nice, France; CHU de Nice, Hôpital Pasteur, Service de neurologie, Nice, France; Hospices Civils de Lyon, Groupe Hospitalier Est, Service de Neurochirurgie D, Lyon, Cedex, France; Institut NeuroMyoGene, INSERM 1217/CNRS 5310, Université de Lyon, Lyon, France
| | - Emmanuelle Uro-Coste
- Hospices Civils de Lyon, Groupe Hospitalier Est, Service de Neuropathologie, Lyon, Cedex, France; Université Claude Bernard Lyon 1, Lyon, France; Department of Cancer Cell Plasticity, Cancer Research Centre of Lyon, INSERM U1052, CNRS UMR5286, Lyon, France; Hospices Civils de Lyon, Groupe Hospitalier Est, Service de Neuro-Oncologie, Lyon, Cedex, France; Hospices Civils de Lyon, Hôpital Edouard Herriot, Service d'Anatomie et Cytologie Pathologiques, Lyon, Cedex, France; CHU Toulouse, Hôpital de Rangueil, Service d'Anatomie et Cytologie Pathologique, Toulouse, France; CHU Toulouse, Hôpital Pierre-Paul Riquet, Service de Neurologie, Toulouse, France; CHU Saint-Etienne, Hôpital Nord, Service d'Anatomie et Cytologie Pathologique, Saint-Etienne, France; CHU de Tours, Hôpital Bretonneau, Service d'anatomie et cytologie pathologiques, Tours, Cedex, France; CHU de Nice, Hôpital Pasteur, Service d'anatomie et cytologie pathologiques, Nice, France; CHU de Nice, Hôpital Pasteur, Service de neurologie, Nice, France; Hospices Civils de Lyon, Groupe Hospitalier Est, Service de Neurochirurgie D, Lyon, Cedex, France; Institut NeuroMyoGene, INSERM 1217/CNRS 5310, Université de Lyon, Lyon, France
| | - Alexandra Amiel-Benouaich
- Hospices Civils de Lyon, Groupe Hospitalier Est, Service de Neuropathologie, Lyon, Cedex, France; Université Claude Bernard Lyon 1, Lyon, France; Department of Cancer Cell Plasticity, Cancer Research Centre of Lyon, INSERM U1052, CNRS UMR5286, Lyon, France; Hospices Civils de Lyon, Groupe Hospitalier Est, Service de Neuro-Oncologie, Lyon, Cedex, France; Hospices Civils de Lyon, Hôpital Edouard Herriot, Service d'Anatomie et Cytologie Pathologiques, Lyon, Cedex, France; CHU Toulouse, Hôpital de Rangueil, Service d'Anatomie et Cytologie Pathologique, Toulouse, France; CHU Toulouse, Hôpital Pierre-Paul Riquet, Service de Neurologie, Toulouse, France; CHU Saint-Etienne, Hôpital Nord, Service d'Anatomie et Cytologie Pathologique, Saint-Etienne, France; CHU de Tours, Hôpital Bretonneau, Service d'anatomie et cytologie pathologiques, Tours, Cedex, France; CHU de Nice, Hôpital Pasteur, Service d'anatomie et cytologie pathologiques, Nice, France; CHU de Nice, Hôpital Pasteur, Service de neurologie, Nice, France; Hospices Civils de Lyon, Groupe Hospitalier Est, Service de Neurochirurgie D, Lyon, Cedex, France; Institut NeuroMyoGene, INSERM 1217/CNRS 5310, Université de Lyon, Lyon, France
| | - Fabien Forest
- Hospices Civils de Lyon, Groupe Hospitalier Est, Service de Neuropathologie, Lyon, Cedex, France; Université Claude Bernard Lyon 1, Lyon, France; Department of Cancer Cell Plasticity, Cancer Research Centre of Lyon, INSERM U1052, CNRS UMR5286, Lyon, France; Hospices Civils de Lyon, Groupe Hospitalier Est, Service de Neuro-Oncologie, Lyon, Cedex, France; Hospices Civils de Lyon, Hôpital Edouard Herriot, Service d'Anatomie et Cytologie Pathologiques, Lyon, Cedex, France; CHU Toulouse, Hôpital de Rangueil, Service d'Anatomie et Cytologie Pathologique, Toulouse, France; CHU Toulouse, Hôpital Pierre-Paul Riquet, Service de Neurologie, Toulouse, France; CHU Saint-Etienne, Hôpital Nord, Service d'Anatomie et Cytologie Pathologique, Saint-Etienne, France; CHU de Tours, Hôpital Bretonneau, Service d'anatomie et cytologie pathologiques, Tours, Cedex, France; CHU de Nice, Hôpital Pasteur, Service d'anatomie et cytologie pathologiques, Nice, France; CHU de Nice, Hôpital Pasteur, Service de neurologie, Nice, France; Hospices Civils de Lyon, Groupe Hospitalier Est, Service de Neurochirurgie D, Lyon, Cedex, France; Institut NeuroMyoGene, INSERM 1217/CNRS 5310, Université de Lyon, Lyon, France
| | - Cécilia Rousselot-Denis
- Hospices Civils de Lyon, Groupe Hospitalier Est, Service de Neuropathologie, Lyon, Cedex, France; Université Claude Bernard Lyon 1, Lyon, France; Department of Cancer Cell Plasticity, Cancer Research Centre of Lyon, INSERM U1052, CNRS UMR5286, Lyon, France; Hospices Civils de Lyon, Groupe Hospitalier Est, Service de Neuro-Oncologie, Lyon, Cedex, France; Hospices Civils de Lyon, Hôpital Edouard Herriot, Service d'Anatomie et Cytologie Pathologiques, Lyon, Cedex, France; CHU Toulouse, Hôpital de Rangueil, Service d'Anatomie et Cytologie Pathologique, Toulouse, France; CHU Toulouse, Hôpital Pierre-Paul Riquet, Service de Neurologie, Toulouse, France; CHU Saint-Etienne, Hôpital Nord, Service d'Anatomie et Cytologie Pathologique, Saint-Etienne, France; CHU de Tours, Hôpital Bretonneau, Service d'anatomie et cytologie pathologiques, Tours, Cedex, France; CHU de Nice, Hôpital Pasteur, Service d'anatomie et cytologie pathologiques, Nice, France; CHU de Nice, Hôpital Pasteur, Service de neurologie, Nice, France; Hospices Civils de Lyon, Groupe Hospitalier Est, Service de Neurochirurgie D, Lyon, Cedex, France; Institut NeuroMyoGene, INSERM 1217/CNRS 5310, Université de Lyon, Lyon, France
| | - Fanny Burel-Vandenbos
- Hospices Civils de Lyon, Groupe Hospitalier Est, Service de Neuropathologie, Lyon, Cedex, France; Université Claude Bernard Lyon 1, Lyon, France; Department of Cancer Cell Plasticity, Cancer Research Centre of Lyon, INSERM U1052, CNRS UMR5286, Lyon, France; Hospices Civils de Lyon, Groupe Hospitalier Est, Service de Neuro-Oncologie, Lyon, Cedex, France; Hospices Civils de Lyon, Hôpital Edouard Herriot, Service d'Anatomie et Cytologie Pathologiques, Lyon, Cedex, France; CHU Toulouse, Hôpital de Rangueil, Service d'Anatomie et Cytologie Pathologique, Toulouse, France; CHU Toulouse, Hôpital Pierre-Paul Riquet, Service de Neurologie, Toulouse, France; CHU Saint-Etienne, Hôpital Nord, Service d'Anatomie et Cytologie Pathologique, Saint-Etienne, France; CHU de Tours, Hôpital Bretonneau, Service d'anatomie et cytologie pathologiques, Tours, Cedex, France; CHU de Nice, Hôpital Pasteur, Service d'anatomie et cytologie pathologiques, Nice, France; CHU de Nice, Hôpital Pasteur, Service de neurologie, Nice, France; Hospices Civils de Lyon, Groupe Hospitalier Est, Service de Neurochirurgie D, Lyon, Cedex, France; Institut NeuroMyoGene, INSERM 1217/CNRS 5310, Université de Lyon, Lyon, France
| | - Véronique Bourg
- Hospices Civils de Lyon, Groupe Hospitalier Est, Service de Neuropathologie, Lyon, Cedex, France; Université Claude Bernard Lyon 1, Lyon, France; Department of Cancer Cell Plasticity, Cancer Research Centre of Lyon, INSERM U1052, CNRS UMR5286, Lyon, France; Hospices Civils de Lyon, Groupe Hospitalier Est, Service de Neuro-Oncologie, Lyon, Cedex, France; Hospices Civils de Lyon, Hôpital Edouard Herriot, Service d'Anatomie et Cytologie Pathologiques, Lyon, Cedex, France; CHU Toulouse, Hôpital de Rangueil, Service d'Anatomie et Cytologie Pathologique, Toulouse, France; CHU Toulouse, Hôpital Pierre-Paul Riquet, Service de Neurologie, Toulouse, France; CHU Saint-Etienne, Hôpital Nord, Service d'Anatomie et Cytologie Pathologique, Saint-Etienne, France; CHU de Tours, Hôpital Bretonneau, Service d'anatomie et cytologie pathologiques, Tours, Cedex, France; CHU de Nice, Hôpital Pasteur, Service d'anatomie et cytologie pathologiques, Nice, France; CHU de Nice, Hôpital Pasteur, Service de neurologie, Nice, France; Hospices Civils de Lyon, Groupe Hospitalier Est, Service de Neurochirurgie D, Lyon, Cedex, France; Institut NeuroMyoGene, INSERM 1217/CNRS 5310, Université de Lyon, Lyon, France
| | - Jacques Guyotat
- Hospices Civils de Lyon, Groupe Hospitalier Est, Service de Neuropathologie, Lyon, Cedex, France; Université Claude Bernard Lyon 1, Lyon, France; Department of Cancer Cell Plasticity, Cancer Research Centre of Lyon, INSERM U1052, CNRS UMR5286, Lyon, France; Hospices Civils de Lyon, Groupe Hospitalier Est, Service de Neuro-Oncologie, Lyon, Cedex, France; Hospices Civils de Lyon, Hôpital Edouard Herriot, Service d'Anatomie et Cytologie Pathologiques, Lyon, Cedex, France; CHU Toulouse, Hôpital de Rangueil, Service d'Anatomie et Cytologie Pathologique, Toulouse, France; CHU Toulouse, Hôpital Pierre-Paul Riquet, Service de Neurologie, Toulouse, France; CHU Saint-Etienne, Hôpital Nord, Service d'Anatomie et Cytologie Pathologique, Saint-Etienne, France; CHU de Tours, Hôpital Bretonneau, Service d'anatomie et cytologie pathologiques, Tours, Cedex, France; CHU de Nice, Hôpital Pasteur, Service d'anatomie et cytologie pathologiques, Nice, France; CHU de Nice, Hôpital Pasteur, Service de neurologie, Nice, France; Hospices Civils de Lyon, Groupe Hospitalier Est, Service de Neurochirurgie D, Lyon, Cedex, France; Institut NeuroMyoGene, INSERM 1217/CNRS 5310, Université de Lyon, Lyon, France
| | - Tanguy Fenouil
- Hospices Civils de Lyon, Groupe Hospitalier Est, Service de Neuropathologie, Lyon, Cedex, France; Université Claude Bernard Lyon 1, Lyon, France; Department of Cancer Cell Plasticity, Cancer Research Centre of Lyon, INSERM U1052, CNRS UMR5286, Lyon, France; Hospices Civils de Lyon, Groupe Hospitalier Est, Service de Neuro-Oncologie, Lyon, Cedex, France; Hospices Civils de Lyon, Hôpital Edouard Herriot, Service d'Anatomie et Cytologie Pathologiques, Lyon, Cedex, France; CHU Toulouse, Hôpital de Rangueil, Service d'Anatomie et Cytologie Pathologique, Toulouse, France; CHU Toulouse, Hôpital Pierre-Paul Riquet, Service de Neurologie, Toulouse, France; CHU Saint-Etienne, Hôpital Nord, Service d'Anatomie et Cytologie Pathologique, Saint-Etienne, France; CHU de Tours, Hôpital Bretonneau, Service d'anatomie et cytologie pathologiques, Tours, Cedex, France; CHU de Nice, Hôpital Pasteur, Service d'anatomie et cytologie pathologiques, Nice, France; CHU de Nice, Hôpital Pasteur, Service de neurologie, Nice, France; Hospices Civils de Lyon, Groupe Hospitalier Est, Service de Neurochirurgie D, Lyon, Cedex, France; Institut NeuroMyoGene, INSERM 1217/CNRS 5310, Université de Lyon, Lyon, France
| | - Anne Jouvet
- Hospices Civils de Lyon, Groupe Hospitalier Est, Service de Neuropathologie, Lyon, Cedex, France; Université Claude Bernard Lyon 1, Lyon, France; Department of Cancer Cell Plasticity, Cancer Research Centre of Lyon, INSERM U1052, CNRS UMR5286, Lyon, France; Hospices Civils de Lyon, Groupe Hospitalier Est, Service de Neuro-Oncologie, Lyon, Cedex, France; Hospices Civils de Lyon, Hôpital Edouard Herriot, Service d'Anatomie et Cytologie Pathologiques, Lyon, Cedex, France; CHU Toulouse, Hôpital de Rangueil, Service d'Anatomie et Cytologie Pathologique, Toulouse, France; CHU Toulouse, Hôpital Pierre-Paul Riquet, Service de Neurologie, Toulouse, France; CHU Saint-Etienne, Hôpital Nord, Service d'Anatomie et Cytologie Pathologique, Saint-Etienne, France; CHU de Tours, Hôpital Bretonneau, Service d'anatomie et cytologie pathologiques, Tours, Cedex, France; CHU de Nice, Hôpital Pasteur, Service d'anatomie et cytologie pathologiques, Nice, France; CHU de Nice, Hôpital Pasteur, Service de neurologie, Nice, France; Hospices Civils de Lyon, Groupe Hospitalier Est, Service de Neurochirurgie D, Lyon, Cedex, France; Institut NeuroMyoGene, INSERM 1217/CNRS 5310, Université de Lyon, Lyon, France
| | - Jérôme Honnorat
- Hospices Civils de Lyon, Groupe Hospitalier Est, Service de Neuropathologie, Lyon, Cedex, France; Université Claude Bernard Lyon 1, Lyon, France; Department of Cancer Cell Plasticity, Cancer Research Centre of Lyon, INSERM U1052, CNRS UMR5286, Lyon, France; Hospices Civils de Lyon, Groupe Hospitalier Est, Service de Neuro-Oncologie, Lyon, Cedex, France; Hospices Civils de Lyon, Hôpital Edouard Herriot, Service d'Anatomie et Cytologie Pathologiques, Lyon, Cedex, France; CHU Toulouse, Hôpital de Rangueil, Service d'Anatomie et Cytologie Pathologique, Toulouse, France; CHU Toulouse, Hôpital Pierre-Paul Riquet, Service de Neurologie, Toulouse, France; CHU Saint-Etienne, Hôpital Nord, Service d'Anatomie et Cytologie Pathologique, Saint-Etienne, France; CHU de Tours, Hôpital Bretonneau, Service d'anatomie et cytologie pathologiques, Tours, Cedex, France; CHU de Nice, Hôpital Pasteur, Service d'anatomie et cytologie pathologiques, Nice, France; CHU de Nice, Hôpital Pasteur, Service de neurologie, Nice, France; Hospices Civils de Lyon, Groupe Hospitalier Est, Service de Neurochirurgie D, Lyon, Cedex, France; Institut NeuroMyoGene, INSERM 1217/CNRS 5310, Université de Lyon, Lyon, France
| | - François Ducray
- Hospices Civils de Lyon, Groupe Hospitalier Est, Service de Neuropathologie, Lyon, Cedex, France; Université Claude Bernard Lyon 1, Lyon, France; Department of Cancer Cell Plasticity, Cancer Research Centre of Lyon, INSERM U1052, CNRS UMR5286, Lyon, France; Hospices Civils de Lyon, Groupe Hospitalier Est, Service de Neuro-Oncologie, Lyon, Cedex, France; Hospices Civils de Lyon, Hôpital Edouard Herriot, Service d'Anatomie et Cytologie Pathologiques, Lyon, Cedex, France; CHU Toulouse, Hôpital de Rangueil, Service d'Anatomie et Cytologie Pathologique, Toulouse, France; CHU Toulouse, Hôpital Pierre-Paul Riquet, Service de Neurologie, Toulouse, France; CHU Saint-Etienne, Hôpital Nord, Service d'Anatomie et Cytologie Pathologique, Saint-Etienne, France; CHU de Tours, Hôpital Bretonneau, Service d'anatomie et cytologie pathologiques, Tours, Cedex, France; CHU de Nice, Hôpital Pasteur, Service d'anatomie et cytologie pathologiques, Nice, France; CHU de Nice, Hôpital Pasteur, Service de neurologie, Nice, France; Hospices Civils de Lyon, Groupe Hospitalier Est, Service de Neurochirurgie D, Lyon, Cedex, France; Institut NeuroMyoGene, INSERM 1217/CNRS 5310, Université de Lyon, Lyon, France
| |
Collapse
|
11
|
Li BK, Vasiljevic A, Ho B, Jouvet A, Hwang EI, Hansford JR, Laquerriere A, Delisle MB, Gururangan S, Fangusaro JR, Forest F, Sumihito N, Toledano H, Fouladi M, Gauchotte G, Ziegler DS, Bouffet E, Grundy RG, Dufour C, Huang AA. Genomic landscape of pineoblastoma. J Clin Oncol 2018. [DOI: 10.1200/jco.2018.36.15_suppl.2028] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
| | | | - Ben Ho
- Hospital for Sick Children, Toronto, ON, Canada
| | - Anne Jouvet
- Hopital Pierre Wertheimer, CHU Lyon, France, Lyon, France
| | | | - Jordan R. Hansford
- Children's Cancer Centre, Royal Children's Hospital, Murdoch Children's Research Institute, Melbourne, Australia
| | | | | | - Sridharan Gururangan
- Preston Wells Center for Brain Tumor therapy, McKnight Brain Institute, University of Florida, Gainesville, FL
| | | | - Fabien Forest
- Department of Pathology, CHU St. Etienne, France, Saint-Etienne, France
| | - Nobusawa Sumihito
- Department of Human Pathology, Gunma University, Maebashi City, Japan
| | - Helen Toledano
- Department of Pediatric Hematology Oncology, Schneider Children’s Medical Center of Israel, Petach Tikva, Israel
| | - Maryam Fouladi
- Cincinnati Children's Hospital Medical Center, Cincinnati, OH
| | | | | | - Eric Bouffet
- The Hospital for Sick Children, Toronto, ON, Canada
| | - Richard G Grundy
- Children's Brain Tumour Research Centre, University of Nottingham, Nottingham, United Kingdom
| | - Christelle Dufour
- Institut Gustave Roussy - Paediatric and Adolescent Oncology Department, Villejuif, France
| | | | | |
Collapse
|
12
|
Capper D, Jones DTW, Sill M, Hovestadt V, Schrimpf D, Sturm D, Koelsche C, Sahm F, Chavez L, Reuss DE, Kratz A, Wefers AK, Huang K, Pajtler KW, Schweizer L, Stichel D, Olar A, Engel NW, Lindenberg K, Harter PN, Braczynski AK, Plate KH, Dohmen H, Garvalov BK, Coras R, Hölsken A, Hewer E, Bewerunge-Hudler M, Schick M, Fischer R, Beschorner R, Schittenhelm J, Staszewski O, Wani K, Varlet P, Pages M, Temming P, Lohmann D, Selt F, Witt H, Milde T, Witt O, Aronica E, Giangaspero F, Rushing E, Scheurlen W, Geisenberger C, Rodriguez FJ, Becker A, Preusser M, Haberler C, Bjerkvig R, Cryan J, Farrell M, Deckert M, Hench J, Frank S, Serrano J, Kannan K, Tsirigos A, Brück W, Hofer S, Brehmer S, Seiz-Rosenhagen M, Hänggi D, Hans V, Rozsnoki S, Hansford JR, Kohlhof P, Kristensen BW, Lechner M, Lopes B, Mawrin C, Ketter R, Kulozik A, Khatib Z, Heppner F, Koch A, Jouvet A, Keohane C, Mühleisen H, Mueller W, Pohl U, Prinz M, Benner A, Zapatka M, Gottardo NG, Driever PH, Kramm CM, Müller HL, Rutkowski S, von Hoff K, Frühwald MC, Gnekow A, Fleischhack G, Tippelt S, Calaminus G, Monoranu CM, Perry A, Jones C, Jacques TS, Radlwimmer B, Gessi M, Pietsch T, Schramm J, Schackert G, Westphal M, Reifenberger G, Wesseling P, Weller M, Collins VP, Blümcke I, Bendszus M, Debus J, Huang A, Jabado N, Northcott PA, Paulus W, Gajjar A, Robinson GW, Taylor MD, Jaunmuktane Z, Ryzhova M, Platten M, Unterberg A, Wick W, Karajannis MA, Mittelbronn M, Acker T, Hartmann C, Aldape K, Schüller U, Buslei R, Lichter P, Kool M, Herold-Mende C, Ellison DW, Hasselblatt M, Snuderl M, Brandner S, Korshunov A, von Deimling A, Pfister SM. DNA methylation-based classification of central nervous system tumours. Nature 2018; 555:469-474. [PMID: 29539639 PMCID: PMC6093218 DOI: 10.1038/nature26000] [Citation(s) in RCA: 1580] [Impact Index Per Article: 263.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/05/2017] [Accepted: 02/13/2018] [Indexed: 02/07/2023]
Abstract
Accurate pathological diagnosis is crucial for optimal management of patients with cancer. For the approximately 100 known tumour types of the central nervous system, standardization of the diagnostic process has been shown to be particularly challenging-with substantial inter-observer variability in the histopathological diagnosis of many tumour types. Here we present a comprehensive approach for the DNA methylation-based classification of central nervous system tumours across all entities and age groups, and demonstrate its application in a routine diagnostic setting. We show that the availability of this method may have a substantial impact on diagnostic precision compared to standard methods, resulting in a change of diagnosis in up to 12% of prospective cases. For broader accessibility, we have designed a free online classifier tool, the use of which does not require any additional onsite data processing. Our results provide a blueprint for the generation of machine-learning-based tumour classifiers across other cancer entities, with the potential to fundamentally transform tumour pathology.
Collapse
Affiliation(s)
- David Capper
- Department of Neuropathology, University Hospital Heidelberg, Heidelberg, Germany
- Clinical Cooperation Unit Neuropathology, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany
- Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Neuropathology, Berlin, Germany
- German Cancer Consortium (DKTK), Partner Site Berlin, German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - David T W Jones
- Hopp Children's Cancer Center at the NCT Heidelberg (KiTZ), Heidelberg, Germany
- Division of Pediatric Neurooncology, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - Martin Sill
- Hopp Children's Cancer Center at the NCT Heidelberg (KiTZ), Heidelberg, Germany
- Division of Pediatric Neurooncology, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany
- Division of Biostatistics, German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - Volker Hovestadt
- Division of Molecular Genetics, German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - Daniel Schrimpf
- Department of Neuropathology, University Hospital Heidelberg, Heidelberg, Germany
- Clinical Cooperation Unit Neuropathology, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - Dominik Sturm
- Hopp Children's Cancer Center at the NCT Heidelberg (KiTZ), Heidelberg, Germany
- Division of Pediatric Neurooncology, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany
- Department of Pediatric Oncology, Hematology and Immunology, University Hospital Heidelberg, Heidelberg, Germany
| | - Christian Koelsche
- Department of Neuropathology, University Hospital Heidelberg, Heidelberg, Germany
- Clinical Cooperation Unit Neuropathology, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - Felix Sahm
- Department of Neuropathology, University Hospital Heidelberg, Heidelberg, Germany
- Clinical Cooperation Unit Neuropathology, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - Lukas Chavez
- Hopp Children's Cancer Center at the NCT Heidelberg (KiTZ), Heidelberg, Germany
- Division of Pediatric Neurooncology, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - David E Reuss
- Department of Neuropathology, University Hospital Heidelberg, Heidelberg, Germany
- Clinical Cooperation Unit Neuropathology, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - Annekathrin Kratz
- Department of Neuropathology, University Hospital Heidelberg, Heidelberg, Germany
- Clinical Cooperation Unit Neuropathology, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - Annika K Wefers
- Department of Neuropathology, University Hospital Heidelberg, Heidelberg, Germany
- Clinical Cooperation Unit Neuropathology, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - Kristin Huang
- Department of Neuropathology, University Hospital Heidelberg, Heidelberg, Germany
- Clinical Cooperation Unit Neuropathology, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - Kristian W Pajtler
- Hopp Children's Cancer Center at the NCT Heidelberg (KiTZ), Heidelberg, Germany
- Division of Pediatric Neurooncology, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany
- Department of Pediatric Oncology, Hematology and Immunology, University Hospital Heidelberg, Heidelberg, Germany
| | - Leonille Schweizer
- Department of Neuropathology, University Hospital Heidelberg, Heidelberg, Germany
- Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Neuropathology, Berlin, Germany
| | - Damian Stichel
- Department of Neuropathology, University Hospital Heidelberg, Heidelberg, Germany
- Clinical Cooperation Unit Neuropathology, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - Adriana Olar
- Department of Pathology and Laboratory Medicine, Medical University of South Carolina, Charleston, South Carolina 29425, USA
- Department of Neurosurgery, Medical University of South Carolina, Charleston, South Carolina 29425, USA
- Hollings Cancer Center, Charleston, South Carolina 29425, USA
| | - Nils W Engel
- Department of Oncology and Hematology with Sections Bone Marrow Transplant and Pneumology, Hubertus Wald Tumorzentrum/University Cancer Center Hamburg, University Medical Center Hamburg, Hamburg, Germany
- Center for Neuropathology and Prion Research, Ludwig-Maximilians-University, Munich, Germany
| | - Kerstin Lindenberg
- Clinical Cooperation Unit Neuropathology, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - Patrick N Harter
- Institute of Neurology (Edinger Institute), Goethe-University Frankfurt am Main, Frankfurt am Main, Germany
- German Cancer Consortium (DKTK), Partner Site Frankfurt/Mainz, Frankfurt am Main, German Cancer Research Center (DKFZ) Heidelberg, Germany
| | - Anne K Braczynski
- Institute of Neurology (Edinger Institute), Goethe-University Frankfurt am Main, Frankfurt am Main, Germany
- German Cancer Consortium (DKTK), Partner Site Frankfurt/Mainz, Frankfurt am Main, German Cancer Research Center (DKFZ) Heidelberg, Germany
| | - Karl H Plate
- Institute of Neurology (Edinger Institute), Goethe-University Frankfurt am Main, Frankfurt am Main, Germany
- German Cancer Consortium (DKTK), Partner Site Frankfurt/Mainz, Frankfurt am Main, German Cancer Research Center (DKFZ) Heidelberg, Germany
| | - Hildegard Dohmen
- Institute of Neuropathology, University of Giessen, Giessen, Germany
| | - Boyan K Garvalov
- Institute of Neuropathology, University of Giessen, Giessen, Germany
| | - Roland Coras
- Neuropathological Institute, University Hospital Erlangen, Friedrich Alexander University Erlangen-Nuremberg, Erlangen, Germany
| | - Annett Hölsken
- Neuropathological Institute, University Hospital Erlangen, Friedrich Alexander University Erlangen-Nuremberg, Erlangen, Germany
| | - Ekkehard Hewer
- Institute of Pathology, University of Bern, Bern, Switzerland
| | - Melanie Bewerunge-Hudler
- Genomics and Proteomics Core Facility, German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - Matthias Schick
- Genomics and Proteomics Core Facility, German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - Roger Fischer
- Genomics and Proteomics Core Facility, German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - Rudi Beschorner
- Institute of Pathology and Neuropathology, Department of Neuropathology, University Hospital Tübingen, Tübingen, Germany
| | - Jens Schittenhelm
- Institute of Pathology and Neuropathology, Department of Neuropathology, University Hospital Tübingen, Tübingen, Germany
| | - Ori Staszewski
- Institute of Neuropathology, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Germany
| | - Khalida Wani
- Department of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
| | - Pascale Varlet
- Department of Neuropathology, Centre Hospitalier Sainte Anne, Paris, France
| | - Melanie Pages
- Department of Neuropathology, Centre Hospitalier Sainte Anne, Paris, France
| | - Petra Temming
- Pediatrics III, Pediatric Oncology and Hematology, University Hospital Essen, Essen, Germany
| | - Dietmar Lohmann
- Eye Cancer Research Group, Faculty of Medicine, University of Duisburg-Essen, Essen, Germany
| | - Florian Selt
- Hopp Children's Cancer Center at the NCT Heidelberg (KiTZ), Heidelberg, Germany
- Department of Pediatric Oncology, Hematology and Immunology, University Hospital Heidelberg, Heidelberg, Germany
- CCU Pediatric Oncology (G340), German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), Heidelberg, Germany
| | - Hendrik Witt
- Hopp Children's Cancer Center at the NCT Heidelberg (KiTZ), Heidelberg, Germany
- Division of Pediatric Neurooncology, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany
- Department of Pediatric Oncology, Hematology and Immunology, University Hospital Heidelberg, Heidelberg, Germany
| | - Till Milde
- Hopp Children's Cancer Center at the NCT Heidelberg (KiTZ), Heidelberg, Germany
- Department of Pediatric Oncology, Hematology and Immunology, University Hospital Heidelberg, Heidelberg, Germany
- CCU Pediatric Oncology (G340), German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), Heidelberg, Germany
| | - Olaf Witt
- Hopp Children's Cancer Center at the NCT Heidelberg (KiTZ), Heidelberg, Germany
- Department of Pediatric Oncology, Hematology and Immunology, University Hospital Heidelberg, Heidelberg, Germany
- CCU Pediatric Oncology (G340), German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), Heidelberg, Germany
| | - Eleonora Aronica
- Department of (Neuro)Pathology, Academic Medisch Centrum (AMC), University of Amsterdam, Amsterdam, The Netherlands
- Swammerdam Institute for Life Sciences, Center for Neuroscience, University of Amsterdam, Amsterdam, The Netherlands
- Stichting Epilepsie Instellingen Nederland (SEIN), Amsterdam, The Netherlands
| | - Felice Giangaspero
- Department of Radiological, Oncological and Anatomo-Pathological Sciences, Sapienza University, Rome, Italy
- IRCCS Neuromed, Pozzilli, Italy
| | - Elisabeth Rushing
- Department of Neuropathology, University Hospital Zurich, Zurich, Switzerland
| | | | - Christoph Geisenberger
- Department of Neurosurgery, Heidelberg University Hospital, Heidelberg, Germany
- Hubrecht Institute-KNAW (Royal Netherlands Academy of Arts and Sciences), Uppsalalaan 8, 3584 CT Utrecht, The Netherlands
| | - Fausto J Rodriguez
- Division of Neuropathology of the Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
| | - Albert Becker
- Department of Neuropathology, University of Bonn, Bonn, Germany
| | - Matthias Preusser
- Department of Medicine I, Comprehensive Cancer Center Vienna, CNS Unit (CCC-CNS), Medical University of Vienna, Vienna, Austria
| | | | - Rolf Bjerkvig
- Department of Biomedicine, University of Bergen, Bergen, Norway
- NORLUX Neuro-Oncology Laboratory, Department of Oncology, Luxembourg Institute of Health, Luxembourg, Luxembourg
| | - Jane Cryan
- Department of Neuropathology, Beaumont Hospital, Dublin, Ireland
| | - Michael Farrell
- Department of Neuropathology, Beaumont Hospital, Dublin, Ireland
| | - Martina Deckert
- Department of Neuropathology, University Hospital of Cologne, Cologne, Germany
| | - Jürgen Hench
- Department of Neuropathology, Institute of Pathology, Basel University Hospital, Basel, Switzerland
| | - Stephan Frank
- Department of Neuropathology, Institute of Pathology, Basel University Hospital, Basel, Switzerland
| | | | | | | | - Wolfgang Brück
- Institute of Neuropathology, University Medical Center Göttingen, Göttingen, Germany
| | - Silvia Hofer
- Division of Oncology, Luzerner Kantonsspital, Luzern, Switzerland
| | - Stefanie Brehmer
- Department of Neurosurgery, University Medical Center Mannheim, University of Heidelberg, Mannheim, Germany
| | - Marcel Seiz-Rosenhagen
- Department of Neurosurgery, University Medical Center Mannheim, University of Heidelberg, Mannheim, Germany
| | - Daniel Hänggi
- Department of Neurosurgery, University Medical Center Mannheim, University of Heidelberg, Mannheim, Germany
| | - Volkmar Hans
- Institut für Neuropathologie, Evangelisches Krankenhaus Bielefeld gGmbH, Bielefeld, Germany
- Institut für Neuropathologie, Universitätskinikum Essen, Essen, Germany
| | - Stephanie Rozsnoki
- Institute of Neuropathology, University Hospital Münster, Münster, Germany
| | - Jordan R Hansford
- Children's Cancer Centre, Royal Children's Hospital, University of Melbourne, Melbourne, Victoria, Australia
- Murdoch Children's Research Institute, University of Melbourne, Melbourne, Victoria, Australia
- Department of Pediatrics, University of Melbourne, Melbourne, Victoria, Australia
| | - Patricia Kohlhof
- Institute for Pathology, Katharinenhospital Stuttgart, Stuttgart, Germany
| | - Bjarne W Kristensen
- Department of Pathology, Odense University Hospital, Department of Clinical Research, University of Southern Denmark, Odense, Denmark
| | - Matt Lechner
- University College London Cancer Institute and University College London Hospitals, London, UK
| | - Beatriz Lopes
- Department of Pathology, University of Virginia, Charlottesville, Virginia, USA
| | - Christian Mawrin
- Institute of Neuropathology, Otto-von-Guericke-University, Magdeburg, Germany
| | - Ralf Ketter
- Department of Neurosurgery, University Hospital Saarland, Homburg, Saar, Germany
| | - Andreas Kulozik
- Hopp Children's Cancer Center at the NCT Heidelberg (KiTZ), Heidelberg, Germany
- Department of Pediatric Oncology, Hematology and Immunology, University Hospital Heidelberg, Heidelberg, Germany
| | - Ziad Khatib
- Nicklaus Children's Hospital Brain Institute, Miami, Florida 33155, USA
| | - Frank Heppner
- Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Neuropathology, Berlin, Germany
- Cluster of Excellence, NeuroCure, Berlin, Germany
- Berlin Institute of Health (BIH), Berlin, Germany
| | - Arend Koch
- Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Neuropathology, Berlin, Germany
| | - Anne Jouvet
- Département de Pathologie et Neuropathologie, Hôpital Neurologique, Hospices Civils de Lyon, Lyon, France
| | - Catherine Keohane
- Department of Neuropathology, Cork University Hospital, Cork, Ireland
| | - Helmut Mühleisen
- Department of Pathology, Ludwigsburg Hospital, Ludwigsburg, Germany
| | - Wolf Mueller
- Department of Neuropathology, Leipzig University, Leipzig, Germany
| | - Ute Pohl
- Department of Cellular Pathology, Queen's Hospital, Romford, UK
| | - Marco Prinz
- Institute of Neuropathology, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Germany
- BIOSS Centre for Biological Signalling Studies, University of Freiburg, Freiburg, Germany
| | - Axel Benner
- Division of Biostatistics, German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - Marc Zapatka
- Division of Molecular Genetics, German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - Nicholas G Gottardo
- Department of Pediatric Oncology and Haematology, Princess Margaret Hospital for Children, GPO Box D184, Perth, Western Australia 6840, Australia
- Telethon Kids Institute, University of Western Australia, PO Box 855, Perth, Western Australia 6872, Australia
- School of Paediatrics and Child Health, University of Western Australia, GPO Box D184, Perth, Western Australia 6840, Australia
| | - Pablo Hernáiz Driever
- Department of Pediatric Oncology/Hematology, Charité-Universitätsmedizin Berlin, Berlin, Germany
| | - Christof M Kramm
- Division of Pediatric Hematology and Oncology, University Medical Center Göttingen, Göttingen, Germany
| | - Hermann L Müller
- Department of Pediatrics and Pediatric Hematology/Oncology, Klinikum Oldenburg AöR, Medical Campus University Oldenburg, 26133 Oldenburg, Germany
| | - Stefan Rutkowski
- Department for Pediatric Hematology and Oncology, University Hospital Hamburg-Eppendorf, Hamburg, Germany
| | - Katja von Hoff
- Department of Pediatric Oncology/Hematology, Charité-Universitätsmedizin Berlin, Berlin, Germany
- Department for Pediatric Hematology and Oncology, University Hospital Hamburg-Eppendorf, Hamburg, Germany
| | - Michael C Frühwald
- Children's Hospital Augsburg, Swabian Children's Cancer Centre, Augsburg, Germany
| | - Astrid Gnekow
- Children's Hospital Augsburg, Swabian Children's Cancer Centre, Augsburg, Germany
| | - Gudrun Fleischhack
- Pediatrics III, Pediatric Oncology and Hematology, University Hospital Essen, Essen, Germany
| | - Stephan Tippelt
- Pediatrics III, Pediatric Oncology and Hematology, University Hospital Essen, Essen, Germany
| | - Gabriele Calaminus
- Department of Pediatric Hematology/Oncology, University of Bonn Medical Center, Bonn, Germany
| | - Camelia-Maria Monoranu
- Department of Neuropathology, Insitute of Pathology, Comprehensive Cancer Center (CCC) Mainfranken, University of Würzburg, Würzburg, Germany
| | - Arie Perry
- Department of Pathology, University of California San Francisco, San Francisco, California, USA
| | - Chris Jones
- Division of Molecular Pathology, Institute of Cancer Research, London, UK
| | - Thomas S Jacques
- Developmental Biology and Cancer Programme, UCL Great Ormond Street Institute of Child Health and Histopathology Department, Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK
| | - Bernhard Radlwimmer
- Division of Molecular Genetics, German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - Marco Gessi
- Department of Neuropathology, University of Bonn, Bonn, Germany
| | - Torsten Pietsch
- Department of Neuropathology, University of Bonn, Bonn, Germany
| | - Johannes Schramm
- Medical Faculty, University of Bonn Medical School, Bonn, Germany
| | - Gabriele Schackert
- Department of Neurosurgery, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany
| | - Manfred Westphal
- Department of Neurosurgery, University Hospital Hamburg-Eppendorf, Hamburg, Germany
| | - Guido Reifenberger
- Department of Neuropathology, Heinrich Heine University Düsseldorf, Düsseldorf, Germany
- German Cancer Consortium (DKTK), partner site Essen/Düsseldorf, German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - Pieter Wesseling
- Department of Pathology, Princess Máxima Center for Pediatric Oncology and University Medical Center Utrecht, Utrecht, The Netherlands
- Department of Pathology, VU University Medical Center, Amsterdam, The Netherlands
| | - Michael Weller
- Department of Neurology, University Hospital and University of Zurich, Zurich, Switzerland
| | - Vincent Peter Collins
- Department of Pathology, Division of Molecular Histopathology, University of Cambridge, Cambridge, UK
| | - Ingmar Blümcke
- Neuropathological Institute, University Hospital Erlangen, Friedrich Alexander University Erlangen-Nuremberg, Erlangen, Germany
| | - Martin Bendszus
- Department of Neuroradiology, Heidelberg University Hospital, Heidelberg, Germany
| | - Jürgen Debus
- Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany
| | - Annie Huang
- Department of Pediatrics, Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada
| | - Nada Jabado
- Division of Hematology/Oncology, McGill University, Montreal, Quebec, Canada
| | - Paul A Northcott
- Department of Developmental Neurobiology, St Jude Children's Research Hospital, Memphis, Tennessee, USA
| | - Werner Paulus
- Institute of Neuropathology, University Hospital Münster, Münster, Germany
| | - Amar Gajjar
- Department of Oncology, St Jude Children's Research Hospital, Memphis, Tennessee, USA
| | - Giles W Robinson
- Department of Oncology, St Jude Children's Research Hospital, Memphis, Tennessee, USA
| | - Michael D Taylor
- Division of Neurosurgery, Arthur and Sonia Labatt Brain Tumor Research Centre, Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada
| | - Zane Jaunmuktane
- Division of Neuropathology, UCL Hospitals, Institute of Neurology, University College London, Queen Square, WC1N 3BG London, UK
- Department of Molecular Neuroscience, Institute of Neurology, University College London, Queen Square, WC1N 3BG London, UK
- Department of Neurodegeneration, Institute of Neurology, University College London, Queen Square, WC1N 3BG London, UK
| | | | - Michael Platten
- Department of Neurology, Universitätsmedizin Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany
| | - Andreas Unterberg
- Department of Neurosurgery, Heidelberg University Hospital, Heidelberg, Germany
| | - Wolfgang Wick
- Department of Neurology, Heidelberg University Hospital, Heidelberg, Germany
| | - Matthias A Karajannis
- Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York, USA
| | - Michel Mittelbronn
- Institute of Neurology (Edinger Institute), Goethe-University Frankfurt am Main, Frankfurt am Main, Germany
- German Cancer Consortium (DKTK), Partner Site Frankfurt/Mainz, Frankfurt am Main, German Cancer Research Center (DKFZ) Heidelberg, Germany
- NORLUX Neuro-Oncology Laboratory, Luxembourg Institute of Health (LIH), Luxembourg, Luxembourg
- Luxembourg Centre for Systems Biomedicine (LCSB), University of Luxembourg, Luxembourg, Luxembourg
- Laboratoire national de santé (LNS), Dudelange, Luxembourg
- Luxembourg Centre of Neuropathology (LCNP), Luxembourg, Luxembourg
| | - Till Acker
- Institute of Neuropathology, University of Giessen, Giessen, Germany
| | - Christian Hartmann
- Department of Neuropathology, Hannover Medical School (MHH), Hannover, Germany
| | - Kenneth Aldape
- Department of Pathology, University of Toronto, Toronto, Ontario, Canada
| | - Ulrich Schüller
- Center for Neuropathology and Prion Research, Ludwig-Maximilians-University, Munich, Germany
- Institute of Neuropathology, University Medical Center, Hamburg-Eppendorf, Hamburg, Germany
- Research Institute Children's Cancer Center, Hamburg, Germany
- Department of Pediatric Hematology and Oncology, University Medical Center, Hamburg-Eppendorf, Hamburg, Germany
| | - Rolf Buslei
- Neuropathological Institute, University Hospital Erlangen, Friedrich Alexander University Erlangen-Nuremberg, Erlangen, Germany
- Section Neuropathology, Institute of Pathology, Sozialstiftung Bamberg, Klinikum am Bruderwald, Bamberg, Germany
| | - Peter Lichter
- Division of Molecular Genetics, German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - Marcel Kool
- Hopp Children's Cancer Center at the NCT Heidelberg (KiTZ), Heidelberg, Germany
- Division of Pediatric Neurooncology, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany
| | | | - David W Ellison
- Department of Pathology, St Jude Children's Research Hospital, Memphis, Tennessee, USA
| | - Martin Hasselblatt
- Institute of Neuropathology, University Hospital Münster, Münster, Germany
| | - Matija Snuderl
- Division of Neuropathology, Department of Pathology, NYU Langone Medical Center, New York, New York, USA
| | - Sebastian Brandner
- Division of Neuropathology, UCL Hospitals, Institute of Neurology, University College London, Queen Square, WC1N 3BG London, UK
- Department of Neurodegeneration, Institute of Neurology, University College London, Queen Square, WC1N 3BG London, UK
| | - Andrey Korshunov
- Department of Neuropathology, University Hospital Heidelberg, Heidelberg, Germany
- Clinical Cooperation Unit Neuropathology, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - Andreas von Deimling
- Department of Neuropathology, University Hospital Heidelberg, Heidelberg, Germany
- Clinical Cooperation Unit Neuropathology, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - Stefan M Pfister
- Hopp Children's Cancer Center at the NCT Heidelberg (KiTZ), Heidelberg, Germany
- Division of Pediatric Neurooncology, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany
- Department of Pediatric Oncology, Hematology and Immunology, University Hospital Heidelberg, Heidelberg, Germany
| |
Collapse
|
13
|
Bertrand A, Rondenet C, Masliah-Planchon J, Leblond P, de la Fourchardière A, Pissaloux D, Aït-Raïs K, Lequin D, Jouvet A, Freneaux P, Sevestre H, Ranchere-Vince D, Tauziede-Espariat A, Maurage CA, Silva K, Pierron G, Delattre O, Varlet P, Frappaz D, Bourdeaut F. Rhabdoid component emerging as a subclonal evolution of paediatric glioneuronal tumours. Neuropathol Appl Neurobiol 2018; 44:224-228. [DOI: 10.1111/nan.12379] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/31/2016] [Revised: 11/28/2016] [Accepted: 12/23/2016] [Indexed: 10/20/2022]
Affiliation(s)
- A. Bertrand
- Pediatric Oncology Unit; Centre Leon Berard; Lyon France
| | - C. Rondenet
- Department of Neuropathology; Sainte-Anne Hospital; Paris France
| | - J. Masliah-Planchon
- Institut Curie; Somatic Genetics Unit; Paris France
- Cancer Genetics and Biology Laboratory; Institut Curie; INSERM U830; Paris France
| | - P. Leblond
- Pediatric Oncology Unit; Centre Oscar Lambret; Lille France
| | | | - D. Pissaloux
- Biopathology Unit; Centre Leon Berard; Lyon France
| | - K. Aït-Raïs
- Institut Curie; Somatic Genetics Unit; Paris France
| | - D. Lequin
- Institut Curie; Somatic Genetics Unit; Paris France
| | - A. Jouvet
- Department of Neuropathology; Groupement Hospitalier Est; Bron France
| | - P. Freneaux
- Department of Pathology; Institut Curie; Paris France
| | - H. Sevestre
- Neuropathology; University Hospital; Amiens France
| | | | | | - C.-A. Maurage
- Department of Neuropathology; Lille University Hospital; Lille France
| | - K. Silva
- Department of Neuropathology; Groupement Hospitalier Est; Bron France
| | - G. Pierron
- Institut Curie; Somatic Genetics Unit; Paris France
| | - O. Delattre
- Cancer Genetics and Biology Laboratory; Institut Curie; INSERM U830; Paris France
| | - P. Varlet
- Department of Neuropathology; Sainte-Anne Hospital; Paris France
| | - D. Frappaz
- Pediatric Oncology Unit; Centre Leon Berard; Lyon France
| | - F. Bourdeaut
- Cancer Genetics and Biology Laboratory; Institut Curie; INSERM U830; Paris France
- Pediatric Oncology Translational Research Laboratory; SiRIC Institut Curie; Paris France
| |
Collapse
|
14
|
Delteil C, Meyronet D, Maues de Paula A, Jouvet A, Piercecchi-Marti MD. [Neuropathology of sudden infant death syndrome: Review of the literature and proposal of a protocol for neuropathological examination]. Ann Pathol 2018; 38:103-109. [PMID: 29429858 DOI: 10.1016/j.annpat.2018.01.001] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/03/2017] [Revised: 12/05/2017] [Accepted: 01/08/2018] [Indexed: 10/18/2022]
Abstract
According to the French High Authority for Health, sudden unexpected death in infants (SUDI) is defined as "a sudden death that occurs in an infant, whereas nothing in its known history could have predicted it". This is an exclusion diagnosis. There are great interregional disparities despite the professional recommendations established in February 2007. For the examination of the brain, instructions are not adapted to current and research practice. The role of the pathologist, like anyone involved in SUDI, is to eliminate an abuse head trauma and to determine the cause of death. Major neuropathological lesions by definition do not exist. Lesions of hypoxia/ischemia are the most frequent but not specific. The accessibility of anti-APP immunoblotting has highlighted the role of anoxia in the development of axonal diffuse damages. Many studies are looking for a neurological substratum of the SUDI (neuropathological and/or neurobiochinic). This article aims to define a detailed sampling protocol based on foreign consensus and current data of science in order to assist pathologists and to promote a homogeneous data bank in France.
Collapse
Affiliation(s)
- Clémence Delteil
- Institut médicolégal de Marseille, hôpital Timone adultes, 264, rue Saint-Pierre, 13385 Marseille cedex 5, France; CNRS, EFS, ADES UMR 7268, Aix-Marseille université, 13916 Marseille, France.
| | - David Meyronet
- Service de biopathologie, hôpital mère-enfant, Lyon Est-Bron, 32, avenue Doyen-Jean-Lépine, 69500 Bron, France
| | - Andre Maues de Paula
- Laboratoire d'anatomie pathologique-neuropathologique, hôpital de la Timone, 264, rue Saint-Pierre, 13385 Marseille cedex 5, France
| | - Anne Jouvet
- Service de biopathologie, hôpital mère-enfant, Lyon Est-Bron, 32, avenue Doyen-Jean-Lépine, 69500 Bron, France
| | - Marie-Dominique Piercecchi-Marti
- Institut médicolégal de Marseille, hôpital Timone adultes, 264, rue Saint-Pierre, 13385 Marseille cedex 5, France; CNRS, EFS, ADES UMR 7268, Aix-Marseille université, 13916 Marseille, France
| |
Collapse
|
15
|
Figarella-Branger D, Mokhtari K, Dehais C, Carpentier C, Colin C, Jouvet A, Uro-Coste E, Forest F, Maurage CA, Vignaud JM, Polivka M, Lechapt-Zalcman E, Eimer S, Viennet G, Quintin-Roué I, Aubriot-Lorton MH, Diebold MD, Loussouarn D, Lacroix C, Rigau V, Laquerrière A, Vandenbos F, Michalak S, Sevestre H, Peoch M, Labrousse F, Christov C, Kemeny JL, Chenard MP, Chiforeanu D, Ducray F, Idbaih A, Delattre JY. Mitotic index, microvascular proliferation, and necrosis define 3 pathological subgroups of prognostic relevance among 1p/19q co-deleted anaplastic oligodendrogliomas. Neuro Oncol 2018; 18:888-90. [PMID: 27175000 DOI: 10.1093/neuonc/now085] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/04/2016] [Accepted: 03/22/2016] [Indexed: 11/13/2022] Open
Affiliation(s)
- Dominique Figarella-Branger
- APHM, Hôpital de la Timone, Service d'Anatomie Pathologique et de Neuropathologie, Marseille, France (D.F.B.); Aix-Marseille Université, Inserm, CRO2 UMR_S 911, Marseille, France (D.F.B., C.C.); AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Service de Neuropathologie Raymond Escourolle, Paris, France (K.M.); Inserm U 1127, CNRS UMR 7225, Sorbonne Universités, UPMCUniv Paris 06 UMR S 1127, Institut du Cerveau et de la Moelle épinière, ICM, F-75013, Paris, France (K.M., C.D., C.C., A.I., J.-Y.D.); AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Service de Neurologie 2-Mazarin, F75013, Paris, France (K.M., C.D., C.C., A.I., J.-Y.D.); Centre de Pathologie et de Neuropathologie Est, Bron, France (A.J.); CHU Toulouse, Hôpital Rangueil, Service d'Anatomie Pathologique et Histologie-Cytologie, Toulouse, France (E.U.-C.); Inserm U1037, Centre de Recherche en Cancérologie de Toulouse, Université de Toulouse, France (E.U.-C.); CHU Saint-Etienne, Hôpital Nord, Service d'Anatomie et Cytologie Pathologiques, Saint-Etienne, France (F.F., M.P.); CHU Lille, Pôle Pathologie Biologique, Service Anatomie Pathologique, Lille, France (C.-A.M.); CHU Nancy, Hôpital Central, Laboratoire d'Anatomie Pathologique, Nancy, France (J.-M.V.); APHP, Hôpital Lariboisière, Service d'Anatomie et Cytologie Pathologique, Paris, France (M.P.); CHU Caen, Hôpital de la Côte de Nacre, Service d'anatomie Pathologique, Caen, France (E.L.-Z.); CNRS, UMR 6301 ISTCT, CERVOxy, GIP CYCERON, Caen, France (E.L.-Z.); CHU Bordeaux, Hôpital Pellegrin, Service de Pathologie - Neuropathologie, Bordeaux, France (S.E.); EA2406, Histologie et pathologie moléculaire des tumeurs, Université Bordeaux Segalen, Bordeaux, France (S.E.); CHU Besançon, Hôpital Jean Minjoz, Service Anatomie et Cytologie Pathologiques, Besançon, France (G.V.); CHU Brest, Hôpital de la Cavale Blanche, Service Anatomie Pathologique, Brest, France (I.Q.-R.); CHU Dijon, Plateau technique de biologie G. Mack
| | - Karima Mokhtari
- APHM, Hôpital de la Timone, Service d'Anatomie Pathologique et de Neuropathologie, Marseille, France (D.F.B.); Aix-Marseille Université, Inserm, CRO2 UMR_S 911, Marseille, France (D.F.B., C.C.); AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Service de Neuropathologie Raymond Escourolle, Paris, France (K.M.); Inserm U 1127, CNRS UMR 7225, Sorbonne Universités, UPMCUniv Paris 06 UMR S 1127, Institut du Cerveau et de la Moelle épinière, ICM, F-75013, Paris, France (K.M., C.D., C.C., A.I., J.-Y.D.); AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Service de Neurologie 2-Mazarin, F75013, Paris, France (K.M., C.D., C.C., A.I., J.-Y.D.); Centre de Pathologie et de Neuropathologie Est, Bron, France (A.J.); CHU Toulouse, Hôpital Rangueil, Service d'Anatomie Pathologique et Histologie-Cytologie, Toulouse, France (E.U.-C.); Inserm U1037, Centre de Recherche en Cancérologie de Toulouse, Université de Toulouse, France (E.U.-C.); CHU Saint-Etienne, Hôpital Nord, Service d'Anatomie et Cytologie Pathologiques, Saint-Etienne, France (F.F., M.P.); CHU Lille, Pôle Pathologie Biologique, Service Anatomie Pathologique, Lille, France (C.-A.M.); CHU Nancy, Hôpital Central, Laboratoire d'Anatomie Pathologique, Nancy, France (J.-M.V.); APHP, Hôpital Lariboisière, Service d'Anatomie et Cytologie Pathologique, Paris, France (M.P.); CHU Caen, Hôpital de la Côte de Nacre, Service d'anatomie Pathologique, Caen, France (E.L.-Z.); CNRS, UMR 6301 ISTCT, CERVOxy, GIP CYCERON, Caen, France (E.L.-Z.); CHU Bordeaux, Hôpital Pellegrin, Service de Pathologie - Neuropathologie, Bordeaux, France (S.E.); EA2406, Histologie et pathologie moléculaire des tumeurs, Université Bordeaux Segalen, Bordeaux, France (S.E.); CHU Besançon, Hôpital Jean Minjoz, Service Anatomie et Cytologie Pathologiques, Besançon, France (G.V.); CHU Brest, Hôpital de la Cavale Blanche, Service Anatomie Pathologique, Brest, France (I.Q.-R.); CHU Dijon, Plateau technique de biologie G. Mack
| | - Caroline Dehais
- APHM, Hôpital de la Timone, Service d'Anatomie Pathologique et de Neuropathologie, Marseille, France (D.F.B.); Aix-Marseille Université, Inserm, CRO2 UMR_S 911, Marseille, France (D.F.B., C.C.); AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Service de Neuropathologie Raymond Escourolle, Paris, France (K.M.); Inserm U 1127, CNRS UMR 7225, Sorbonne Universités, UPMCUniv Paris 06 UMR S 1127, Institut du Cerveau et de la Moelle épinière, ICM, F-75013, Paris, France (K.M., C.D., C.C., A.I., J.-Y.D.); AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Service de Neurologie 2-Mazarin, F75013, Paris, France (K.M., C.D., C.C., A.I., J.-Y.D.); Centre de Pathologie et de Neuropathologie Est, Bron, France (A.J.); CHU Toulouse, Hôpital Rangueil, Service d'Anatomie Pathologique et Histologie-Cytologie, Toulouse, France (E.U.-C.); Inserm U1037, Centre de Recherche en Cancérologie de Toulouse, Université de Toulouse, France (E.U.-C.); CHU Saint-Etienne, Hôpital Nord, Service d'Anatomie et Cytologie Pathologiques, Saint-Etienne, France (F.F., M.P.); CHU Lille, Pôle Pathologie Biologique, Service Anatomie Pathologique, Lille, France (C.-A.M.); CHU Nancy, Hôpital Central, Laboratoire d'Anatomie Pathologique, Nancy, France (J.-M.V.); APHP, Hôpital Lariboisière, Service d'Anatomie et Cytologie Pathologique, Paris, France (M.P.); CHU Caen, Hôpital de la Côte de Nacre, Service d'anatomie Pathologique, Caen, France (E.L.-Z.); CNRS, UMR 6301 ISTCT, CERVOxy, GIP CYCERON, Caen, France (E.L.-Z.); CHU Bordeaux, Hôpital Pellegrin, Service de Pathologie - Neuropathologie, Bordeaux, France (S.E.); EA2406, Histologie et pathologie moléculaire des tumeurs, Université Bordeaux Segalen, Bordeaux, France (S.E.); CHU Besançon, Hôpital Jean Minjoz, Service Anatomie et Cytologie Pathologiques, Besançon, France (G.V.); CHU Brest, Hôpital de la Cavale Blanche, Service Anatomie Pathologique, Brest, France (I.Q.-R.); CHU Dijon, Plateau technique de biologie G. Mack
| | - Catherine Carpentier
- APHM, Hôpital de la Timone, Service d'Anatomie Pathologique et de Neuropathologie, Marseille, France (D.F.B.); Aix-Marseille Université, Inserm, CRO2 UMR_S 911, Marseille, France (D.F.B., C.C.); AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Service de Neuropathologie Raymond Escourolle, Paris, France (K.M.); Inserm U 1127, CNRS UMR 7225, Sorbonne Universités, UPMCUniv Paris 06 UMR S 1127, Institut du Cerveau et de la Moelle épinière, ICM, F-75013, Paris, France (K.M., C.D., C.C., A.I., J.-Y.D.); AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Service de Neurologie 2-Mazarin, F75013, Paris, France (K.M., C.D., C.C., A.I., J.-Y.D.); Centre de Pathologie et de Neuropathologie Est, Bron, France (A.J.); CHU Toulouse, Hôpital Rangueil, Service d'Anatomie Pathologique et Histologie-Cytologie, Toulouse, France (E.U.-C.); Inserm U1037, Centre de Recherche en Cancérologie de Toulouse, Université de Toulouse, France (E.U.-C.); CHU Saint-Etienne, Hôpital Nord, Service d'Anatomie et Cytologie Pathologiques, Saint-Etienne, France (F.F., M.P.); CHU Lille, Pôle Pathologie Biologique, Service Anatomie Pathologique, Lille, France (C.-A.M.); CHU Nancy, Hôpital Central, Laboratoire d'Anatomie Pathologique, Nancy, France (J.-M.V.); APHP, Hôpital Lariboisière, Service d'Anatomie et Cytologie Pathologique, Paris, France (M.P.); CHU Caen, Hôpital de la Côte de Nacre, Service d'anatomie Pathologique, Caen, France (E.L.-Z.); CNRS, UMR 6301 ISTCT, CERVOxy, GIP CYCERON, Caen, France (E.L.-Z.); CHU Bordeaux, Hôpital Pellegrin, Service de Pathologie - Neuropathologie, Bordeaux, France (S.E.); EA2406, Histologie et pathologie moléculaire des tumeurs, Université Bordeaux Segalen, Bordeaux, France (S.E.); CHU Besançon, Hôpital Jean Minjoz, Service Anatomie et Cytologie Pathologiques, Besançon, France (G.V.); CHU Brest, Hôpital de la Cavale Blanche, Service Anatomie Pathologique, Brest, France (I.Q.-R.); CHU Dijon, Plateau technique de biologie G. Mack
| | - Carole Colin
- APHM, Hôpital de la Timone, Service d'Anatomie Pathologique et de Neuropathologie, Marseille, France (D.F.B.); Aix-Marseille Université, Inserm, CRO2 UMR_S 911, Marseille, France (D.F.B., C.C.); AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Service de Neuropathologie Raymond Escourolle, Paris, France (K.M.); Inserm U 1127, CNRS UMR 7225, Sorbonne Universités, UPMCUniv Paris 06 UMR S 1127, Institut du Cerveau et de la Moelle épinière, ICM, F-75013, Paris, France (K.M., C.D., C.C., A.I., J.-Y.D.); AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Service de Neurologie 2-Mazarin, F75013, Paris, France (K.M., C.D., C.C., A.I., J.-Y.D.); Centre de Pathologie et de Neuropathologie Est, Bron, France (A.J.); CHU Toulouse, Hôpital Rangueil, Service d'Anatomie Pathologique et Histologie-Cytologie, Toulouse, France (E.U.-C.); Inserm U1037, Centre de Recherche en Cancérologie de Toulouse, Université de Toulouse, France (E.U.-C.); CHU Saint-Etienne, Hôpital Nord, Service d'Anatomie et Cytologie Pathologiques, Saint-Etienne, France (F.F., M.P.); CHU Lille, Pôle Pathologie Biologique, Service Anatomie Pathologique, Lille, France (C.-A.M.); CHU Nancy, Hôpital Central, Laboratoire d'Anatomie Pathologique, Nancy, France (J.-M.V.); APHP, Hôpital Lariboisière, Service d'Anatomie et Cytologie Pathologique, Paris, France (M.P.); CHU Caen, Hôpital de la Côte de Nacre, Service d'anatomie Pathologique, Caen, France (E.L.-Z.); CNRS, UMR 6301 ISTCT, CERVOxy, GIP CYCERON, Caen, France (E.L.-Z.); CHU Bordeaux, Hôpital Pellegrin, Service de Pathologie - Neuropathologie, Bordeaux, France (S.E.); EA2406, Histologie et pathologie moléculaire des tumeurs, Université Bordeaux Segalen, Bordeaux, France (S.E.); CHU Besançon, Hôpital Jean Minjoz, Service Anatomie et Cytologie Pathologiques, Besançon, France (G.V.); CHU Brest, Hôpital de la Cavale Blanche, Service Anatomie Pathologique, Brest, France (I.Q.-R.); CHU Dijon, Plateau technique de biologie G. Mack
| | - Anne Jouvet
- APHM, Hôpital de la Timone, Service d'Anatomie Pathologique et de Neuropathologie, Marseille, France (D.F.B.); Aix-Marseille Université, Inserm, CRO2 UMR_S 911, Marseille, France (D.F.B., C.C.); AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Service de Neuropathologie Raymond Escourolle, Paris, France (K.M.); Inserm U 1127, CNRS UMR 7225, Sorbonne Universités, UPMCUniv Paris 06 UMR S 1127, Institut du Cerveau et de la Moelle épinière, ICM, F-75013, Paris, France (K.M., C.D., C.C., A.I., J.-Y.D.); AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Service de Neurologie 2-Mazarin, F75013, Paris, France (K.M., C.D., C.C., A.I., J.-Y.D.); Centre de Pathologie et de Neuropathologie Est, Bron, France (A.J.); CHU Toulouse, Hôpital Rangueil, Service d'Anatomie Pathologique et Histologie-Cytologie, Toulouse, France (E.U.-C.); Inserm U1037, Centre de Recherche en Cancérologie de Toulouse, Université de Toulouse, France (E.U.-C.); CHU Saint-Etienne, Hôpital Nord, Service d'Anatomie et Cytologie Pathologiques, Saint-Etienne, France (F.F., M.P.); CHU Lille, Pôle Pathologie Biologique, Service Anatomie Pathologique, Lille, France (C.-A.M.); CHU Nancy, Hôpital Central, Laboratoire d'Anatomie Pathologique, Nancy, France (J.-M.V.); APHP, Hôpital Lariboisière, Service d'Anatomie et Cytologie Pathologique, Paris, France (M.P.); CHU Caen, Hôpital de la Côte de Nacre, Service d'anatomie Pathologique, Caen, France (E.L.-Z.); CNRS, UMR 6301 ISTCT, CERVOxy, GIP CYCERON, Caen, France (E.L.-Z.); CHU Bordeaux, Hôpital Pellegrin, Service de Pathologie - Neuropathologie, Bordeaux, France (S.E.); EA2406, Histologie et pathologie moléculaire des tumeurs, Université Bordeaux Segalen, Bordeaux, France (S.E.); CHU Besançon, Hôpital Jean Minjoz, Service Anatomie et Cytologie Pathologiques, Besançon, France (G.V.); CHU Brest, Hôpital de la Cavale Blanche, Service Anatomie Pathologique, Brest, France (I.Q.-R.); CHU Dijon, Plateau technique de biologie G. Mack
| | - Emmanuelle Uro-Coste
- APHM, Hôpital de la Timone, Service d'Anatomie Pathologique et de Neuropathologie, Marseille, France (D.F.B.); Aix-Marseille Université, Inserm, CRO2 UMR_S 911, Marseille, France (D.F.B., C.C.); AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Service de Neuropathologie Raymond Escourolle, Paris, France (K.M.); Inserm U 1127, CNRS UMR 7225, Sorbonne Universités, UPMCUniv Paris 06 UMR S 1127, Institut du Cerveau et de la Moelle épinière, ICM, F-75013, Paris, France (K.M., C.D., C.C., A.I., J.-Y.D.); AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Service de Neurologie 2-Mazarin, F75013, Paris, France (K.M., C.D., C.C., A.I., J.-Y.D.); Centre de Pathologie et de Neuropathologie Est, Bron, France (A.J.); CHU Toulouse, Hôpital Rangueil, Service d'Anatomie Pathologique et Histologie-Cytologie, Toulouse, France (E.U.-C.); Inserm U1037, Centre de Recherche en Cancérologie de Toulouse, Université de Toulouse, France (E.U.-C.); CHU Saint-Etienne, Hôpital Nord, Service d'Anatomie et Cytologie Pathologiques, Saint-Etienne, France (F.F., M.P.); CHU Lille, Pôle Pathologie Biologique, Service Anatomie Pathologique, Lille, France (C.-A.M.); CHU Nancy, Hôpital Central, Laboratoire d'Anatomie Pathologique, Nancy, France (J.-M.V.); APHP, Hôpital Lariboisière, Service d'Anatomie et Cytologie Pathologique, Paris, France (M.P.); CHU Caen, Hôpital de la Côte de Nacre, Service d'anatomie Pathologique, Caen, France (E.L.-Z.); CNRS, UMR 6301 ISTCT, CERVOxy, GIP CYCERON, Caen, France (E.L.-Z.); CHU Bordeaux, Hôpital Pellegrin, Service de Pathologie - Neuropathologie, Bordeaux, France (S.E.); EA2406, Histologie et pathologie moléculaire des tumeurs, Université Bordeaux Segalen, Bordeaux, France (S.E.); CHU Besançon, Hôpital Jean Minjoz, Service Anatomie et Cytologie Pathologiques, Besançon, France (G.V.); CHU Brest, Hôpital de la Cavale Blanche, Service Anatomie Pathologique, Brest, France (I.Q.-R.); CHU Dijon, Plateau technique de biologie G. Mack
| | - Fabien Forest
- APHM, Hôpital de la Timone, Service d'Anatomie Pathologique et de Neuropathologie, Marseille, France (D.F.B.); Aix-Marseille Université, Inserm, CRO2 UMR_S 911, Marseille, France (D.F.B., C.C.); AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Service de Neuropathologie Raymond Escourolle, Paris, France (K.M.); Inserm U 1127, CNRS UMR 7225, Sorbonne Universités, UPMCUniv Paris 06 UMR S 1127, Institut du Cerveau et de la Moelle épinière, ICM, F-75013, Paris, France (K.M., C.D., C.C., A.I., J.-Y.D.); AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Service de Neurologie 2-Mazarin, F75013, Paris, France (K.M., C.D., C.C., A.I., J.-Y.D.); Centre de Pathologie et de Neuropathologie Est, Bron, France (A.J.); CHU Toulouse, Hôpital Rangueil, Service d'Anatomie Pathologique et Histologie-Cytologie, Toulouse, France (E.U.-C.); Inserm U1037, Centre de Recherche en Cancérologie de Toulouse, Université de Toulouse, France (E.U.-C.); CHU Saint-Etienne, Hôpital Nord, Service d'Anatomie et Cytologie Pathologiques, Saint-Etienne, France (F.F., M.P.); CHU Lille, Pôle Pathologie Biologique, Service Anatomie Pathologique, Lille, France (C.-A.M.); CHU Nancy, Hôpital Central, Laboratoire d'Anatomie Pathologique, Nancy, France (J.-M.V.); APHP, Hôpital Lariboisière, Service d'Anatomie et Cytologie Pathologique, Paris, France (M.P.); CHU Caen, Hôpital de la Côte de Nacre, Service d'anatomie Pathologique, Caen, France (E.L.-Z.); CNRS, UMR 6301 ISTCT, CERVOxy, GIP CYCERON, Caen, France (E.L.-Z.); CHU Bordeaux, Hôpital Pellegrin, Service de Pathologie - Neuropathologie, Bordeaux, France (S.E.); EA2406, Histologie et pathologie moléculaire des tumeurs, Université Bordeaux Segalen, Bordeaux, France (S.E.); CHU Besançon, Hôpital Jean Minjoz, Service Anatomie et Cytologie Pathologiques, Besançon, France (G.V.); CHU Brest, Hôpital de la Cavale Blanche, Service Anatomie Pathologique, Brest, France (I.Q.-R.); CHU Dijon, Plateau technique de biologie G. Mack
| | - Claude-Alain Maurage
- APHM, Hôpital de la Timone, Service d'Anatomie Pathologique et de Neuropathologie, Marseille, France (D.F.B.); Aix-Marseille Université, Inserm, CRO2 UMR_S 911, Marseille, France (D.F.B., C.C.); AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Service de Neuropathologie Raymond Escourolle, Paris, France (K.M.); Inserm U 1127, CNRS UMR 7225, Sorbonne Universités, UPMCUniv Paris 06 UMR S 1127, Institut du Cerveau et de la Moelle épinière, ICM, F-75013, Paris, France (K.M., C.D., C.C., A.I., J.-Y.D.); AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Service de Neurologie 2-Mazarin, F75013, Paris, France (K.M., C.D., C.C., A.I., J.-Y.D.); Centre de Pathologie et de Neuropathologie Est, Bron, France (A.J.); CHU Toulouse, Hôpital Rangueil, Service d'Anatomie Pathologique et Histologie-Cytologie, Toulouse, France (E.U.-C.); Inserm U1037, Centre de Recherche en Cancérologie de Toulouse, Université de Toulouse, France (E.U.-C.); CHU Saint-Etienne, Hôpital Nord, Service d'Anatomie et Cytologie Pathologiques, Saint-Etienne, France (F.F., M.P.); CHU Lille, Pôle Pathologie Biologique, Service Anatomie Pathologique, Lille, France (C.-A.M.); CHU Nancy, Hôpital Central, Laboratoire d'Anatomie Pathologique, Nancy, France (J.-M.V.); APHP, Hôpital Lariboisière, Service d'Anatomie et Cytologie Pathologique, Paris, France (M.P.); CHU Caen, Hôpital de la Côte de Nacre, Service d'anatomie Pathologique, Caen, France (E.L.-Z.); CNRS, UMR 6301 ISTCT, CERVOxy, GIP CYCERON, Caen, France (E.L.-Z.); CHU Bordeaux, Hôpital Pellegrin, Service de Pathologie - Neuropathologie, Bordeaux, France (S.E.); EA2406, Histologie et pathologie moléculaire des tumeurs, Université Bordeaux Segalen, Bordeaux, France (S.E.); CHU Besançon, Hôpital Jean Minjoz, Service Anatomie et Cytologie Pathologiques, Besançon, France (G.V.); CHU Brest, Hôpital de la Cavale Blanche, Service Anatomie Pathologique, Brest, France (I.Q.-R.); CHU Dijon, Plateau technique de biologie G. Mack
| | - Jean-Michel Vignaud
- APHM, Hôpital de la Timone, Service d'Anatomie Pathologique et de Neuropathologie, Marseille, France (D.F.B.); Aix-Marseille Université, Inserm, CRO2 UMR_S 911, Marseille, France (D.F.B., C.C.); AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Service de Neuropathologie Raymond Escourolle, Paris, France (K.M.); Inserm U 1127, CNRS UMR 7225, Sorbonne Universités, UPMCUniv Paris 06 UMR S 1127, Institut du Cerveau et de la Moelle épinière, ICM, F-75013, Paris, France (K.M., C.D., C.C., A.I., J.-Y.D.); AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Service de Neurologie 2-Mazarin, F75013, Paris, France (K.M., C.D., C.C., A.I., J.-Y.D.); Centre de Pathologie et de Neuropathologie Est, Bron, France (A.J.); CHU Toulouse, Hôpital Rangueil, Service d'Anatomie Pathologique et Histologie-Cytologie, Toulouse, France (E.U.-C.); Inserm U1037, Centre de Recherche en Cancérologie de Toulouse, Université de Toulouse, France (E.U.-C.); CHU Saint-Etienne, Hôpital Nord, Service d'Anatomie et Cytologie Pathologiques, Saint-Etienne, France (F.F., M.P.); CHU Lille, Pôle Pathologie Biologique, Service Anatomie Pathologique, Lille, France (C.-A.M.); CHU Nancy, Hôpital Central, Laboratoire d'Anatomie Pathologique, Nancy, France (J.-M.V.); APHP, Hôpital Lariboisière, Service d'Anatomie et Cytologie Pathologique, Paris, France (M.P.); CHU Caen, Hôpital de la Côte de Nacre, Service d'anatomie Pathologique, Caen, France (E.L.-Z.); CNRS, UMR 6301 ISTCT, CERVOxy, GIP CYCERON, Caen, France (E.L.-Z.); CHU Bordeaux, Hôpital Pellegrin, Service de Pathologie - Neuropathologie, Bordeaux, France (S.E.); EA2406, Histologie et pathologie moléculaire des tumeurs, Université Bordeaux Segalen, Bordeaux, France (S.E.); CHU Besançon, Hôpital Jean Minjoz, Service Anatomie et Cytologie Pathologiques, Besançon, France (G.V.); CHU Brest, Hôpital de la Cavale Blanche, Service Anatomie Pathologique, Brest, France (I.Q.-R.); CHU Dijon, Plateau technique de biologie G. Mack
| | - Marc Polivka
- APHM, Hôpital de la Timone, Service d'Anatomie Pathologique et de Neuropathologie, Marseille, France (D.F.B.); Aix-Marseille Université, Inserm, CRO2 UMR_S 911, Marseille, France (D.F.B., C.C.); AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Service de Neuropathologie Raymond Escourolle, Paris, France (K.M.); Inserm U 1127, CNRS UMR 7225, Sorbonne Universités, UPMCUniv Paris 06 UMR S 1127, Institut du Cerveau et de la Moelle épinière, ICM, F-75013, Paris, France (K.M., C.D., C.C., A.I., J.-Y.D.); AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Service de Neurologie 2-Mazarin, F75013, Paris, France (K.M., C.D., C.C., A.I., J.-Y.D.); Centre de Pathologie et de Neuropathologie Est, Bron, France (A.J.); CHU Toulouse, Hôpital Rangueil, Service d'Anatomie Pathologique et Histologie-Cytologie, Toulouse, France (E.U.-C.); Inserm U1037, Centre de Recherche en Cancérologie de Toulouse, Université de Toulouse, France (E.U.-C.); CHU Saint-Etienne, Hôpital Nord, Service d'Anatomie et Cytologie Pathologiques, Saint-Etienne, France (F.F., M.P.); CHU Lille, Pôle Pathologie Biologique, Service Anatomie Pathologique, Lille, France (C.-A.M.); CHU Nancy, Hôpital Central, Laboratoire d'Anatomie Pathologique, Nancy, France (J.-M.V.); APHP, Hôpital Lariboisière, Service d'Anatomie et Cytologie Pathologique, Paris, France (M.P.); CHU Caen, Hôpital de la Côte de Nacre, Service d'anatomie Pathologique, Caen, France (E.L.-Z.); CNRS, UMR 6301 ISTCT, CERVOxy, GIP CYCERON, Caen, France (E.L.-Z.); CHU Bordeaux, Hôpital Pellegrin, Service de Pathologie - Neuropathologie, Bordeaux, France (S.E.); EA2406, Histologie et pathologie moléculaire des tumeurs, Université Bordeaux Segalen, Bordeaux, France (S.E.); CHU Besançon, Hôpital Jean Minjoz, Service Anatomie et Cytologie Pathologiques, Besançon, France (G.V.); CHU Brest, Hôpital de la Cavale Blanche, Service Anatomie Pathologique, Brest, France (I.Q.-R.); CHU Dijon, Plateau technique de biologie G. Mack
| | - Emmanuèle Lechapt-Zalcman
- APHM, Hôpital de la Timone, Service d'Anatomie Pathologique et de Neuropathologie, Marseille, France (D.F.B.); Aix-Marseille Université, Inserm, CRO2 UMR_S 911, Marseille, France (D.F.B., C.C.); AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Service de Neuropathologie Raymond Escourolle, Paris, France (K.M.); Inserm U 1127, CNRS UMR 7225, Sorbonne Universités, UPMCUniv Paris 06 UMR S 1127, Institut du Cerveau et de la Moelle épinière, ICM, F-75013, Paris, France (K.M., C.D., C.C., A.I., J.-Y.D.); AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Service de Neurologie 2-Mazarin, F75013, Paris, France (K.M., C.D., C.C., A.I., J.-Y.D.); Centre de Pathologie et de Neuropathologie Est, Bron, France (A.J.); CHU Toulouse, Hôpital Rangueil, Service d'Anatomie Pathologique et Histologie-Cytologie, Toulouse, France (E.U.-C.); Inserm U1037, Centre de Recherche en Cancérologie de Toulouse, Université de Toulouse, France (E.U.-C.); CHU Saint-Etienne, Hôpital Nord, Service d'Anatomie et Cytologie Pathologiques, Saint-Etienne, France (F.F., M.P.); CHU Lille, Pôle Pathologie Biologique, Service Anatomie Pathologique, Lille, France (C.-A.M.); CHU Nancy, Hôpital Central, Laboratoire d'Anatomie Pathologique, Nancy, France (J.-M.V.); APHP, Hôpital Lariboisière, Service d'Anatomie et Cytologie Pathologique, Paris, France (M.P.); CHU Caen, Hôpital de la Côte de Nacre, Service d'anatomie Pathologique, Caen, France (E.L.-Z.); CNRS, UMR 6301 ISTCT, CERVOxy, GIP CYCERON, Caen, France (E.L.-Z.); CHU Bordeaux, Hôpital Pellegrin, Service de Pathologie - Neuropathologie, Bordeaux, France (S.E.); EA2406, Histologie et pathologie moléculaire des tumeurs, Université Bordeaux Segalen, Bordeaux, France (S.E.); CHU Besançon, Hôpital Jean Minjoz, Service Anatomie et Cytologie Pathologiques, Besançon, France (G.V.); CHU Brest, Hôpital de la Cavale Blanche, Service Anatomie Pathologique, Brest, France (I.Q.-R.); CHU Dijon, Plateau technique de biologie G. Mack
| | - Sandrine Eimer
- APHM, Hôpital de la Timone, Service d'Anatomie Pathologique et de Neuropathologie, Marseille, France (D.F.B.); Aix-Marseille Université, Inserm, CRO2 UMR_S 911, Marseille, France (D.F.B., C.C.); AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Service de Neuropathologie Raymond Escourolle, Paris, France (K.M.); Inserm U 1127, CNRS UMR 7225, Sorbonne Universités, UPMCUniv Paris 06 UMR S 1127, Institut du Cerveau et de la Moelle épinière, ICM, F-75013, Paris, France (K.M., C.D., C.C., A.I., J.-Y.D.); AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Service de Neurologie 2-Mazarin, F75013, Paris, France (K.M., C.D., C.C., A.I., J.-Y.D.); Centre de Pathologie et de Neuropathologie Est, Bron, France (A.J.); CHU Toulouse, Hôpital Rangueil, Service d'Anatomie Pathologique et Histologie-Cytologie, Toulouse, France (E.U.-C.); Inserm U1037, Centre de Recherche en Cancérologie de Toulouse, Université de Toulouse, France (E.U.-C.); CHU Saint-Etienne, Hôpital Nord, Service d'Anatomie et Cytologie Pathologiques, Saint-Etienne, France (F.F., M.P.); CHU Lille, Pôle Pathologie Biologique, Service Anatomie Pathologique, Lille, France (C.-A.M.); CHU Nancy, Hôpital Central, Laboratoire d'Anatomie Pathologique, Nancy, France (J.-M.V.); APHP, Hôpital Lariboisière, Service d'Anatomie et Cytologie Pathologique, Paris, France (M.P.); CHU Caen, Hôpital de la Côte de Nacre, Service d'anatomie Pathologique, Caen, France (E.L.-Z.); CNRS, UMR 6301 ISTCT, CERVOxy, GIP CYCERON, Caen, France (E.L.-Z.); CHU Bordeaux, Hôpital Pellegrin, Service de Pathologie - Neuropathologie, Bordeaux, France (S.E.); EA2406, Histologie et pathologie moléculaire des tumeurs, Université Bordeaux Segalen, Bordeaux, France (S.E.); CHU Besançon, Hôpital Jean Minjoz, Service Anatomie et Cytologie Pathologiques, Besançon, France (G.V.); CHU Brest, Hôpital de la Cavale Blanche, Service Anatomie Pathologique, Brest, France (I.Q.-R.); CHU Dijon, Plateau technique de biologie G. Mack
| | - Gabriel Viennet
- APHM, Hôpital de la Timone, Service d'Anatomie Pathologique et de Neuropathologie, Marseille, France (D.F.B.); Aix-Marseille Université, Inserm, CRO2 UMR_S 911, Marseille, France (D.F.B., C.C.); AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Service de Neuropathologie Raymond Escourolle, Paris, France (K.M.); Inserm U 1127, CNRS UMR 7225, Sorbonne Universités, UPMCUniv Paris 06 UMR S 1127, Institut du Cerveau et de la Moelle épinière, ICM, F-75013, Paris, France (K.M., C.D., C.C., A.I., J.-Y.D.); AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Service de Neurologie 2-Mazarin, F75013, Paris, France (K.M., C.D., C.C., A.I., J.-Y.D.); Centre de Pathologie et de Neuropathologie Est, Bron, France (A.J.); CHU Toulouse, Hôpital Rangueil, Service d'Anatomie Pathologique et Histologie-Cytologie, Toulouse, France (E.U.-C.); Inserm U1037, Centre de Recherche en Cancérologie de Toulouse, Université de Toulouse, France (E.U.-C.); CHU Saint-Etienne, Hôpital Nord, Service d'Anatomie et Cytologie Pathologiques, Saint-Etienne, France (F.F., M.P.); CHU Lille, Pôle Pathologie Biologique, Service Anatomie Pathologique, Lille, France (C.-A.M.); CHU Nancy, Hôpital Central, Laboratoire d'Anatomie Pathologique, Nancy, France (J.-M.V.); APHP, Hôpital Lariboisière, Service d'Anatomie et Cytologie Pathologique, Paris, France (M.P.); CHU Caen, Hôpital de la Côte de Nacre, Service d'anatomie Pathologique, Caen, France (E.L.-Z.); CNRS, UMR 6301 ISTCT, CERVOxy, GIP CYCERON, Caen, France (E.L.-Z.); CHU Bordeaux, Hôpital Pellegrin, Service de Pathologie - Neuropathologie, Bordeaux, France (S.E.); EA2406, Histologie et pathologie moléculaire des tumeurs, Université Bordeaux Segalen, Bordeaux, France (S.E.); CHU Besançon, Hôpital Jean Minjoz, Service Anatomie et Cytologie Pathologiques, Besançon, France (G.V.); CHU Brest, Hôpital de la Cavale Blanche, Service Anatomie Pathologique, Brest, France (I.Q.-R.); CHU Dijon, Plateau technique de biologie G. Mack
| | - Isabelle Quintin-Roué
- APHM, Hôpital de la Timone, Service d'Anatomie Pathologique et de Neuropathologie, Marseille, France (D.F.B.); Aix-Marseille Université, Inserm, CRO2 UMR_S 911, Marseille, France (D.F.B., C.C.); AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Service de Neuropathologie Raymond Escourolle, Paris, France (K.M.); Inserm U 1127, CNRS UMR 7225, Sorbonne Universités, UPMCUniv Paris 06 UMR S 1127, Institut du Cerveau et de la Moelle épinière, ICM, F-75013, Paris, France (K.M., C.D., C.C., A.I., J.-Y.D.); AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Service de Neurologie 2-Mazarin, F75013, Paris, France (K.M., C.D., C.C., A.I., J.-Y.D.); Centre de Pathologie et de Neuropathologie Est, Bron, France (A.J.); CHU Toulouse, Hôpital Rangueil, Service d'Anatomie Pathologique et Histologie-Cytologie, Toulouse, France (E.U.-C.); Inserm U1037, Centre de Recherche en Cancérologie de Toulouse, Université de Toulouse, France (E.U.-C.); CHU Saint-Etienne, Hôpital Nord, Service d'Anatomie et Cytologie Pathologiques, Saint-Etienne, France (F.F., M.P.); CHU Lille, Pôle Pathologie Biologique, Service Anatomie Pathologique, Lille, France (C.-A.M.); CHU Nancy, Hôpital Central, Laboratoire d'Anatomie Pathologique, Nancy, France (J.-M.V.); APHP, Hôpital Lariboisière, Service d'Anatomie et Cytologie Pathologique, Paris, France (M.P.); CHU Caen, Hôpital de la Côte de Nacre, Service d'anatomie Pathologique, Caen, France (E.L.-Z.); CNRS, UMR 6301 ISTCT, CERVOxy, GIP CYCERON, Caen, France (E.L.-Z.); CHU Bordeaux, Hôpital Pellegrin, Service de Pathologie - Neuropathologie, Bordeaux, France (S.E.); EA2406, Histologie et pathologie moléculaire des tumeurs, Université Bordeaux Segalen, Bordeaux, France (S.E.); CHU Besançon, Hôpital Jean Minjoz, Service Anatomie et Cytologie Pathologiques, Besançon, France (G.V.); CHU Brest, Hôpital de la Cavale Blanche, Service Anatomie Pathologique, Brest, France (I.Q.-R.); CHU Dijon, Plateau technique de biologie G. Mack
| | - Marie-Hélène Aubriot-Lorton
- APHM, Hôpital de la Timone, Service d'Anatomie Pathologique et de Neuropathologie, Marseille, France (D.F.B.); Aix-Marseille Université, Inserm, CRO2 UMR_S 911, Marseille, France (D.F.B., C.C.); AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Service de Neuropathologie Raymond Escourolle, Paris, France (K.M.); Inserm U 1127, CNRS UMR 7225, Sorbonne Universités, UPMCUniv Paris 06 UMR S 1127, Institut du Cerveau et de la Moelle épinière, ICM, F-75013, Paris, France (K.M., C.D., C.C., A.I., J.-Y.D.); AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Service de Neurologie 2-Mazarin, F75013, Paris, France (K.M., C.D., C.C., A.I., J.-Y.D.); Centre de Pathologie et de Neuropathologie Est, Bron, France (A.J.); CHU Toulouse, Hôpital Rangueil, Service d'Anatomie Pathologique et Histologie-Cytologie, Toulouse, France (E.U.-C.); Inserm U1037, Centre de Recherche en Cancérologie de Toulouse, Université de Toulouse, France (E.U.-C.); CHU Saint-Etienne, Hôpital Nord, Service d'Anatomie et Cytologie Pathologiques, Saint-Etienne, France (F.F., M.P.); CHU Lille, Pôle Pathologie Biologique, Service Anatomie Pathologique, Lille, France (C.-A.M.); CHU Nancy, Hôpital Central, Laboratoire d'Anatomie Pathologique, Nancy, France (J.-M.V.); APHP, Hôpital Lariboisière, Service d'Anatomie et Cytologie Pathologique, Paris, France (M.P.); CHU Caen, Hôpital de la Côte de Nacre, Service d'anatomie Pathologique, Caen, France (E.L.-Z.); CNRS, UMR 6301 ISTCT, CERVOxy, GIP CYCERON, Caen, France (E.L.-Z.); CHU Bordeaux, Hôpital Pellegrin, Service de Pathologie - Neuropathologie, Bordeaux, France (S.E.); EA2406, Histologie et pathologie moléculaire des tumeurs, Université Bordeaux Segalen, Bordeaux, France (S.E.); CHU Besançon, Hôpital Jean Minjoz, Service Anatomie et Cytologie Pathologiques, Besançon, France (G.V.); CHU Brest, Hôpital de la Cavale Blanche, Service Anatomie Pathologique, Brest, France (I.Q.-R.); CHU Dijon, Plateau technique de biologie G. Mack
| | - Marie-Danièle Diebold
- APHM, Hôpital de la Timone, Service d'Anatomie Pathologique et de Neuropathologie, Marseille, France (D.F.B.); Aix-Marseille Université, Inserm, CRO2 UMR_S 911, Marseille, France (D.F.B., C.C.); AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Service de Neuropathologie Raymond Escourolle, Paris, France (K.M.); Inserm U 1127, CNRS UMR 7225, Sorbonne Universités, UPMCUniv Paris 06 UMR S 1127, Institut du Cerveau et de la Moelle épinière, ICM, F-75013, Paris, France (K.M., C.D., C.C., A.I., J.-Y.D.); AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Service de Neurologie 2-Mazarin, F75013, Paris, France (K.M., C.D., C.C., A.I., J.-Y.D.); Centre de Pathologie et de Neuropathologie Est, Bron, France (A.J.); CHU Toulouse, Hôpital Rangueil, Service d'Anatomie Pathologique et Histologie-Cytologie, Toulouse, France (E.U.-C.); Inserm U1037, Centre de Recherche en Cancérologie de Toulouse, Université de Toulouse, France (E.U.-C.); CHU Saint-Etienne, Hôpital Nord, Service d'Anatomie et Cytologie Pathologiques, Saint-Etienne, France (F.F., M.P.); CHU Lille, Pôle Pathologie Biologique, Service Anatomie Pathologique, Lille, France (C.-A.M.); CHU Nancy, Hôpital Central, Laboratoire d'Anatomie Pathologique, Nancy, France (J.-M.V.); APHP, Hôpital Lariboisière, Service d'Anatomie et Cytologie Pathologique, Paris, France (M.P.); CHU Caen, Hôpital de la Côte de Nacre, Service d'anatomie Pathologique, Caen, France (E.L.-Z.); CNRS, UMR 6301 ISTCT, CERVOxy, GIP CYCERON, Caen, France (E.L.-Z.); CHU Bordeaux, Hôpital Pellegrin, Service de Pathologie - Neuropathologie, Bordeaux, France (S.E.); EA2406, Histologie et pathologie moléculaire des tumeurs, Université Bordeaux Segalen, Bordeaux, France (S.E.); CHU Besançon, Hôpital Jean Minjoz, Service Anatomie et Cytologie Pathologiques, Besançon, France (G.V.); CHU Brest, Hôpital de la Cavale Blanche, Service Anatomie Pathologique, Brest, France (I.Q.-R.); CHU Dijon, Plateau technique de biologie G. Mack
| | - Delphine Loussouarn
- APHM, Hôpital de la Timone, Service d'Anatomie Pathologique et de Neuropathologie, Marseille, France (D.F.B.); Aix-Marseille Université, Inserm, CRO2 UMR_S 911, Marseille, France (D.F.B., C.C.); AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Service de Neuropathologie Raymond Escourolle, Paris, France (K.M.); Inserm U 1127, CNRS UMR 7225, Sorbonne Universités, UPMCUniv Paris 06 UMR S 1127, Institut du Cerveau et de la Moelle épinière, ICM, F-75013, Paris, France (K.M., C.D., C.C., A.I., J.-Y.D.); AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Service de Neurologie 2-Mazarin, F75013, Paris, France (K.M., C.D., C.C., A.I., J.-Y.D.); Centre de Pathologie et de Neuropathologie Est, Bron, France (A.J.); CHU Toulouse, Hôpital Rangueil, Service d'Anatomie Pathologique et Histologie-Cytologie, Toulouse, France (E.U.-C.); Inserm U1037, Centre de Recherche en Cancérologie de Toulouse, Université de Toulouse, France (E.U.-C.); CHU Saint-Etienne, Hôpital Nord, Service d'Anatomie et Cytologie Pathologiques, Saint-Etienne, France (F.F., M.P.); CHU Lille, Pôle Pathologie Biologique, Service Anatomie Pathologique, Lille, France (C.-A.M.); CHU Nancy, Hôpital Central, Laboratoire d'Anatomie Pathologique, Nancy, France (J.-M.V.); APHP, Hôpital Lariboisière, Service d'Anatomie et Cytologie Pathologique, Paris, France (M.P.); CHU Caen, Hôpital de la Côte de Nacre, Service d'anatomie Pathologique, Caen, France (E.L.-Z.); CNRS, UMR 6301 ISTCT, CERVOxy, GIP CYCERON, Caen, France (E.L.-Z.); CHU Bordeaux, Hôpital Pellegrin, Service de Pathologie - Neuropathologie, Bordeaux, France (S.E.); EA2406, Histologie et pathologie moléculaire des tumeurs, Université Bordeaux Segalen, Bordeaux, France (S.E.); CHU Besançon, Hôpital Jean Minjoz, Service Anatomie et Cytologie Pathologiques, Besançon, France (G.V.); CHU Brest, Hôpital de la Cavale Blanche, Service Anatomie Pathologique, Brest, France (I.Q.-R.); CHU Dijon, Plateau technique de biologie G. Mack
| | - Catherine Lacroix
- APHM, Hôpital de la Timone, Service d'Anatomie Pathologique et de Neuropathologie, Marseille, France (D.F.B.); Aix-Marseille Université, Inserm, CRO2 UMR_S 911, Marseille, France (D.F.B., C.C.); AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Service de Neuropathologie Raymond Escourolle, Paris, France (K.M.); Inserm U 1127, CNRS UMR 7225, Sorbonne Universités, UPMCUniv Paris 06 UMR S 1127, Institut du Cerveau et de la Moelle épinière, ICM, F-75013, Paris, France (K.M., C.D., C.C., A.I., J.-Y.D.); AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Service de Neurologie 2-Mazarin, F75013, Paris, France (K.M., C.D., C.C., A.I., J.-Y.D.); Centre de Pathologie et de Neuropathologie Est, Bron, France (A.J.); CHU Toulouse, Hôpital Rangueil, Service d'Anatomie Pathologique et Histologie-Cytologie, Toulouse, France (E.U.-C.); Inserm U1037, Centre de Recherche en Cancérologie de Toulouse, Université de Toulouse, France (E.U.-C.); CHU Saint-Etienne, Hôpital Nord, Service d'Anatomie et Cytologie Pathologiques, Saint-Etienne, France (F.F., M.P.); CHU Lille, Pôle Pathologie Biologique, Service Anatomie Pathologique, Lille, France (C.-A.M.); CHU Nancy, Hôpital Central, Laboratoire d'Anatomie Pathologique, Nancy, France (J.-M.V.); APHP, Hôpital Lariboisière, Service d'Anatomie et Cytologie Pathologique, Paris, France (M.P.); CHU Caen, Hôpital de la Côte de Nacre, Service d'anatomie Pathologique, Caen, France (E.L.-Z.); CNRS, UMR 6301 ISTCT, CERVOxy, GIP CYCERON, Caen, France (E.L.-Z.); CHU Bordeaux, Hôpital Pellegrin, Service de Pathologie - Neuropathologie, Bordeaux, France (S.E.); EA2406, Histologie et pathologie moléculaire des tumeurs, Université Bordeaux Segalen, Bordeaux, France (S.E.); CHU Besançon, Hôpital Jean Minjoz, Service Anatomie et Cytologie Pathologiques, Besançon, France (G.V.); CHU Brest, Hôpital de la Cavale Blanche, Service Anatomie Pathologique, Brest, France (I.Q.-R.); CHU Dijon, Plateau technique de biologie G. Mack
| | - Valérie Rigau
- APHM, Hôpital de la Timone, Service d'Anatomie Pathologique et de Neuropathologie, Marseille, France (D.F.B.); Aix-Marseille Université, Inserm, CRO2 UMR_S 911, Marseille, France (D.F.B., C.C.); AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Service de Neuropathologie Raymond Escourolle, Paris, France (K.M.); Inserm U 1127, CNRS UMR 7225, Sorbonne Universités, UPMCUniv Paris 06 UMR S 1127, Institut du Cerveau et de la Moelle épinière, ICM, F-75013, Paris, France (K.M., C.D., C.C., A.I., J.-Y.D.); AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Service de Neurologie 2-Mazarin, F75013, Paris, France (K.M., C.D., C.C., A.I., J.-Y.D.); Centre de Pathologie et de Neuropathologie Est, Bron, France (A.J.); CHU Toulouse, Hôpital Rangueil, Service d'Anatomie Pathologique et Histologie-Cytologie, Toulouse, France (E.U.-C.); Inserm U1037, Centre de Recherche en Cancérologie de Toulouse, Université de Toulouse, France (E.U.-C.); CHU Saint-Etienne, Hôpital Nord, Service d'Anatomie et Cytologie Pathologiques, Saint-Etienne, France (F.F., M.P.); CHU Lille, Pôle Pathologie Biologique, Service Anatomie Pathologique, Lille, France (C.-A.M.); CHU Nancy, Hôpital Central, Laboratoire d'Anatomie Pathologique, Nancy, France (J.-M.V.); APHP, Hôpital Lariboisière, Service d'Anatomie et Cytologie Pathologique, Paris, France (M.P.); CHU Caen, Hôpital de la Côte de Nacre, Service d'anatomie Pathologique, Caen, France (E.L.-Z.); CNRS, UMR 6301 ISTCT, CERVOxy, GIP CYCERON, Caen, France (E.L.-Z.); CHU Bordeaux, Hôpital Pellegrin, Service de Pathologie - Neuropathologie, Bordeaux, France (S.E.); EA2406, Histologie et pathologie moléculaire des tumeurs, Université Bordeaux Segalen, Bordeaux, France (S.E.); CHU Besançon, Hôpital Jean Minjoz, Service Anatomie et Cytologie Pathologiques, Besançon, France (G.V.); CHU Brest, Hôpital de la Cavale Blanche, Service Anatomie Pathologique, Brest, France (I.Q.-R.); CHU Dijon, Plateau technique de biologie G. Mack
| | - Annie Laquerrière
- APHM, Hôpital de la Timone, Service d'Anatomie Pathologique et de Neuropathologie, Marseille, France (D.F.B.); Aix-Marseille Université, Inserm, CRO2 UMR_S 911, Marseille, France (D.F.B., C.C.); AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Service de Neuropathologie Raymond Escourolle, Paris, France (K.M.); Inserm U 1127, CNRS UMR 7225, Sorbonne Universités, UPMCUniv Paris 06 UMR S 1127, Institut du Cerveau et de la Moelle épinière, ICM, F-75013, Paris, France (K.M., C.D., C.C., A.I., J.-Y.D.); AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Service de Neurologie 2-Mazarin, F75013, Paris, France (K.M., C.D., C.C., A.I., J.-Y.D.); Centre de Pathologie et de Neuropathologie Est, Bron, France (A.J.); CHU Toulouse, Hôpital Rangueil, Service d'Anatomie Pathologique et Histologie-Cytologie, Toulouse, France (E.U.-C.); Inserm U1037, Centre de Recherche en Cancérologie de Toulouse, Université de Toulouse, France (E.U.-C.); CHU Saint-Etienne, Hôpital Nord, Service d'Anatomie et Cytologie Pathologiques, Saint-Etienne, France (F.F., M.P.); CHU Lille, Pôle Pathologie Biologique, Service Anatomie Pathologique, Lille, France (C.-A.M.); CHU Nancy, Hôpital Central, Laboratoire d'Anatomie Pathologique, Nancy, France (J.-M.V.); APHP, Hôpital Lariboisière, Service d'Anatomie et Cytologie Pathologique, Paris, France (M.P.); CHU Caen, Hôpital de la Côte de Nacre, Service d'anatomie Pathologique, Caen, France (E.L.-Z.); CNRS, UMR 6301 ISTCT, CERVOxy, GIP CYCERON, Caen, France (E.L.-Z.); CHU Bordeaux, Hôpital Pellegrin, Service de Pathologie - Neuropathologie, Bordeaux, France (S.E.); EA2406, Histologie et pathologie moléculaire des tumeurs, Université Bordeaux Segalen, Bordeaux, France (S.E.); CHU Besançon, Hôpital Jean Minjoz, Service Anatomie et Cytologie Pathologiques, Besançon, France (G.V.); CHU Brest, Hôpital de la Cavale Blanche, Service Anatomie Pathologique, Brest, France (I.Q.-R.); CHU Dijon, Plateau technique de biologie G. Mack
| | - Fanny Vandenbos
- APHM, Hôpital de la Timone, Service d'Anatomie Pathologique et de Neuropathologie, Marseille, France (D.F.B.); Aix-Marseille Université, Inserm, CRO2 UMR_S 911, Marseille, France (D.F.B., C.C.); AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Service de Neuropathologie Raymond Escourolle, Paris, France (K.M.); Inserm U 1127, CNRS UMR 7225, Sorbonne Universités, UPMCUniv Paris 06 UMR S 1127, Institut du Cerveau et de la Moelle épinière, ICM, F-75013, Paris, France (K.M., C.D., C.C., A.I., J.-Y.D.); AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Service de Neurologie 2-Mazarin, F75013, Paris, France (K.M., C.D., C.C., A.I., J.-Y.D.); Centre de Pathologie et de Neuropathologie Est, Bron, France (A.J.); CHU Toulouse, Hôpital Rangueil, Service d'Anatomie Pathologique et Histologie-Cytologie, Toulouse, France (E.U.-C.); Inserm U1037, Centre de Recherche en Cancérologie de Toulouse, Université de Toulouse, France (E.U.-C.); CHU Saint-Etienne, Hôpital Nord, Service d'Anatomie et Cytologie Pathologiques, Saint-Etienne, France (F.F., M.P.); CHU Lille, Pôle Pathologie Biologique, Service Anatomie Pathologique, Lille, France (C.-A.M.); CHU Nancy, Hôpital Central, Laboratoire d'Anatomie Pathologique, Nancy, France (J.-M.V.); APHP, Hôpital Lariboisière, Service d'Anatomie et Cytologie Pathologique, Paris, France (M.P.); CHU Caen, Hôpital de la Côte de Nacre, Service d'anatomie Pathologique, Caen, France (E.L.-Z.); CNRS, UMR 6301 ISTCT, CERVOxy, GIP CYCERON, Caen, France (E.L.-Z.); CHU Bordeaux, Hôpital Pellegrin, Service de Pathologie - Neuropathologie, Bordeaux, France (S.E.); EA2406, Histologie et pathologie moléculaire des tumeurs, Université Bordeaux Segalen, Bordeaux, France (S.E.); CHU Besançon, Hôpital Jean Minjoz, Service Anatomie et Cytologie Pathologiques, Besançon, France (G.V.); CHU Brest, Hôpital de la Cavale Blanche, Service Anatomie Pathologique, Brest, France (I.Q.-R.); CHU Dijon, Plateau technique de biologie G. Mack
| | - Sophie Michalak
- APHM, Hôpital de la Timone, Service d'Anatomie Pathologique et de Neuropathologie, Marseille, France (D.F.B.); Aix-Marseille Université, Inserm, CRO2 UMR_S 911, Marseille, France (D.F.B., C.C.); AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Service de Neuropathologie Raymond Escourolle, Paris, France (K.M.); Inserm U 1127, CNRS UMR 7225, Sorbonne Universités, UPMCUniv Paris 06 UMR S 1127, Institut du Cerveau et de la Moelle épinière, ICM, F-75013, Paris, France (K.M., C.D., C.C., A.I., J.-Y.D.); AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Service de Neurologie 2-Mazarin, F75013, Paris, France (K.M., C.D., C.C., A.I., J.-Y.D.); Centre de Pathologie et de Neuropathologie Est, Bron, France (A.J.); CHU Toulouse, Hôpital Rangueil, Service d'Anatomie Pathologique et Histologie-Cytologie, Toulouse, France (E.U.-C.); Inserm U1037, Centre de Recherche en Cancérologie de Toulouse, Université de Toulouse, France (E.U.-C.); CHU Saint-Etienne, Hôpital Nord, Service d'Anatomie et Cytologie Pathologiques, Saint-Etienne, France (F.F., M.P.); CHU Lille, Pôle Pathologie Biologique, Service Anatomie Pathologique, Lille, France (C.-A.M.); CHU Nancy, Hôpital Central, Laboratoire d'Anatomie Pathologique, Nancy, France (J.-M.V.); APHP, Hôpital Lariboisière, Service d'Anatomie et Cytologie Pathologique, Paris, France (M.P.); CHU Caen, Hôpital de la Côte de Nacre, Service d'anatomie Pathologique, Caen, France (E.L.-Z.); CNRS, UMR 6301 ISTCT, CERVOxy, GIP CYCERON, Caen, France (E.L.-Z.); CHU Bordeaux, Hôpital Pellegrin, Service de Pathologie - Neuropathologie, Bordeaux, France (S.E.); EA2406, Histologie et pathologie moléculaire des tumeurs, Université Bordeaux Segalen, Bordeaux, France (S.E.); CHU Besançon, Hôpital Jean Minjoz, Service Anatomie et Cytologie Pathologiques, Besançon, France (G.V.); CHU Brest, Hôpital de la Cavale Blanche, Service Anatomie Pathologique, Brest, France (I.Q.-R.); CHU Dijon, Plateau technique de biologie G. Mack
| | - Henri Sevestre
- APHM, Hôpital de la Timone, Service d'Anatomie Pathologique et de Neuropathologie, Marseille, France (D.F.B.); Aix-Marseille Université, Inserm, CRO2 UMR_S 911, Marseille, France (D.F.B., C.C.); AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Service de Neuropathologie Raymond Escourolle, Paris, France (K.M.); Inserm U 1127, CNRS UMR 7225, Sorbonne Universités, UPMCUniv Paris 06 UMR S 1127, Institut du Cerveau et de la Moelle épinière, ICM, F-75013, Paris, France (K.M., C.D., C.C., A.I., J.-Y.D.); AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Service de Neurologie 2-Mazarin, F75013, Paris, France (K.M., C.D., C.C., A.I., J.-Y.D.); Centre de Pathologie et de Neuropathologie Est, Bron, France (A.J.); CHU Toulouse, Hôpital Rangueil, Service d'Anatomie Pathologique et Histologie-Cytologie, Toulouse, France (E.U.-C.); Inserm U1037, Centre de Recherche en Cancérologie de Toulouse, Université de Toulouse, France (E.U.-C.); CHU Saint-Etienne, Hôpital Nord, Service d'Anatomie et Cytologie Pathologiques, Saint-Etienne, France (F.F., M.P.); CHU Lille, Pôle Pathologie Biologique, Service Anatomie Pathologique, Lille, France (C.-A.M.); CHU Nancy, Hôpital Central, Laboratoire d'Anatomie Pathologique, Nancy, France (J.-M.V.); APHP, Hôpital Lariboisière, Service d'Anatomie et Cytologie Pathologique, Paris, France (M.P.); CHU Caen, Hôpital de la Côte de Nacre, Service d'anatomie Pathologique, Caen, France (E.L.-Z.); CNRS, UMR 6301 ISTCT, CERVOxy, GIP CYCERON, Caen, France (E.L.-Z.); CHU Bordeaux, Hôpital Pellegrin, Service de Pathologie - Neuropathologie, Bordeaux, France (S.E.); EA2406, Histologie et pathologie moléculaire des tumeurs, Université Bordeaux Segalen, Bordeaux, France (S.E.); CHU Besançon, Hôpital Jean Minjoz, Service Anatomie et Cytologie Pathologiques, Besançon, France (G.V.); CHU Brest, Hôpital de la Cavale Blanche, Service Anatomie Pathologique, Brest, France (I.Q.-R.); CHU Dijon, Plateau technique de biologie G. Mack
| | - Michel Peoch
- APHM, Hôpital de la Timone, Service d'Anatomie Pathologique et de Neuropathologie, Marseille, France (D.F.B.); Aix-Marseille Université, Inserm, CRO2 UMR_S 911, Marseille, France (D.F.B., C.C.); AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Service de Neuropathologie Raymond Escourolle, Paris, France (K.M.); Inserm U 1127, CNRS UMR 7225, Sorbonne Universités, UPMCUniv Paris 06 UMR S 1127, Institut du Cerveau et de la Moelle épinière, ICM, F-75013, Paris, France (K.M., C.D., C.C., A.I., J.-Y.D.); AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Service de Neurologie 2-Mazarin, F75013, Paris, France (K.M., C.D., C.C., A.I., J.-Y.D.); Centre de Pathologie et de Neuropathologie Est, Bron, France (A.J.); CHU Toulouse, Hôpital Rangueil, Service d'Anatomie Pathologique et Histologie-Cytologie, Toulouse, France (E.U.-C.); Inserm U1037, Centre de Recherche en Cancérologie de Toulouse, Université de Toulouse, France (E.U.-C.); CHU Saint-Etienne, Hôpital Nord, Service d'Anatomie et Cytologie Pathologiques, Saint-Etienne, France (F.F., M.P.); CHU Lille, Pôle Pathologie Biologique, Service Anatomie Pathologique, Lille, France (C.-A.M.); CHU Nancy, Hôpital Central, Laboratoire d'Anatomie Pathologique, Nancy, France (J.-M.V.); APHP, Hôpital Lariboisière, Service d'Anatomie et Cytologie Pathologique, Paris, France (M.P.); CHU Caen, Hôpital de la Côte de Nacre, Service d'anatomie Pathologique, Caen, France (E.L.-Z.); CNRS, UMR 6301 ISTCT, CERVOxy, GIP CYCERON, Caen, France (E.L.-Z.); CHU Bordeaux, Hôpital Pellegrin, Service de Pathologie - Neuropathologie, Bordeaux, France (S.E.); EA2406, Histologie et pathologie moléculaire des tumeurs, Université Bordeaux Segalen, Bordeaux, France (S.E.); CHU Besançon, Hôpital Jean Minjoz, Service Anatomie et Cytologie Pathologiques, Besançon, France (G.V.); CHU Brest, Hôpital de la Cavale Blanche, Service Anatomie Pathologique, Brest, France (I.Q.-R.); CHU Dijon, Plateau technique de biologie G. Mack
| | - François Labrousse
- APHM, Hôpital de la Timone, Service d'Anatomie Pathologique et de Neuropathologie, Marseille, France (D.F.B.); Aix-Marseille Université, Inserm, CRO2 UMR_S 911, Marseille, France (D.F.B., C.C.); AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Service de Neuropathologie Raymond Escourolle, Paris, France (K.M.); Inserm U 1127, CNRS UMR 7225, Sorbonne Universités, UPMCUniv Paris 06 UMR S 1127, Institut du Cerveau et de la Moelle épinière, ICM, F-75013, Paris, France (K.M., C.D., C.C., A.I., J.-Y.D.); AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Service de Neurologie 2-Mazarin, F75013, Paris, France (K.M., C.D., C.C., A.I., J.-Y.D.); Centre de Pathologie et de Neuropathologie Est, Bron, France (A.J.); CHU Toulouse, Hôpital Rangueil, Service d'Anatomie Pathologique et Histologie-Cytologie, Toulouse, France (E.U.-C.); Inserm U1037, Centre de Recherche en Cancérologie de Toulouse, Université de Toulouse, France (E.U.-C.); CHU Saint-Etienne, Hôpital Nord, Service d'Anatomie et Cytologie Pathologiques, Saint-Etienne, France (F.F., M.P.); CHU Lille, Pôle Pathologie Biologique, Service Anatomie Pathologique, Lille, France (C.-A.M.); CHU Nancy, Hôpital Central, Laboratoire d'Anatomie Pathologique, Nancy, France (J.-M.V.); APHP, Hôpital Lariboisière, Service d'Anatomie et Cytologie Pathologique, Paris, France (M.P.); CHU Caen, Hôpital de la Côte de Nacre, Service d'anatomie Pathologique, Caen, France (E.L.-Z.); CNRS, UMR 6301 ISTCT, CERVOxy, GIP CYCERON, Caen, France (E.L.-Z.); CHU Bordeaux, Hôpital Pellegrin, Service de Pathologie - Neuropathologie, Bordeaux, France (S.E.); EA2406, Histologie et pathologie moléculaire des tumeurs, Université Bordeaux Segalen, Bordeaux, France (S.E.); CHU Besançon, Hôpital Jean Minjoz, Service Anatomie et Cytologie Pathologiques, Besançon, France (G.V.); CHU Brest, Hôpital de la Cavale Blanche, Service Anatomie Pathologique, Brest, France (I.Q.-R.); CHU Dijon, Plateau technique de biologie G. Mack
| | - Christo Christov
- APHM, Hôpital de la Timone, Service d'Anatomie Pathologique et de Neuropathologie, Marseille, France (D.F.B.); Aix-Marseille Université, Inserm, CRO2 UMR_S 911, Marseille, France (D.F.B., C.C.); AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Service de Neuropathologie Raymond Escourolle, Paris, France (K.M.); Inserm U 1127, CNRS UMR 7225, Sorbonne Universités, UPMCUniv Paris 06 UMR S 1127, Institut du Cerveau et de la Moelle épinière, ICM, F-75013, Paris, France (K.M., C.D., C.C., A.I., J.-Y.D.); AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Service de Neurologie 2-Mazarin, F75013, Paris, France (K.M., C.D., C.C., A.I., J.-Y.D.); Centre de Pathologie et de Neuropathologie Est, Bron, France (A.J.); CHU Toulouse, Hôpital Rangueil, Service d'Anatomie Pathologique et Histologie-Cytologie, Toulouse, France (E.U.-C.); Inserm U1037, Centre de Recherche en Cancérologie de Toulouse, Université de Toulouse, France (E.U.-C.); CHU Saint-Etienne, Hôpital Nord, Service d'Anatomie et Cytologie Pathologiques, Saint-Etienne, France (F.F., M.P.); CHU Lille, Pôle Pathologie Biologique, Service Anatomie Pathologique, Lille, France (C.-A.M.); CHU Nancy, Hôpital Central, Laboratoire d'Anatomie Pathologique, Nancy, France (J.-M.V.); APHP, Hôpital Lariboisière, Service d'Anatomie et Cytologie Pathologique, Paris, France (M.P.); CHU Caen, Hôpital de la Côte de Nacre, Service d'anatomie Pathologique, Caen, France (E.L.-Z.); CNRS, UMR 6301 ISTCT, CERVOxy, GIP CYCERON, Caen, France (E.L.-Z.); CHU Bordeaux, Hôpital Pellegrin, Service de Pathologie - Neuropathologie, Bordeaux, France (S.E.); EA2406, Histologie et pathologie moléculaire des tumeurs, Université Bordeaux Segalen, Bordeaux, France (S.E.); CHU Besançon, Hôpital Jean Minjoz, Service Anatomie et Cytologie Pathologiques, Besançon, France (G.V.); CHU Brest, Hôpital de la Cavale Blanche, Service Anatomie Pathologique, Brest, France (I.Q.-R.); CHU Dijon, Plateau technique de biologie G. Mack
| | - Jean-Louis Kemeny
- APHM, Hôpital de la Timone, Service d'Anatomie Pathologique et de Neuropathologie, Marseille, France (D.F.B.); Aix-Marseille Université, Inserm, CRO2 UMR_S 911, Marseille, France (D.F.B., C.C.); AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Service de Neuropathologie Raymond Escourolle, Paris, France (K.M.); Inserm U 1127, CNRS UMR 7225, Sorbonne Universités, UPMCUniv Paris 06 UMR S 1127, Institut du Cerveau et de la Moelle épinière, ICM, F-75013, Paris, France (K.M., C.D., C.C., A.I., J.-Y.D.); AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Service de Neurologie 2-Mazarin, F75013, Paris, France (K.M., C.D., C.C., A.I., J.-Y.D.); Centre de Pathologie et de Neuropathologie Est, Bron, France (A.J.); CHU Toulouse, Hôpital Rangueil, Service d'Anatomie Pathologique et Histologie-Cytologie, Toulouse, France (E.U.-C.); Inserm U1037, Centre de Recherche en Cancérologie de Toulouse, Université de Toulouse, France (E.U.-C.); CHU Saint-Etienne, Hôpital Nord, Service d'Anatomie et Cytologie Pathologiques, Saint-Etienne, France (F.F., M.P.); CHU Lille, Pôle Pathologie Biologique, Service Anatomie Pathologique, Lille, France (C.-A.M.); CHU Nancy, Hôpital Central, Laboratoire d'Anatomie Pathologique, Nancy, France (J.-M.V.); APHP, Hôpital Lariboisière, Service d'Anatomie et Cytologie Pathologique, Paris, France (M.P.); CHU Caen, Hôpital de la Côte de Nacre, Service d'anatomie Pathologique, Caen, France (E.L.-Z.); CNRS, UMR 6301 ISTCT, CERVOxy, GIP CYCERON, Caen, France (E.L.-Z.); CHU Bordeaux, Hôpital Pellegrin, Service de Pathologie - Neuropathologie, Bordeaux, France (S.E.); EA2406, Histologie et pathologie moléculaire des tumeurs, Université Bordeaux Segalen, Bordeaux, France (S.E.); CHU Besançon, Hôpital Jean Minjoz, Service Anatomie et Cytologie Pathologiques, Besançon, France (G.V.); CHU Brest, Hôpital de la Cavale Blanche, Service Anatomie Pathologique, Brest, France (I.Q.-R.); CHU Dijon, Plateau technique de biologie G. Mack
| | - Marie-Pierre Chenard
- APHM, Hôpital de la Timone, Service d'Anatomie Pathologique et de Neuropathologie, Marseille, France (D.F.B.); Aix-Marseille Université, Inserm, CRO2 UMR_S 911, Marseille, France (D.F.B., C.C.); AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Service de Neuropathologie Raymond Escourolle, Paris, France (K.M.); Inserm U 1127, CNRS UMR 7225, Sorbonne Universités, UPMCUniv Paris 06 UMR S 1127, Institut du Cerveau et de la Moelle épinière, ICM, F-75013, Paris, France (K.M., C.D., C.C., A.I., J.-Y.D.); AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Service de Neurologie 2-Mazarin, F75013, Paris, France (K.M., C.D., C.C., A.I., J.-Y.D.); Centre de Pathologie et de Neuropathologie Est, Bron, France (A.J.); CHU Toulouse, Hôpital Rangueil, Service d'Anatomie Pathologique et Histologie-Cytologie, Toulouse, France (E.U.-C.); Inserm U1037, Centre de Recherche en Cancérologie de Toulouse, Université de Toulouse, France (E.U.-C.); CHU Saint-Etienne, Hôpital Nord, Service d'Anatomie et Cytologie Pathologiques, Saint-Etienne, France (F.F., M.P.); CHU Lille, Pôle Pathologie Biologique, Service Anatomie Pathologique, Lille, France (C.-A.M.); CHU Nancy, Hôpital Central, Laboratoire d'Anatomie Pathologique, Nancy, France (J.-M.V.); APHP, Hôpital Lariboisière, Service d'Anatomie et Cytologie Pathologique, Paris, France (M.P.); CHU Caen, Hôpital de la Côte de Nacre, Service d'anatomie Pathologique, Caen, France (E.L.-Z.); CNRS, UMR 6301 ISTCT, CERVOxy, GIP CYCERON, Caen, France (E.L.-Z.); CHU Bordeaux, Hôpital Pellegrin, Service de Pathologie - Neuropathologie, Bordeaux, France (S.E.); EA2406, Histologie et pathologie moléculaire des tumeurs, Université Bordeaux Segalen, Bordeaux, France (S.E.); CHU Besançon, Hôpital Jean Minjoz, Service Anatomie et Cytologie Pathologiques, Besançon, France (G.V.); CHU Brest, Hôpital de la Cavale Blanche, Service Anatomie Pathologique, Brest, France (I.Q.-R.); CHU Dijon, Plateau technique de biologie G. Mack
| | - Danchristian Chiforeanu
- APHM, Hôpital de la Timone, Service d'Anatomie Pathologique et de Neuropathologie, Marseille, France (D.F.B.); Aix-Marseille Université, Inserm, CRO2 UMR_S 911, Marseille, France (D.F.B., C.C.); AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Service de Neuropathologie Raymond Escourolle, Paris, France (K.M.); Inserm U 1127, CNRS UMR 7225, Sorbonne Universités, UPMCUniv Paris 06 UMR S 1127, Institut du Cerveau et de la Moelle épinière, ICM, F-75013, Paris, France (K.M., C.D., C.C., A.I., J.-Y.D.); AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Service de Neurologie 2-Mazarin, F75013, Paris, France (K.M., C.D., C.C., A.I., J.-Y.D.); Centre de Pathologie et de Neuropathologie Est, Bron, France (A.J.); CHU Toulouse, Hôpital Rangueil, Service d'Anatomie Pathologique et Histologie-Cytologie, Toulouse, France (E.U.-C.); Inserm U1037, Centre de Recherche en Cancérologie de Toulouse, Université de Toulouse, France (E.U.-C.); CHU Saint-Etienne, Hôpital Nord, Service d'Anatomie et Cytologie Pathologiques, Saint-Etienne, France (F.F., M.P.); CHU Lille, Pôle Pathologie Biologique, Service Anatomie Pathologique, Lille, France (C.-A.M.); CHU Nancy, Hôpital Central, Laboratoire d'Anatomie Pathologique, Nancy, France (J.-M.V.); APHP, Hôpital Lariboisière, Service d'Anatomie et Cytologie Pathologique, Paris, France (M.P.); CHU Caen, Hôpital de la Côte de Nacre, Service d'anatomie Pathologique, Caen, France (E.L.-Z.); CNRS, UMR 6301 ISTCT, CERVOxy, GIP CYCERON, Caen, France (E.L.-Z.); CHU Bordeaux, Hôpital Pellegrin, Service de Pathologie - Neuropathologie, Bordeaux, France (S.E.); EA2406, Histologie et pathologie moléculaire des tumeurs, Université Bordeaux Segalen, Bordeaux, France (S.E.); CHU Besançon, Hôpital Jean Minjoz, Service Anatomie et Cytologie Pathologiques, Besançon, France (G.V.); CHU Brest, Hôpital de la Cavale Blanche, Service Anatomie Pathologique, Brest, France (I.Q.-R.); CHU Dijon, Plateau technique de biologie G. Mack
| | - François Ducray
- APHM, Hôpital de la Timone, Service d'Anatomie Pathologique et de Neuropathologie, Marseille, France (D.F.B.); Aix-Marseille Université, Inserm, CRO2 UMR_S 911, Marseille, France (D.F.B., C.C.); AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Service de Neuropathologie Raymond Escourolle, Paris, France (K.M.); Inserm U 1127, CNRS UMR 7225, Sorbonne Universités, UPMCUniv Paris 06 UMR S 1127, Institut du Cerveau et de la Moelle épinière, ICM, F-75013, Paris, France (K.M., C.D., C.C., A.I., J.-Y.D.); AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Service de Neurologie 2-Mazarin, F75013, Paris, France (K.M., C.D., C.C., A.I., J.-Y.D.); Centre de Pathologie et de Neuropathologie Est, Bron, France (A.J.); CHU Toulouse, Hôpital Rangueil, Service d'Anatomie Pathologique et Histologie-Cytologie, Toulouse, France (E.U.-C.); Inserm U1037, Centre de Recherche en Cancérologie de Toulouse, Université de Toulouse, France (E.U.-C.); CHU Saint-Etienne, Hôpital Nord, Service d'Anatomie et Cytologie Pathologiques, Saint-Etienne, France (F.F., M.P.); CHU Lille, Pôle Pathologie Biologique, Service Anatomie Pathologique, Lille, France (C.-A.M.); CHU Nancy, Hôpital Central, Laboratoire d'Anatomie Pathologique, Nancy, France (J.-M.V.); APHP, Hôpital Lariboisière, Service d'Anatomie et Cytologie Pathologique, Paris, France (M.P.); CHU Caen, Hôpital de la Côte de Nacre, Service d'anatomie Pathologique, Caen, France (E.L.-Z.); CNRS, UMR 6301 ISTCT, CERVOxy, GIP CYCERON, Caen, France (E.L.-Z.); CHU Bordeaux, Hôpital Pellegrin, Service de Pathologie - Neuropathologie, Bordeaux, France (S.E.); EA2406, Histologie et pathologie moléculaire des tumeurs, Université Bordeaux Segalen, Bordeaux, France (S.E.); CHU Besançon, Hôpital Jean Minjoz, Service Anatomie et Cytologie Pathologiques, Besançon, France (G.V.); CHU Brest, Hôpital de la Cavale Blanche, Service Anatomie Pathologique, Brest, France (I.Q.-R.); CHU Dijon, Plateau technique de biologie G. Mack
| | - Ahmed Idbaih
- APHM, Hôpital de la Timone, Service d'Anatomie Pathologique et de Neuropathologie, Marseille, France (D.F.B.); Aix-Marseille Université, Inserm, CRO2 UMR_S 911, Marseille, France (D.F.B., C.C.); AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Service de Neuropathologie Raymond Escourolle, Paris, France (K.M.); Inserm U 1127, CNRS UMR 7225, Sorbonne Universités, UPMCUniv Paris 06 UMR S 1127, Institut du Cerveau et de la Moelle épinière, ICM, F-75013, Paris, France (K.M., C.D., C.C., A.I., J.-Y.D.); AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Service de Neurologie 2-Mazarin, F75013, Paris, France (K.M., C.D., C.C., A.I., J.-Y.D.); Centre de Pathologie et de Neuropathologie Est, Bron, France (A.J.); CHU Toulouse, Hôpital Rangueil, Service d'Anatomie Pathologique et Histologie-Cytologie, Toulouse, France (E.U.-C.); Inserm U1037, Centre de Recherche en Cancérologie de Toulouse, Université de Toulouse, France (E.U.-C.); CHU Saint-Etienne, Hôpital Nord, Service d'Anatomie et Cytologie Pathologiques, Saint-Etienne, France (F.F., M.P.); CHU Lille, Pôle Pathologie Biologique, Service Anatomie Pathologique, Lille, France (C.-A.M.); CHU Nancy, Hôpital Central, Laboratoire d'Anatomie Pathologique, Nancy, France (J.-M.V.); APHP, Hôpital Lariboisière, Service d'Anatomie et Cytologie Pathologique, Paris, France (M.P.); CHU Caen, Hôpital de la Côte de Nacre, Service d'anatomie Pathologique, Caen, France (E.L.-Z.); CNRS, UMR 6301 ISTCT, CERVOxy, GIP CYCERON, Caen, France (E.L.-Z.); CHU Bordeaux, Hôpital Pellegrin, Service de Pathologie - Neuropathologie, Bordeaux, France (S.E.); EA2406, Histologie et pathologie moléculaire des tumeurs, Université Bordeaux Segalen, Bordeaux, France (S.E.); CHU Besançon, Hôpital Jean Minjoz, Service Anatomie et Cytologie Pathologiques, Besançon, France (G.V.); CHU Brest, Hôpital de la Cavale Blanche, Service Anatomie Pathologique, Brest, France (I.Q.-R.); CHU Dijon, Plateau technique de biologie G. Mack
| | - Jean-Yves Delattre
- APHM, Hôpital de la Timone, Service d'Anatomie Pathologique et de Neuropathologie, Marseille, France (D.F.B.); Aix-Marseille Université, Inserm, CRO2 UMR_S 911, Marseille, France (D.F.B., C.C.); AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Service de Neuropathologie Raymond Escourolle, Paris, France (K.M.); Inserm U 1127, CNRS UMR 7225, Sorbonne Universités, UPMCUniv Paris 06 UMR S 1127, Institut du Cerveau et de la Moelle épinière, ICM, F-75013, Paris, France (K.M., C.D., C.C., A.I., J.-Y.D.); AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Service de Neurologie 2-Mazarin, F75013, Paris, France (K.M., C.D., C.C., A.I., J.-Y.D.); Centre de Pathologie et de Neuropathologie Est, Bron, France (A.J.); CHU Toulouse, Hôpital Rangueil, Service d'Anatomie Pathologique et Histologie-Cytologie, Toulouse, France (E.U.-C.); Inserm U1037, Centre de Recherche en Cancérologie de Toulouse, Université de Toulouse, France (E.U.-C.); CHU Saint-Etienne, Hôpital Nord, Service d'Anatomie et Cytologie Pathologiques, Saint-Etienne, France (F.F., M.P.); CHU Lille, Pôle Pathologie Biologique, Service Anatomie Pathologique, Lille, France (C.-A.M.); CHU Nancy, Hôpital Central, Laboratoire d'Anatomie Pathologique, Nancy, France (J.-M.V.); APHP, Hôpital Lariboisière, Service d'Anatomie et Cytologie Pathologique, Paris, France (M.P.); CHU Caen, Hôpital de la Côte de Nacre, Service d'anatomie Pathologique, Caen, France (E.L.-Z.); CNRS, UMR 6301 ISTCT, CERVOxy, GIP CYCERON, Caen, France (E.L.-Z.); CHU Bordeaux, Hôpital Pellegrin, Service de Pathologie - Neuropathologie, Bordeaux, France (S.E.); EA2406, Histologie et pathologie moléculaire des tumeurs, Université Bordeaux Segalen, Bordeaux, France (S.E.); CHU Besançon, Hôpital Jean Minjoz, Service Anatomie et Cytologie Pathologiques, Besançon, France (G.V.); CHU Brest, Hôpital de la Cavale Blanche, Service Anatomie Pathologique, Brest, France (I.Q.-R.); CHU Dijon, Plateau technique de biologie G. Mack
| | | |
Collapse
|
16
|
Cavalli FMG, Remke M, Rampasek L, Peacock J, Shih DJH, Luu B, Garzia L, Torchia J, Nor C, Morrissy AS, Agnihotri S, Thompson YY, Kuzan-Fischer CM, Farooq H, Isaev K, Daniels C, Cho BK, Kim SK, Wang KC, Lee JY, Grajkowska WA, Perek-Polnik M, Vasiljevic A, Faure-Conter C, Jouvet A, Giannini C, Nageswara Rao AA, Li KKW, Ng HK, Eberhart CG, Pollack IF, Hamilton RL, Gillespie GY, Olson JM, Leary S, Weiss WA, Lach B, Chambless LB, Thompson RC, Cooper MK, Vibhakar R, Hauser P, van Veelen MLC, Kros JM, French PJ, Ra YS, Kumabe T, López-Aguilar E, Zitterbart K, Sterba J, Finocchiaro G, Massimino M, Van Meir EG, Osuka S, Shofuda T, Klekner A, Zollo M, Leonard JR, Rubin JB, Jabado N, Albrecht S, Mora J, Van Meter TE, Jung S, Moore AS, Hallahan AR, Chan JA, Tirapelli DPC, Carlotti CG, Fouladi M, Pimentel J, Faria CC, Saad AG, Massimi L, Liau LM, Wheeler H, Nakamura H, Elbabaa SK, Perezpeña-Diazconti M, Chico Ponce de León F, Robinson S, Zapotocky M, Lassaletta A, Huang A, Hawkins CE, Tabori U, Bouffet E, Bartels U, Dirks PB, Rutka JT, Bader GD, Reimand J, Goldenberg A, Ramaswamy V, Taylor MD. Intertumoral Heterogeneity within Medulloblastoma Subgroups. Cancer Cell 2017; 31:737-754.e6. [PMID: 28609654 PMCID: PMC6163053 DOI: 10.1016/j.ccell.2017.05.005] [Citation(s) in RCA: 720] [Impact Index Per Article: 102.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/23/2016] [Revised: 03/24/2017] [Accepted: 05/08/2017] [Indexed: 02/07/2023]
Abstract
While molecular subgrouping has revolutionized medulloblastoma classification, the extent of heterogeneity within subgroups is unknown. Similarity network fusion (SNF) applied to genome-wide DNA methylation and gene expression data across 763 primary samples identifies very homogeneous clusters of patients, supporting the presence of medulloblastoma subtypes. After integration of somatic copy-number alterations, and clinical features specific to each cluster, we identify 12 different subtypes of medulloblastoma. Integrative analysis using SNF further delineates group 3 from group 4 medulloblastoma, which is not as readily apparent through analyses of individual data types. Two clear subtypes of infants with Sonic Hedgehog medulloblastoma with disparate outcomes and biology are identified. Medulloblastoma subtypes identified through integrative clustering have important implications for stratification of future clinical trials.
Collapse
Affiliation(s)
- Florence M G Cavalli
- The Arthur and Sonia Labatt Brain Tumour Research Centre, The Hospital for Sick Children, Toronto, ON M5G 1X8, Canada; Developmental & Stem Cell Biology Program, The Hospital for Sick Children, Toronto, ON M5G 1X8, Canada
| | - Marc Remke
- Department of Pediatric Oncology, Hematology, and Clinical Immunology, Medical Faculty, University Hospital Düsseldorf, Düsseldorf 40225, Germany; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON M5S 1A1, Canada; Department of Pediatric Neuro-Oncogenomics, German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Düsseldorf 40225, Germany
| | - Ladislav Rampasek
- Department of Computer Science, University of Toronto, Toronto, ON M5S 2E4, Canada; Program in Genetics and Genome Biology, The Hospital for Sick Children, Toronto, ON M5G 1X8, Canada
| | - John Peacock
- The Arthur and Sonia Labatt Brain Tumour Research Centre, The Hospital for Sick Children, Toronto, ON M5G 1X8, Canada; Developmental & Stem Cell Biology Program, The Hospital for Sick Children, Toronto, ON M5G 1X8, Canada; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON M5S 1A1, Canada
| | - David J H Shih
- The Arthur and Sonia Labatt Brain Tumour Research Centre, The Hospital for Sick Children, Toronto, ON M5G 1X8, Canada; Developmental & Stem Cell Biology Program, The Hospital for Sick Children, Toronto, ON M5G 1X8, Canada; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON M5S 1A1, Canada
| | - Betty Luu
- The Arthur and Sonia Labatt Brain Tumour Research Centre, The Hospital for Sick Children, Toronto, ON M5G 1X8, Canada; Developmental & Stem Cell Biology Program, The Hospital for Sick Children, Toronto, ON M5G 1X8, Canada
| | - Livia Garzia
- The Arthur and Sonia Labatt Brain Tumour Research Centre, The Hospital for Sick Children, Toronto, ON M5G 1X8, Canada; Developmental & Stem Cell Biology Program, The Hospital for Sick Children, Toronto, ON M5G 1X8, Canada
| | - Jonathon Torchia
- The Arthur and Sonia Labatt Brain Tumour Research Centre, The Hospital for Sick Children, Toronto, ON M5G 1X8, Canada; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON M5S 1A1, Canada
| | - Carolina Nor
- The Arthur and Sonia Labatt Brain Tumour Research Centre, The Hospital for Sick Children, Toronto, ON M5G 1X8, Canada; Developmental & Stem Cell Biology Program, The Hospital for Sick Children, Toronto, ON M5G 1X8, Canada
| | - A Sorana Morrissy
- The Arthur and Sonia Labatt Brain Tumour Research Centre, The Hospital for Sick Children, Toronto, ON M5G 1X8, Canada; Developmental & Stem Cell Biology Program, The Hospital for Sick Children, Toronto, ON M5G 1X8, Canada
| | - Sameer Agnihotri
- UPCI Brain Tumor Program, University of Pittsburgh, Children's Hospital of Pittsburgh, Pittsburgh, PA 15224, USA
| | - Yuan Yao Thompson
- The Arthur and Sonia Labatt Brain Tumour Research Centre, The Hospital for Sick Children, Toronto, ON M5G 1X8, Canada; Developmental & Stem Cell Biology Program, The Hospital for Sick Children, Toronto, ON M5G 1X8, Canada; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON M5S 1A1, Canada
| | - Claudia M Kuzan-Fischer
- The Arthur and Sonia Labatt Brain Tumour Research Centre, The Hospital for Sick Children, Toronto, ON M5G 1X8, Canada; Developmental & Stem Cell Biology Program, The Hospital for Sick Children, Toronto, ON M5G 1X8, Canada
| | - Hamza Farooq
- The Arthur and Sonia Labatt Brain Tumour Research Centre, The Hospital for Sick Children, Toronto, ON M5G 1X8, Canada; Developmental & Stem Cell Biology Program, The Hospital for Sick Children, Toronto, ON M5G 1X8, Canada; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON M5S 1A1, Canada
| | - Keren Isaev
- Informatics Program, Ontario Institute for Cancer Research, Toronto, ON M5G 0A3, Canada; Department of Medical Biophysics, University of Toronto, Toronto, ON M5G 1L7, Canada
| | - Craig Daniels
- The Arthur and Sonia Labatt Brain Tumour Research Centre, The Hospital for Sick Children, Toronto, ON M5G 1X8, Canada; Developmental & Stem Cell Biology Program, The Hospital for Sick Children, Toronto, ON M5G 1X8, Canada
| | - Byung-Kyu Cho
- Department of Neurosurgery, Division of Pediatric Neurosurgery, Seoul National University Children's Hospital, Seoul 30322, South Korea
| | - Seung-Ki Kim
- Department of Neurosurgery, Division of Pediatric Neurosurgery, Seoul National University Children's Hospital, Seoul 30322, South Korea
| | - Kyu-Chang Wang
- Department of Neurosurgery, Division of Pediatric Neurosurgery, Seoul National University Children's Hospital, Seoul 30322, South Korea
| | - Ji Yeoun Lee
- Department of Neurosurgery, Division of Pediatric Neurosurgery, Seoul National University Children's Hospital, Seoul 30322, South Korea
| | - Wieslawa A Grajkowska
- Department of Pathology, The Children's Memorial Health Institute, University of Warsaw, Warsaw 04-730, Poland
| | - Marta Perek-Polnik
- Department of Oncology, The Children's Memorial Health Institute, University of Warsaw, Warsaw 04-730, Poland
| | - Alexandre Vasiljevic
- Centre de Pathologie et Neuropathologie Est, Centre de Biologie et Pathologie Est, Groupement Hospitalier Est, Hospices Civils de Lyon, Bron 69677, France; ONCOFLAM - Neuro-Oncologie et Neuro-Inflammation Centre de Recherche en Neurosciences de Lyon, Lyon 69008, France
| | | | - Anne Jouvet
- Centre de Pathologie EST, Groupement Hospitalier EST, Université de Lyon, Bron 69677, France
| | - Caterina Giannini
- Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905, USA
| | | | - Kay Ka Wai Li
- Department of Anatomical and Cellular Pathology, The Chinese University of Hong Kong, Shatin, New Territories, Hong Kong, China
| | - Ho-Keung Ng
- Department of Anatomical and Cellular Pathology, The Chinese University of Hong Kong, Shatin, New Territories, Hong Kong, China
| | - Charles G Eberhart
- Departments of Pathology, Ophthalmology and Oncology, John Hopkins University School of Medicine, Baltimore, MD 21287, USA
| | - Ian F Pollack
- Department of Neurological Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA
| | - Ronald L Hamilton
- Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15261, USA
| | - G Yancey Gillespie
- Department of Surgery, Division of Neurosurgery, University of Alabama at Birmingham, Birmingham, AL 35233, USA
| | - James M Olson
- Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109-1024, USA; Division of Pediatric Hematology/Oncology, University of Washington School of Medicine, Seattle Children's Hospital, Seattle, WA 98145-5005, USA
| | - Sarah Leary
- Division of Pediatric Hematology/Oncology, University of Washington School of Medicine, Seattle Children's Hospital, Seattle, WA 98145-5005, USA
| | - William A Weiss
- Departments of Pediatrics, Neurological Surgery and Neurology, University of California San Francisco, San Francisco, CA 94143-0112, USA
| | - Boleslaw Lach
- Division of Anatomical Pathology, Department of Pathology and Molecular Medicine, McMaster University, Hamilton, ON L8S 4K1, Canada; Department of Pathology and Laboratory Medicine, Hamilton General Hospital, Hamilton, ON L8L 2X2, Canada
| | - Lola B Chambless
- Department of Neurological Surgery, Vanderbilt Medical Center, Nashville, TN 37232, USA
| | - Reid C Thompson
- Department of Neurological Surgery, Vanderbilt Medical Center, Nashville, TN 37232, USA
| | - Michael K Cooper
- Department of Neurology, Vanderbilt Medical Center, Nashville, TN 37232, USA
| | - Rajeev Vibhakar
- Department of Pediatrics, University of Colorado Denver, Aurora, CO 80045, USA
| | - Peter Hauser
- 2nd Department of Pediatrics, Semmelweis University, Budapest 1094, Hungary
| | - Marie-Lise C van Veelen
- Department of Neurosurgery, Erasmus University Medical Center, Rotterdam 3015 CE, the Netherlands
| | - Johan M Kros
- Department of Pathology, Erasmus University Medical Center, Rotterdam 3015 CN, the Netherlands
| | - Pim J French
- Department of Neurology, Erasmus University Medical Center, Rotterdam 3015 CE, the Netherlands
| | - Young Shin Ra
- Department of Neurosurgery, University of Ulsan, Asan Medical Center, Seoul 05505, South Korea
| | - Toshihiro Kumabe
- Department of Neurosurgery, Kitasato University School of Medicine, Sagamihara, Kanagawa 252-0374, Japan
| | - Enrique López-Aguilar
- Division of Pediatric Hematology/Oncology, Hospital Pediatría Centro Médico Nacional Century XXI, Mexico City 06720, Mexico
| | - Karel Zitterbart
- Department of Pediatric Oncology, School of Medicine, Masaryk University, Brno 625 00, Czech Republic
| | - Jaroslav Sterba
- Department of Pediatric Oncology, School of Medicine, Masaryk University, Brno 625 00, Czech Republic
| | - Gaetano Finocchiaro
- Department of Neuro-Oncology, Istituto Neurologico Besta, Milan 20133, Italy
| | - Maura Massimino
- Fondazione IRCCS Istituto Nazionale Tumori, Milan 20133, Italy
| | - Erwin G Van Meir
- Department of Hematology & Medical Oncology, School of Medicine and Winship Cancer Institute, Emory University, Atlanta, GA 30322, USA
| | - Satoru Osuka
- Department of Hematology & Medical Oncology, School of Medicine and Winship Cancer Institute, Emory University, Atlanta, GA 30322, USA
| | - Tomoko Shofuda
- Division of Stem Cell Research, Institute for Clinical Research, Osaka National Hospital, Osaka 540-0006, Japan
| | - Almos Klekner
- Department of Neurosurgery, University of Debrecen, Medical and Health Science Centre, Debrecen 4032, Hungary
| | - Massimo Zollo
- Dipartimento di Biochimica e Biotecnologie Mediche, University of Naples, Naples 80145, Italy
| | - Jeffrey R Leonard
- Division of Pediatric Neurosurgery, Department of Neurosurgery, Washington University School of Medicine and St. Louis Children's Hospital, St. Louis, MO 63110, USA
| | - Joshua B Rubin
- Departments of Pediatrics, Anatomy and Neurobiology, Washington University School of Medicine and St. Louis Children's Hospital, St. Louis, MO 63110, USA
| | - Nada Jabado
- Division of Hematology/Oncology, Department of Pediatrics, McGill University, Montreal, QC H4A 3J1, Canada
| | - Steffen Albrecht
- Department of Pathology, McGill University, Montreal, QC H4A 3J1, Canada; Department of Pathology, Montreal Children's Hospital, Montreal, QC H4A 3J1, Canada
| | - Jaume Mora
- Developmental Tumor Biology Laboratory, Hospital Sant Joan de Déu, Esplugues de Llobregat, Barcelona 08950, Spain
| | - Timothy E Van Meter
- Department of Pediatrics, Virginia Commonwealth University, School of Medicine, Richmond, VA 23298-0646, USA
| | - Shin Jung
- Department of Neurosurgery, Chonnam National University Research Institute of Medical Sciences, Chonnam National University Hwasun Hospital and Medical School, Hwasun-gun 519-763, Chonnam South Korea
| | - Andrew S Moore
- Lady Cilento Children's Hospital, The University of Queensland, Brisbane QLD 4102, Australia; Oncology Service, Children's Health Queensland Hospital and Health Service, South Brisbane, QLD 4029, Australia
| | - Andrew R Hallahan
- Lady Cilento Children's Hospital, The University of Queensland, Brisbane QLD 4102, Australia; Oncology Service, Children's Health Queensland Hospital and Health Service, South Brisbane, QLD 4029, Australia
| | - Jennifer A Chan
- Department of Pathology and Laboratory Medicine, University of Calgary, Calgary, AB T2N 2T9, Canada
| | - Daniela P C Tirapelli
- Department of Surgery and Anatomy, Faculty of Medicine of Ribeirão Preto, University of São Paulo, São Paulo 14049-900, Brazil
| | - Carlos G Carlotti
- Department of Surgery and Anatomy, Faculty of Medicine of Ribeirão Preto, University of São Paulo, São Paulo 14049-900, Brazil
| | - Maryam Fouladi
- Division of Hematology/Oncology, University of Cincinnati, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, USA
| | - José Pimentel
- Divison of Pathology, Centro Hospitalar Lisboa Norte, Hospital de Santa Maria, Lisbon 1649-035, Portugal
| | - Claudia C Faria
- Division of Neurosurgery, Centro Hospitalar Lisboa Norte, Hospital de Santa Maria, Lisbon 1649-035, Portugal
| | - Ali G Saad
- Department of Pathology, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
| | - Luca Massimi
- Department of Pediatric Neurosurgery, Catholic University Medical School, Rome 00198, Italy
| | - Linda M Liau
- Department of Neurosurgery, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA
| | - Helen Wheeler
- Kolling Institute of Medical Research, The University of Sydney, Sydney, NSW 2065, Australia
| | - Hideo Nakamura
- Department of Neurosurgery, Kumamoto University Graduate School of Medical Science, Kumamoto 860-8555, Japan
| | - Samer K Elbabaa
- Division of Pediatric Neurosurgery, Department of Neurosurgery, Saint Louis University School of Medicine, St. Louis, MO, USA
| | | | | | - Shenandoah Robinson
- Division of Pediatric Neurosurgery, Rainbow & Babies Children's Hospital, Case Western Reserve, Cleveland, OH 44106, USA
| | - Michal Zapotocky
- Division of Haematology / Oncology, The Hospital for Sick Children, Toronto, ON M5G 1X8, Canada
| | - Alvaro Lassaletta
- Division of Haematology / Oncology, The Hospital for Sick Children, Toronto, ON M5G 1X8, Canada
| | - Annie Huang
- The Arthur and Sonia Labatt Brain Tumour Research Centre, The Hospital for Sick Children, Toronto, ON M5G 1X8, Canada; Division of Haematology / Oncology, The Hospital for Sick Children, Toronto, ON M5G 1X8, Canada
| | - Cynthia E Hawkins
- The Arthur and Sonia Labatt Brain Tumour Research Centre, The Hospital for Sick Children, Toronto, ON M5G 1X8, Canada; Division of Pathology, The Hospital for Sick Children, Toronto, ON M5G 1X8, Canada
| | - Uri Tabori
- The Arthur and Sonia Labatt Brain Tumour Research Centre, The Hospital for Sick Children, Toronto, ON M5G 1X8, Canada; Division of Haematology / Oncology, The Hospital for Sick Children, Toronto, ON M5G 1X8, Canada
| | - Eric Bouffet
- The Arthur and Sonia Labatt Brain Tumour Research Centre, The Hospital for Sick Children, Toronto, ON M5G 1X8, Canada; Division of Haematology / Oncology, The Hospital for Sick Children, Toronto, ON M5G 1X8, Canada
| | - Ute Bartels
- Division of Haematology / Oncology, The Hospital for Sick Children, Toronto, ON M5G 1X8, Canada
| | - Peter B Dirks
- The Arthur and Sonia Labatt Brain Tumour Research Centre, The Hospital for Sick Children, Toronto, ON M5G 1X8, Canada; Division of Neurosurgery, The Hospital for Sick Children, Toronto, ON M5G 1X8, Canada
| | - James T Rutka
- The Arthur and Sonia Labatt Brain Tumour Research Centre, The Hospital for Sick Children, Toronto, ON M5G 1X8, Canada; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON M5S 1A1, Canada; Division of Neurosurgery, The Hospital for Sick Children, Toronto, ON M5G 1X8, Canada
| | - Gary D Bader
- The Donnelly Centre, University of Toronto, Toronto, ON M5S 3E1, Canada; Banting and Best Department of Medical Research, University of Toronto, Toronto, ON M5G 1L6, Canada; McLaughlin Centre, University of Toronto, Toronto, ON M5G 0A4, Canada; Department of Molecular Genetics, University of Toronto, Toronto, ON M5S 1A8, Canada; Samuel Lunenfeld Research Institute at Mount Sinai Hospital, University of Toronto, Toronto, ON M5G 1X5, Canada
| | - Jüri Reimand
- Informatics Program, Ontario Institute for Cancer Research, Toronto, ON M5G 0A3, Canada; Department of Medical Biophysics, University of Toronto, Toronto, ON M5G 1L7, Canada
| | - Anna Goldenberg
- Department of Computer Science, University of Toronto, Toronto, ON M5S 2E4, Canada; Program in Genetics and Genome Biology, The Hospital for Sick Children, Toronto, ON M5G 1X8, Canada.
| | - Vijay Ramaswamy
- The Arthur and Sonia Labatt Brain Tumour Research Centre, The Hospital for Sick Children, Toronto, ON M5G 1X8, Canada; Division of Haematology / Oncology, The Hospital for Sick Children, Toronto, ON M5G 1X8, Canada; Program in Neuroscience and Mental Health and Division of Neurology, The Hospital for Sick Children, Toronto, ON M5G 1X8, Canada.
| | - Michael D Taylor
- The Arthur and Sonia Labatt Brain Tumour Research Centre, The Hospital for Sick Children, Toronto, ON M5G 1X8, Canada; Developmental & Stem Cell Biology Program, The Hospital for Sick Children, Toronto, ON M5G 1X8, Canada; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON M5S 1A1, Canada; Division of Neurosurgery, The Hospital for Sick Children, Toronto, ON M5G 1X8, Canada.
| |
Collapse
|
17
|
Grassiot B, Szathmari A, Beuriat PA, Frappaz D, Jouvet A, Mottolese C. Évolution des stratégies thérapeutiques du médulloblastome chez l’enfant. Étude de la série lyonnaise de 2000 à 2015. Neurochirurgie 2017. [DOI: 10.1016/j.neuchi.2016.11.016] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
18
|
Dadone B, Fontaine D, Mondot L, Cristofari G, Jouvet A, Godfraind C, Varlet P, Ranchère‐Vince D, Coindre J, Gastaud L, Baudoin C, Peyron A, Thyss A, Coutts M, Michiels J, Pedeutour F, Burel‐Vandenbos F. Meningeal SWI/SNF related, matrix‐associated, actin‐dependent regulator of chromatin, subfamily B member 1 (SMARCB1)‐deficient tumours: an emerging group of meningeal tumours. Neuropathol Appl Neurobiol 2016; 43:433-449. [DOI: 10.1111/nan.12364] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/23/2016] [Revised: 09/22/2016] [Accepted: 10/12/2016] [Indexed: 12/12/2022]
Affiliation(s)
- B. Dadone
- Central Laboratory of Pathology of Nice University Hospital France
- Laboratory of Solid Tumors Genetics Nice University Hospital France
| | - D. Fontaine
- Department of Neurosurgery Nice University Hospital France
| | - L. Mondot
- Department of Radiology Nice University Hospital France
| | - G. Cristofari
- Institute for Research on Cancer and Aging of Nice (IRCAN) CNRS UMR 7284/INSERM U1081 University of Nice Sophia‐Antipolis Nice France
| | - A. Jouvet
- Department of Pathology and Neuropathology Groupement Hospitalier Est Lyon Bron France
| | - C. Godfraind
- Department of Pathology University Hospital of Clermont‐Ferrand Clermont‐Ferrand France
| | - P. Varlet
- Department of Neuropathology Sainte‐Anne Hospital Paris France
| | | | - J.‐M. Coindre
- Department of Pathology Institut Bergonié Bordeaux France
| | - L. Gastaud
- Department of Oncology Centre Antoine Lacassagne Nice France
| | - C. Baudoin
- Institute for Research on Cancer and Aging of Nice (IRCAN) CNRS UMR 7284/INSERM U1081 University of Nice Sophia‐Antipolis Nice France
| | - A.‐C. Peyron
- Laboratory of Solid Tumors Genetics Nice University Hospital France
- Institute for Research on Cancer and Aging of Nice (IRCAN) CNRS UMR 7284/INSERM U1081 University of Nice Sophia‐Antipolis Nice France
| | - A. Thyss
- Department of Oncology Centre Antoine Lacassagne Nice France
| | - M. Coutts
- Department of Pathology West Kent Cancer Centre Maidstone UK
| | - J.‐F. Michiels
- Central Laboratory of Pathology of Nice University Hospital France
| | - F. Pedeutour
- Laboratory of Solid Tumors Genetics Nice University Hospital France
- Institute for Research on Cancer and Aging of Nice (IRCAN) CNRS UMR 7284/INSERM U1081 University of Nice Sophia‐Antipolis Nice France
| | | | | |
Collapse
|
19
|
Esteban Mader M, Bonnet C, Meyronet D, Joly M, Uro-Coste E, Forest F, Guyotat J, Jouvet A, Honnorat J, Ducray F. P08.39 Characteristics of adults’ gliomas with H3-K27M mutations. Neuro Oncol 2016. [DOI: 10.1093/neuonc/now188.172] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
20
|
Sturm D, Orr BA, Toprak UH, Hovestadt V, Jones DTW, Capper D, Sill M, Buchhalter I, Northcott PA, Leis I, Ryzhova M, Koelsche C, Pfaff E, Allen SJ, Balasubramanian G, Worst BC, Pajtler KW, Brabetz S, Johann PD, Sahm F, Reimand J, Mackay A, Carvalho DM, Remke M, Phillips JJ, Perry A, Cowdrey C, Drissi R, Fouladi M, Giangaspero F, Łastowska M, Grajkowska W, Scheurlen W, Pietsch T, Hagel C, Gojo J, Lötsch D, Berger W, Slavc I, Haberler C, Jouvet A, Holm S, Hofer S, Prinz M, Keohane C, Fried I, Mawrin C, Scheie D, Mobley BC, Schniederjan MJ, Santi M, Buccoliero AM, Dahiya S, Kramm CM, von Bueren AO, von Hoff K, Rutkowski S, Herold-Mende C, Frühwald MC, Milde T, Hasselblatt M, Wesseling P, Rößler J, Schüller U, Ebinger M, Schittenhelm J, Frank S, Grobholz R, Vajtai I, Hans V, Schneppenheim R, Zitterbart K, Collins VP, Aronica E, Varlet P, Puget S, Dufour C, Grill J, Figarella-Branger D, Wolter M, Schuhmann MU, Shalaby T, Grotzer M, van Meter T, Monoranu CM, Felsberg J, Reifenberger G, Snuderl M, Forrester LA, Koster J, Versteeg R, Volckmann R, van Sluis P, Wolf S, Mikkelsen T, Gajjar A, Aldape K, Moore AS, Taylor MD, Jones C, Jabado N, Karajannis MA, Eils R, Schlesner M, Lichter P, von Deimling A, Pfister SM, Ellison DW, Korshunov A, Kool M. New Brain Tumor Entities Emerge from Molecular Classification of CNS-PNETs. Cell 2016; 164:1060-1072. [PMID: 26919435 DOI: 10.1016/j.cell.2016.01.015] [Citation(s) in RCA: 576] [Impact Index Per Article: 72.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/14/2015] [Revised: 12/22/2015] [Accepted: 01/08/2016] [Indexed: 12/11/2022]
Abstract
Primitive neuroectodermal tumors of the central nervous system (CNS-PNETs) are highly aggressive, poorly differentiated embryonal tumors occurring predominantly in young children but also affecting adolescents and adults. Herein, we demonstrate that a significant proportion of institutionally diagnosed CNS-PNETs display molecular profiles indistinguishable from those of various other well-defined CNS tumor entities, facilitating diagnosis and appropriate therapy for patients with these tumors. From the remaining fraction of CNS-PNETs, we identify four new CNS tumor entities, each associated with a recurrent genetic alteration and distinct histopathological and clinical features. These new molecular entities, designated "CNS neuroblastoma with FOXR2 activation (CNS NB-FOXR2)," "CNS Ewing sarcoma family tumor with CIC alteration (CNS EFT-CIC)," "CNS high-grade neuroepithelial tumor with MN1 alteration (CNS HGNET-MN1)," and "CNS high-grade neuroepithelial tumor with BCOR alteration (CNS HGNET-BCOR)," will enable meaningful clinical trials and the development of therapeutic strategies for patients affected by poorly differentiated CNS tumors.
Collapse
Affiliation(s)
- Dominik Sturm
- Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), 69120 Heidelberg, Germany.,Department of Pediatric Oncology, Hematology & Immunology, Heidelberg University Hospital, 69120 Heidelberg, Germany
| | - Brent A Orr
- Department of Pathology, St. Jude Children's Research Hospital, Memphis, TN 38105-3678, USA
| | - Umut H Toprak
- Division of Theoretical Bioinformatics, German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), 69120 Heidelberg, Germany
| | - Volker Hovestadt
- Division of Molecular Genetics, German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), 69120 Heidelberg, Germany
| | - David T W Jones
- Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), 69120 Heidelberg, Germany
| | - David Capper
- Department of Neuropathology, Heidelberg University Hospital, 69120 Heidelberg, Germany.,Clinical Cooperation Unit Neuropathology, German Cancer Research Center (DKFZ), 69120 Heidelberg
| | - Martin Sill
- Division of Biostatistics, German Cancer Research Center (DKFZ) Heidelberg and German Cancer Consortium (DKTK), 69120 Heidelberg, Germany
| | - Ivo Buchhalter
- Division of Theoretical Bioinformatics, German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), 69120 Heidelberg, Germany
| | - Paul A Northcott
- Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), 69120 Heidelberg, Germany
| | - Irina Leis
- Department of Neuropathology, Heidelberg University Hospital, 69120 Heidelberg, Germany
| | - Marina Ryzhova
- NN Burdenko Neurosurgical Institute, Moscow, 125047 Russia
| | - Christian Koelsche
- Department of Neuropathology, Heidelberg University Hospital, 69120 Heidelberg, Germany.,Clinical Cooperation Unit Neuropathology, German Cancer Research Center (DKFZ), 69120 Heidelberg
| | - Elke Pfaff
- Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), 69120 Heidelberg, Germany.,Department of Pediatric Oncology, Hematology & Immunology, Heidelberg University Hospital, 69120 Heidelberg, Germany
| | - Sariah J Allen
- Department of Pathology, St. Jude Children's Research Hospital, Memphis, TN 38105-3678, USA
| | - Gnanaprakash Balasubramanian
- Division of Applied Bioinformatics, German Cancer Research Center (DKFZ), National Center for Tumor Diseases (NCT), and German Cancer Consortium (DKTK), 69120 Heidelberg, Germany
| | - Barbara C Worst
- Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), 69120 Heidelberg, Germany.,Department of Pediatric Oncology, Hematology & Immunology, Heidelberg University Hospital, 69120 Heidelberg, Germany
| | - Kristian W Pajtler
- Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), 69120 Heidelberg, Germany
| | - Sebastian Brabetz
- Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), 69120 Heidelberg, Germany
| | - Pascal D Johann
- Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), 69120 Heidelberg, Germany.,Department of Pediatric Oncology, Hematology & Immunology, Heidelberg University Hospital, 69120 Heidelberg, Germany
| | - Felix Sahm
- Department of Neuropathology, Heidelberg University Hospital, 69120 Heidelberg, Germany.,Clinical Cooperation Unit Neuropathology, German Cancer Research Center (DKFZ), 69120 Heidelberg
| | - Jüri Reimand
- Ontario Institute for Cancer Research, M5G 0A3, Toronto, ON M5G 1L7, Canada.,Department of Medical Biophysics, University of Toronto, Toronto, ON M5G 1L7, Canada
| | - Alan Mackay
- Division of Molecular Pathology, The Institute of Cancer Research, SW7 3RP, London, United Kingdom
| | - Diana M Carvalho
- Division of Molecular Pathology, The Institute of Cancer Research, SW7 3RP, London, United Kingdom
| | - Marc Remke
- Program in Developmental and Stem Cell Biology, Division of Neurosurgery, Arthur and Sonia Labatt Brain Tumour Research Centre, Hospital for Sick Children, University of Toronto, Toronto, ON M4N 1X8, Canada
| | - Joanna J Phillips
- Brain Tumor Research Center, University of California, San Francisco, CA 94158-9001, USA.,Neuropathology, Department of Pathology, University of California, San Francisco, CA 94143-0102, USA.,Department of Neurological Surgery, University of California, San Francisco, CA 94143-0112, USA
| | - Arie Perry
- Brain Tumor Research Center, University of California, San Francisco, CA 94158-9001, USA.,Neuropathology, Department of Pathology, University of California, San Francisco, CA 94143-0102, USA.,Department of Neurological Surgery, University of California, San Francisco, CA 94143-0112, USA
| | - Cynthia Cowdrey
- Brain Tumor Research Center, University of California, San Francisco, CA 94158-9001, USA
| | - Rachid Drissi
- Division of Oncology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, USA
| | - Maryam Fouladi
- Division of Oncology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, USA
| | - Felice Giangaspero
- Department of Radiological, Oncological and Anatomic-Pathological Sciences, Sapienza University of Rome, 00185 Rome, Italy.,IRCCS Neuromed, 86077 Pozzilli, Molise, Italy
| | - Maria Łastowska
- Department of Pathology, Children's Memorial Health Institute, 04-730 Warsaw, Poland
| | - Wiesława Grajkowska
- Department of Pathology, Children's Memorial Health Institute, 04-730 Warsaw, Poland
| | - Wolfram Scheurlen
- Cnopf'sche Kinderklinik, Nürnberg Children's Hospital, 90419 Nürnberg, Germany
| | - Torsten Pietsch
- Department of Neuropathology, University of Bonn Medical School, 53105 Bonn, Germany
| | - Christian Hagel
- Institute of Neuropathology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany
| | - Johannes Gojo
- Department of Pediatrics and Adolescent Medicine, Medical University of Vienna, 1090 Vienna, Austria.,Department of Medicine I, Institute of Cancer Research and Comprehensive Cancer Center, Medical University of Vienna, 1090 Vienna, Austria
| | - Daniela Lötsch
- Department of Medicine I, Institute of Cancer Research and Comprehensive Cancer Center, Medical University of Vienna, 1090 Vienna, Austria
| | - Walter Berger
- Department of Medicine I, Institute of Cancer Research and Comprehensive Cancer Center, Medical University of Vienna, 1090 Vienna, Austria
| | - Irene Slavc
- Department of Pediatrics and Adolescent Medicine, Medical University of Vienna, 1090 Vienna, Austria
| | - Christine Haberler
- Institute of Neurology, Medical University of Vienna, 1097 Vienna, Austria
| | - Anne Jouvet
- Neuro-Oncology and Neuro-Inflammation Team, Inserm U1028, CNRS UMR 5292, University Lyon-1, Neuroscience Center, 69000 Lyon, France, and Centre de Pathologie et de Neuropathologie Est, Hospices Civils de Lyon, 69003 Lyon, France
| | - Stefan Holm
- Department of Women's and Children's Health (KBH), Karolinska Institutet, SE-171 77 Stockholm, Sweden
| | - Silvia Hofer
- Department of Oncology, Luzerner Kantonsspital, 6000 Luzern 16, Luzern, Switzerland
| | - Marco Prinz
- Institute of Neuropathology, University of Freiburg, Germany & BIOSS Centre for Biological Signalling Studies, University of Freiburg, 79106 Freiburg, Germany
| | - Catherine Keohane
- Department of Pathology, University College Cork and Cork University Hospital Wilton, Cork, Ireland
| | - Iris Fried
- Department of Pediatric Hematology and Oncology, Hadassah Medical Center, Jerusalem, Israel
| | - Christian Mawrin
- Institute of Neuropathology, University Hospital, Otto-von-Guericke University, 39120 Magdeburg, Germany
| | - David Scheie
- Department of Pathology, Copenhagen University Hospital, 2100 København Ø, Denmark
| | - Bret C Mobley
- Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, TN 37232, USA
| | - Matthew J Schniederjan
- Department of Pathology and Laboratory Administration, Children's Healthcare of Atlanta, Atlanta, GA 30322, USA
| | - Mariarita Santi
- Department of Pathology, Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA
| | - Anna M Buccoliero
- Pathology Unit, Anna Meyer Children's University Hospital, 50141 Florence, Italy
| | - Sonika Dahiya
- Department of Pathology and Immunology, Washington University, St. Louis, MO 63110, USA
| | - Christof M Kramm
- Division of Pediatric Hematology and Oncology, Department of Child and Adolescent Health, University Medical Center Göttingen, 37075 Göttingen, Germany
| | - André O von Bueren
- Division of Pediatric Hematology and Oncology, Department of Child and Adolescent Health, University Medical Center Göttingen, 37075 Göttingen, Germany
| | - Katja von Hoff
- Department of Pediatric Haematology and Oncology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany
| | - Stefan Rutkowski
- Department of Pediatric Haematology and Oncology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany
| | - Christel Herold-Mende
- Department of Neurosurgery, Heidelberg University Hospital, 69120 Heidelberg, Germany
| | | | - Till Milde
- Department of Pediatric Oncology, Hematology & Immunology, Heidelberg University Hospital, 69120 Heidelberg, Germany.,Clinical Cooperation Unit Pediatric Oncology, German Cancer Research Center (DKFZ) Heidelberg, 69120 Heidelberg, Germany
| | - Martin Hasselblatt
- Institute of Neuropathology, University Hospital Münster, 48149 Münster, Germany
| | - Pieter Wesseling
- Department of Pathology, VU University Medical Center Amsterdam, 1008 MB Amsterdam, The Netherlands.,Department of Pathology, Radboud University Nijmegen Medical Center, Nijmegen, 6525 GA, The Netherlands
| | - Jochen Rößler
- Department of Pediatric Hematology/Oncology, Center of Pediatrics and Adolescent Medicine, University Medical Center Freiburg, 79106 Freiburg, Germany
| | - Ulrich Schüller
- Department of Neuropathology, Ludwig-Maximilians-University, and German Cancer Consortium (DKTK) partner site Munich, 81377 Munich, Germany
| | - Martin Ebinger
- Department of Hematology and Oncology, Children's University Hospital Tübingen, and German Cancer Consortium (DKTK) partner site Tübingen, 72076 Tübingen, Germany
| | - Jens Schittenhelm
- Department of Neuropathology, Institute of Pathology and Neuropathology, University of Tübingen, and German Cancer Consortium (DKTK) partner site Tübingen, 72076 Tübingen, Germany
| | - Stephan Frank
- Department of Neuropathology, Institute of Pathology, Basel University Hospital, 4031 Basel, Switzerland
| | - Rainer Grobholz
- Department of Pathology, Medical Center Aarau, 5001 Aarau, Switzerland
| | - Istvan Vajtai
- Department of Pathology, University Hospital Bern, 3010 Bern, Switzerland
| | - Volkmar Hans
- Department of Neuropathology, Medical Center Bielefeld, 33617 Bielefeld, Germany
| | - Reinhard Schneppenheim
- Department of Pediatric Haematology and Oncology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany
| | - Karel Zitterbart
- Department of Pediatric Oncology, University Hospital Brno and Masaryk University, Faculty of Medicine, 613 00 Brno, Czech Republic
| | - V Peter Collins
- Division of Molecular Histopathology, Department of Pathology, University of Cambridge, Cambridge, CB2 0QQ, United Kingdom
| | - Eleonora Aronica
- Department of Neuropathology, AMC, University of Amsterdam, Amsterdam, 1105 AZ, The Netherlands
| | - Pascale Varlet
- Department of Neuropathology, Hôpital Sainte-Anne, 75674, Paris, France
| | - Stephanie Puget
- Pediatric Neurosurgery Department, Necker Enfants Malades Hospital, 75015, Paris, France
| | - Christelle Dufour
- Brain Tumor Program, Department of Pediatric and Adolescent Oncology, Gustave Roussy Cancer Institute, University Paris Sud, 94805, Villejuif, France
| | - Jacques Grill
- Brain Tumor Program, Department of Pediatric and Adolescent Oncology, Gustave Roussy Cancer Institute, University Paris Sud, 94805, Villejuif, France
| | - Dominique Figarella-Branger
- Department of Pathology and Neuropathology, la Timone Hospital, AP-HM and UMR911 CR02, Aix-Marseille University, 13385 Marseille, France
| | - Marietta Wolter
- Department of Neuropathology, Heinrich-Heine-University, and German Cancer Consortium (DKTK) partner site Essen/Düsseldorf, 40225 Düsseldorf, Germany
| | - Martin U Schuhmann
- Department of Neurosurgery, Section of Pediatric Neurosurgery, University Hospital Tübingen, and German Cancer Consortium (DKTK) partner site Tübingen, 72076 Tübingen, Germany
| | - Tarek Shalaby
- Neuro-Oncology Program, Division of Oncology, University Children's Hospital Zurich, 8032 Zürich, Switzerland
| | - Michael Grotzer
- Neuro-Oncology Program, Division of Oncology, University Children's Hospital Zurich, 8032 Zürich, Switzerland
| | | | - Camelia-Maria Monoranu
- Department of Neuropathology, Institute of Pathology, University of Würzburg, and Comprehensive Cancer Center (CCC) Mainfranken, University and University Hospital, 97080 Würzburg, Germany
| | - Jörg Felsberg
- Department of Neuropathology, Heinrich-Heine-University, and German Cancer Consortium (DKTK) partner site Essen/Düsseldorf, 40225 Düsseldorf, Germany
| | - Guido Reifenberger
- Department of Neuropathology, Heinrich-Heine-University, and German Cancer Consortium (DKTK) partner site Essen/Düsseldorf, 40225 Düsseldorf, Germany
| | - Matija Snuderl
- Department of Pathology, Division of Neuropathology, NYU Langone Medical Center, New York, NY 10016, USA
| | | | - Jan Koster
- Department of Oncogenomics, AMC, University of Amsterdam, Amsterdam, 1105 AZ, The Netherlands
| | - Rogier Versteeg
- Department of Oncogenomics, AMC, University of Amsterdam, Amsterdam, 1105 AZ, The Netherlands
| | - Richard Volckmann
- Department of Oncogenomics, AMC, University of Amsterdam, Amsterdam, 1105 AZ, The Netherlands
| | - Peter van Sluis
- Department of Oncogenomics, AMC, University of Amsterdam, Amsterdam, 1105 AZ, The Netherlands
| | - Stephan Wolf
- Genomics and Proteomics Core Facility, High Throughput Sequencing Unit, German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), 69120 Heidelberg, Germany
| | - Tom Mikkelsen
- Departments of Neurology and Neurosurgery, Henry Ford Hospital, Detroit, MI 48202, USA
| | - Amar Gajjar
- Department of Oncology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA
| | - Kenneth Aldape
- Department of Neuro-Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
| | - Andrew S Moore
- The University of Queensland Diamantina Institute, Translational Research Institute; UQ Child Health Research Centre, The University of Queensland; Queensland Children's Medical Research Institute, Children's Health Queensland Hospital and Health Service; Brisbane, Australia
| | - Michael D Taylor
- Program in Developmental and Stem Cell Biology, Division of Neurosurgery, Arthur and Sonia Labatt Brain Tumour Research Centre, Hospital for Sick Children, University of Toronto, Toronto, ON M4N 1X8, Canada
| | - Chris Jones
- Division of Molecular Pathology, The Institute of Cancer Research, SW7 3RP, London, United Kingdom
| | - Nada Jabado
- McGill University and Genome Quebec Innovation Centre, Montreal, QC H3A 1A4, Canada
| | - Matthias A Karajannis
- Departments of Pediatrics and Otolaryngology, Division of Pediatric Hematology/Oncology, NYU Langone Medical Center and Laura and Isaac Perlmutter Cancer Center, NY 10016, New York, USA
| | - Roland Eils
- Division of Theoretical Bioinformatics, German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), 69120 Heidelberg, Germany.,Department for Bioinformatics and Functional Genomics, Institute for Pharmacy and Molecular Biotechnology (IPMB) and BioQuant, Heidelberg University, Heidelberg, Germany.,Heidelberg Center for Personalized Oncology, DKFZ-HIPO, DKFZ, Im Neuenheimer Feld 580, 69120 Heidelberg, Germany
| | - Matthias Schlesner
- Division of Theoretical Bioinformatics, German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), 69120 Heidelberg, Germany
| | - Peter Lichter
- Division of Molecular Genetics, German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), 69120 Heidelberg, Germany.,Heidelberg Center for Personalized Oncology, DKFZ-HIPO, DKFZ, Im Neuenheimer Feld 580, 69120 Heidelberg, Germany
| | - Andreas von Deimling
- Department of Neuropathology, Heidelberg University Hospital, 69120 Heidelberg, Germany.,Clinical Cooperation Unit Neuropathology, German Cancer Research Center (DKFZ), 69120 Heidelberg
| | - Stefan M Pfister
- Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), 69120 Heidelberg, Germany.,Department of Pediatric Oncology, Hematology & Immunology, Heidelberg University Hospital, 69120 Heidelberg, Germany
| | - David W Ellison
- Department of Pathology, St. Jude Children's Research Hospital, Memphis, TN 38105-3678, USA
| | - Andrey Korshunov
- Department of Neuropathology, Heidelberg University Hospital, 69120 Heidelberg, Germany.,Clinical Cooperation Unit Neuropathology, German Cancer Research Center (DKFZ), 69120 Heidelberg
| | - Marcel Kool
- Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), 69120 Heidelberg, Germany
| |
Collapse
|
21
|
Norman J, Torchia J, De Jay N, Picard D, Rakopoulos P, Adamek D, Catchpoole D, Clifford S, Fan X, Fangusaro J, Forest F, Fouladi M, Garjjar A, Gillespie Y, Hansford J, Hayden J, Hoffman L, Hongeng S, Jones C, Jouvet A, Kaorshunov A, Lau C, Miller S, Muraszko K, Ng HK, Pfister S, Phillips J, Pomeroy S, Reddy A, Rogers H, Toledano H, Van Meter T, Wang Y, Ho CY, Young-Shin R, Taylor M, Birks D, Hawkins C, Bouffet E, Grundy R, Jabado N, Kleinman C, Huang A. PNR-39DISTINCT GENE FUSIONS SEGREGATE SUB-CLASSES OF CNS-PNETs. Neuro Oncol 2016. [DOI: 10.1093/neuonc/now067.33] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
22
|
Lassaletta A, Mistry M, Arnaldo A, Ryall S, Guerreiro-Stucklin A, Krishnatry R, Ling C, Honnorat M, Zhukova N, Zapotocky M, McKeown T, Ramaswamy V, Bartels U, Huang A, Jabado N, Cruz O, de Torres C, Cherry H, Packer R, Tatevossian R, Ellison D, Harreld J, Dalton J, Mulcahy-Levy J, Foreman N, Karajannis M, Mueller S, Nicolaides T, Eisenstat D, Carret AS, Kieran M, Ligon K, Jouvet A, Perbert R, Vasiljevic A, Frappaz D, Joly MO, Chambeless L, Thompson R, Rao AN, Chan A, NG H, Garre ML, Nozza P, Massimino M, Leary S, Crane C, Bouffet E, Hawkins C, Tabori U. LG-46INFERIOR OUTCOME AND POOR RESPONSE TO CONVENTIONAL THERAPIES IN PEDIATRIC LOW-GRADE GLIOMAS HARBORING THE BRAF V600E MUTATION. Neuro Oncol 2016. [DOI: 10.1093/neuonc/now075.46] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
23
|
Bertrand A, Rondenet C, Masliah-Planchon J, Leblond P, Fouchardière ADL, Pissaloux D, Rais KA, Lequin D, Jouvet A, Delion M, Vinchon M, Puget S, Freneaux P, Sevestre H, Delteil C, Ranchere-Vince D, Lacroix L, Tauziede-Espariat A, Boddaert N, Maurage CA, Silva K, Michalak S, Pierron G, Delattre O, Varlet P, Frappaz D, Bourdeaut F. LG-32RHABDOID COMPONENT EMERGING AS A SUBCLONAL EVOLUTION OF PEDIATRIC GLIONEURONAL TUMORS. Neuro Oncol 2016. [DOI: 10.1093/neuonc/now075.32] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
24
|
Tabouret E, Nguyen AT, Dehais C, Carpentier C, Lebouil L, Ducray F, Idbaih A, Moktari K, Jouvet A, uro-Coste E, Delattre JY, Figarella-Branger D. Validation of the new glioma WHO classification in the french POLA network: Analysis of 1041 cases. J Clin Oncol 2016. [DOI: 10.1200/jco.2016.34.15_suppl.2015] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- Emeline Tabouret
- Aix-Marseille University, AP-HM, Service de Neuro-Oncologie, CHU Timone, Marseille, France
| | | | - Caroline Dehais
- Pitie-Salpetriere Hospital- Pierre et Marie Curie Paris VI University, Paris, France
| | - Catherine Carpentier
- Institut Du Cerveau et de La Moelle - Groupe Hospitalier Pitié Salpétrière, Paris, France
| | | | | | - Ahmed Idbaih
- Universite Pierre et Marie Curie Paris VI, Paris, France
| | | | | | | | - Jean-Yves Delattre
- Pitie-Salpetriere Hospital-Pierre et Marie Curie Paris VI University, Paris, France
| | - Dominique Figarella-Branger
- Aix-Marseille University, AP-HM, Service d'Anatomopathologie et de Neuropathologie, CHU Timone, Marseille, France
| |
Collapse
|
25
|
Kamoun A, Idbaih A, Dehais C, Elarouci N, Carpentier C, Letouzé E, Colin C, Mokhtari K, Jouvet A, Uro-Coste E, Martin-Duverneuil N, Sanson M, Delattre JY, Figarella-Branger D, de Reyniès A, Ducray F. Integrated multi-omics analysis of oligodendroglial tumours identifies three subgroups of 1p/19q co-deleted gliomas. Nat Commun 2016; 7:11263. [PMID: 27090007 DOI: 10.1038/ncomms11263] [Citation(s) in RCA: 61] [Impact Index Per Article: 7.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/01/2015] [Accepted: 03/07/2016] [Indexed: 12/26/2022] Open
Abstract
Oligodendroglial tumours (OT) are a heterogeneous group of gliomas. Three molecular subgroups are currently distinguished on the basis of the IDH mutation and 1p/19q co-deletion. Here we present an integrated analysis of the transcriptome, genome and methylome of 156 OT. Not only does our multi-omics classification match the current classification but also reveals three subgroups within 1p/19q co-deleted tumours, associated with specific expression patterns of nervous system cell types: oligodendrocyte, oligodendrocyte precursor cell (OPC) and neuronal lineage. We confirm the validity of these three subgroups using public datasets. Importantly, the OPC-like group is associated with more aggressive clinical and molecular patterns, including MYC activation. We show that the MYC activation occurs through various alterations, including MYC genomic gain, MAX genomic loss, MYC hypomethylation and microRNA-34b/c down-regulation. In the lower grade glioma TCGA dataset, the OPC-like group is associated with a poorer outcome independently of histological grade. Our study reveals previously unrecognized heterogeneity among 1p/19q co-deleted tumours.
Collapse
Affiliation(s)
- Aurélie Kamoun
- Programme Cartes d'Identité des Tumeurs (CIT), Ligue Nationale Contre Le Cancer, 75013 Paris, France
| | - Ahmed Idbaih
- Université Pierre et Marie Curie Paris 6, Centre de Recherche de l'Institut de Cerveau et de la Moelle Epinière (CRICM), UMR 975, 75013 Paris, France.,INSERM U975, 75013 Paris, France.,CNRS, UMR 7225, 75013 Paris, France.,AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Service de Neurologie 2-Mazarin, 75013 Paris, France
| | - Caroline Dehais
- AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Service de Neurologie 2-Mazarin, 75013 Paris, France
| | - Nabila Elarouci
- Programme Cartes d'Identité des Tumeurs (CIT), Ligue Nationale Contre Le Cancer, 75013 Paris, France
| | - Catherine Carpentier
- Université Pierre et Marie Curie Paris 6, Centre de Recherche de l'Institut de Cerveau et de la Moelle Epinière (CRICM), UMR 975, 75013 Paris, France.,INSERM U975, 75013 Paris, France.,CNRS, UMR 7225, 75013 Paris, France
| | - Eric Letouzé
- Programme Cartes d'Identité des Tumeurs (CIT), Ligue Nationale Contre Le Cancer, 75013 Paris, France
| | - Carole Colin
- Université de la Méditerranée, Aix-Marseille, Faculté de Médecine La Timone, CRO2, UMR 911, 13885 Marseille, France
| | - Karima Mokhtari
- Université Pierre et Marie Curie Paris 6, Centre de Recherche de l'Institut de Cerveau et de la Moelle Epinière (CRICM), UMR 975, 75013 Paris, France.,INSERM U975, 75013 Paris, France.,CNRS, UMR 7225, 75013 Paris, France.,AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Laboratoire de Neuropathologie R. Escourolle, 75013 Paris, France
| | - Anne Jouvet
- Département de Pathologie et Neuropathologie, Hôpital Neurologique, Hospices Civils de Lyon, 69374 Lyon, France
| | - Emmanuelle Uro-Coste
- CHU Toulouse, Hôpital de Rangueil, Service d'Anatomie et Cytologie Pathologique, 31400 Toulouse, France
| | | | - Marc Sanson
- Université Pierre et Marie Curie Paris 6, Centre de Recherche de l'Institut de Cerveau et de la Moelle Epinière (CRICM), UMR 975, 75013 Paris, France.,INSERM U975, 75013 Paris, France.,CNRS, UMR 7225, 75013 Paris, France.,AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Service de Neurologie 2-Mazarin, 75013 Paris, France
| | - Jean-Yves Delattre
- Université Pierre et Marie Curie Paris 6, Centre de Recherche de l'Institut de Cerveau et de la Moelle Epinière (CRICM), UMR 975, 75013 Paris, France.,INSERM U975, 75013 Paris, France.,CNRS, UMR 7225, 75013 Paris, France.,AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Service de Neurologie 2-Mazarin, 75013 Paris, France.,Onconeurotek, Groupe Hospitalier Pitié-Salpêtrière, 75013 Paris, France
| | - Dominique Figarella-Branger
- Université de la Méditerranée, Aix-Marseille, Faculté de Médecine La Timone, CRO2, UMR 911, 13885 Marseille, France.,AP-HM, Hôpital de la Timone, Service d'Anatomie Pathologique et de Neuropathologie, 13885 Marseille, France
| | - Aurélien de Reyniès
- Programme Cartes d'Identité des Tumeurs (CIT), Ligue Nationale Contre Le Cancer, 75013 Paris, France
| | - François Ducray
- Hospices Civils de Lyon, Hôpital Neurologique, Service de Neuro-Oncologie, 69374 Lyon, France.,Department of Cancer Cell Plasticity, Cancer Research Centre of Lyon, INSERM U1052, CNRS UMR5286, 69008 Lyon, France.,Université Claude Bernard Lyon 1, 69000 Lyon, France
| | | |
Collapse
|
26
|
Figarella-Branger D, Lechapt-Zalcman E, Tabouret E, Jünger S, de Paula AM, Bouvier C, Colin C, Jouvet A, Forest F, Andreiuolo F, Quintin-Roue I, Machet MC, Heitzmann A, Milin S, Sevestre H, Godfraind C, Labrousse F, Metellus P, Scavarda D, Pietsch T. Supratentorial clear cell ependymomas with branching capillaries demonstrate characteristic clinicopathological features and pathological activation of nuclear factor-kappaB signaling. Neuro Oncol 2016; 18:919-27. [PMID: 26984744 DOI: 10.1093/neuonc/now025] [Citation(s) in RCA: 59] [Impact Index Per Article: 7.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/16/2015] [Accepted: 01/31/2016] [Indexed: 01/16/2023] Open
Abstract
BACKGROUND Clear cell ependymoma is one of the 4 main histological subtypes of ependymomas defined by the World Health Organization (WHO) classification of tumors of the CNS. DNA methylation profiling can distinguish 4 subgroups of intracranial ependymomas, including supratentorial (ST) ependymomas with Yes-associated protein 1 fusion (YAP1), ST ependymomas with fusion of v-rel avian reticuloendotheliosis viral oncogene homolog A (RELA), posterior fossa ependymomas with balanced genome, and posterior fossa ependymomas with chromosomal instability. In addition, trisomy 19 is a genomic hallmark of ependymomas with rich branching capillaries. However, the relation of histological and molecular subtypes is unclear. METHODS Here, we report a series of 20 ependymomas histologically defined by clear cells and branching capillaries. RESULTS We observed a strong male predominance. Median age at surgery was 10.4 years (range, 0.8-68.4). All cases were ST, cortical, contrast enhancing, and most often frontal, cystic, and calcified. All tumors qualified as WHO grade III. Some of them exhibited neuronal differentiation. Trisomy 19 was recorded in 13 cases. All samples strongly accumulated p65RelA protein within nuclei, indicating pathological activation of the nuclear factor-kappaB pathway. We identified causative C11ORF95-RELA fusion in almost all cases. Median progression-free survival and overall survival were 11.4 years (95% CI: 5.1-17.8) and not reached, respectively. CONCLUSION ST clear cell ependymomas with branching capillaries display characteristic clinicopathological features and are associated with pathological activation of nuclear factor-kappaB signaling, which may indicate a potential novel target for therapy in these patients.
Collapse
Affiliation(s)
- Dominique Figarella-Branger
- Department of Pathology and Neuropathology, Assistance Publique des Hôpitaux de Marseille (APHM), CHU Timone, Marseille, France (D.F.-B, E.T., A.M.d.P, C.B.); Aix-Marseille Université, Inserm, Marseille, France (D.F.-B, E.T., C.B., C.C.); Department of Pathology, CHU Caen, Hôpital de la Côte de Nacre, Caen, France (E.L.-Z); Department of Neurooncology, APHM, Marseille, France (E.T.); Department of Neuropathology, University of Bonn, Medical Center Sigmund-Freud, Bonn, Germany (S.J., T.P.); Department of Pathology and Neuropathology, Hospices civils de Lyon, Bron, France (A.J.); Department of Pathology, CHU de Saint-Etienne, Saint-Etienne, France (F.F.); Department of Neuropathology, CHU Sainte Anne, Paris, France (F.A.); Department of Pathology, CHU de Brest, Hôpital de la Cavale Blanche, Brest, France (I.Q.-R); Department of Pathology, CHU de Tours, Hôpital Trousseau, Tours, France (M.-C.M.); Department of Pathology, CHR d'Orléans, Hôpital de la Source, Orléans, France (A.H.); Department of Pathology, CHU de Poitiers, Hôpital la Milétrie, Poitiers, France (S.M.); Department of Pathology, CHU d'Amiens, Amiens, France (H.S.); Department of Pathology, CHU de Clermont-Ferrand, Clermont-Ferrand, France (C.G.); Department of Pathology, CHU de Limoges, Limoges, France (F.L.); Department of Neurosurgery, APHM, CHU Timone, Marseille, France (P.M.); Department of Pediatric Neurosurgery, APHM, CHU Timone, Marseille, France (D.S.)
| | - Emmanuèle Lechapt-Zalcman
- Department of Pathology and Neuropathology, Assistance Publique des Hôpitaux de Marseille (APHM), CHU Timone, Marseille, France (D.F.-B, E.T., A.M.d.P, C.B.); Aix-Marseille Université, Inserm, Marseille, France (D.F.-B, E.T., C.B., C.C.); Department of Pathology, CHU Caen, Hôpital de la Côte de Nacre, Caen, France (E.L.-Z); Department of Neurooncology, APHM, Marseille, France (E.T.); Department of Neuropathology, University of Bonn, Medical Center Sigmund-Freud, Bonn, Germany (S.J., T.P.); Department of Pathology and Neuropathology, Hospices civils de Lyon, Bron, France (A.J.); Department of Pathology, CHU de Saint-Etienne, Saint-Etienne, France (F.F.); Department of Neuropathology, CHU Sainte Anne, Paris, France (F.A.); Department of Pathology, CHU de Brest, Hôpital de la Cavale Blanche, Brest, France (I.Q.-R); Department of Pathology, CHU de Tours, Hôpital Trousseau, Tours, France (M.-C.M.); Department of Pathology, CHR d'Orléans, Hôpital de la Source, Orléans, France (A.H.); Department of Pathology, CHU de Poitiers, Hôpital la Milétrie, Poitiers, France (S.M.); Department of Pathology, CHU d'Amiens, Amiens, France (H.S.); Department of Pathology, CHU de Clermont-Ferrand, Clermont-Ferrand, France (C.G.); Department of Pathology, CHU de Limoges, Limoges, France (F.L.); Department of Neurosurgery, APHM, CHU Timone, Marseille, France (P.M.); Department of Pediatric Neurosurgery, APHM, CHU Timone, Marseille, France (D.S.)
| | - Emeline Tabouret
- Department of Pathology and Neuropathology, Assistance Publique des Hôpitaux de Marseille (APHM), CHU Timone, Marseille, France (D.F.-B, E.T., A.M.d.P, C.B.); Aix-Marseille Université, Inserm, Marseille, France (D.F.-B, E.T., C.B., C.C.); Department of Pathology, CHU Caen, Hôpital de la Côte de Nacre, Caen, France (E.L.-Z); Department of Neurooncology, APHM, Marseille, France (E.T.); Department of Neuropathology, University of Bonn, Medical Center Sigmund-Freud, Bonn, Germany (S.J., T.P.); Department of Pathology and Neuropathology, Hospices civils de Lyon, Bron, France (A.J.); Department of Pathology, CHU de Saint-Etienne, Saint-Etienne, France (F.F.); Department of Neuropathology, CHU Sainte Anne, Paris, France (F.A.); Department of Pathology, CHU de Brest, Hôpital de la Cavale Blanche, Brest, France (I.Q.-R); Department of Pathology, CHU de Tours, Hôpital Trousseau, Tours, France (M.-C.M.); Department of Pathology, CHR d'Orléans, Hôpital de la Source, Orléans, France (A.H.); Department of Pathology, CHU de Poitiers, Hôpital la Milétrie, Poitiers, France (S.M.); Department of Pathology, CHU d'Amiens, Amiens, France (H.S.); Department of Pathology, CHU de Clermont-Ferrand, Clermont-Ferrand, France (C.G.); Department of Pathology, CHU de Limoges, Limoges, France (F.L.); Department of Neurosurgery, APHM, CHU Timone, Marseille, France (P.M.); Department of Pediatric Neurosurgery, APHM, CHU Timone, Marseille, France (D.S.)
| | - Stephanie Jünger
- Department of Pathology and Neuropathology, Assistance Publique des Hôpitaux de Marseille (APHM), CHU Timone, Marseille, France (D.F.-B, E.T., A.M.d.P, C.B.); Aix-Marseille Université, Inserm, Marseille, France (D.F.-B, E.T., C.B., C.C.); Department of Pathology, CHU Caen, Hôpital de la Côte de Nacre, Caen, France (E.L.-Z); Department of Neurooncology, APHM, Marseille, France (E.T.); Department of Neuropathology, University of Bonn, Medical Center Sigmund-Freud, Bonn, Germany (S.J., T.P.); Department of Pathology and Neuropathology, Hospices civils de Lyon, Bron, France (A.J.); Department of Pathology, CHU de Saint-Etienne, Saint-Etienne, France (F.F.); Department of Neuropathology, CHU Sainte Anne, Paris, France (F.A.); Department of Pathology, CHU de Brest, Hôpital de la Cavale Blanche, Brest, France (I.Q.-R); Department of Pathology, CHU de Tours, Hôpital Trousseau, Tours, France (M.-C.M.); Department of Pathology, CHR d'Orléans, Hôpital de la Source, Orléans, France (A.H.); Department of Pathology, CHU de Poitiers, Hôpital la Milétrie, Poitiers, France (S.M.); Department of Pathology, CHU d'Amiens, Amiens, France (H.S.); Department of Pathology, CHU de Clermont-Ferrand, Clermont-Ferrand, France (C.G.); Department of Pathology, CHU de Limoges, Limoges, France (F.L.); Department of Neurosurgery, APHM, CHU Timone, Marseille, France (P.M.); Department of Pediatric Neurosurgery, APHM, CHU Timone, Marseille, France (D.S.)
| | - André Maues de Paula
- Department of Pathology and Neuropathology, Assistance Publique des Hôpitaux de Marseille (APHM), CHU Timone, Marseille, France (D.F.-B, E.T., A.M.d.P, C.B.); Aix-Marseille Université, Inserm, Marseille, France (D.F.-B, E.T., C.B., C.C.); Department of Pathology, CHU Caen, Hôpital de la Côte de Nacre, Caen, France (E.L.-Z); Department of Neurooncology, APHM, Marseille, France (E.T.); Department of Neuropathology, University of Bonn, Medical Center Sigmund-Freud, Bonn, Germany (S.J., T.P.); Department of Pathology and Neuropathology, Hospices civils de Lyon, Bron, France (A.J.); Department of Pathology, CHU de Saint-Etienne, Saint-Etienne, France (F.F.); Department of Neuropathology, CHU Sainte Anne, Paris, France (F.A.); Department of Pathology, CHU de Brest, Hôpital de la Cavale Blanche, Brest, France (I.Q.-R); Department of Pathology, CHU de Tours, Hôpital Trousseau, Tours, France (M.-C.M.); Department of Pathology, CHR d'Orléans, Hôpital de la Source, Orléans, France (A.H.); Department of Pathology, CHU de Poitiers, Hôpital la Milétrie, Poitiers, France (S.M.); Department of Pathology, CHU d'Amiens, Amiens, France (H.S.); Department of Pathology, CHU de Clermont-Ferrand, Clermont-Ferrand, France (C.G.); Department of Pathology, CHU de Limoges, Limoges, France (F.L.); Department of Neurosurgery, APHM, CHU Timone, Marseille, France (P.M.); Department of Pediatric Neurosurgery, APHM, CHU Timone, Marseille, France (D.S.)
| | - Corinne Bouvier
- Department of Pathology and Neuropathology, Assistance Publique des Hôpitaux de Marseille (APHM), CHU Timone, Marseille, France (D.F.-B, E.T., A.M.d.P, C.B.); Aix-Marseille Université, Inserm, Marseille, France (D.F.-B, E.T., C.B., C.C.); Department of Pathology, CHU Caen, Hôpital de la Côte de Nacre, Caen, France (E.L.-Z); Department of Neurooncology, APHM, Marseille, France (E.T.); Department of Neuropathology, University of Bonn, Medical Center Sigmund-Freud, Bonn, Germany (S.J., T.P.); Department of Pathology and Neuropathology, Hospices civils de Lyon, Bron, France (A.J.); Department of Pathology, CHU de Saint-Etienne, Saint-Etienne, France (F.F.); Department of Neuropathology, CHU Sainte Anne, Paris, France (F.A.); Department of Pathology, CHU de Brest, Hôpital de la Cavale Blanche, Brest, France (I.Q.-R); Department of Pathology, CHU de Tours, Hôpital Trousseau, Tours, France (M.-C.M.); Department of Pathology, CHR d'Orléans, Hôpital de la Source, Orléans, France (A.H.); Department of Pathology, CHU de Poitiers, Hôpital la Milétrie, Poitiers, France (S.M.); Department of Pathology, CHU d'Amiens, Amiens, France (H.S.); Department of Pathology, CHU de Clermont-Ferrand, Clermont-Ferrand, France (C.G.); Department of Pathology, CHU de Limoges, Limoges, France (F.L.); Department of Neurosurgery, APHM, CHU Timone, Marseille, France (P.M.); Department of Pediatric Neurosurgery, APHM, CHU Timone, Marseille, France (D.S.)
| | - Carole Colin
- Department of Pathology and Neuropathology, Assistance Publique des Hôpitaux de Marseille (APHM), CHU Timone, Marseille, France (D.F.-B, E.T., A.M.d.P, C.B.); Aix-Marseille Université, Inserm, Marseille, France (D.F.-B, E.T., C.B., C.C.); Department of Pathology, CHU Caen, Hôpital de la Côte de Nacre, Caen, France (E.L.-Z); Department of Neurooncology, APHM, Marseille, France (E.T.); Department of Neuropathology, University of Bonn, Medical Center Sigmund-Freud, Bonn, Germany (S.J., T.P.); Department of Pathology and Neuropathology, Hospices civils de Lyon, Bron, France (A.J.); Department of Pathology, CHU de Saint-Etienne, Saint-Etienne, France (F.F.); Department of Neuropathology, CHU Sainte Anne, Paris, France (F.A.); Department of Pathology, CHU de Brest, Hôpital de la Cavale Blanche, Brest, France (I.Q.-R); Department of Pathology, CHU de Tours, Hôpital Trousseau, Tours, France (M.-C.M.); Department of Pathology, CHR d'Orléans, Hôpital de la Source, Orléans, France (A.H.); Department of Pathology, CHU de Poitiers, Hôpital la Milétrie, Poitiers, France (S.M.); Department of Pathology, CHU d'Amiens, Amiens, France (H.S.); Department of Pathology, CHU de Clermont-Ferrand, Clermont-Ferrand, France (C.G.); Department of Pathology, CHU de Limoges, Limoges, France (F.L.); Department of Neurosurgery, APHM, CHU Timone, Marseille, France (P.M.); Department of Pediatric Neurosurgery, APHM, CHU Timone, Marseille, France (D.S.)
| | - Anne Jouvet
- Department of Pathology and Neuropathology, Assistance Publique des Hôpitaux de Marseille (APHM), CHU Timone, Marseille, France (D.F.-B, E.T., A.M.d.P, C.B.); Aix-Marseille Université, Inserm, Marseille, France (D.F.-B, E.T., C.B., C.C.); Department of Pathology, CHU Caen, Hôpital de la Côte de Nacre, Caen, France (E.L.-Z); Department of Neurooncology, APHM, Marseille, France (E.T.); Department of Neuropathology, University of Bonn, Medical Center Sigmund-Freud, Bonn, Germany (S.J., T.P.); Department of Pathology and Neuropathology, Hospices civils de Lyon, Bron, France (A.J.); Department of Pathology, CHU de Saint-Etienne, Saint-Etienne, France (F.F.); Department of Neuropathology, CHU Sainte Anne, Paris, France (F.A.); Department of Pathology, CHU de Brest, Hôpital de la Cavale Blanche, Brest, France (I.Q.-R); Department of Pathology, CHU de Tours, Hôpital Trousseau, Tours, France (M.-C.M.); Department of Pathology, CHR d'Orléans, Hôpital de la Source, Orléans, France (A.H.); Department of Pathology, CHU de Poitiers, Hôpital la Milétrie, Poitiers, France (S.M.); Department of Pathology, CHU d'Amiens, Amiens, France (H.S.); Department of Pathology, CHU de Clermont-Ferrand, Clermont-Ferrand, France (C.G.); Department of Pathology, CHU de Limoges, Limoges, France (F.L.); Department of Neurosurgery, APHM, CHU Timone, Marseille, France (P.M.); Department of Pediatric Neurosurgery, APHM, CHU Timone, Marseille, France (D.S.)
| | - Fabien Forest
- Department of Pathology and Neuropathology, Assistance Publique des Hôpitaux de Marseille (APHM), CHU Timone, Marseille, France (D.F.-B, E.T., A.M.d.P, C.B.); Aix-Marseille Université, Inserm, Marseille, France (D.F.-B, E.T., C.B., C.C.); Department of Pathology, CHU Caen, Hôpital de la Côte de Nacre, Caen, France (E.L.-Z); Department of Neurooncology, APHM, Marseille, France (E.T.); Department of Neuropathology, University of Bonn, Medical Center Sigmund-Freud, Bonn, Germany (S.J., T.P.); Department of Pathology and Neuropathology, Hospices civils de Lyon, Bron, France (A.J.); Department of Pathology, CHU de Saint-Etienne, Saint-Etienne, France (F.F.); Department of Neuropathology, CHU Sainte Anne, Paris, France (F.A.); Department of Pathology, CHU de Brest, Hôpital de la Cavale Blanche, Brest, France (I.Q.-R); Department of Pathology, CHU de Tours, Hôpital Trousseau, Tours, France (M.-C.M.); Department of Pathology, CHR d'Orléans, Hôpital de la Source, Orléans, France (A.H.); Department of Pathology, CHU de Poitiers, Hôpital la Milétrie, Poitiers, France (S.M.); Department of Pathology, CHU d'Amiens, Amiens, France (H.S.); Department of Pathology, CHU de Clermont-Ferrand, Clermont-Ferrand, France (C.G.); Department of Pathology, CHU de Limoges, Limoges, France (F.L.); Department of Neurosurgery, APHM, CHU Timone, Marseille, France (P.M.); Department of Pediatric Neurosurgery, APHM, CHU Timone, Marseille, France (D.S.)
| | - Felipe Andreiuolo
- Department of Pathology and Neuropathology, Assistance Publique des Hôpitaux de Marseille (APHM), CHU Timone, Marseille, France (D.F.-B, E.T., A.M.d.P, C.B.); Aix-Marseille Université, Inserm, Marseille, France (D.F.-B, E.T., C.B., C.C.); Department of Pathology, CHU Caen, Hôpital de la Côte de Nacre, Caen, France (E.L.-Z); Department of Neurooncology, APHM, Marseille, France (E.T.); Department of Neuropathology, University of Bonn, Medical Center Sigmund-Freud, Bonn, Germany (S.J., T.P.); Department of Pathology and Neuropathology, Hospices civils de Lyon, Bron, France (A.J.); Department of Pathology, CHU de Saint-Etienne, Saint-Etienne, France (F.F.); Department of Neuropathology, CHU Sainte Anne, Paris, France (F.A.); Department of Pathology, CHU de Brest, Hôpital de la Cavale Blanche, Brest, France (I.Q.-R); Department of Pathology, CHU de Tours, Hôpital Trousseau, Tours, France (M.-C.M.); Department of Pathology, CHR d'Orléans, Hôpital de la Source, Orléans, France (A.H.); Department of Pathology, CHU de Poitiers, Hôpital la Milétrie, Poitiers, France (S.M.); Department of Pathology, CHU d'Amiens, Amiens, France (H.S.); Department of Pathology, CHU de Clermont-Ferrand, Clermont-Ferrand, France (C.G.); Department of Pathology, CHU de Limoges, Limoges, France (F.L.); Department of Neurosurgery, APHM, CHU Timone, Marseille, France (P.M.); Department of Pediatric Neurosurgery, APHM, CHU Timone, Marseille, France (D.S.)
| | - Isabelle Quintin-Roue
- Department of Pathology and Neuropathology, Assistance Publique des Hôpitaux de Marseille (APHM), CHU Timone, Marseille, France (D.F.-B, E.T., A.M.d.P, C.B.); Aix-Marseille Université, Inserm, Marseille, France (D.F.-B, E.T., C.B., C.C.); Department of Pathology, CHU Caen, Hôpital de la Côte de Nacre, Caen, France (E.L.-Z); Department of Neurooncology, APHM, Marseille, France (E.T.); Department of Neuropathology, University of Bonn, Medical Center Sigmund-Freud, Bonn, Germany (S.J., T.P.); Department of Pathology and Neuropathology, Hospices civils de Lyon, Bron, France (A.J.); Department of Pathology, CHU de Saint-Etienne, Saint-Etienne, France (F.F.); Department of Neuropathology, CHU Sainte Anne, Paris, France (F.A.); Department of Pathology, CHU de Brest, Hôpital de la Cavale Blanche, Brest, France (I.Q.-R); Department of Pathology, CHU de Tours, Hôpital Trousseau, Tours, France (M.-C.M.); Department of Pathology, CHR d'Orléans, Hôpital de la Source, Orléans, France (A.H.); Department of Pathology, CHU de Poitiers, Hôpital la Milétrie, Poitiers, France (S.M.); Department of Pathology, CHU d'Amiens, Amiens, France (H.S.); Department of Pathology, CHU de Clermont-Ferrand, Clermont-Ferrand, France (C.G.); Department of Pathology, CHU de Limoges, Limoges, France (F.L.); Department of Neurosurgery, APHM, CHU Timone, Marseille, France (P.M.); Department of Pediatric Neurosurgery, APHM, CHU Timone, Marseille, France (D.S.)
| | - Marie-Christine Machet
- Department of Pathology and Neuropathology, Assistance Publique des Hôpitaux de Marseille (APHM), CHU Timone, Marseille, France (D.F.-B, E.T., A.M.d.P, C.B.); Aix-Marseille Université, Inserm, Marseille, France (D.F.-B, E.T., C.B., C.C.); Department of Pathology, CHU Caen, Hôpital de la Côte de Nacre, Caen, France (E.L.-Z); Department of Neurooncology, APHM, Marseille, France (E.T.); Department of Neuropathology, University of Bonn, Medical Center Sigmund-Freud, Bonn, Germany (S.J., T.P.); Department of Pathology and Neuropathology, Hospices civils de Lyon, Bron, France (A.J.); Department of Pathology, CHU de Saint-Etienne, Saint-Etienne, France (F.F.); Department of Neuropathology, CHU Sainte Anne, Paris, France (F.A.); Department of Pathology, CHU de Brest, Hôpital de la Cavale Blanche, Brest, France (I.Q.-R); Department of Pathology, CHU de Tours, Hôpital Trousseau, Tours, France (M.-C.M.); Department of Pathology, CHR d'Orléans, Hôpital de la Source, Orléans, France (A.H.); Department of Pathology, CHU de Poitiers, Hôpital la Milétrie, Poitiers, France (S.M.); Department of Pathology, CHU d'Amiens, Amiens, France (H.S.); Department of Pathology, CHU de Clermont-Ferrand, Clermont-Ferrand, France (C.G.); Department of Pathology, CHU de Limoges, Limoges, France (F.L.); Department of Neurosurgery, APHM, CHU Timone, Marseille, France (P.M.); Department of Pediatric Neurosurgery, APHM, CHU Timone, Marseille, France (D.S.)
| | - Anne Heitzmann
- Department of Pathology and Neuropathology, Assistance Publique des Hôpitaux de Marseille (APHM), CHU Timone, Marseille, France (D.F.-B, E.T., A.M.d.P, C.B.); Aix-Marseille Université, Inserm, Marseille, France (D.F.-B, E.T., C.B., C.C.); Department of Pathology, CHU Caen, Hôpital de la Côte de Nacre, Caen, France (E.L.-Z); Department of Neurooncology, APHM, Marseille, France (E.T.); Department of Neuropathology, University of Bonn, Medical Center Sigmund-Freud, Bonn, Germany (S.J., T.P.); Department of Pathology and Neuropathology, Hospices civils de Lyon, Bron, France (A.J.); Department of Pathology, CHU de Saint-Etienne, Saint-Etienne, France (F.F.); Department of Neuropathology, CHU Sainte Anne, Paris, France (F.A.); Department of Pathology, CHU de Brest, Hôpital de la Cavale Blanche, Brest, France (I.Q.-R); Department of Pathology, CHU de Tours, Hôpital Trousseau, Tours, France (M.-C.M.); Department of Pathology, CHR d'Orléans, Hôpital de la Source, Orléans, France (A.H.); Department of Pathology, CHU de Poitiers, Hôpital la Milétrie, Poitiers, France (S.M.); Department of Pathology, CHU d'Amiens, Amiens, France (H.S.); Department of Pathology, CHU de Clermont-Ferrand, Clermont-Ferrand, France (C.G.); Department of Pathology, CHU de Limoges, Limoges, France (F.L.); Department of Neurosurgery, APHM, CHU Timone, Marseille, France (P.M.); Department of Pediatric Neurosurgery, APHM, CHU Timone, Marseille, France (D.S.)
| | - Serge Milin
- Department of Pathology and Neuropathology, Assistance Publique des Hôpitaux de Marseille (APHM), CHU Timone, Marseille, France (D.F.-B, E.T., A.M.d.P, C.B.); Aix-Marseille Université, Inserm, Marseille, France (D.F.-B, E.T., C.B., C.C.); Department of Pathology, CHU Caen, Hôpital de la Côte de Nacre, Caen, France (E.L.-Z); Department of Neurooncology, APHM, Marseille, France (E.T.); Department of Neuropathology, University of Bonn, Medical Center Sigmund-Freud, Bonn, Germany (S.J., T.P.); Department of Pathology and Neuropathology, Hospices civils de Lyon, Bron, France (A.J.); Department of Pathology, CHU de Saint-Etienne, Saint-Etienne, France (F.F.); Department of Neuropathology, CHU Sainte Anne, Paris, France (F.A.); Department of Pathology, CHU de Brest, Hôpital de la Cavale Blanche, Brest, France (I.Q.-R); Department of Pathology, CHU de Tours, Hôpital Trousseau, Tours, France (M.-C.M.); Department of Pathology, CHR d'Orléans, Hôpital de la Source, Orléans, France (A.H.); Department of Pathology, CHU de Poitiers, Hôpital la Milétrie, Poitiers, France (S.M.); Department of Pathology, CHU d'Amiens, Amiens, France (H.S.); Department of Pathology, CHU de Clermont-Ferrand, Clermont-Ferrand, France (C.G.); Department of Pathology, CHU de Limoges, Limoges, France (F.L.); Department of Neurosurgery, APHM, CHU Timone, Marseille, France (P.M.); Department of Pediatric Neurosurgery, APHM, CHU Timone, Marseille, France (D.S.)
| | - Henri Sevestre
- Department of Pathology and Neuropathology, Assistance Publique des Hôpitaux de Marseille (APHM), CHU Timone, Marseille, France (D.F.-B, E.T., A.M.d.P, C.B.); Aix-Marseille Université, Inserm, Marseille, France (D.F.-B, E.T., C.B., C.C.); Department of Pathology, CHU Caen, Hôpital de la Côte de Nacre, Caen, France (E.L.-Z); Department of Neurooncology, APHM, Marseille, France (E.T.); Department of Neuropathology, University of Bonn, Medical Center Sigmund-Freud, Bonn, Germany (S.J., T.P.); Department of Pathology and Neuropathology, Hospices civils de Lyon, Bron, France (A.J.); Department of Pathology, CHU de Saint-Etienne, Saint-Etienne, France (F.F.); Department of Neuropathology, CHU Sainte Anne, Paris, France (F.A.); Department of Pathology, CHU de Brest, Hôpital de la Cavale Blanche, Brest, France (I.Q.-R); Department of Pathology, CHU de Tours, Hôpital Trousseau, Tours, France (M.-C.M.); Department of Pathology, CHR d'Orléans, Hôpital de la Source, Orléans, France (A.H.); Department of Pathology, CHU de Poitiers, Hôpital la Milétrie, Poitiers, France (S.M.); Department of Pathology, CHU d'Amiens, Amiens, France (H.S.); Department of Pathology, CHU de Clermont-Ferrand, Clermont-Ferrand, France (C.G.); Department of Pathology, CHU de Limoges, Limoges, France (F.L.); Department of Neurosurgery, APHM, CHU Timone, Marseille, France (P.M.); Department of Pediatric Neurosurgery, APHM, CHU Timone, Marseille, France (D.S.)
| | - Catherine Godfraind
- Department of Pathology and Neuropathology, Assistance Publique des Hôpitaux de Marseille (APHM), CHU Timone, Marseille, France (D.F.-B, E.T., A.M.d.P, C.B.); Aix-Marseille Université, Inserm, Marseille, France (D.F.-B, E.T., C.B., C.C.); Department of Pathology, CHU Caen, Hôpital de la Côte de Nacre, Caen, France (E.L.-Z); Department of Neurooncology, APHM, Marseille, France (E.T.); Department of Neuropathology, University of Bonn, Medical Center Sigmund-Freud, Bonn, Germany (S.J., T.P.); Department of Pathology and Neuropathology, Hospices civils de Lyon, Bron, France (A.J.); Department of Pathology, CHU de Saint-Etienne, Saint-Etienne, France (F.F.); Department of Neuropathology, CHU Sainte Anne, Paris, France (F.A.); Department of Pathology, CHU de Brest, Hôpital de la Cavale Blanche, Brest, France (I.Q.-R); Department of Pathology, CHU de Tours, Hôpital Trousseau, Tours, France (M.-C.M.); Department of Pathology, CHR d'Orléans, Hôpital de la Source, Orléans, France (A.H.); Department of Pathology, CHU de Poitiers, Hôpital la Milétrie, Poitiers, France (S.M.); Department of Pathology, CHU d'Amiens, Amiens, France (H.S.); Department of Pathology, CHU de Clermont-Ferrand, Clermont-Ferrand, France (C.G.); Department of Pathology, CHU de Limoges, Limoges, France (F.L.); Department of Neurosurgery, APHM, CHU Timone, Marseille, France (P.M.); Department of Pediatric Neurosurgery, APHM, CHU Timone, Marseille, France (D.S.)
| | - François Labrousse
- Department of Pathology and Neuropathology, Assistance Publique des Hôpitaux de Marseille (APHM), CHU Timone, Marseille, France (D.F.-B, E.T., A.M.d.P, C.B.); Aix-Marseille Université, Inserm, Marseille, France (D.F.-B, E.T., C.B., C.C.); Department of Pathology, CHU Caen, Hôpital de la Côte de Nacre, Caen, France (E.L.-Z); Department of Neurooncology, APHM, Marseille, France (E.T.); Department of Neuropathology, University of Bonn, Medical Center Sigmund-Freud, Bonn, Germany (S.J., T.P.); Department of Pathology and Neuropathology, Hospices civils de Lyon, Bron, France (A.J.); Department of Pathology, CHU de Saint-Etienne, Saint-Etienne, France (F.F.); Department of Neuropathology, CHU Sainte Anne, Paris, France (F.A.); Department of Pathology, CHU de Brest, Hôpital de la Cavale Blanche, Brest, France (I.Q.-R); Department of Pathology, CHU de Tours, Hôpital Trousseau, Tours, France (M.-C.M.); Department of Pathology, CHR d'Orléans, Hôpital de la Source, Orléans, France (A.H.); Department of Pathology, CHU de Poitiers, Hôpital la Milétrie, Poitiers, France (S.M.); Department of Pathology, CHU d'Amiens, Amiens, France (H.S.); Department of Pathology, CHU de Clermont-Ferrand, Clermont-Ferrand, France (C.G.); Department of Pathology, CHU de Limoges, Limoges, France (F.L.); Department of Neurosurgery, APHM, CHU Timone, Marseille, France (P.M.); Department of Pediatric Neurosurgery, APHM, CHU Timone, Marseille, France (D.S.)
| | - Philippe Metellus
- Department of Pathology and Neuropathology, Assistance Publique des Hôpitaux de Marseille (APHM), CHU Timone, Marseille, France (D.F.-B, E.T., A.M.d.P, C.B.); Aix-Marseille Université, Inserm, Marseille, France (D.F.-B, E.T., C.B., C.C.); Department of Pathology, CHU Caen, Hôpital de la Côte de Nacre, Caen, France (E.L.-Z); Department of Neurooncology, APHM, Marseille, France (E.T.); Department of Neuropathology, University of Bonn, Medical Center Sigmund-Freud, Bonn, Germany (S.J., T.P.); Department of Pathology and Neuropathology, Hospices civils de Lyon, Bron, France (A.J.); Department of Pathology, CHU de Saint-Etienne, Saint-Etienne, France (F.F.); Department of Neuropathology, CHU Sainte Anne, Paris, France (F.A.); Department of Pathology, CHU de Brest, Hôpital de la Cavale Blanche, Brest, France (I.Q.-R); Department of Pathology, CHU de Tours, Hôpital Trousseau, Tours, France (M.-C.M.); Department of Pathology, CHR d'Orléans, Hôpital de la Source, Orléans, France (A.H.); Department of Pathology, CHU de Poitiers, Hôpital la Milétrie, Poitiers, France (S.M.); Department of Pathology, CHU d'Amiens, Amiens, France (H.S.); Department of Pathology, CHU de Clermont-Ferrand, Clermont-Ferrand, France (C.G.); Department of Pathology, CHU de Limoges, Limoges, France (F.L.); Department of Neurosurgery, APHM, CHU Timone, Marseille, France (P.M.); Department of Pediatric Neurosurgery, APHM, CHU Timone, Marseille, France (D.S.)
| | - Didier Scavarda
- Department of Pathology and Neuropathology, Assistance Publique des Hôpitaux de Marseille (APHM), CHU Timone, Marseille, France (D.F.-B, E.T., A.M.d.P, C.B.); Aix-Marseille Université, Inserm, Marseille, France (D.F.-B, E.T., C.B., C.C.); Department of Pathology, CHU Caen, Hôpital de la Côte de Nacre, Caen, France (E.L.-Z); Department of Neurooncology, APHM, Marseille, France (E.T.); Department of Neuropathology, University of Bonn, Medical Center Sigmund-Freud, Bonn, Germany (S.J., T.P.); Department of Pathology and Neuropathology, Hospices civils de Lyon, Bron, France (A.J.); Department of Pathology, CHU de Saint-Etienne, Saint-Etienne, France (F.F.); Department of Neuropathology, CHU Sainte Anne, Paris, France (F.A.); Department of Pathology, CHU de Brest, Hôpital de la Cavale Blanche, Brest, France (I.Q.-R); Department of Pathology, CHU de Tours, Hôpital Trousseau, Tours, France (M.-C.M.); Department of Pathology, CHR d'Orléans, Hôpital de la Source, Orléans, France (A.H.); Department of Pathology, CHU de Poitiers, Hôpital la Milétrie, Poitiers, France (S.M.); Department of Pathology, CHU d'Amiens, Amiens, France (H.S.); Department of Pathology, CHU de Clermont-Ferrand, Clermont-Ferrand, France (C.G.); Department of Pathology, CHU de Limoges, Limoges, France (F.L.); Department of Neurosurgery, APHM, CHU Timone, Marseille, France (P.M.); Department of Pediatric Neurosurgery, APHM, CHU Timone, Marseille, France (D.S.)
| | - Torsten Pietsch
- Department of Pathology and Neuropathology, Assistance Publique des Hôpitaux de Marseille (APHM), CHU Timone, Marseille, France (D.F.-B, E.T., A.M.d.P, C.B.); Aix-Marseille Université, Inserm, Marseille, France (D.F.-B, E.T., C.B., C.C.); Department of Pathology, CHU Caen, Hôpital de la Côte de Nacre, Caen, France (E.L.-Z); Department of Neurooncology, APHM, Marseille, France (E.T.); Department of Neuropathology, University of Bonn, Medical Center Sigmund-Freud, Bonn, Germany (S.J., T.P.); Department of Pathology and Neuropathology, Hospices civils de Lyon, Bron, France (A.J.); Department of Pathology, CHU de Saint-Etienne, Saint-Etienne, France (F.F.); Department of Neuropathology, CHU Sainte Anne, Paris, France (F.A.); Department of Pathology, CHU de Brest, Hôpital de la Cavale Blanche, Brest, France (I.Q.-R); Department of Pathology, CHU de Tours, Hôpital Trousseau, Tours, France (M.-C.M.); Department of Pathology, CHR d'Orléans, Hôpital de la Source, Orléans, France (A.H.); Department of Pathology, CHU de Poitiers, Hôpital la Milétrie, Poitiers, France (S.M.); Department of Pathology, CHU d'Amiens, Amiens, France (H.S.); Department of Pathology, CHU de Clermont-Ferrand, Clermont-Ferrand, France (C.G.); Department of Pathology, CHU de Limoges, Limoges, France (F.L.); Department of Neurosurgery, APHM, CHU Timone, Marseille, France (P.M.); Department of Pediatric Neurosurgery, APHM, CHU Timone, Marseille, France (D.S.)
| |
Collapse
|
27
|
Thompson EM, Hielscher T, Bouffet E, Remke M, Luu B, Gururangan S, McLendon RE, Bigner DD, Lipp ES, Perreault S, Cho YJ, Grant G, Kim SK, Lee JY, Rao AAN, Giannini C, Li KKW, Ng HK, Yao Y, Kumabe T, Tominaga T, Grajkowska WA, Perek-Polnik M, Low DCY, Seow WT, Chang KTE, Mora J, Pollack IF, Hamilton RL, Leary S, Moore AS, Ingram WJ, Hallahan AR, Jouvet A, Fèvre-Montange M, Vasiljevic A, Faure-Conter C, Shofuda T, Kagawa N, Hashimoto N, Jabado N, Weil AG, Gayden T, Wataya T, Shalaby T, Grotzer M, Zitterbart K, Sterba J, Kren L, Hortobágyi T, Klekner A, László B, Pócza T, Hauser P, Schüller U, Jung S, Jang WY, French PJ, Kros JM, van Veelen MLC, Massimi L, Leonard JR, Rubin JB, Vibhakar R, Chambless LB, Cooper MK, Thompson RC, Faria CC, Carvalho A, Nunes S, Pimentel J, Fan X, Muraszko KM, López-Aguilar E, Lyden D, Garzia L, Shih DJH, Kijima N, Schneider C, Adamski J, Northcott PA, Kool M, Jones DTW, Chan JA, Nikolic A, Garre ML, Van Meir EG, Osuka S, Olson JJ, Jahangiri A, Castro BA, Gupta N, Weiss WA, Moxon-Emre I, Mabbott DJ, Lassaletta A, Hawkins CE, Tabori U, Drake J, Kulkarni A, Dirks P, Rutka JT, Korshunov A, Pfister SM, Packer RJ, Ramaswamy V, Taylor MD. Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis. Lancet Oncol 2016; 17:484-495. [PMID: 26976201 PMCID: PMC4907853 DOI: 10.1016/s1470-2045(15)00581-1] [Citation(s) in RCA: 223] [Impact Index Per Article: 27.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/24/2015] [Revised: 12/01/2015] [Accepted: 12/03/2015] [Indexed: 12/12/2022]
Abstract
Background Incomplete surgical resection of medulloblastoma is controversially considered a marker of high-risk disease; driving aggressive surgical resections, “second-look” surgeries, and/or intensified chemoradiotherapy. All prior publications evaluating the clinical importance of extent of resection (EOR) failed to account for molecular subgroup. We analysed the prognostic value of EOR across 787 medulloblastoma samples in a subgroup-specific manner. Methods We retrospectively identified patients from Medulloblastoma Advanced Genomics International Consortium (MAGIC) centres with a histological diagnosis of medulloblastoma and complete extent of resection and survival data. Specimens were collected from 35 international institutions. Medulloblastoma subgroup affiliation was determined using nanoString gene expression profiling on frozen or formalin-fixed paraffin-embedded tissues. Extent of resection (EOR) based on post-operative imaging was classified as gross total (GTR), near total (NTR, <1·5cm2), or subtotal (STR, ≥ 1·5cm2). Overall survival (OS) and progression-free survival (PFS) multivariable analyses including subgroup, age, metastatic status, geographical location of therapy (North America/Australia vs world), and adjuvant therapy regimen were performed. The primary endpoint was the impact of surgical EOR by molecular subgroup and other clinical variables on OS and PFS. Findings 787 medulloblastoma patients (86 WNT, 242 SHH, 163 Group 3, and 296 Group 4) were included in a multivariable Cox model of PFS and OS. The marked benefit of EOR in the overall cohort was greatly attenuated after including molecular subgroup in the multivariable analysis. There was an observed PFS benefit of GTR over STR (hazard ration [HR] 1·45, 95% CI; 1·07–1·96, p=0·02) but there was no observed PFS or OS benefit of GTR over NTR (HR 1·05, 0·71–1·53, p=0·82 and HR 1·14, 0·75–1·72, p=0.55). There was no statistically significant survival benefit to greater EOR for patients with WNT, SHH, or Group 3 patients (HR 1·03, 0·67–1·58, p=0·9 for STR vs. GTR). There was a PFS benefit for GTR over STR in patients with Group 4 medulloblastoma (HR1·97, 1·22–3·17, p=0·01), particularly those with metastatic disease (HR 2·22, 1–4·93, p=0·05). A nomogram based on this multivariable cox proportional hazards model shows the comparably smaller impact of EOR on relative risk for PFS and OS than subgroup affiliation, metastatic status, radiation dose, and adjuvant chemotherapy. Interpretation The prognostic benefit of EOR for patients with medulloblastoma is attenuated after accounting for molecular subgroup affiliation. Although maximal safe surgical resection should remain the standard of care, surgical removal of small residual portions of medulloblastoma is not recommended when the likelihood of neurological morbidity is high as there is no definitive benefit to GTR over NTR. Our results suggest a re-evaluation of the long-term implications of intensified craniospinal irradiation (36 Gy) in children with small residual portions of medulloblastoma. Funding Funding Canadian Cancer Society Research Institute, Terry Fox Research Institute, Canadian Institutes of Health Research, National Institutes of Health, Pediatric Brain Tumor Foundation, Garron Family Chair in Childhood Cancer Research.
Collapse
Affiliation(s)
- Eric M Thompson
- Division of Neurosurgery, The Hospital for Sick Children, Toronto, ON, Canada; Department of Neurosurgery, Duke University, Durham, NC, USA
| | - Thomas Hielscher
- Division of Biostatistics, German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - Eric Bouffet
- Division of Haematology/Oncology, The Hospital for Sick Children, Toronto, ON, Canada; The Arthur and Sonia Labatt Brain Tumour Research Centre, The Hospital for Sick Children, Toronto, ON, Canada
| | - Marc Remke
- Department of Pediatric Oncology, Hematology, and Clinical Immunology, University Hospital Düsseldorf, Düsseldorf, Germany
| | - Betty Luu
- Developmental & Stem Cell Biology Program, The Hospital for Sick Children, Toronto, ON, Canada
| | | | | | - Darell D Bigner
- Department of Pathology, Duke University, Durham, NC, USA; The Preston Robert Tisch Brain Tumor Center, Duke University, Durham, NC, USA
| | - Eric S Lipp
- Department of Pathology, Duke University, Durham, NC, USA
| | | | - Yoon-Jae Cho
- Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA; Department of Neurosurgery, Stanford University School of Medicine, Stanford, CA, USA
| | - Gerald Grant
- Department of Neurosurgery, Stanford University School of Medicine, Stanford, CA, USA; Department of Neurosurgery, Lucille Packard Children's Hospital, Stanford, CA, USA
| | - Seung-Ki Kim
- Department of Neurosurgery, Division of Pediatric Neurosurgery, Seoul National University Children's Hospital, Seoul, South Korea
| | - Ji Yeoun Lee
- Department of Neurosurgery, Division of Pediatric Neurosurgery, Seoul National University Children's Hospital, Seoul, South Korea
| | | | - Caterina Giannini
- Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA
| | - Kay Ka Wai Li
- Department of Anatomical and Cellular Pathology, The Chinese University of Hong Kong, Shatin, New Territories, Hong Kong Special Administrative Region, China
| | - Ho-Keung Ng
- Department of Anatomical and Cellular Pathology, The Chinese University of Hong Kong, Shatin, New Territories, Hong Kong Special Administrative Region, China
| | - Yu Yao
- Department of Neurosurgery, Hua Shan Hospital, Fudan University, Shanghai, China
| | - Toshihiro Kumabe
- Department of Neurosurgery, Kitasato University School of Medicine, Sagamihara, Kanagawa, Japan
| | - Teiji Tominaga
- Department of Neurosurgery, Tohoku University Graduate School of Medicine, Sendai, Japan
| | | | - Marta Perek-Polnik
- Department of Oncology, The Children's Memorial Health Institute, Warsaw, Poland
| | - David C Y Low
- Neurosurgical Service, KK Women's and Children's Hospital, Singapore, Singapore
| | - Wan Tew Seow
- Neurosurgical Service, KK Women's and Children's Hospital, Singapore, Singapore
| | - Kenneth T E Chang
- Department of Pathology & Laboratory Medicine, KK Women's and Children's Hospital, Singapore, Singapore
| | - Jaume Mora
- Developmental Tumor Biology Laboratory, Hospital Sant Joan de Déu, Esplugues de Llobregat, Barcelona, Spain
| | - Ian F Pollack
- Department of Neurological Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
| | - Ronald L Hamilton
- Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
| | - Sarah Leary
- Cancer and Blood Disorders Center, Seattle Children's Hospital, Seattle, WA, USA
| | - Andrew S Moore
- UQ Child Health Research Centre, University of Queensland, Brisbane, QLD, Australia; Oncology Service, Lady Cilento Children's Hospital, Children's Health Queensland, Brisbane, QLD, Australia
| | - Wendy J Ingram
- UQ Child Health Research Centre, University of Queensland, Brisbane, QLD, Australia
| | - Andrew R Hallahan
- UQ Child Health Research Centre, University of Queensland, Brisbane, QLD, Australia; Oncology Service, Lady Cilento Children's Hospital, Children's Health Queensland, Brisbane, QLD, Australia
| | - Anne Jouvet
- Centre de Pathologie EST, Groupement Hospitalier EST, Université de Lyon, Lyon, France
| | - Michelle Fèvre-Montange
- INSERM U1028, CNRS UMR5292, Centre de Recherche en Neurosciences, Université de Lyon, Lyon, France
| | - Alexandre Vasiljevic
- Centre de Pathologie et Neuropathologie Est, Centre de Biologie et Pathologie Est, Groupement Hospitalier Est, Hospices Civils de Lyon, Bron; ONCOFLAM, Neuro-Oncologie et Neuro-Inflammation Centre de Recherche en Neurosciences de Lyon, Lyon, France
| | | | - Tomoko Shofuda
- Division of Stem Cell Research, Institute for Clinical Research, Osaka National Hospital, Osaka, Japan
| | - Naoki Kagawa
- Department of Neurosurgery, Osaka University Graduate School of Medicine, Osaka, Japan
| | - Naoya Hashimoto
- Department of Neurosurgery, Osaka University Graduate School of Medicine, Osaka, Japan
| | - Nada Jabado
- Division of Hematology/Oncology, McGill University, Montreal, QC, Canada
| | - Alexander G Weil
- Departments of Pediatrics and Human Genetics, McGill University, Montreal, QC, Canada
| | - Tenzin Gayden
- Departments of Pediatrics and Human Genetics, McGill University, Montreal, QC, Canada
| | - Takafumi Wataya
- Department of Pediatric Neurosurgery, Shizuoka Children's Hospital, Shizuoka, Japan
| | - Tarek Shalaby
- Departments of Oncology and Neuro-Oncology, University Children's Hospital of Zurich, Zurich, Switzerland
| | - Michael Grotzer
- Departments of Oncology and Neuro-Oncology, University Children's Hospital of Zurich, Zurich, Switzerland
| | - Karel Zitterbart
- Department of Pediatric Oncology, School of Medicine, Masaryk University, Brno, Czech Republic
| | - Jaroslav Sterba
- Department of Pediatric Oncology, School of Medicine, Masaryk University, Brno, Czech Republic
| | - Leos Kren
- Department of Pathology, University Hospital Brno, Brno, Czech Republic
| | - Tibor Hortobágyi
- Division of Neuropathology, University of Debrecen, Medical and Health Science Centre, Debrecen, Hungary
| | - Almos Klekner
- Division of Neuropathology, University of Debrecen, Medical and Health Science Centre, Debrecen, Hungary
| | - Bognár László
- Division of Neuropathology, University of Debrecen, Medical and Health Science Centre, Debrecen, Hungary
| | - Tímea Pócza
- 2nd Department of Pediatrics, Semmelweis University, Budapest, Hungary
| | - Peter Hauser
- 2nd Department of Pediatrics, Semmelweis University, Budapest, Hungary
| | - Ulrich Schüller
- Center for Neuropathology, Ludwig-Maximilians-Universität, Munich, Germany
| | - Shin Jung
- Department of Neurosurgery, Chonnam National University Research Institute of Medical Sciences, Chonnam National University Hwasun Hospital and Medical School, Hwasun-gun, Chonnam South Korea
| | - Woo-Youl Jang
- Department of Neurosurgery, Chonnam National University Research Institute of Medical Sciences, Chonnam National University Hwasun Hospital and Medical School, Hwasun-gun, Chonnam South Korea
| | - Pim J French
- Department of Neurosurgery, Erasmus University Medical Center, Rotterdam, Netherlands
| | - Johan M Kros
- Department of Pathology, Erasmus University Medical Center, Rotterdam, Netherlands
| | | | - Luca Massimi
- Pediatric Neurosurgery, Catholic University Medical School, Rome, Italy
| | - Jeffrey R Leonard
- Department of Neurosurgery, Division of Pediatric Neurosurgery, Washington University School of Medicine and St Louis Children's Hospital, St Louis, MO, USA
| | - Joshua B Rubin
- Departments of Pediatrics, Anatomy and Neurobiology, Washington University School of Medicine and St Louis Children's Hospital, St Louis, MO, USA
| | - Rajeev Vibhakar
- Department of Pediatrics, University of Colorado Denver, Aurora, CO, USA
| | - Lola B Chambless
- Department of Neurological Surgery, Vanderbilt Medical Center, Nashville, TN, USA
| | - Michael K Cooper
- Department of Neurology, Vanderbilt Medical Center, Nashville, TN, USA
| | - Reid C Thompson
- Department of Neurological Surgery, Vanderbilt Medical Center, Nashville, TN, USA
| | - Claudia C Faria
- Division of Neurosurgery, Centro Hospitalar Lisboa Norte, Hospital de Santa Maria, Lisbon, Portugal
| | - Alice Carvalho
- Departamento de Oncologia Pediátrica, Hospital Pediátrico de Coimbra, Centro Hospitalar de Coimbra, Coimbra, Portugal
| | - Sofia Nunes
- Unidade de Neuro-Oncologia Pediátrica, Instituto Português de Oncologia de Lisboa Francisco Gentil, Lisbon, Portugal
| | - José Pimentel
- Divison of Pathology, Centro Hospitalar Lisboa Norte, Hospital de Santa Maria, Lisbon, Portugal
| | - Xing Fan
- Department of Neurosurgery and Cell and Developmental Biology, University of Michigan Medical School, Ann Arbor, MI, USA
| | - Karin M Muraszko
- Department of Neurosurgery, University of Michigan Medical School, Ann Arbor, MI, USA
| | - Enrique López-Aguilar
- Division of Pediatric Hematology/Oncology, Hospital Pediatría Centro Médico Nacional Century XXI, Mexico City, Mexico
| | - David Lyden
- Department of Pediatrics and Cell and Developmental Biology, Weill Cornell Medical College, New York, NY, USA
| | - Livia Garzia
- Developmental & Stem Cell Biology Program, The Hospital for Sick Children, Toronto, ON, Canada
| | - David J H Shih
- Developmental & Stem Cell Biology Program, The Hospital for Sick Children, Toronto, ON, Canada; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada
| | - Noriyuki Kijima
- Developmental & Stem Cell Biology Program, The Hospital for Sick Children, Toronto, ON, Canada
| | - Christian Schneider
- Division of Neurosurgery, The Hospital for Sick Children, Toronto, ON, Canada
| | - Jennifer Adamski
- Division of Haematology/Oncology, The Hospital for Sick Children, Toronto, ON, Canada
| | - Paul A Northcott
- Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - Marcel Kool
- Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - David T W Jones
- Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - Jennifer A Chan
- Department of Pathology and Laboratory Medicine, University of Calgary, Calgary, AB, Canada
| | - Ana Nikolic
- Department of Pathology and Laboratory Medicine, University of Calgary, Calgary, AB, Canada
| | | | - Erwin G Van Meir
- Department of Hematology & Medical Oncology, School of Medicine and Winship Cancer Institute, Emory University, Atlanta, GA, USA
| | - Satoru Osuka
- Department of Hematology & Medical Oncology, School of Medicine and Winship Cancer Institute, Emory University, Atlanta, GA, USA
| | - Jeffrey J Olson
- Department of Neurosurgery, School of Medicine and Winship Cancer Institute, Emory University, Atlanta, GA, USA
| | - Arman Jahangiri
- Department of Neurological Surgery, University of California San Francisco, San Francisco, CA, USA
| | - Brandyn A Castro
- Department of Neurological Surgery, University of California San Francisco, San Francisco, CA, USA
| | - Nalin Gupta
- Department of Neurological Surgery, University of California San Francisco, San Francisco, CA, USA; Department of Pediatrics, University of California San Francisco, San Francisco, CA, USA
| | - William A Weiss
- Department of Neurological Surgery, University of California San Francisco, San Francisco, CA, USA; Department of Pediatrics, University of California San Francisco, San Francisco, CA, USA; Department of Neurology, University of California San Francisco, San Francisco, CA, USA
| | - Iska Moxon-Emre
- Program in Neuroscience and Mental Health and Department of Psychology, The Hospital for Sick Children, Toronto, ON, Canada
| | - Donald J Mabbott
- Program in Neuroscience and Mental Health and Department of Psychology, The Hospital for Sick Children, Toronto, ON, Canada
| | - Alvaro Lassaletta
- Division of Haematology/Oncology, The Hospital for Sick Children, Toronto, ON, Canada
| | - Cynthia E Hawkins
- Division of Pathology, The Hospital for Sick Children, Toronto, ON, Canada
| | - Uri Tabori
- Division of Haematology/Oncology, The Hospital for Sick Children, Toronto, ON, Canada; The Arthur and Sonia Labatt Brain Tumour Research Centre, The Hospital for Sick Children, Toronto, ON, Canada
| | - James Drake
- Division of Neurosurgery, The Hospital for Sick Children, Toronto, ON, Canada
| | - Abhaya Kulkarni
- Division of Neurosurgery, The Hospital for Sick Children, Toronto, ON, Canada
| | - Peter Dirks
- Division of Neurosurgery, The Hospital for Sick Children, Toronto, ON, Canada; The Arthur and Sonia Labatt Brain Tumour Research Centre, The Hospital for Sick Children, Toronto, ON, Canada
| | - James T Rutka
- Division of Neurosurgery, The Hospital for Sick Children, Toronto, ON, Canada; The Arthur and Sonia Labatt Brain Tumour Research Centre, The Hospital for Sick Children, Toronto, ON, Canada; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada
| | - Andrey Korshunov
- Clinical Cooperation Unit Neuropathology, German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - Stefan M Pfister
- Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ), Heidelberg, Germany; Department of Pediatric Oncology, University Hospital Heidelberg, Heidelberg, Germany
| | - Roger J Packer
- Department of Neurology, Children's National Medical Center, Washington, DC, USA
| | - Vijay Ramaswamy
- Division of Neurosurgery, The Hospital for Sick Children, Toronto, ON, Canada; Division of Haematology/Oncology, The Hospital for Sick Children, Toronto, ON, Canada; The Arthur and Sonia Labatt Brain Tumour Research Centre, The Hospital for Sick Children, Toronto, ON, Canada; Developmental & Stem Cell Biology Program, The Hospital for Sick Children, Toronto, ON, Canada; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada
| | - Michael D Taylor
- Division of Neurosurgery, The Hospital for Sick Children, Toronto, ON, Canada; The Arthur and Sonia Labatt Brain Tumour Research Centre, The Hospital for Sick Children, Toronto, ON, Canada; Developmental & Stem Cell Biology Program, The Hospital for Sick Children, Toronto, ON, Canada; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada.
| |
Collapse
|
28
|
Masliah-Planchon J, Machet MC, Fréneaux P, Jourdain A, Mortemousque I, Raïs KA, Ballet S, Jouvet A, Figarella-Branger D, Delattre O, Bourdeaut F. SMARCA4-Mutated Atypical Teratoid/Rhabdoid Tumor with Retained BRG1 Expression. Pediatr Blood Cancer 2016; 63:568-9. [PMID: 26469284 DOI: 10.1002/pbc.25772] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/20/2015] [Accepted: 09/02/2015] [Indexed: 02/03/2023]
Affiliation(s)
- Julien Masliah-Planchon
- Unité de génétique somatique, Institut Curie, Paris, France.,Inserm U830, Unité de Génétique et Biologie des Cancers, Institut Curie, Paris, France
| | | | - Paul Fréneaux
- Département de pathologie, Institut Curie, Paris, France
| | - Anne Jourdain
- Unité d'onco-hématologie pédiatrique, Hôpital de Clocheville, Tours, France
| | | | | | - Stelly Ballet
- Unité de génétique somatique, Institut Curie, Paris, France
| | - Anne Jouvet
- Centre de pathologie Est et groupement hospitalier Est, Bron, France
| | - Dominique Figarella-Branger
- Service d'Anatomie Pathologique et de Neuropathologie, Hôpital de la Timone, APHM, Aix-Marseille Université, Marseille, France
| | - Olivier Delattre
- Inserm U830, Unité de Génétique et Biologie des Cancers, Institut Curie, Paris, France
| | - Franck Bourdeaut
- Inserm U830, Unité de Génétique et Biologie des Cancers, Institut Curie, Paris, France.,Département d'oncologie pédiatrique, Institut Curie, Paris, France.,SiRIC Institut Curie, Recherche Translationnelle en Oncologie Pédiatrique, Paris, France
| |
Collapse
|
29
|
Horwitz M, Dufour C, Leblond P, Bourdeaut F, Faure-Conter C, Bertozzi AI, Delisle MB, Palenzuela G, Jouvet A, Scavarda D, Vinchon M, Padovani L, Gaudart J, Branger DF, Andre N. Embryonal tumors with multilayered rosettes in children: the SFCE experience. Childs Nerv Syst 2016; 32:299-305. [PMID: 26438544 DOI: 10.1007/s00381-015-2920-2] [Citation(s) in RCA: 37] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/22/2015] [Accepted: 09/23/2015] [Indexed: 10/23/2022]
Abstract
PURPOSES The purpose of this study was to retrospectively study embryonal tumors with multilayered rosettes (ETMR), a rare new entity that gathers ETAN-TR (embryonal tumor with abundant neuropil and true rosettes), ependymoblastomas, and medulloepitheliomas, in order to improve their descriptions and try to better define therapeutic modalities. METHODS Patients with ETMR, ETAN-TR, ependymoblastoma, and medulloepithelioma treated in SFCE centres (Société Française de lutte contre les Cancers et les leucémies de l'Enfant et de l'adolescent) since 2000 were collected. Data were retrieved from clinical charts. RESULTS Thirty-eight patients were included in the analysis. Seventeen had an ETAN-TR, 13 had a medulloepithelioma, and 8 had an ETMR. No ependymoblastoma was included. The median age at diagnosis was 31 months (range, 2.8-141 months). The predominant tumor location was supratentorial (66%); 18.4% patients had metastatic lesion. LIN28A expression was positive in 11/11 patients. Amplification of the locus 19q13.42 was positive in 10/12 patients. Thirty patients were treated according to the primitive neuroectodermal tumors of high risk (PNET-HR) protocol. The median time of follow-up was 0.9 years (range 0.1 to 15.3 years). The 1-year event-free survival (EFS) and overall survival (OS) were, respectively, 36% CI 95% (23-55) and 45% CI 95% (31-64). On multivariate analysis, complete surgical resection, radiotherapy, and high-dose chemotherapy were associated with a better overall survival with a relative risk of, respectively, 7.9 CI 95% (2.6-23.5) p < 0.0002, 41.8 CI 95% (9.4-186) p < 0.0001, and 3.5 CI 95% (1.3-9.5) p = 0.012. CONCLUSION Prognosis of ETMR remains dismal despite multimodal therapy. LIN28A immunostaining and 19q13.42 amplification should be systematically done to secure the diagnosis. Complete surgical resection, radiotherapy, and high-dose chemotherapy are associated with better outcome.
Collapse
Affiliation(s)
- Meryl Horwitz
- Department of Pediatric Hematology-Oncology, APHM, La Timone Hospital, 264 rue Saint-Pierre, 13005, Marseille, France.
| | - Christelle Dufour
- Department of Pediatric and Adolescent Oncology, Gustave Roussy Campus, 114, rue Edouard-Vaillant, 94805, Villejuif Cedex, France.
| | - Pierre Leblond
- Department of Pediatric Oncology, Oscar Lambret, 3 rue Frederic Combemale, BP 307, 59020, Lille Cedex, France.
| | - Franck Bourdeaut
- Department of Pediatric Oncology, Institut Curie, 26, rue d'Ulm, 75005, Paris, France. .,INSERM U830, Laboratory of Genetics and Cancer Biology, Institut Curie, Paris, France.
| | - Cécile Faure-Conter
- Department of Pediatrics, Centre Léon Bérard, 28 Prom. Léa et Napoléon Bullukian, 69008, Lyon, France.
| | - Anne-Isabelle Bertozzi
- Department of Hematology-Oncology, Children University Hospital, 330 Avenue de Grande Bretagne, 31300, Toulouse, France.
| | - Marie Bernadette Delisle
- Department of Neuropathology, Toulouse Rangueil University Hospital, 1, avenue du Pr Jean Poulhès, 31400, Toulouse, France.
| | - Gilles Palenzuela
- Department of Pediatric Hematology-Oncology, University Hospital of Montpellier, 191, avenue du doyen Gaston Giraud, 34295, Montpellier cedex, France.
| | - Anne Jouvet
- Department of Pathology and neuropathology, "Pierre Werthmeier" Hospital, Boulevard Pinel, 69677, Bron, France.
| | - Didier Scavarda
- Department of Neurosurgery, APHM, La Timone Hospital, 264 rue Saint-Pierre, 13005, Marseille, France.
| | - Matthieu Vinchon
- Department of Pediatric Neurosurgery, Lille University Hospital, 2 Avenue Oscar Lambret, 59000, Lille, France.
| | - Laetitia Padovani
- Department of Radiation Oncology and Pediatrics, APHM, La Timone Hospital, 264 rue Saint-Pierre, 13005, Marseille, France.
| | - Jean Gaudart
- BIOSTIC, Pôle de Santé Publique, AP-HM, Marseille, 264 rue Saint-Pierre, 13005, Marseille, France. .,UMR912 SESSTIM, Aix-Marseille University, Marseille, France.
| | - Dominique Figarella Branger
- Department of Pathology, APHM, La Timone Hospital, Université Aix-Marseille, 264 rue Saint-Pierre, 13005, Marseille, France.
| | - Nicolas Andre
- Department of Pediatric Hematology-Oncology, APHM, La Timone Hospital, 264 rue Saint-Pierre, 13005, Marseille, France. .,INSERM UMR 911, Centre de Recherche en Oncologie biologique et en Oncopharmacologie, Aix-Marseille University, 264 rue Saint-Pierre, 13005, Marseille, France. .,Department of Pediatric Hematology and Oncology, Children Hospital of La Timone, 264, rue Saint-Pierre, 13005, Marseille, France.
| |
Collapse
|
30
|
Nguyen AT, Colin C, Nanni-Metellus I, Padovani L, Maurage CA, Varlet P, Miquel C, Uro-Coste E, Godfraind C, Lechapt-Zalcman E, Labrousse F, Gauchotte G, Silva K, Jouvet A, Figarella-Branger D. Evidence for BRAF V600E and H3F3A K27M double mutations in paediatric glial and glioneuronal tumours. Neuropathol Appl Neurobiol 2015; 41:403-8. [PMID: 25389051 DOI: 10.1111/nan.12196] [Citation(s) in RCA: 43] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/16/2014] [Accepted: 09/25/2014] [Indexed: 11/27/2022]
Affiliation(s)
- Anh Tuan Nguyen
- Service d'Anatomie Pathologique et de Neuropathologie, APHM, Hôpital de la Timone, Marseille, France
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
31
|
Collardeau-Frachon S, Vasiljevic A, Jouvet A, Bouvier R, Senée V, Nicolino M. Microscopic and ultrastructural features in Wolcott-Rallison syndrome, a permanent neonatal diabetes mellitus: about two autopsy cases. Pediatr Diabetes 2015; 16:510-20. [PMID: 25131821 DOI: 10.1111/pedi.12201] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/25/2014] [Revised: 05/25/2014] [Accepted: 07/03/2014] [Indexed: 01/08/2023] Open
Abstract
BACKGROUND Wolcott-Rallison syndrome (WRS) is a rare autosomal recessive disorder characterized by the association of permanent neonatal or early-infancy insulin-dependent diabetes, multiple bone dysplasia, hepatic dysfunction, and growth retardation. All clinical manifestations result from gene mutations encoding pancreatic endoplasmic reticulum eIF2 α kinase (PERK), an endoplasmic reticulum transmembrane protein that plays a role in the unfolded protein response. Histological and ultrastructural lesions of bone and pancreas have been described in animal models and WRS patients. However, histological and ultrastructural findings of other organs, especially of the liver, are lacking. METHODS Autopsy specimens from two pediatric patients with WRS were analyzed. An immunohistochemical study was performed on the pancreas. An ultrastructural study was realized from samples of liver, pancreas, kidney, and myocardium. Our findings were compared with those of the literature and correlated with the molecular data. RESULTS Hepatocytes and pancreatic exocrine cells exhibited very peculiar features of necrosis suggestive of secondary changes because of endoplasmic reticulum overload. Steatosis occurred in renal tubular cells, hepatocytes, and myocardial fibers. Abnormal mitochondria were noted in renal and myocardial fibers. Pancreas islets were characterized by a marked reduction in the number of insulin-secreting β cells. CONCLUSIONS The histological and ultrastructural features that occur in WRS are directly or indirectly linked to endoplasmic reticulum (ER) dysfunction and can explain the peculiar phenotype of this syndrome.
Collapse
Affiliation(s)
- Sophie Collardeau-Frachon
- Department of Pathology, Children and Mother's Hospital, Groupement Hospitalier Est, CHU de Lyon-Bron, France
| | - Alexandre Vasiljevic
- Department of Pathology, Children and Mother's Hospital, Groupement Hospitalier Est, CHU de Lyon-Bron, France
| | - Anne Jouvet
- Department of Pathology, Children and Mother's Hospital, Groupement Hospitalier Est, CHU de Lyon-Bron, France
| | - Raymonde Bouvier
- Department of Pathology, Children and Mother's Hospital, Groupement Hospitalier Est, CHU de Lyon-Bron, France
| | - Valérie Senée
- Medical Faculty Paris 7, Inserm UMR-S958, Paris, France
| | - Marc Nicolino
- Department of Endocrinology, Children and Mother's Hospital, Groupement Hospitalier Est, CHU de Lyon-Bron, France
| |
Collapse
|
32
|
Bruno A, Daniau M, Mokhtari K, Rahimian A, Polivka M, Jouvet A, Adam C, Figarella-Branger D, Miquel C, Eimer S, Houillier C, Soussain C, Alentorn A, Hoang-Xuan K. Abstract 3896: Recurrent TERT promoter mutations in primary central nervous system lymphoma. Cancer Res 2015. [DOI: 10.1158/1538-7445.am2015-3896] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Primary central nervous system lymphoma (PCNSL) is a rare extranodal diffuse large B-cell lymphoma (DLBCL) restricted to the CNS and associated with a poor prognosis. Despite a notable effort contributing to better characterize the genomic basis of these tumors, few molecular abnormalities were proposed as predictive or prognostic biomarkers. Recently, two hotspot mutations, C228T and C250T, and the polymorphism rs2853669, located within TERT core promoter region have known a growing interest due to their prognostic value in a wide range of tumors, including melanoma, hepatocellular carcinoma or glioblastoma.
Forty-one PCNSL tumor samples of newly diagnosed PCNSL were sequenced for C228T and C250T TERT somatic mutations. TERT promoter mutations status was correlated with clinical outcome and rs2853669 genotype.
We identified C228T and C250T mutations and rs2853669 genotype in 20%, 9.4% and 50%, respectively. No case with co-occurrence of C228T and C250T mutations was identified. C228T mutations, but not C250T, were significantly associated with shorter overall survival (OS) (median OS = 4.5 months vs 33 months for non-mutated, p = 0.0048) and progression free survival (PFS) (median PFS = 3 months vs 11.5 months for non-mutated, p = 0.0260). We found no association between TERT promoter mutations and the rs2853669 genotype.
To our knowledge, we showed the presence of TERT promoter mutations in PCNSL for the first time. In addition, C228T promoter mutation was associated with a poor outcome. Considering that these mutations are known to confer enhanced TERT promoter activity, we speculate that an increased telomerase activity could play a role in PCNSL aggressiveness.
This work was granted by the LOC study group network (réseau national de centres experts des lymphomes primitifs du SNC, INCa), the Ligue contre le Cancer (Comité du Val d’Oise), the Fondation pour la Recherche Médicale (FDT20140930968), the APHP-CRIC 2013 (assistance publique - hôpitaux de Paris), and the Association pour la Recherche sur les Tumeurs Cérébrales.
Citation Format: Aurélie Bruno, Mailys Daniau, Karima Mokhtari, Amithys Rahimian, Marc Polivka, Anne Jouvet, Clovis Adam, Dominique Figarella-Branger, Catherine Miquel, Sandrine Eimer, Caroline Houillier, Carole Soussain, Agusti Alentorn, Khê Hoang-Xuan. Recurrent TERT promoter mutations in primary central nervous system lymphoma. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 3896. doi:10.1158/1538-7445.AM2015-3896
Collapse
Affiliation(s)
- Aurélie Bruno
- 1Groupe Hospitalier Pitié-Salpêtrière, AP-HP, UPMC-Paris 6, ICM, INSERM U1127, CNRS UMR 7225, Paris, France
| | - Mailys Daniau
- 2Groupe Hospitalier Pitié-Salpêtrière, AP-HP, UPMC-Paris 6, ICM, INSERM U1127, CNRS UMR 7225 and Plateforme de Génotypage Séquençage ICM, Paris, France
| | - Karima Mokhtari
- 3Groupe Hospitalier Pitié-Salpêtrière, AP-HP, UPMC-Paris 6, ICM, INSERM U1127, CNRS UMR 7225 and Onconeurotek, GH Pitié Salpêtrière, APHP, Paris, France
| | - Amithys Rahimian
- 3Groupe Hospitalier Pitié-Salpêtrière, AP-HP, UPMC-Paris 6, ICM, INSERM U1127, CNRS UMR 7225 and Onconeurotek, GH Pitié Salpêtrière, APHP, Paris, France
| | - Marc Polivka
- 4Centre Hospitalier Universitaire Lariboisière, Assistance Publique-Hôpitaux de Paris, Service d'Anatomopathologie, Paris, France
| | - Anne Jouvet
- 5Hospices Civils de Lyon, Hôpital Neurologique and Université Lyon 1, INSERM U842, Lyon, France
| | - Clovis Adam
- 6Centre Hospitalier Universitaire Bicêtre, AP-HP, Service d'anatomopathologie, Bicêtre, France
| | - Dominique Figarella-Branger
- 7CHU La Timone, AP-HM, INSERM U911, Centre de Recherches en Oncologie biologique et Onco-pharmacologie, Université de la Méditerranée and Tumorothèque de l'AP-HM, Marseille, France
| | - Catherine Miquel
- 8Centre hospitalier Sainte Anne, Université Paris Descartes, Sorbonne Paris Cité, Paris, France
| | | | - Caroline Houillier
- 1Groupe Hospitalier Pitié-Salpêtrière, AP-HP, UPMC-Paris 6, ICM, INSERM U1127, CNRS UMR 7225, Paris, France
| | - Carole Soussain
- 10Hôpital René Huguenin, Institut Curie, Service d'Hématologie, Saint Cloud, France
| | - Agusti Alentorn
- 1Groupe Hospitalier Pitié-Salpêtrière, AP-HP, UPMC-Paris 6, ICM, INSERM U1127, CNRS UMR 7225, Paris, France
| | - Khê Hoang-Xuan
- 1Groupe Hospitalier Pitié-Salpêtrière, AP-HP, UPMC-Paris 6, ICM, INSERM U1127, CNRS UMR 7225, Paris, France
| |
Collapse
|
33
|
Heim S, Sill M, Jones DTW, Vasiljevic A, Jouvet A, Fèvre-Montange M, Wesseling P, Beschorner R, Mittelbronn M, Kohlhof P, Hovestadt V, Johann P, Kool M, Pajtler KW, Korshunov A, Ruland V, Sperveslage J, Thomas C, Witt H, von Deimling A, Paulus W, Pfister SM, Capper D, Hasselblatt M. Papillary Tumor of the Pineal Region: A Distinct Molecular Entity. Brain Pathol 2015; 26:199-205. [PMID: 26113311 DOI: 10.1111/bpa.12282] [Citation(s) in RCA: 32] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/29/2015] [Accepted: 06/15/2015] [Indexed: 12/26/2022] Open
Abstract
Papillary tumor of the pineal region (PTPR) is a neuroepithelial brain tumor, which might pose diagnostic difficulties and recurs often. Little is known about underlying molecular alterations. We therefore investigated chromosomal copy number alterations, DNA methylation patterns and mRNA expression profiles in a series of 24 PTPRs. Losses of chromosome 10 were identified in all 13 PTPRs examined. Losses of chromosomes 3 and 22q (54%) as well as gains of chromosomes 8p (62%) and 12 (46%) were also common. DNA methylation profiling using Illumina 450k arrays reliably distinguished PTPR from ependymomas and pineal parenchymal tumors of intermediate differentiation. PTPR could be divided into two subgroups based on methylation pattern, PTPR group 2 showing higher global methylation and a tendency toward shorter progression-free survival (P = 0.06). Genes overexpressed in PTPR as compared with ependymal tumors included SPDEF, known to be expressed in the rodent subcommissural organ. Notable SPDEF protein expression was encountered in 15/19 PTPRs as compared with only 2/36 ependymal tumors, 2/19 choroid plexus tumors and 0/23 samples of other central nervous system (CNS) tumor entities. In conclusion, PTPRs show typical chromosomal alterations as well as distinct DNA methylation and expression profiles, which might serve as useful diagnostic tools.
Collapse
Affiliation(s)
- Stephanie Heim
- Institute of Neuropathology, University Hospital Münster, Münster, Germany
| | - Martin Sill
- Division of Biostatistics, German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - David T W Jones
- Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - Alexandre Vasiljevic
- Centre de Pathologie et Neuropathologie Est, Centre de Biologie et Pathologie Est, Groupement Hospitalier Est, Hospices Civils de Lyon, Bron Cedex, France.,CRNL, INSERM U1028, CNRS UMR 5292, Equipe Neuro-oncologie et Neuro-inflammation, Université de Lyon, Lyon Cedex, France
| | - Anne Jouvet
- Centre de Pathologie et Neuropathologie Est, Centre de Biologie et Pathologie Est, Groupement Hospitalier Est, Hospices Civils de Lyon, Bron Cedex, France.,CRNL, INSERM U1028, CNRS UMR 5292, Equipe Neuro-oncologie et Neuro-inflammation, Université de Lyon, Lyon Cedex, France
| | - Michelle Fèvre-Montange
- CRNL, INSERM U1028, CNRS UMR 5292, Equipe Neuro-oncologie et Neuro-inflammation, Université de Lyon, Lyon Cedex, France
| | - Pieter Wesseling
- Department of Pathology, Radboud University Medical Center, Nijmegen, the Netherlands.,Department of Pathology, VU University Medical Center, Amsterdam, the Netherlands
| | - Rudi Beschorner
- Department of Neuropathology, Institute for Pathology and Neuropathology, University of Tübingen, Tübingen, Germany
| | - Michel Mittelbronn
- Institute of Neurology (Edinger Institute), Goethe University, Frankfurt, Germany
| | | | - Volker Hovestadt
- Division of Molecular Genetics, German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - Pascal Johann
- Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ), Heidelberg, Germany.,Department of Pediatric Oncology and Hematology, University Hospital Heidelberg, Heidelberg, Germany
| | - Marcel Kool
- Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ), Heidelberg, Germany.,Department of Pediatric Oncology and Hematology, University Hospital Heidelberg, Heidelberg, Germany
| | - Kristian W Pajtler
- Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - Andrey Korshunov
- Clinical Cooperation Unit Neuropathology, German Cancer Research Center (DKFZ), Heidelberg, Germany.,German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.,Department of Neuropathology, University Hospital Heidelberg, Heidelberg, Germany
| | - Vincent Ruland
- Institute of Neuropathology, University Hospital Münster, Münster, Germany
| | - Jan Sperveslage
- Gerhard-Domagk-Institute of Pathology, University Hospital Münster, Münster, Germany
| | - Christian Thomas
- Institute of Neuropathology, University Hospital Münster, Münster, Germany
| | - Hendrik Witt
- Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ), Heidelberg, Germany.,Department of Pediatric Oncology and Hematology, University Hospital Heidelberg, Heidelberg, Germany
| | - Andreas von Deimling
- Clinical Cooperation Unit Neuropathology, German Cancer Research Center (DKFZ), Heidelberg, Germany.,German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.,Department of Neuropathology, University Hospital Heidelberg, Heidelberg, Germany
| | - Werner Paulus
- Institute of Neuropathology, University Hospital Münster, Münster, Germany
| | - Stefan M Pfister
- Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ), Heidelberg, Germany.,German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.,Department of Pediatric Oncology and Hematology, University Hospital Heidelberg, Heidelberg, Germany
| | - David Capper
- Clinical Cooperation Unit Neuropathology, German Cancer Research Center (DKFZ), Heidelberg, Germany.,German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.,Department of Neuropathology, University Hospital Heidelberg, Heidelberg, Germany
| | - Martin Hasselblatt
- Institute of Neuropathology, University Hospital Münster, Münster, Germany
| |
Collapse
|
34
|
Figarella‐Branger D, Mokhtari K, Colin C, Uro‐Coste E, Jouvet A, Dehais C, Carpentier C, Villa C, Maurage C, Eimer S, Polivka M, Vignaud J, Laquerriere A, Sevestre H, Lechapt‐Zalcman E, Quintin‐Roué I, Aubriot‐Lorton M, Diebold M, Viennet G, Adam C, Loussouarn D, Michalak S, Rigau V, Heitzmann A, Vandenbos F, Forest F, Chiforeanu D, Tortel M, Labrousse F, Chenard M, Nguyen AT, Varlet P, Kemeny JL, Levillain P, Cazals‐Hatem D, Richard P, Delattre J. Prognostic Relevance of Histomolecular Classification of Diffuse Adult High-Grade Gliomas with Necrosis. Brain Pathol 2015; 25:418-28. [PMID: 25407774 PMCID: PMC8029113 DOI: 10.1111/bpa.12227] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/31/2014] [Accepted: 11/07/2014] [Indexed: 12/26/2022] Open
Abstract
Diffuse adult high-grade gliomas (HGGs) with necrosis encompass anaplastic oligodendrogliomas (AOs) with necrosis (grade III), glioblastomas (GBM, grade IV) and glioblastomas with an oligodendroglial component (GBMO, grade IV). Here, we aimed to search for prognostic relevance of histological classification and molecular alterations of these tumors. About 210 patients were included (63 AO, 56 GBM and 91 GBMO). GBMO group was split into "anaplastic oligoastrocytoma (AOA) with necrosis grade IV/GBMO," restricted to tumors showing intermingled astrocytic and oligodendroglial component, and "GBM/GBMO" based on tumors presenting oligodendroglial foci and features of GBM. Genomic arrays, IDH1 R132H expression analyses and IDH direct sequencing were performed. 1p/19q co-deletion characterized AO, whereas no IDH1 R132H expression and intact 1p/19q characterized both GBM and GBM/GBMO. AOA with necrosis/GBMO mainly demonstrated IDH1 R132H expression and intact 1p/19q. Other IDH1 or IDH2 mutations were extremely rare. Both histological and molecular classifications were predictive of progression free survival (PFS) and overall survival (OS) (P < 10(-4) ). Diffuse adult HGGs with necrosis can be split into three histomolecular groups of prognostic relevance: 1p/19q co-deleted AO, IDH1 R132H-GBM and 1p/19q intact IDH1 R132H+ gliomas that might be classified as IDH1 R132H+ GBM. Because of histomolecular heterogeneity, we suggest to remove the name GBMO.
Collapse
Affiliation(s)
- Dominique Figarella‐Branger
- Service d'Anatomie Pathologique et de NeuropathologieHôpital de la TimoneAPHMMarseilleFrance
- INSERMCRO2 UMR_S 911Aix‐Marseille UniversitéMarseilleFrance
| | - Karima Mokhtari
- Département de Neuropathologie Raymond EscourolleGroupe Hospitalier Pitié‐SalpêtrièreAP‐HPParisFrance
- Centre de Recherche de l'Institut du Cerveau et de la Moelle Épinière (CRICM)UMR 7225Université Pierre et Marie Curie—Paris 6ParisFrance
- INSERM U1127ParisFrance
| | - Carole Colin
- INSERMCRO2 UMR_S 911Aix‐Marseille UniversitéMarseilleFrance
| | - Emmanuelle Uro‐Coste
- Service d'Anatomie Pathologique et Histologie‐CytologieHôpital RangueilCHU ToulouseToulouseFrance
- INSERM U1037Centre de Recherche en Cancérologie de ToulouseUniversité de ToulouseToulouseFrance
| | - Anne Jouvet
- Centre de Pathologie et de Neuropathologie EstHospices Civils de LyonBronFrance
| | - Caroline Dehais
- Service de Neurologie 2—MazarinGroupe Hospitalier Pitié‐SalpêtrièreAP‐HPParisFrance
| | - Catherine Carpentier
- Centre de Recherche de l'Institut du Cerveau et de la Moelle Épinière (CRICM)UMR 7225Université Pierre et Marie Curie—Paris 6ParisFrance
- INSERM U1127ParisFrance
| | - Chiara Villa
- Département de Neuropathologie Raymond EscourolleGroupe Hospitalier Pitié‐SalpêtrièreAP‐HPParisFrance
- Service d'Anatomie PathologiqueHôpital FochSuresnesFrance
| | | | - Sandrine Eimer
- Service de Pathologie—NeuropathologieHôpital PellegrinCHU BordeauxBordeauxFrance
- EA2406Histologie et Pathologie Moléculaire des TumeursUniversité Bordeaux SegalenBordeauxFrance
| | - Marc Polivka
- Service d'Anatomie et Cytologie PathologiqueHôpital LariboisièreAP‐HPParisFrance
| | | | - Annie Laquerriere
- Laboratoire de PathologieHôpital Charles NicolleCHU RouenRouenFrance
| | - Henri Sevestre
- Service d'Anatomie et Cytologie PathologiquesCHU AmiensAmiensFrance
| | - Emmanuelle Lechapt‐Zalcman
- Service d'Anatomie PathologiqueHôpital de la Côte de NacreCHU CaenCaenFrance
- GIP CYCERONCERVOxyUMR 6301 ISTCTCNRSCaenFrance
| | | | | | - Marie‐Danièle Diebold
- Laboratoire d'Anatomie et Cytologie PathologiquesHôpital Robert DebréCHU ReimsReimsFrance
| | - Gabriel Viennet
- Service Anatomie et Cytologie PathologiquesHôpital Jean MinjozCHU BesançonBesançonFrance
| | - Clovis Adam
- Service Anatomie et Cytologie PathologiquesHôpital BicêtreAP‐HPKremlin‐BicêtreFrance
| | | | - Sophie Michalak
- Département Pathologie Cellulaire et TissulaireCHU AngersAngersFrance
| | - Valérie Rigau
- Laboratoire d'Anatomie et Cytologie PathologiquesHôpital Gui de ChaulliacCHU MontpellierMontpellierFrance
| | - Anne Heitzmann
- Service d'Anatomie PathologiqueHôpital la SourceCHR OrléansOrléansFrance
| | - Fanny Vandenbos
- Laboratoire d'Anatomie et Cytologie PathologiquesHôpital PasteurCHU NiceNiceFrance
| | - Fabien Forest
- Service d'Anatomie et Cytologie PathologiquesHôpital NordCHU Saint‐EtienneSaint‐EtienneFrance
| | | | | | | | - Marie‐Pierre Chenard
- Service d'Anatomie PathologiqueHôpital HautepierreCHU StrasbourgStrasbourgFrance
| | | | | | - Jean Louis Kemeny
- Service d'Anatomie et Cytologie PathologiquesHôpital Gabriel MontpiedCHU Clermont‐FerrandClermont‐FerrandFrance
| | - Pierre‐Marie Levillain
- Laboratoire d'Anatomie et Cytologie PathologiquesHôpital la MilétrieCHU PoitiersPoitiersFrance
| | | | - Pomone Richard
- Laboratoire d'Anatomie et Cytologie Pathologiques des FeuillantsToulouseFrance
| | - Jean‐Yves Delattre
- Centre de Recherche de l'Institut du Cerveau et de la Moelle Épinière (CRICM)UMR 7225Université Pierre et Marie Curie—Paris 6ParisFrance
- INSERM U1127ParisFrance
- Service de Neurologie 2—MazarinGroupe Hospitalier Pitié‐SalpêtrièreAP‐HPParisFrance
| | | |
Collapse
|
35
|
Bruno A, Boisselier B, Labreche K, Marie Y, Polivka M, Jouvet A, Adam C, Figarella-Branger D, Miquel C, Eimer S, Houillier C, Soussain C, Mokhtari K, Daveau R, Hoang-Xuan K. Mutational analysis of primary central nervous system lymphoma. Oncotarget 2015; 5:5065-75. [PMID: 24970810 PMCID: PMC4148122 DOI: 10.18632/oncotarget.2080] [Citation(s) in RCA: 130] [Impact Index Per Article: 14.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022] Open
Abstract
Little is known about the genomic basis of primary central nervous system lymphoma (PCNSL) tumorigenesis. To investigate the mutational profile of PCNSL, we analyzed nine paired tumor and germline DNA samples from PCNSL patients by high throughput exome sequencing. Eight genes of interest have been further investigated by focused resequencing in 28 additional PCNSL tumors to better estimate their incidence. Our study identified recurrent somatic mutations in 37 genes, some involved in key signaling pathways such as NFKB, B cell differentiation and cell cycle control. Focused resequencing in the larger cohort revealed high mutation rates for genes already described as mutated in PCNSL such as MYD88 (38%), CD79B (30%), PIM1 (22%) and TBL1XR1 (19%) and for genes not previously reported to be involved in PCNSL tumorigenesis such as ETV6 (16%), IRF4 (14%), IRF2BP2 (11%) and EBF1 (11%). Of note, only 3 somatically acquired SNVs were annotated in the COSMIC database. Our results demonstrate a high genetic heterogeneity of PCNSL and mutational pattern similarities with extracerebral diffuse large B cell lymphomas, particularly of the activated B-cell (ABC) subtype, suggesting shared underlying biological mechanisms. The present study provides new insights into the mutational profile of PCNSL and potential targets for therapeutic strategies.
Collapse
Affiliation(s)
- Aurélie Bruno
- Sorbonne Universités, UPMC Univ Paris 06, UM 75, ICM, F-75013, Paris, France. Institut National de la Santé et de la Recherche Médicale, U 1127, ICM, F-75013, Paris, France. Centre National de la Recherche Scientifique, UMR 7225, ICM, F-75013, Paris, France. ICM, F-75013, Paris, France
| | - Blandine Boisselier
- Sorbonne Universités, UPMC Univ Paris 06, UM 75, ICM, F-75013, Paris, France. Institut National de la Santé et de la Recherche Médicale, U 1127, ICM, F-75013, Paris, France. Centre National de la Recherche Scientifique, UMR 7225, ICM, F-75013, Paris, France. ICM, F-75013, Paris, France. Plateforme de Génotypage Séquençage, ICM, F-75013, Paris, France
| | - Karim Labreche
- Sorbonne Universités, UPMC Univ Paris 06, UM 75, ICM, F-75013, Paris, France. Institut National de la Santé et de la Recherche Médicale, U 1127, ICM, F-75013, Paris, France. Centre National de la Recherche Scientifique, UMR 7225, ICM, F-75013, Paris, France. ICM, F-75013, Paris, France
| | - Yannick Marie
- Plateforme de Génotypage Séquençage, ICM, F-75013, Paris, France. Onconeurothèque, Groupe Hospitalier Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Marc Polivka
- Centre Hospitalier Universitaire Lariboisière, Assistance Publique-Hôpitaux de Paris, Service d'Anatomopathologie, Paris, France
| | - Anne Jouvet
- Hospices Civils de Lyon, Hôpital Neurologique, Bron, France and Université Lyon 1, Institut National de la Santé et de la Recherche Médicale Unité 842, Lyon, France
| | - Clovis Adam
- Centre Hospitalier Universitaire Bicêtre, Assistance Publique-Hôpitaux de Paris, Service d'anatomopathologie, Bicêtre, France
| | - Dominique Figarella-Branger
- Centre Hospitalier Universitaire La Timone, Assistance Publique-Hôpitaux de Marseille, Institut National de la Santé et de la Recherche Médicale Unité 911, Centre de Recherches en Oncologie biologique et Onco-pharmacologie, Université de la Méditerranée and Tumorothèque de l'Assistance Publique-Hôpitaux de Marseille (AC 2013-1786), Marseille, France
| | - Catherine Miquel
- Centre hospitalier Sainte Anne, Université Paris Descartes, Sorbonne Paris Cité, Paris, France
| | - Sandrine Eimer
- Service de Pathologie, CRB Tumorothèque, Centre Hospitalier Universitaire Bordeaux, Bordeaux, France
| | - Caroline Houillier
- Assistance Publique-Hôpitaux de Paris, Hôpital de la Pitié-Salpêtrière, Service de Neurologie 2-Mazarin, Paris, France
| | - Carole Soussain
- Hôpital René Huguenin, Institut Curie, Service d'Hématologie, Saint Cloud, France
| | - Karima Mokhtari
- Sorbonne Universités, UPMC Univ Paris 06, UM 75, ICM, F-75013, Paris, France. Institut National de la Santé et de la Recherche Médicale, U 1127, ICM, F-75013, Paris, France. Centre National de la Recherche Scientifique, UMR 7225, ICM, F-75013, Paris, France. ICM, F-75013, Paris, France. Onconeurothèque, Groupe Hospitalier Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Romain Daveau
- Institut National de la Santé et de la Recherche Médicale Unité 830, Génétique et Biologie des Cancers, Institut Curie, Paris, France
| | - Khê Hoang-Xuan
- Sorbonne Universités, UPMC Univ Paris 06, UM 75, ICM, F-75013, Paris, France. Institut National de la Santé et de la Recherche Médicale, U 1127, ICM, F-75013, Paris, France. Centre National de la Recherche Scientifique, UMR 7225, ICM, F-75013, Paris, France. ICM, F-75013, Paris, France. Assistance Publique-Hôpitaux de Paris, Hôpital de la Pitié-Salpêtrière, Service de Neurologie 2-Mazarin, Paris, France
| |
Collapse
|
36
|
Jouvet A, Vasiljevic A, Champier J, Fèvre Montange M. Pineal parenchymal tumours and pineal cysts. Neurochirurgie 2015; 61:123-9. [DOI: 10.1016/j.neuchi.2013.04.003] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/25/2013] [Revised: 04/12/2013] [Accepted: 04/15/2013] [Indexed: 12/25/2022]
|
37
|
Joly M, Valmary-Degano S, Cattin F, Vasiljevic A, Jouvet A, Viennet G. [Cerebellar gangliocytoma in an 11-year-old child]. Ann Pathol 2014; 34:477-80. [PMID: 25499864 DOI: 10.1016/j.annpat.2014.09.008] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/28/2012] [Revised: 12/14/2013] [Accepted: 09/24/2014] [Indexed: 10/24/2022]
Abstract
Cerebellar gangliocytoma can correspond to Lhermitte-Duclos disease, a benign hamartomatous malformation encountered in young adults. It can also be a part of gangliogliomas/gangliocytomas family, which usually encompasses temporal pediatric neoplasms associated with longstanding seizures. We report a case of a young 11-year-old patient who presented with a gangliocytoma of the cerebellum revealed by neurologic manifestations (headache, dyspraxia, equilibrium and gait disturbances). Diagnosis was made on surgical material. Tumour was characterized by dysplastic mature ganglion cells, perivascular lymphocytic infiltrates and no glial neoplastic component. By immunohistochemistry, ganglion cells expressed neurofilaments, MAP2 protein, synaptophysin, chromogranin A and S100 protein. BRAF V600E mutation was absent. Clinical characteristics, radiology, histopathology of the two main diagnoses are discussed.
Collapse
Affiliation(s)
- Marie Joly
- Service d'anatomie et cytologie pathologiques, CHU de Besançon, 3, boulevard Alexandre-Fleming, 25000 Besançon, France
| | - Séverine Valmary-Degano
- Service d'anatomie et cytologie pathologiques, CHU de Besançon, 3, boulevard Alexandre-Fleming, 25000 Besançon, France; Université de Franche-Comté, EA 3181, IFR 133, 19, rue Ambroise-Paré, 25030 Besançon cedex, France.
| | - Françoise Cattin
- Service de neuroradiologie, CHU de Besançon, 3, boulevard Alexandre-Fleming, 25000 Besançon, France
| | - Alexandre Vasiljevic
- Centre de pathologie Est et groupement hospitalier Est, 59, boulevard Pinel, 69677 Bron, France
| | - Anne Jouvet
- Centre de pathologie Est et groupement hospitalier Est, 59, boulevard Pinel, 69677 Bron, France
| | - Gabriel Viennet
- Service d'anatomie et cytologie pathologiques, CHU de Besançon, 3, boulevard Alexandre-Fleming, 25000 Besançon, France; Université de Franche-Comté, EA 3922, 19, rue Ambroise-Paré, 25030 Besançon cedex, France
| |
Collapse
|
38
|
Szathmari A, Grassiot B, Beuriat P, Picart T, Frappaz D, Jouvet A, Montange M, Vasiljevic A, Mottolese C. Tumeurs de la pinéale chez l’enfant. Expérience du Registre français des tumeurs de la pinéale. Neurochirurgie 2014. [DOI: 10.1016/j.neuchi.2014.10.050] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
39
|
Mottolese C, Szathmari A, Beuriat PA, Frappaz D, Jouvet A, Hermier M. Tectal plate tumours. Our experience with a paediatric surgical series. Neurochirurgie 2014; 61:193-200. [PMID: 25441707 DOI: 10.1016/j.neuchi.2013.12.007] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/29/2013] [Revised: 11/23/2013] [Accepted: 12/23/2013] [Indexed: 10/24/2022]
Abstract
INTRODUCTION Exophytic tectal plate tumours are a particular kind of brain stem tumour that can be treated with microsurgical resection. This paper reports our surgical experience with a paediatric series stressing and underlines the fact that this surgery can be possible because the rate of surgical mortality is low in experienced hands with acceptable morbidity. MATERIAL AND METHODS From 1997 to 2010, 27 patients were treated for exophytic tectal plate tumours. The clinical symptomatology was characterized by an intracranial hypertensive syndrome in 77% of cases, visual disorders in 36% of cases and a Parinaud's syndrome in 12% of cases. All patients were studied using a pre-operative cranio-spinal MRI with and without gadolinium. Hydrocephalus was present in 20 cases treated with a VP shunt in 6 cases and an ETV in the other cases. The surgical removal was total in 60% of cases, partial in 28% of cases and only a large biopsy in 12% of cases. From an histological point of view benign gliomas were diagnosed in 84% of cases and in 16% of cases were classified as WHO grade II and III. Eight patients needed complementary treatment, four with chemotherapy and four with chemotherapy associated to radiotherapy. As a surgical complication two patients had hydrocephalus, one patient had a sub-dural acute haematoma, two patients had an infectious complication requiring surgical treatment and antibiotic therapy, and 5 patients a mechanical shunt dysfunction. No post-surgical mortality was observed. RESULTS The most recent results after a median survival of 4.3 years show that 22 patients are still alive while 5 patients died of a progressive disease. Twenty patients in school age continue to follow a normal school programme but 10 patients need assistance. CONCLUSION Exophytic tectal plate tumours can be treated based on a microsurgical approach in paediatric patients. In experienced hands surgery can be performed with an acceptable morbidity and with zero percent mortality. In our experience, the sub-occipital transtentorial approach permits a wide view of the region and safe surgical removal.
Collapse
Affiliation(s)
- C Mottolese
- Pediatric Service of Neurosurgery Service E, "Pierre Wertheimer" Hospital, 59, boulevard Pinel, 69677 Lyon, France.
| | - A Szathmari
- Pediatric Service of Neurosurgery Service E, "Pierre Wertheimer" Hospital, 59, boulevard Pinel, 69677 Lyon, France
| | - P A Beuriat
- Pediatric Service of Neurosurgery Service E, "Pierre Wertheimer" Hospital, 59, boulevard Pinel, 69677 Lyon, France
| | - D Frappaz
- Pediatric Neuro-oncological Service, Leon-Berard Hospital, Lyon, France
| | - A Jouvet
- Anatomo-Pathological Service, "P. Wertheimer" Hospital, 59, boulevard Pinel, 69677 Lyon, France
| | - M Hermier
- Neuroradiological Service "P. Wertheimer" Hospital, 59, boulevard Pinel, 69677 Lyon, France
| |
Collapse
|
40
|
Bruno A, Boisselier B, Labreche K, Marie Y, Polivka M, Jouvet A, Adam C, Figarella-Branger D, Miquel C, Vital A, Houillier C, Soussain C, Mokhtari K, Daveau R, Hoang-Xuan K. Abstract 5192: Mutational analysis of primary central nervous system lymphoma. Cancer Res 2014. [DOI: 10.1158/1538-7445.am2014-5192] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Primary central nervous system lymphoma (PCNSL) is a rare extranodal diffuse large B-cell lymphoma (DLBCL). Little is known about the genomic basis of tumorigenesis in PCNSL partly explained by the rarity of biological material available for research studies. PCNSL patients display poor outcomes compared to systemic DLBCL and it is still unclear whether this is linked to the organ-specific microenvironment or reflects a specific, aggressive, intrinsic biological behavior. To our knowledge, the mutational landscape of PCNSL has never been investigated
Experimental design: We analyzed 9 paired tumor and germline DNA samples from PCNSL patients by high throughput exome sequencing. Then, we performed focused sequencing in 28 additional PCNSL tumors to validate somatic genomic alterations and better estimate their incidence. Mutational data were correlated with copy number variations (CNV) identified by SNP and CGH arrays and clinical data.
Results: We identified recurrent somatic mutations in genes involved in key signalling pathways such as NFκB (i.e. MYD88, CD79B, TBL1XR1), B cell differentiation (i.e. ETV6, EBF1, IRF4) and cell cycle control (i.e. BTG1, PIM1). We found somatic mutations on MYD88 (38%), CD79B (30%), TBL1XR1 (22%) or ETV6 (16%) genes and described bi-allelic inactivation of TBL1XR1 and ETV6 genes. Interestingly, the correlation with the outcome showed a significant negative impact of TBL1XR1 mutation on survival in a multivariate analysis.
Conclusions: The present study showed that PCNSLs have high genetic heterogeneity and that their mutational patterns display similarities with extracerebral DLBCL, particularly of the ABC subtype, suggesting shared underlying biological mechanisms. These results provide new insights into the mutational landscape of PCNSL and potential targets for therapeutic strategies. This work benefited from the LOC study group network (réseau national de centres experts des lymphomes primitifs du SNC, INCa).
Citation Format: Aurélie Bruno, Blandine Boisselier, Karim Labreche, Yannick Marie, Marc Polivka, Anne Jouvet, Clovis Adam, Dominique Figarella-Branger, Catherine Miquel, Anne Vital, Caroline Houillier, Carole Soussain, Karima Mokhtari, Romain Daveau, Khê Hoang-Xuan. Mutational analysis of primary central nervous system lymphoma. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 5192. doi:10.1158/1538-7445.AM2014-5192
Collapse
Affiliation(s)
- Aurélie Bruno
- 1Research Center of Brain and Spine Institute, INSERM U975, Paris, France
| | | | - Karim Labreche
- 1Research Center of Brain and Spine Institute, INSERM U975, Paris, France
| | - Yannick Marie
- 2Research Center of Brain and Spine Institute, Plateforme de Génotypage Séquençage and Groupe Hospitalier Pitié-Salpêtrière, Onconeurothèque, Paris, France
| | - Marc Polivka
- 3Centre Hospitalier Universitaire Lariboisière, Service d'Anatomopathologie, Paris, France
| | - Anne Jouvet
- 4Hospices Civils de Lyon - Hôpital Neurologique de Bron and Université Lyon 1 INSERM U842, Lyon, France
| | - Clovis Adam
- 5Centre Hospitalier Universitaire Bicêtre, Service d'Aatomopathologie, Bicêtre, France
| | - Dominique Figarella-Branger
- 6Centre Hospitalier Universitaire La Timone, INSERM U911, Tumorothèque de l'Assistance Publique-Hôpitaux de Marseille, Marseille, France
| | - Catherine Miquel
- 7Centre Hospitalier Sainte Anne, Université Paris Descartes, Sorbonne Paris Cité, Paris, France
| | - Anne Vital
- 8Centre Hospitalier Universitaire Bordeaux, Service de Pathologie, Bordeaux, France
| | - Caroline Houillier
- 9Groupe Hospitalier Pitié-Salpêtrière, Université Pierre et Marie Curie, Paris, France
| | - Carole Soussain
- 10Hôpital René Huguenin, Institut Curie, Service d'Hématologie, Saint Cloud, France
| | - Karima Mokhtari
- 11Groupe Hospitalier Pitié-Salpêtrière, Service d'anatomopathologie and Onconeurothèque, Paris, France
| | - Romain Daveau
- 12INSERM U830, Génétique et Biologie des Cancers, Institut Curie, Paris, France
| | - Khê Hoang-Xuan
- 1Research Center of Brain and Spine Institute, INSERM U975, Paris, France
| |
Collapse
|
41
|
Bekaert L, Bazille C, Borha A, Vasiljevic A, Jouvet A, Lechapt-Zalcman E. P04.05 * HISTONE MUTATIONS IN CHILDHOOD AND YOUNG ADULT HIGH GRADE GLIOMA. Neuro Oncol 2014. [DOI: 10.1093/neuonc/nou174.137] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
42
|
Vasiljevic A, Szathmari A, Champier J, Fèvre-Montange M, Jouvet A. Histopathology of pineal germ cell tumors. Neurochirurgie 2014; 61:130-7. [PMID: 24726316 DOI: 10.1016/j.neuchi.2013.06.006] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/30/2013] [Revised: 05/13/2013] [Accepted: 06/09/2013] [Indexed: 10/25/2022]
Abstract
Germ cell tumors (GCTs) classically occur in gonads. However, they are the most frequent neoplasms in the pineal region. The pineal location of GCTs may be caused by the neoplastic transformation of a primordial germ cell that has mismigrated. The World Health Organization (WHO) recognizes 5 histological types of intracranial GCTs: germinoma and non-germinomatous tumors including embryonal carcinoma, yolk sac tumor, choriocarcinoma and mature or immature teratoma. Germinomas and teratomas are frequently encountered as pure tumors whereas the other types are mostly part of mixed GCTs. In this situation, the neuropathologist has to be able to identify each component of a GCT. When diagnosis is difficult, use of recent immunohistochemical markers such as OCT(octamer-binding transcription factor)3/4, Glypican 3, SALL(sal-like protein)4 may be required. OCT3/4 is helpful in the diagnosis of germinomas, Glypican 3 in the diagnosis of yolk sac tumors and SALL4 in the diagnosis of the germ cell nature of an intracranial tumor. When the germ cell nature of a pineal tumor is doubtful, the finding of an isochromosome 12p suggests the diagnosis of GCT. The final pathological report should always be confronted with the clinical data, especially the serum or cerebrospinal fluid levels of β-human chorionic gonadotropin (HCG) and alpha-fetoprotein.
Collapse
Affiliation(s)
- A Vasiljevic
- Centre de pathologie et neuropathologie EST, groupement hospitalier EST, hospices civils de Lyon, 59, boulevard Pinel, 69677 Bron cedex, France; Centre de recherche en neurosciences de Lyon, Inserm U1028, CNRS UMR5292, équipe neuro-oncologie et neuro-inflammation, Lyon, France.
| | - A Szathmari
- Service de neurochirurgie pédiatrique E, hôpital Pierre-Wertheimer, groupement hospitalier EST, hospices civils de Lyon, 59, boulevard Pinel, 69677 Bron cedex, France
| | - J Champier
- Centre de recherche en neurosciences de Lyon, Inserm U1028, CNRS UMR5292, équipe neuro-oncologie et neuro-inflammation, Lyon, France
| | - M Fèvre-Montange
- Centre de recherche en neurosciences de Lyon, Inserm U1028, CNRS UMR5292, équipe neuro-oncologie et neuro-inflammation, Lyon, France
| | - A Jouvet
- Centre de pathologie et neuropathologie EST, groupement hospitalier EST, hospices civils de Lyon, 59, boulevard Pinel, 69677 Bron cedex, France; Centre de recherche en neurosciences de Lyon, Inserm U1028, CNRS UMR5292, équipe neuro-oncologie et neuro-inflammation, Lyon, France
| |
Collapse
|
43
|
Figarella-Branger D, Mokhtari K, Dehais C, Jouvet A, Uro-Coste E, Colin C, Carpentier C, Forest F, Maurage CA, Vignaud JM, Polivka M, Lechapt-Zalcman E, Eimer S, Viennet G, Quintin-Roué I, Aubriot-Lorton MH, Diebold MD, Loussouarn D, Lacroix C, Rigau V, Laquerrière A, Vandenbos F, Michalak S, Sevestre H, Peoch M, Labrousse F, Christov C, Kemeny JL, Chenard MP, Chiforeanu D, Ducray F, Idbaih A. Mitotic index, microvascular proliferation, and necrosis define 3 groups of 1p/19q codeleted anaplastic oligodendrogliomas associated with different genomic alterations. Neuro Oncol 2014; 16:1244-54. [PMID: 24723566 DOI: 10.1093/neuonc/nou047] [Citation(s) in RCA: 44] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023] Open
Abstract
BACKGROUND The aim of this study was to correlate histological features and molecular characteristics in anaplastic oligodendrogliomas (AOs). METHODS The histological characteristics of 203 AO patients, enrolled in the French national network POLA, were analyzed. The genomic profiles of 191 cases were studied using genomic arrays. IDH mutational status was assessed by immunohistochemistry and direct sequencing. RESULTS 1p/19q codeletion was present in 79% of cases and was associated with alpha-internexin expression (P < 10(-4)), IDH1/2 mutation (P < 10(-4)), chromosome 4 loss (P < 10(-3)), and better overall survival (P < 10(-4)). Based on mitotic index, microvascular proliferation (MVP), and necrosis, 3 groups of 1p/19q codeleted AOs were identified: (group 1) AO with more than 5 mitoses per 10-HPF, no MVP, and no necrosis; (group 2) AO with MVP and no necrosis; and (group 3) AO with MVP and necrosis. Compared with group 1, groups 2 and 3 AOs had a higher mean Ki-67 proliferation index and a higher rate of 9p and 9q losses. Compared with group 2, group 3 AOs had a higher number of chromosomal alterations including chromosome 4 loss. In the subgroup of 157 1p/19q codeleted AOs, chromosomal instability was associated with shorter progression-free survival (P = .024) and shorter overall survival (P = .023). CONCLUSIONS The present study shows that oligodendrogliomas with classic histological features remain a molecularly heterogeneous entity and should be stratified according to 1p/19q status because of its major prognostic relevance. Moreover, 1p/19q codeleted AOs are also heterogeneous. Interestingly, mitotic index, MVP, and necrosis help to classify them into 3 groups associated with distinct genomic alterations.
Collapse
Affiliation(s)
- Dominique Figarella-Branger
- APHM, Hôpital de la Timone, Service d'Anatomie Pathologique et de Neuropathologie, Marseille, France (D.F.-B.); Aix-Marseille Université, Inserm, CRO2 UMR_S 911, Marseille, France (D.F.-B., C.Co.); AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Service de Neuropathologie Raymond Escourolle, Paris, France (K.M., A.I.); Université Pierre et Marie Curie - Paris 6, Centre de Recherche de l'Institut du Cerveau et de la Moelle épinière (CRICM), UMRS 975, Paris, France (K.M., C.Ca., A.I.); Inserm U975, Paris, France (K.M., C.Ca., A.I.); AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Service de Neurologie 2 - Mazarin, Paris, France (C.D.); Centre de Pathologie et de Neuropathologie Est, Bron, France (A.J.); CHU Toulouse, Hôpital Rangueil, Service d'Anatomie Pathologique et Histologie-Cytologie, Toulouse, France (E.U.-C.); Inserm U1037, Centre de Recherche en Cancérologie de Toulouse, Université de Toulouse, France (E.U.-C.); CHU Saint-Etienne, Hôpital Nord, Service d'Anatomie et Cytologie Pathologiques, Saint-Etienne, France (F.F., M.P.); CHU Lille, Pôle Pathologie Biologique, Service Anatomie Pathologique, Lille, France (C.-A.M.); CHU Nancy, Hôpital Central, Laboratoire d'Anatomie Pathologique, Nancy, France (J.-M.V.); AP-HP, Hôpital Lariboisière, Service d'Anatomie et Cytologie Pathologique, Paris, France (M.P.); CHU Caen, Hôpital de la Côte de Nacre, Service d'Anatomie Pathologique, Caen, France (E.L.-Z.); CNRS, UMR 6301 ISTCT, CERVOxy, GIP CYCERON, Caen, France (E.L.-Z.); CHU Bordeaux, Hôpital Pellegrin, Service de Pathologie - Neuropathologie, Bordeaux, France (S.E.); EA2406, Histologie et Pathologie Moléculaire des Tumeurs, Université Bordeaux Segalen, Bordeaux, France (S.E.); CHU Besançon, Hôpital Jean Minjoz, Service Anatomie et Cytologie Pathologiques, Besançon, France (G.V.); CHU Brest, Hôpital de la Cavale Blanche, Service Anatomie Pathologique, Brest, France (I.Q.-R.); CHU Dijon, Plateau Technique de Biologie G. Mack, Service Anatomie et
| | - Karima Mokhtari
- APHM, Hôpital de la Timone, Service d'Anatomie Pathologique et de Neuropathologie, Marseille, France (D.F.-B.); Aix-Marseille Université, Inserm, CRO2 UMR_S 911, Marseille, France (D.F.-B., C.Co.); AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Service de Neuropathologie Raymond Escourolle, Paris, France (K.M., A.I.); Université Pierre et Marie Curie - Paris 6, Centre de Recherche de l'Institut du Cerveau et de la Moelle épinière (CRICM), UMRS 975, Paris, France (K.M., C.Ca., A.I.); Inserm U975, Paris, France (K.M., C.Ca., A.I.); AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Service de Neurologie 2 - Mazarin, Paris, France (C.D.); Centre de Pathologie et de Neuropathologie Est, Bron, France (A.J.); CHU Toulouse, Hôpital Rangueil, Service d'Anatomie Pathologique et Histologie-Cytologie, Toulouse, France (E.U.-C.); Inserm U1037, Centre de Recherche en Cancérologie de Toulouse, Université de Toulouse, France (E.U.-C.); CHU Saint-Etienne, Hôpital Nord, Service d'Anatomie et Cytologie Pathologiques, Saint-Etienne, France (F.F., M.P.); CHU Lille, Pôle Pathologie Biologique, Service Anatomie Pathologique, Lille, France (C.-A.M.); CHU Nancy, Hôpital Central, Laboratoire d'Anatomie Pathologique, Nancy, France (J.-M.V.); AP-HP, Hôpital Lariboisière, Service d'Anatomie et Cytologie Pathologique, Paris, France (M.P.); CHU Caen, Hôpital de la Côte de Nacre, Service d'Anatomie Pathologique, Caen, France (E.L.-Z.); CNRS, UMR 6301 ISTCT, CERVOxy, GIP CYCERON, Caen, France (E.L.-Z.); CHU Bordeaux, Hôpital Pellegrin, Service de Pathologie - Neuropathologie, Bordeaux, France (S.E.); EA2406, Histologie et Pathologie Moléculaire des Tumeurs, Université Bordeaux Segalen, Bordeaux, France (S.E.); CHU Besançon, Hôpital Jean Minjoz, Service Anatomie et Cytologie Pathologiques, Besançon, France (G.V.); CHU Brest, Hôpital de la Cavale Blanche, Service Anatomie Pathologique, Brest, France (I.Q.-R.); CHU Dijon, Plateau Technique de Biologie G. Mack, Service Anatomie et
| | - Caroline Dehais
- APHM, Hôpital de la Timone, Service d'Anatomie Pathologique et de Neuropathologie, Marseille, France (D.F.-B.); Aix-Marseille Université, Inserm, CRO2 UMR_S 911, Marseille, France (D.F.-B., C.Co.); AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Service de Neuropathologie Raymond Escourolle, Paris, France (K.M., A.I.); Université Pierre et Marie Curie - Paris 6, Centre de Recherche de l'Institut du Cerveau et de la Moelle épinière (CRICM), UMRS 975, Paris, France (K.M., C.Ca., A.I.); Inserm U975, Paris, France (K.M., C.Ca., A.I.); AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Service de Neurologie 2 - Mazarin, Paris, France (C.D.); Centre de Pathologie et de Neuropathologie Est, Bron, France (A.J.); CHU Toulouse, Hôpital Rangueil, Service d'Anatomie Pathologique et Histologie-Cytologie, Toulouse, France (E.U.-C.); Inserm U1037, Centre de Recherche en Cancérologie de Toulouse, Université de Toulouse, France (E.U.-C.); CHU Saint-Etienne, Hôpital Nord, Service d'Anatomie et Cytologie Pathologiques, Saint-Etienne, France (F.F., M.P.); CHU Lille, Pôle Pathologie Biologique, Service Anatomie Pathologique, Lille, France (C.-A.M.); CHU Nancy, Hôpital Central, Laboratoire d'Anatomie Pathologique, Nancy, France (J.-M.V.); AP-HP, Hôpital Lariboisière, Service d'Anatomie et Cytologie Pathologique, Paris, France (M.P.); CHU Caen, Hôpital de la Côte de Nacre, Service d'Anatomie Pathologique, Caen, France (E.L.-Z.); CNRS, UMR 6301 ISTCT, CERVOxy, GIP CYCERON, Caen, France (E.L.-Z.); CHU Bordeaux, Hôpital Pellegrin, Service de Pathologie - Neuropathologie, Bordeaux, France (S.E.); EA2406, Histologie et Pathologie Moléculaire des Tumeurs, Université Bordeaux Segalen, Bordeaux, France (S.E.); CHU Besançon, Hôpital Jean Minjoz, Service Anatomie et Cytologie Pathologiques, Besançon, France (G.V.); CHU Brest, Hôpital de la Cavale Blanche, Service Anatomie Pathologique, Brest, France (I.Q.-R.); CHU Dijon, Plateau Technique de Biologie G. Mack, Service Anatomie et
| | - Anne Jouvet
- APHM, Hôpital de la Timone, Service d'Anatomie Pathologique et de Neuropathologie, Marseille, France (D.F.-B.); Aix-Marseille Université, Inserm, CRO2 UMR_S 911, Marseille, France (D.F.-B., C.Co.); AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Service de Neuropathologie Raymond Escourolle, Paris, France (K.M., A.I.); Université Pierre et Marie Curie - Paris 6, Centre de Recherche de l'Institut du Cerveau et de la Moelle épinière (CRICM), UMRS 975, Paris, France (K.M., C.Ca., A.I.); Inserm U975, Paris, France (K.M., C.Ca., A.I.); AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Service de Neurologie 2 - Mazarin, Paris, France (C.D.); Centre de Pathologie et de Neuropathologie Est, Bron, France (A.J.); CHU Toulouse, Hôpital Rangueil, Service d'Anatomie Pathologique et Histologie-Cytologie, Toulouse, France (E.U.-C.); Inserm U1037, Centre de Recherche en Cancérologie de Toulouse, Université de Toulouse, France (E.U.-C.); CHU Saint-Etienne, Hôpital Nord, Service d'Anatomie et Cytologie Pathologiques, Saint-Etienne, France (F.F., M.P.); CHU Lille, Pôle Pathologie Biologique, Service Anatomie Pathologique, Lille, France (C.-A.M.); CHU Nancy, Hôpital Central, Laboratoire d'Anatomie Pathologique, Nancy, France (J.-M.V.); AP-HP, Hôpital Lariboisière, Service d'Anatomie et Cytologie Pathologique, Paris, France (M.P.); CHU Caen, Hôpital de la Côte de Nacre, Service d'Anatomie Pathologique, Caen, France (E.L.-Z.); CNRS, UMR 6301 ISTCT, CERVOxy, GIP CYCERON, Caen, France (E.L.-Z.); CHU Bordeaux, Hôpital Pellegrin, Service de Pathologie - Neuropathologie, Bordeaux, France (S.E.); EA2406, Histologie et Pathologie Moléculaire des Tumeurs, Université Bordeaux Segalen, Bordeaux, France (S.E.); CHU Besançon, Hôpital Jean Minjoz, Service Anatomie et Cytologie Pathologiques, Besançon, France (G.V.); CHU Brest, Hôpital de la Cavale Blanche, Service Anatomie Pathologique, Brest, France (I.Q.-R.); CHU Dijon, Plateau Technique de Biologie G. Mack, Service Anatomie et
| | - Emmanuelle Uro-Coste
- APHM, Hôpital de la Timone, Service d'Anatomie Pathologique et de Neuropathologie, Marseille, France (D.F.-B.); Aix-Marseille Université, Inserm, CRO2 UMR_S 911, Marseille, France (D.F.-B., C.Co.); AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Service de Neuropathologie Raymond Escourolle, Paris, France (K.M., A.I.); Université Pierre et Marie Curie - Paris 6, Centre de Recherche de l'Institut du Cerveau et de la Moelle épinière (CRICM), UMRS 975, Paris, France (K.M., C.Ca., A.I.); Inserm U975, Paris, France (K.M., C.Ca., A.I.); AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Service de Neurologie 2 - Mazarin, Paris, France (C.D.); Centre de Pathologie et de Neuropathologie Est, Bron, France (A.J.); CHU Toulouse, Hôpital Rangueil, Service d'Anatomie Pathologique et Histologie-Cytologie, Toulouse, France (E.U.-C.); Inserm U1037, Centre de Recherche en Cancérologie de Toulouse, Université de Toulouse, France (E.U.-C.); CHU Saint-Etienne, Hôpital Nord, Service d'Anatomie et Cytologie Pathologiques, Saint-Etienne, France (F.F., M.P.); CHU Lille, Pôle Pathologie Biologique, Service Anatomie Pathologique, Lille, France (C.-A.M.); CHU Nancy, Hôpital Central, Laboratoire d'Anatomie Pathologique, Nancy, France (J.-M.V.); AP-HP, Hôpital Lariboisière, Service d'Anatomie et Cytologie Pathologique, Paris, France (M.P.); CHU Caen, Hôpital de la Côte de Nacre, Service d'Anatomie Pathologique, Caen, France (E.L.-Z.); CNRS, UMR 6301 ISTCT, CERVOxy, GIP CYCERON, Caen, France (E.L.-Z.); CHU Bordeaux, Hôpital Pellegrin, Service de Pathologie - Neuropathologie, Bordeaux, France (S.E.); EA2406, Histologie et Pathologie Moléculaire des Tumeurs, Université Bordeaux Segalen, Bordeaux, France (S.E.); CHU Besançon, Hôpital Jean Minjoz, Service Anatomie et Cytologie Pathologiques, Besançon, France (G.V.); CHU Brest, Hôpital de la Cavale Blanche, Service Anatomie Pathologique, Brest, France (I.Q.-R.); CHU Dijon, Plateau Technique de Biologie G. Mack, Service Anatomie et
| | - Carole Colin
- APHM, Hôpital de la Timone, Service d'Anatomie Pathologique et de Neuropathologie, Marseille, France (D.F.-B.); Aix-Marseille Université, Inserm, CRO2 UMR_S 911, Marseille, France (D.F.-B., C.Co.); AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Service de Neuropathologie Raymond Escourolle, Paris, France (K.M., A.I.); Université Pierre et Marie Curie - Paris 6, Centre de Recherche de l'Institut du Cerveau et de la Moelle épinière (CRICM), UMRS 975, Paris, France (K.M., C.Ca., A.I.); Inserm U975, Paris, France (K.M., C.Ca., A.I.); AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Service de Neurologie 2 - Mazarin, Paris, France (C.D.); Centre de Pathologie et de Neuropathologie Est, Bron, France (A.J.); CHU Toulouse, Hôpital Rangueil, Service d'Anatomie Pathologique et Histologie-Cytologie, Toulouse, France (E.U.-C.); Inserm U1037, Centre de Recherche en Cancérologie de Toulouse, Université de Toulouse, France (E.U.-C.); CHU Saint-Etienne, Hôpital Nord, Service d'Anatomie et Cytologie Pathologiques, Saint-Etienne, France (F.F., M.P.); CHU Lille, Pôle Pathologie Biologique, Service Anatomie Pathologique, Lille, France (C.-A.M.); CHU Nancy, Hôpital Central, Laboratoire d'Anatomie Pathologique, Nancy, France (J.-M.V.); AP-HP, Hôpital Lariboisière, Service d'Anatomie et Cytologie Pathologique, Paris, France (M.P.); CHU Caen, Hôpital de la Côte de Nacre, Service d'Anatomie Pathologique, Caen, France (E.L.-Z.); CNRS, UMR 6301 ISTCT, CERVOxy, GIP CYCERON, Caen, France (E.L.-Z.); CHU Bordeaux, Hôpital Pellegrin, Service de Pathologie - Neuropathologie, Bordeaux, France (S.E.); EA2406, Histologie et Pathologie Moléculaire des Tumeurs, Université Bordeaux Segalen, Bordeaux, France (S.E.); CHU Besançon, Hôpital Jean Minjoz, Service Anatomie et Cytologie Pathologiques, Besançon, France (G.V.); CHU Brest, Hôpital de la Cavale Blanche, Service Anatomie Pathologique, Brest, France (I.Q.-R.); CHU Dijon, Plateau Technique de Biologie G. Mack, Service Anatomie et
| | - Catherine Carpentier
- APHM, Hôpital de la Timone, Service d'Anatomie Pathologique et de Neuropathologie, Marseille, France (D.F.-B.); Aix-Marseille Université, Inserm, CRO2 UMR_S 911, Marseille, France (D.F.-B., C.Co.); AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Service de Neuropathologie Raymond Escourolle, Paris, France (K.M., A.I.); Université Pierre et Marie Curie - Paris 6, Centre de Recherche de l'Institut du Cerveau et de la Moelle épinière (CRICM), UMRS 975, Paris, France (K.M., C.Ca., A.I.); Inserm U975, Paris, France (K.M., C.Ca., A.I.); AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Service de Neurologie 2 - Mazarin, Paris, France (C.D.); Centre de Pathologie et de Neuropathologie Est, Bron, France (A.J.); CHU Toulouse, Hôpital Rangueil, Service d'Anatomie Pathologique et Histologie-Cytologie, Toulouse, France (E.U.-C.); Inserm U1037, Centre de Recherche en Cancérologie de Toulouse, Université de Toulouse, France (E.U.-C.); CHU Saint-Etienne, Hôpital Nord, Service d'Anatomie et Cytologie Pathologiques, Saint-Etienne, France (F.F., M.P.); CHU Lille, Pôle Pathologie Biologique, Service Anatomie Pathologique, Lille, France (C.-A.M.); CHU Nancy, Hôpital Central, Laboratoire d'Anatomie Pathologique, Nancy, France (J.-M.V.); AP-HP, Hôpital Lariboisière, Service d'Anatomie et Cytologie Pathologique, Paris, France (M.P.); CHU Caen, Hôpital de la Côte de Nacre, Service d'Anatomie Pathologique, Caen, France (E.L.-Z.); CNRS, UMR 6301 ISTCT, CERVOxy, GIP CYCERON, Caen, France (E.L.-Z.); CHU Bordeaux, Hôpital Pellegrin, Service de Pathologie - Neuropathologie, Bordeaux, France (S.E.); EA2406, Histologie et Pathologie Moléculaire des Tumeurs, Université Bordeaux Segalen, Bordeaux, France (S.E.); CHU Besançon, Hôpital Jean Minjoz, Service Anatomie et Cytologie Pathologiques, Besançon, France (G.V.); CHU Brest, Hôpital de la Cavale Blanche, Service Anatomie Pathologique, Brest, France (I.Q.-R.); CHU Dijon, Plateau Technique de Biologie G. Mack, Service Anatomie et
| | - Fabien Forest
- APHM, Hôpital de la Timone, Service d'Anatomie Pathologique et de Neuropathologie, Marseille, France (D.F.-B.); Aix-Marseille Université, Inserm, CRO2 UMR_S 911, Marseille, France (D.F.-B., C.Co.); AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Service de Neuropathologie Raymond Escourolle, Paris, France (K.M., A.I.); Université Pierre et Marie Curie - Paris 6, Centre de Recherche de l'Institut du Cerveau et de la Moelle épinière (CRICM), UMRS 975, Paris, France (K.M., C.Ca., A.I.); Inserm U975, Paris, France (K.M., C.Ca., A.I.); AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Service de Neurologie 2 - Mazarin, Paris, France (C.D.); Centre de Pathologie et de Neuropathologie Est, Bron, France (A.J.); CHU Toulouse, Hôpital Rangueil, Service d'Anatomie Pathologique et Histologie-Cytologie, Toulouse, France (E.U.-C.); Inserm U1037, Centre de Recherche en Cancérologie de Toulouse, Université de Toulouse, France (E.U.-C.); CHU Saint-Etienne, Hôpital Nord, Service d'Anatomie et Cytologie Pathologiques, Saint-Etienne, France (F.F., M.P.); CHU Lille, Pôle Pathologie Biologique, Service Anatomie Pathologique, Lille, France (C.-A.M.); CHU Nancy, Hôpital Central, Laboratoire d'Anatomie Pathologique, Nancy, France (J.-M.V.); AP-HP, Hôpital Lariboisière, Service d'Anatomie et Cytologie Pathologique, Paris, France (M.P.); CHU Caen, Hôpital de la Côte de Nacre, Service d'Anatomie Pathologique, Caen, France (E.L.-Z.); CNRS, UMR 6301 ISTCT, CERVOxy, GIP CYCERON, Caen, France (E.L.-Z.); CHU Bordeaux, Hôpital Pellegrin, Service de Pathologie - Neuropathologie, Bordeaux, France (S.E.); EA2406, Histologie et Pathologie Moléculaire des Tumeurs, Université Bordeaux Segalen, Bordeaux, France (S.E.); CHU Besançon, Hôpital Jean Minjoz, Service Anatomie et Cytologie Pathologiques, Besançon, France (G.V.); CHU Brest, Hôpital de la Cavale Blanche, Service Anatomie Pathologique, Brest, France (I.Q.-R.); CHU Dijon, Plateau Technique de Biologie G. Mack, Service Anatomie et
| | - Claude-Alain Maurage
- APHM, Hôpital de la Timone, Service d'Anatomie Pathologique et de Neuropathologie, Marseille, France (D.F.-B.); Aix-Marseille Université, Inserm, CRO2 UMR_S 911, Marseille, France (D.F.-B., C.Co.); AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Service de Neuropathologie Raymond Escourolle, Paris, France (K.M., A.I.); Université Pierre et Marie Curie - Paris 6, Centre de Recherche de l'Institut du Cerveau et de la Moelle épinière (CRICM), UMRS 975, Paris, France (K.M., C.Ca., A.I.); Inserm U975, Paris, France (K.M., C.Ca., A.I.); AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Service de Neurologie 2 - Mazarin, Paris, France (C.D.); Centre de Pathologie et de Neuropathologie Est, Bron, France (A.J.); CHU Toulouse, Hôpital Rangueil, Service d'Anatomie Pathologique et Histologie-Cytologie, Toulouse, France (E.U.-C.); Inserm U1037, Centre de Recherche en Cancérologie de Toulouse, Université de Toulouse, France (E.U.-C.); CHU Saint-Etienne, Hôpital Nord, Service d'Anatomie et Cytologie Pathologiques, Saint-Etienne, France (F.F., M.P.); CHU Lille, Pôle Pathologie Biologique, Service Anatomie Pathologique, Lille, France (C.-A.M.); CHU Nancy, Hôpital Central, Laboratoire d'Anatomie Pathologique, Nancy, France (J.-M.V.); AP-HP, Hôpital Lariboisière, Service d'Anatomie et Cytologie Pathologique, Paris, France (M.P.); CHU Caen, Hôpital de la Côte de Nacre, Service d'Anatomie Pathologique, Caen, France (E.L.-Z.); CNRS, UMR 6301 ISTCT, CERVOxy, GIP CYCERON, Caen, France (E.L.-Z.); CHU Bordeaux, Hôpital Pellegrin, Service de Pathologie - Neuropathologie, Bordeaux, France (S.E.); EA2406, Histologie et Pathologie Moléculaire des Tumeurs, Université Bordeaux Segalen, Bordeaux, France (S.E.); CHU Besançon, Hôpital Jean Minjoz, Service Anatomie et Cytologie Pathologiques, Besançon, France (G.V.); CHU Brest, Hôpital de la Cavale Blanche, Service Anatomie Pathologique, Brest, France (I.Q.-R.); CHU Dijon, Plateau Technique de Biologie G. Mack, Service Anatomie et
| | - Jean-Michel Vignaud
- APHM, Hôpital de la Timone, Service d'Anatomie Pathologique et de Neuropathologie, Marseille, France (D.F.-B.); Aix-Marseille Université, Inserm, CRO2 UMR_S 911, Marseille, France (D.F.-B., C.Co.); AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Service de Neuropathologie Raymond Escourolle, Paris, France (K.M., A.I.); Université Pierre et Marie Curie - Paris 6, Centre de Recherche de l'Institut du Cerveau et de la Moelle épinière (CRICM), UMRS 975, Paris, France (K.M., C.Ca., A.I.); Inserm U975, Paris, France (K.M., C.Ca., A.I.); AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Service de Neurologie 2 - Mazarin, Paris, France (C.D.); Centre de Pathologie et de Neuropathologie Est, Bron, France (A.J.); CHU Toulouse, Hôpital Rangueil, Service d'Anatomie Pathologique et Histologie-Cytologie, Toulouse, France (E.U.-C.); Inserm U1037, Centre de Recherche en Cancérologie de Toulouse, Université de Toulouse, France (E.U.-C.); CHU Saint-Etienne, Hôpital Nord, Service d'Anatomie et Cytologie Pathologiques, Saint-Etienne, France (F.F., M.P.); CHU Lille, Pôle Pathologie Biologique, Service Anatomie Pathologique, Lille, France (C.-A.M.); CHU Nancy, Hôpital Central, Laboratoire d'Anatomie Pathologique, Nancy, France (J.-M.V.); AP-HP, Hôpital Lariboisière, Service d'Anatomie et Cytologie Pathologique, Paris, France (M.P.); CHU Caen, Hôpital de la Côte de Nacre, Service d'Anatomie Pathologique, Caen, France (E.L.-Z.); CNRS, UMR 6301 ISTCT, CERVOxy, GIP CYCERON, Caen, France (E.L.-Z.); CHU Bordeaux, Hôpital Pellegrin, Service de Pathologie - Neuropathologie, Bordeaux, France (S.E.); EA2406, Histologie et Pathologie Moléculaire des Tumeurs, Université Bordeaux Segalen, Bordeaux, France (S.E.); CHU Besançon, Hôpital Jean Minjoz, Service Anatomie et Cytologie Pathologiques, Besançon, France (G.V.); CHU Brest, Hôpital de la Cavale Blanche, Service Anatomie Pathologique, Brest, France (I.Q.-R.); CHU Dijon, Plateau Technique de Biologie G. Mack, Service Anatomie et
| | - Marc Polivka
- APHM, Hôpital de la Timone, Service d'Anatomie Pathologique et de Neuropathologie, Marseille, France (D.F.-B.); Aix-Marseille Université, Inserm, CRO2 UMR_S 911, Marseille, France (D.F.-B., C.Co.); AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Service de Neuropathologie Raymond Escourolle, Paris, France (K.M., A.I.); Université Pierre et Marie Curie - Paris 6, Centre de Recherche de l'Institut du Cerveau et de la Moelle épinière (CRICM), UMRS 975, Paris, France (K.M., C.Ca., A.I.); Inserm U975, Paris, France (K.M., C.Ca., A.I.); AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Service de Neurologie 2 - Mazarin, Paris, France (C.D.); Centre de Pathologie et de Neuropathologie Est, Bron, France (A.J.); CHU Toulouse, Hôpital Rangueil, Service d'Anatomie Pathologique et Histologie-Cytologie, Toulouse, France (E.U.-C.); Inserm U1037, Centre de Recherche en Cancérologie de Toulouse, Université de Toulouse, France (E.U.-C.); CHU Saint-Etienne, Hôpital Nord, Service d'Anatomie et Cytologie Pathologiques, Saint-Etienne, France (F.F., M.P.); CHU Lille, Pôle Pathologie Biologique, Service Anatomie Pathologique, Lille, France (C.-A.M.); CHU Nancy, Hôpital Central, Laboratoire d'Anatomie Pathologique, Nancy, France (J.-M.V.); AP-HP, Hôpital Lariboisière, Service d'Anatomie et Cytologie Pathologique, Paris, France (M.P.); CHU Caen, Hôpital de la Côte de Nacre, Service d'Anatomie Pathologique, Caen, France (E.L.-Z.); CNRS, UMR 6301 ISTCT, CERVOxy, GIP CYCERON, Caen, France (E.L.-Z.); CHU Bordeaux, Hôpital Pellegrin, Service de Pathologie - Neuropathologie, Bordeaux, France (S.E.); EA2406, Histologie et Pathologie Moléculaire des Tumeurs, Université Bordeaux Segalen, Bordeaux, France (S.E.); CHU Besançon, Hôpital Jean Minjoz, Service Anatomie et Cytologie Pathologiques, Besançon, France (G.V.); CHU Brest, Hôpital de la Cavale Blanche, Service Anatomie Pathologique, Brest, France (I.Q.-R.); CHU Dijon, Plateau Technique de Biologie G. Mack, Service Anatomie et
| | - Emmanuelle Lechapt-Zalcman
- APHM, Hôpital de la Timone, Service d'Anatomie Pathologique et de Neuropathologie, Marseille, France (D.F.-B.); Aix-Marseille Université, Inserm, CRO2 UMR_S 911, Marseille, France (D.F.-B., C.Co.); AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Service de Neuropathologie Raymond Escourolle, Paris, France (K.M., A.I.); Université Pierre et Marie Curie - Paris 6, Centre de Recherche de l'Institut du Cerveau et de la Moelle épinière (CRICM), UMRS 975, Paris, France (K.M., C.Ca., A.I.); Inserm U975, Paris, France (K.M., C.Ca., A.I.); AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Service de Neurologie 2 - Mazarin, Paris, France (C.D.); Centre de Pathologie et de Neuropathologie Est, Bron, France (A.J.); CHU Toulouse, Hôpital Rangueil, Service d'Anatomie Pathologique et Histologie-Cytologie, Toulouse, France (E.U.-C.); Inserm U1037, Centre de Recherche en Cancérologie de Toulouse, Université de Toulouse, France (E.U.-C.); CHU Saint-Etienne, Hôpital Nord, Service d'Anatomie et Cytologie Pathologiques, Saint-Etienne, France (F.F., M.P.); CHU Lille, Pôle Pathologie Biologique, Service Anatomie Pathologique, Lille, France (C.-A.M.); CHU Nancy, Hôpital Central, Laboratoire d'Anatomie Pathologique, Nancy, France (J.-M.V.); AP-HP, Hôpital Lariboisière, Service d'Anatomie et Cytologie Pathologique, Paris, France (M.P.); CHU Caen, Hôpital de la Côte de Nacre, Service d'Anatomie Pathologique, Caen, France (E.L.-Z.); CNRS, UMR 6301 ISTCT, CERVOxy, GIP CYCERON, Caen, France (E.L.-Z.); CHU Bordeaux, Hôpital Pellegrin, Service de Pathologie - Neuropathologie, Bordeaux, France (S.E.); EA2406, Histologie et Pathologie Moléculaire des Tumeurs, Université Bordeaux Segalen, Bordeaux, France (S.E.); CHU Besançon, Hôpital Jean Minjoz, Service Anatomie et Cytologie Pathologiques, Besançon, France (G.V.); CHU Brest, Hôpital de la Cavale Blanche, Service Anatomie Pathologique, Brest, France (I.Q.-R.); CHU Dijon, Plateau Technique de Biologie G. Mack, Service Anatomie et
| | - Sandrine Eimer
- APHM, Hôpital de la Timone, Service d'Anatomie Pathologique et de Neuropathologie, Marseille, France (D.F.-B.); Aix-Marseille Université, Inserm, CRO2 UMR_S 911, Marseille, France (D.F.-B., C.Co.); AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Service de Neuropathologie Raymond Escourolle, Paris, France (K.M., A.I.); Université Pierre et Marie Curie - Paris 6, Centre de Recherche de l'Institut du Cerveau et de la Moelle épinière (CRICM), UMRS 975, Paris, France (K.M., C.Ca., A.I.); Inserm U975, Paris, France (K.M., C.Ca., A.I.); AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Service de Neurologie 2 - Mazarin, Paris, France (C.D.); Centre de Pathologie et de Neuropathologie Est, Bron, France (A.J.); CHU Toulouse, Hôpital Rangueil, Service d'Anatomie Pathologique et Histologie-Cytologie, Toulouse, France (E.U.-C.); Inserm U1037, Centre de Recherche en Cancérologie de Toulouse, Université de Toulouse, France (E.U.-C.); CHU Saint-Etienne, Hôpital Nord, Service d'Anatomie et Cytologie Pathologiques, Saint-Etienne, France (F.F., M.P.); CHU Lille, Pôle Pathologie Biologique, Service Anatomie Pathologique, Lille, France (C.-A.M.); CHU Nancy, Hôpital Central, Laboratoire d'Anatomie Pathologique, Nancy, France (J.-M.V.); AP-HP, Hôpital Lariboisière, Service d'Anatomie et Cytologie Pathologique, Paris, France (M.P.); CHU Caen, Hôpital de la Côte de Nacre, Service d'Anatomie Pathologique, Caen, France (E.L.-Z.); CNRS, UMR 6301 ISTCT, CERVOxy, GIP CYCERON, Caen, France (E.L.-Z.); CHU Bordeaux, Hôpital Pellegrin, Service de Pathologie - Neuropathologie, Bordeaux, France (S.E.); EA2406, Histologie et Pathologie Moléculaire des Tumeurs, Université Bordeaux Segalen, Bordeaux, France (S.E.); CHU Besançon, Hôpital Jean Minjoz, Service Anatomie et Cytologie Pathologiques, Besançon, France (G.V.); CHU Brest, Hôpital de la Cavale Blanche, Service Anatomie Pathologique, Brest, France (I.Q.-R.); CHU Dijon, Plateau Technique de Biologie G. Mack, Service Anatomie et
| | - Gabriel Viennet
- APHM, Hôpital de la Timone, Service d'Anatomie Pathologique et de Neuropathologie, Marseille, France (D.F.-B.); Aix-Marseille Université, Inserm, CRO2 UMR_S 911, Marseille, France (D.F.-B., C.Co.); AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Service de Neuropathologie Raymond Escourolle, Paris, France (K.M., A.I.); Université Pierre et Marie Curie - Paris 6, Centre de Recherche de l'Institut du Cerveau et de la Moelle épinière (CRICM), UMRS 975, Paris, France (K.M., C.Ca., A.I.); Inserm U975, Paris, France (K.M., C.Ca., A.I.); AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Service de Neurologie 2 - Mazarin, Paris, France (C.D.); Centre de Pathologie et de Neuropathologie Est, Bron, France (A.J.); CHU Toulouse, Hôpital Rangueil, Service d'Anatomie Pathologique et Histologie-Cytologie, Toulouse, France (E.U.-C.); Inserm U1037, Centre de Recherche en Cancérologie de Toulouse, Université de Toulouse, France (E.U.-C.); CHU Saint-Etienne, Hôpital Nord, Service d'Anatomie et Cytologie Pathologiques, Saint-Etienne, France (F.F., M.P.); CHU Lille, Pôle Pathologie Biologique, Service Anatomie Pathologique, Lille, France (C.-A.M.); CHU Nancy, Hôpital Central, Laboratoire d'Anatomie Pathologique, Nancy, France (J.-M.V.); AP-HP, Hôpital Lariboisière, Service d'Anatomie et Cytologie Pathologique, Paris, France (M.P.); CHU Caen, Hôpital de la Côte de Nacre, Service d'Anatomie Pathologique, Caen, France (E.L.-Z.); CNRS, UMR 6301 ISTCT, CERVOxy, GIP CYCERON, Caen, France (E.L.-Z.); CHU Bordeaux, Hôpital Pellegrin, Service de Pathologie - Neuropathologie, Bordeaux, France (S.E.); EA2406, Histologie et Pathologie Moléculaire des Tumeurs, Université Bordeaux Segalen, Bordeaux, France (S.E.); CHU Besançon, Hôpital Jean Minjoz, Service Anatomie et Cytologie Pathologiques, Besançon, France (G.V.); CHU Brest, Hôpital de la Cavale Blanche, Service Anatomie Pathologique, Brest, France (I.Q.-R.); CHU Dijon, Plateau Technique de Biologie G. Mack, Service Anatomie et
| | - Isabelle Quintin-Roué
- APHM, Hôpital de la Timone, Service d'Anatomie Pathologique et de Neuropathologie, Marseille, France (D.F.-B.); Aix-Marseille Université, Inserm, CRO2 UMR_S 911, Marseille, France (D.F.-B., C.Co.); AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Service de Neuropathologie Raymond Escourolle, Paris, France (K.M., A.I.); Université Pierre et Marie Curie - Paris 6, Centre de Recherche de l'Institut du Cerveau et de la Moelle épinière (CRICM), UMRS 975, Paris, France (K.M., C.Ca., A.I.); Inserm U975, Paris, France (K.M., C.Ca., A.I.); AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Service de Neurologie 2 - Mazarin, Paris, France (C.D.); Centre de Pathologie et de Neuropathologie Est, Bron, France (A.J.); CHU Toulouse, Hôpital Rangueil, Service d'Anatomie Pathologique et Histologie-Cytologie, Toulouse, France (E.U.-C.); Inserm U1037, Centre de Recherche en Cancérologie de Toulouse, Université de Toulouse, France (E.U.-C.); CHU Saint-Etienne, Hôpital Nord, Service d'Anatomie et Cytologie Pathologiques, Saint-Etienne, France (F.F., M.P.); CHU Lille, Pôle Pathologie Biologique, Service Anatomie Pathologique, Lille, France (C.-A.M.); CHU Nancy, Hôpital Central, Laboratoire d'Anatomie Pathologique, Nancy, France (J.-M.V.); AP-HP, Hôpital Lariboisière, Service d'Anatomie et Cytologie Pathologique, Paris, France (M.P.); CHU Caen, Hôpital de la Côte de Nacre, Service d'Anatomie Pathologique, Caen, France (E.L.-Z.); CNRS, UMR 6301 ISTCT, CERVOxy, GIP CYCERON, Caen, France (E.L.-Z.); CHU Bordeaux, Hôpital Pellegrin, Service de Pathologie - Neuropathologie, Bordeaux, France (S.E.); EA2406, Histologie et Pathologie Moléculaire des Tumeurs, Université Bordeaux Segalen, Bordeaux, France (S.E.); CHU Besançon, Hôpital Jean Minjoz, Service Anatomie et Cytologie Pathologiques, Besançon, France (G.V.); CHU Brest, Hôpital de la Cavale Blanche, Service Anatomie Pathologique, Brest, France (I.Q.-R.); CHU Dijon, Plateau Technique de Biologie G. Mack, Service Anatomie et
| | - Marie-Hélène Aubriot-Lorton
- APHM, Hôpital de la Timone, Service d'Anatomie Pathologique et de Neuropathologie, Marseille, France (D.F.-B.); Aix-Marseille Université, Inserm, CRO2 UMR_S 911, Marseille, France (D.F.-B., C.Co.); AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Service de Neuropathologie Raymond Escourolle, Paris, France (K.M., A.I.); Université Pierre et Marie Curie - Paris 6, Centre de Recherche de l'Institut du Cerveau et de la Moelle épinière (CRICM), UMRS 975, Paris, France (K.M., C.Ca., A.I.); Inserm U975, Paris, France (K.M., C.Ca., A.I.); AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Service de Neurologie 2 - Mazarin, Paris, France (C.D.); Centre de Pathologie et de Neuropathologie Est, Bron, France (A.J.); CHU Toulouse, Hôpital Rangueil, Service d'Anatomie Pathologique et Histologie-Cytologie, Toulouse, France (E.U.-C.); Inserm U1037, Centre de Recherche en Cancérologie de Toulouse, Université de Toulouse, France (E.U.-C.); CHU Saint-Etienne, Hôpital Nord, Service d'Anatomie et Cytologie Pathologiques, Saint-Etienne, France (F.F., M.P.); CHU Lille, Pôle Pathologie Biologique, Service Anatomie Pathologique, Lille, France (C.-A.M.); CHU Nancy, Hôpital Central, Laboratoire d'Anatomie Pathologique, Nancy, France (J.-M.V.); AP-HP, Hôpital Lariboisière, Service d'Anatomie et Cytologie Pathologique, Paris, France (M.P.); CHU Caen, Hôpital de la Côte de Nacre, Service d'Anatomie Pathologique, Caen, France (E.L.-Z.); CNRS, UMR 6301 ISTCT, CERVOxy, GIP CYCERON, Caen, France (E.L.-Z.); CHU Bordeaux, Hôpital Pellegrin, Service de Pathologie - Neuropathologie, Bordeaux, France (S.E.); EA2406, Histologie et Pathologie Moléculaire des Tumeurs, Université Bordeaux Segalen, Bordeaux, France (S.E.); CHU Besançon, Hôpital Jean Minjoz, Service Anatomie et Cytologie Pathologiques, Besançon, France (G.V.); CHU Brest, Hôpital de la Cavale Blanche, Service Anatomie Pathologique, Brest, France (I.Q.-R.); CHU Dijon, Plateau Technique de Biologie G. Mack, Service Anatomie et
| | - Marie-Danièle Diebold
- APHM, Hôpital de la Timone, Service d'Anatomie Pathologique et de Neuropathologie, Marseille, France (D.F.-B.); Aix-Marseille Université, Inserm, CRO2 UMR_S 911, Marseille, France (D.F.-B., C.Co.); AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Service de Neuropathologie Raymond Escourolle, Paris, France (K.M., A.I.); Université Pierre et Marie Curie - Paris 6, Centre de Recherche de l'Institut du Cerveau et de la Moelle épinière (CRICM), UMRS 975, Paris, France (K.M., C.Ca., A.I.); Inserm U975, Paris, France (K.M., C.Ca., A.I.); AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Service de Neurologie 2 - Mazarin, Paris, France (C.D.); Centre de Pathologie et de Neuropathologie Est, Bron, France (A.J.); CHU Toulouse, Hôpital Rangueil, Service d'Anatomie Pathologique et Histologie-Cytologie, Toulouse, France (E.U.-C.); Inserm U1037, Centre de Recherche en Cancérologie de Toulouse, Université de Toulouse, France (E.U.-C.); CHU Saint-Etienne, Hôpital Nord, Service d'Anatomie et Cytologie Pathologiques, Saint-Etienne, France (F.F., M.P.); CHU Lille, Pôle Pathologie Biologique, Service Anatomie Pathologique, Lille, France (C.-A.M.); CHU Nancy, Hôpital Central, Laboratoire d'Anatomie Pathologique, Nancy, France (J.-M.V.); AP-HP, Hôpital Lariboisière, Service d'Anatomie et Cytologie Pathologique, Paris, France (M.P.); CHU Caen, Hôpital de la Côte de Nacre, Service d'Anatomie Pathologique, Caen, France (E.L.-Z.); CNRS, UMR 6301 ISTCT, CERVOxy, GIP CYCERON, Caen, France (E.L.-Z.); CHU Bordeaux, Hôpital Pellegrin, Service de Pathologie - Neuropathologie, Bordeaux, France (S.E.); EA2406, Histologie et Pathologie Moléculaire des Tumeurs, Université Bordeaux Segalen, Bordeaux, France (S.E.); CHU Besançon, Hôpital Jean Minjoz, Service Anatomie et Cytologie Pathologiques, Besançon, France (G.V.); CHU Brest, Hôpital de la Cavale Blanche, Service Anatomie Pathologique, Brest, France (I.Q.-R.); CHU Dijon, Plateau Technique de Biologie G. Mack, Service Anatomie et
| | - Delphine Loussouarn
- APHM, Hôpital de la Timone, Service d'Anatomie Pathologique et de Neuropathologie, Marseille, France (D.F.-B.); Aix-Marseille Université, Inserm, CRO2 UMR_S 911, Marseille, France (D.F.-B., C.Co.); AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Service de Neuropathologie Raymond Escourolle, Paris, France (K.M., A.I.); Université Pierre et Marie Curie - Paris 6, Centre de Recherche de l'Institut du Cerveau et de la Moelle épinière (CRICM), UMRS 975, Paris, France (K.M., C.Ca., A.I.); Inserm U975, Paris, France (K.M., C.Ca., A.I.); AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Service de Neurologie 2 - Mazarin, Paris, France (C.D.); Centre de Pathologie et de Neuropathologie Est, Bron, France (A.J.); CHU Toulouse, Hôpital Rangueil, Service d'Anatomie Pathologique et Histologie-Cytologie, Toulouse, France (E.U.-C.); Inserm U1037, Centre de Recherche en Cancérologie de Toulouse, Université de Toulouse, France (E.U.-C.); CHU Saint-Etienne, Hôpital Nord, Service d'Anatomie et Cytologie Pathologiques, Saint-Etienne, France (F.F., M.P.); CHU Lille, Pôle Pathologie Biologique, Service Anatomie Pathologique, Lille, France (C.-A.M.); CHU Nancy, Hôpital Central, Laboratoire d'Anatomie Pathologique, Nancy, France (J.-M.V.); AP-HP, Hôpital Lariboisière, Service d'Anatomie et Cytologie Pathologique, Paris, France (M.P.); CHU Caen, Hôpital de la Côte de Nacre, Service d'Anatomie Pathologique, Caen, France (E.L.-Z.); CNRS, UMR 6301 ISTCT, CERVOxy, GIP CYCERON, Caen, France (E.L.-Z.); CHU Bordeaux, Hôpital Pellegrin, Service de Pathologie - Neuropathologie, Bordeaux, France (S.E.); EA2406, Histologie et Pathologie Moléculaire des Tumeurs, Université Bordeaux Segalen, Bordeaux, France (S.E.); CHU Besançon, Hôpital Jean Minjoz, Service Anatomie et Cytologie Pathologiques, Besançon, France (G.V.); CHU Brest, Hôpital de la Cavale Blanche, Service Anatomie Pathologique, Brest, France (I.Q.-R.); CHU Dijon, Plateau Technique de Biologie G. Mack, Service Anatomie et
| | - Catherine Lacroix
- APHM, Hôpital de la Timone, Service d'Anatomie Pathologique et de Neuropathologie, Marseille, France (D.F.-B.); Aix-Marseille Université, Inserm, CRO2 UMR_S 911, Marseille, France (D.F.-B., C.Co.); AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Service de Neuropathologie Raymond Escourolle, Paris, France (K.M., A.I.); Université Pierre et Marie Curie - Paris 6, Centre de Recherche de l'Institut du Cerveau et de la Moelle épinière (CRICM), UMRS 975, Paris, France (K.M., C.Ca., A.I.); Inserm U975, Paris, France (K.M., C.Ca., A.I.); AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Service de Neurologie 2 - Mazarin, Paris, France (C.D.); Centre de Pathologie et de Neuropathologie Est, Bron, France (A.J.); CHU Toulouse, Hôpital Rangueil, Service d'Anatomie Pathologique et Histologie-Cytologie, Toulouse, France (E.U.-C.); Inserm U1037, Centre de Recherche en Cancérologie de Toulouse, Université de Toulouse, France (E.U.-C.); CHU Saint-Etienne, Hôpital Nord, Service d'Anatomie et Cytologie Pathologiques, Saint-Etienne, France (F.F., M.P.); CHU Lille, Pôle Pathologie Biologique, Service Anatomie Pathologique, Lille, France (C.-A.M.); CHU Nancy, Hôpital Central, Laboratoire d'Anatomie Pathologique, Nancy, France (J.-M.V.); AP-HP, Hôpital Lariboisière, Service d'Anatomie et Cytologie Pathologique, Paris, France (M.P.); CHU Caen, Hôpital de la Côte de Nacre, Service d'Anatomie Pathologique, Caen, France (E.L.-Z.); CNRS, UMR 6301 ISTCT, CERVOxy, GIP CYCERON, Caen, France (E.L.-Z.); CHU Bordeaux, Hôpital Pellegrin, Service de Pathologie - Neuropathologie, Bordeaux, France (S.E.); EA2406, Histologie et Pathologie Moléculaire des Tumeurs, Université Bordeaux Segalen, Bordeaux, France (S.E.); CHU Besançon, Hôpital Jean Minjoz, Service Anatomie et Cytologie Pathologiques, Besançon, France (G.V.); CHU Brest, Hôpital de la Cavale Blanche, Service Anatomie Pathologique, Brest, France (I.Q.-R.); CHU Dijon, Plateau Technique de Biologie G. Mack, Service Anatomie et
| | - Valérie Rigau
- APHM, Hôpital de la Timone, Service d'Anatomie Pathologique et de Neuropathologie, Marseille, France (D.F.-B.); Aix-Marseille Université, Inserm, CRO2 UMR_S 911, Marseille, France (D.F.-B., C.Co.); AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Service de Neuropathologie Raymond Escourolle, Paris, France (K.M., A.I.); Université Pierre et Marie Curie - Paris 6, Centre de Recherche de l'Institut du Cerveau et de la Moelle épinière (CRICM), UMRS 975, Paris, France (K.M., C.Ca., A.I.); Inserm U975, Paris, France (K.M., C.Ca., A.I.); AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Service de Neurologie 2 - Mazarin, Paris, France (C.D.); Centre de Pathologie et de Neuropathologie Est, Bron, France (A.J.); CHU Toulouse, Hôpital Rangueil, Service d'Anatomie Pathologique et Histologie-Cytologie, Toulouse, France (E.U.-C.); Inserm U1037, Centre de Recherche en Cancérologie de Toulouse, Université de Toulouse, France (E.U.-C.); CHU Saint-Etienne, Hôpital Nord, Service d'Anatomie et Cytologie Pathologiques, Saint-Etienne, France (F.F., M.P.); CHU Lille, Pôle Pathologie Biologique, Service Anatomie Pathologique, Lille, France (C.-A.M.); CHU Nancy, Hôpital Central, Laboratoire d'Anatomie Pathologique, Nancy, France (J.-M.V.); AP-HP, Hôpital Lariboisière, Service d'Anatomie et Cytologie Pathologique, Paris, France (M.P.); CHU Caen, Hôpital de la Côte de Nacre, Service d'Anatomie Pathologique, Caen, France (E.L.-Z.); CNRS, UMR 6301 ISTCT, CERVOxy, GIP CYCERON, Caen, France (E.L.-Z.); CHU Bordeaux, Hôpital Pellegrin, Service de Pathologie - Neuropathologie, Bordeaux, France (S.E.); EA2406, Histologie et Pathologie Moléculaire des Tumeurs, Université Bordeaux Segalen, Bordeaux, France (S.E.); CHU Besançon, Hôpital Jean Minjoz, Service Anatomie et Cytologie Pathologiques, Besançon, France (G.V.); CHU Brest, Hôpital de la Cavale Blanche, Service Anatomie Pathologique, Brest, France (I.Q.-R.); CHU Dijon, Plateau Technique de Biologie G. Mack, Service Anatomie et
| | - Annie Laquerrière
- APHM, Hôpital de la Timone, Service d'Anatomie Pathologique et de Neuropathologie, Marseille, France (D.F.-B.); Aix-Marseille Université, Inserm, CRO2 UMR_S 911, Marseille, France (D.F.-B., C.Co.); AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Service de Neuropathologie Raymond Escourolle, Paris, France (K.M., A.I.); Université Pierre et Marie Curie - Paris 6, Centre de Recherche de l'Institut du Cerveau et de la Moelle épinière (CRICM), UMRS 975, Paris, France (K.M., C.Ca., A.I.); Inserm U975, Paris, France (K.M., C.Ca., A.I.); AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Service de Neurologie 2 - Mazarin, Paris, France (C.D.); Centre de Pathologie et de Neuropathologie Est, Bron, France (A.J.); CHU Toulouse, Hôpital Rangueil, Service d'Anatomie Pathologique et Histologie-Cytologie, Toulouse, France (E.U.-C.); Inserm U1037, Centre de Recherche en Cancérologie de Toulouse, Université de Toulouse, France (E.U.-C.); CHU Saint-Etienne, Hôpital Nord, Service d'Anatomie et Cytologie Pathologiques, Saint-Etienne, France (F.F., M.P.); CHU Lille, Pôle Pathologie Biologique, Service Anatomie Pathologique, Lille, France (C.-A.M.); CHU Nancy, Hôpital Central, Laboratoire d'Anatomie Pathologique, Nancy, France (J.-M.V.); AP-HP, Hôpital Lariboisière, Service d'Anatomie et Cytologie Pathologique, Paris, France (M.P.); CHU Caen, Hôpital de la Côte de Nacre, Service d'Anatomie Pathologique, Caen, France (E.L.-Z.); CNRS, UMR 6301 ISTCT, CERVOxy, GIP CYCERON, Caen, France (E.L.-Z.); CHU Bordeaux, Hôpital Pellegrin, Service de Pathologie - Neuropathologie, Bordeaux, France (S.E.); EA2406, Histologie et Pathologie Moléculaire des Tumeurs, Université Bordeaux Segalen, Bordeaux, France (S.E.); CHU Besançon, Hôpital Jean Minjoz, Service Anatomie et Cytologie Pathologiques, Besançon, France (G.V.); CHU Brest, Hôpital de la Cavale Blanche, Service Anatomie Pathologique, Brest, France (I.Q.-R.); CHU Dijon, Plateau Technique de Biologie G. Mack, Service Anatomie et
| | - Fanny Vandenbos
- APHM, Hôpital de la Timone, Service d'Anatomie Pathologique et de Neuropathologie, Marseille, France (D.F.-B.); Aix-Marseille Université, Inserm, CRO2 UMR_S 911, Marseille, France (D.F.-B., C.Co.); AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Service de Neuropathologie Raymond Escourolle, Paris, France (K.M., A.I.); Université Pierre et Marie Curie - Paris 6, Centre de Recherche de l'Institut du Cerveau et de la Moelle épinière (CRICM), UMRS 975, Paris, France (K.M., C.Ca., A.I.); Inserm U975, Paris, France (K.M., C.Ca., A.I.); AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Service de Neurologie 2 - Mazarin, Paris, France (C.D.); Centre de Pathologie et de Neuropathologie Est, Bron, France (A.J.); CHU Toulouse, Hôpital Rangueil, Service d'Anatomie Pathologique et Histologie-Cytologie, Toulouse, France (E.U.-C.); Inserm U1037, Centre de Recherche en Cancérologie de Toulouse, Université de Toulouse, France (E.U.-C.); CHU Saint-Etienne, Hôpital Nord, Service d'Anatomie et Cytologie Pathologiques, Saint-Etienne, France (F.F., M.P.); CHU Lille, Pôle Pathologie Biologique, Service Anatomie Pathologique, Lille, France (C.-A.M.); CHU Nancy, Hôpital Central, Laboratoire d'Anatomie Pathologique, Nancy, France (J.-M.V.); AP-HP, Hôpital Lariboisière, Service d'Anatomie et Cytologie Pathologique, Paris, France (M.P.); CHU Caen, Hôpital de la Côte de Nacre, Service d'Anatomie Pathologique, Caen, France (E.L.-Z.); CNRS, UMR 6301 ISTCT, CERVOxy, GIP CYCERON, Caen, France (E.L.-Z.); CHU Bordeaux, Hôpital Pellegrin, Service de Pathologie - Neuropathologie, Bordeaux, France (S.E.); EA2406, Histologie et Pathologie Moléculaire des Tumeurs, Université Bordeaux Segalen, Bordeaux, France (S.E.); CHU Besançon, Hôpital Jean Minjoz, Service Anatomie et Cytologie Pathologiques, Besançon, France (G.V.); CHU Brest, Hôpital de la Cavale Blanche, Service Anatomie Pathologique, Brest, France (I.Q.-R.); CHU Dijon, Plateau Technique de Biologie G. Mack, Service Anatomie et
| | - Sophie Michalak
- APHM, Hôpital de la Timone, Service d'Anatomie Pathologique et de Neuropathologie, Marseille, France (D.F.-B.); Aix-Marseille Université, Inserm, CRO2 UMR_S 911, Marseille, France (D.F.-B., C.Co.); AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Service de Neuropathologie Raymond Escourolle, Paris, France (K.M., A.I.); Université Pierre et Marie Curie - Paris 6, Centre de Recherche de l'Institut du Cerveau et de la Moelle épinière (CRICM), UMRS 975, Paris, France (K.M., C.Ca., A.I.); Inserm U975, Paris, France (K.M., C.Ca., A.I.); AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Service de Neurologie 2 - Mazarin, Paris, France (C.D.); Centre de Pathologie et de Neuropathologie Est, Bron, France (A.J.); CHU Toulouse, Hôpital Rangueil, Service d'Anatomie Pathologique et Histologie-Cytologie, Toulouse, France (E.U.-C.); Inserm U1037, Centre de Recherche en Cancérologie de Toulouse, Université de Toulouse, France (E.U.-C.); CHU Saint-Etienne, Hôpital Nord, Service d'Anatomie et Cytologie Pathologiques, Saint-Etienne, France (F.F., M.P.); CHU Lille, Pôle Pathologie Biologique, Service Anatomie Pathologique, Lille, France (C.-A.M.); CHU Nancy, Hôpital Central, Laboratoire d'Anatomie Pathologique, Nancy, France (J.-M.V.); AP-HP, Hôpital Lariboisière, Service d'Anatomie et Cytologie Pathologique, Paris, France (M.P.); CHU Caen, Hôpital de la Côte de Nacre, Service d'Anatomie Pathologique, Caen, France (E.L.-Z.); CNRS, UMR 6301 ISTCT, CERVOxy, GIP CYCERON, Caen, France (E.L.-Z.); CHU Bordeaux, Hôpital Pellegrin, Service de Pathologie - Neuropathologie, Bordeaux, France (S.E.); EA2406, Histologie et Pathologie Moléculaire des Tumeurs, Université Bordeaux Segalen, Bordeaux, France (S.E.); CHU Besançon, Hôpital Jean Minjoz, Service Anatomie et Cytologie Pathologiques, Besançon, France (G.V.); CHU Brest, Hôpital de la Cavale Blanche, Service Anatomie Pathologique, Brest, France (I.Q.-R.); CHU Dijon, Plateau Technique de Biologie G. Mack, Service Anatomie et
| | - Henri Sevestre
- APHM, Hôpital de la Timone, Service d'Anatomie Pathologique et de Neuropathologie, Marseille, France (D.F.-B.); Aix-Marseille Université, Inserm, CRO2 UMR_S 911, Marseille, France (D.F.-B., C.Co.); AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Service de Neuropathologie Raymond Escourolle, Paris, France (K.M., A.I.); Université Pierre et Marie Curie - Paris 6, Centre de Recherche de l'Institut du Cerveau et de la Moelle épinière (CRICM), UMRS 975, Paris, France (K.M., C.Ca., A.I.); Inserm U975, Paris, France (K.M., C.Ca., A.I.); AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Service de Neurologie 2 - Mazarin, Paris, France (C.D.); Centre de Pathologie et de Neuropathologie Est, Bron, France (A.J.); CHU Toulouse, Hôpital Rangueil, Service d'Anatomie Pathologique et Histologie-Cytologie, Toulouse, France (E.U.-C.); Inserm U1037, Centre de Recherche en Cancérologie de Toulouse, Université de Toulouse, France (E.U.-C.); CHU Saint-Etienne, Hôpital Nord, Service d'Anatomie et Cytologie Pathologiques, Saint-Etienne, France (F.F., M.P.); CHU Lille, Pôle Pathologie Biologique, Service Anatomie Pathologique, Lille, France (C.-A.M.); CHU Nancy, Hôpital Central, Laboratoire d'Anatomie Pathologique, Nancy, France (J.-M.V.); AP-HP, Hôpital Lariboisière, Service d'Anatomie et Cytologie Pathologique, Paris, France (M.P.); CHU Caen, Hôpital de la Côte de Nacre, Service d'Anatomie Pathologique, Caen, France (E.L.-Z.); CNRS, UMR 6301 ISTCT, CERVOxy, GIP CYCERON, Caen, France (E.L.-Z.); CHU Bordeaux, Hôpital Pellegrin, Service de Pathologie - Neuropathologie, Bordeaux, France (S.E.); EA2406, Histologie et Pathologie Moléculaire des Tumeurs, Université Bordeaux Segalen, Bordeaux, France (S.E.); CHU Besançon, Hôpital Jean Minjoz, Service Anatomie et Cytologie Pathologiques, Besançon, France (G.V.); CHU Brest, Hôpital de la Cavale Blanche, Service Anatomie Pathologique, Brest, France (I.Q.-R.); CHU Dijon, Plateau Technique de Biologie G. Mack, Service Anatomie et
| | - Michel Peoch
- APHM, Hôpital de la Timone, Service d'Anatomie Pathologique et de Neuropathologie, Marseille, France (D.F.-B.); Aix-Marseille Université, Inserm, CRO2 UMR_S 911, Marseille, France (D.F.-B., C.Co.); AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Service de Neuropathologie Raymond Escourolle, Paris, France (K.M., A.I.); Université Pierre et Marie Curie - Paris 6, Centre de Recherche de l'Institut du Cerveau et de la Moelle épinière (CRICM), UMRS 975, Paris, France (K.M., C.Ca., A.I.); Inserm U975, Paris, France (K.M., C.Ca., A.I.); AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Service de Neurologie 2 - Mazarin, Paris, France (C.D.); Centre de Pathologie et de Neuropathologie Est, Bron, France (A.J.); CHU Toulouse, Hôpital Rangueil, Service d'Anatomie Pathologique et Histologie-Cytologie, Toulouse, France (E.U.-C.); Inserm U1037, Centre de Recherche en Cancérologie de Toulouse, Université de Toulouse, France (E.U.-C.); CHU Saint-Etienne, Hôpital Nord, Service d'Anatomie et Cytologie Pathologiques, Saint-Etienne, France (F.F., M.P.); CHU Lille, Pôle Pathologie Biologique, Service Anatomie Pathologique, Lille, France (C.-A.M.); CHU Nancy, Hôpital Central, Laboratoire d'Anatomie Pathologique, Nancy, France (J.-M.V.); AP-HP, Hôpital Lariboisière, Service d'Anatomie et Cytologie Pathologique, Paris, France (M.P.); CHU Caen, Hôpital de la Côte de Nacre, Service d'Anatomie Pathologique, Caen, France (E.L.-Z.); CNRS, UMR 6301 ISTCT, CERVOxy, GIP CYCERON, Caen, France (E.L.-Z.); CHU Bordeaux, Hôpital Pellegrin, Service de Pathologie - Neuropathologie, Bordeaux, France (S.E.); EA2406, Histologie et Pathologie Moléculaire des Tumeurs, Université Bordeaux Segalen, Bordeaux, France (S.E.); CHU Besançon, Hôpital Jean Minjoz, Service Anatomie et Cytologie Pathologiques, Besançon, France (G.V.); CHU Brest, Hôpital de la Cavale Blanche, Service Anatomie Pathologique, Brest, France (I.Q.-R.); CHU Dijon, Plateau Technique de Biologie G. Mack, Service Anatomie et
| | - François Labrousse
- APHM, Hôpital de la Timone, Service d'Anatomie Pathologique et de Neuropathologie, Marseille, France (D.F.-B.); Aix-Marseille Université, Inserm, CRO2 UMR_S 911, Marseille, France (D.F.-B., C.Co.); AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Service de Neuropathologie Raymond Escourolle, Paris, France (K.M., A.I.); Université Pierre et Marie Curie - Paris 6, Centre de Recherche de l'Institut du Cerveau et de la Moelle épinière (CRICM), UMRS 975, Paris, France (K.M., C.Ca., A.I.); Inserm U975, Paris, France (K.M., C.Ca., A.I.); AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Service de Neurologie 2 - Mazarin, Paris, France (C.D.); Centre de Pathologie et de Neuropathologie Est, Bron, France (A.J.); CHU Toulouse, Hôpital Rangueil, Service d'Anatomie Pathologique et Histologie-Cytologie, Toulouse, France (E.U.-C.); Inserm U1037, Centre de Recherche en Cancérologie de Toulouse, Université de Toulouse, France (E.U.-C.); CHU Saint-Etienne, Hôpital Nord, Service d'Anatomie et Cytologie Pathologiques, Saint-Etienne, France (F.F., M.P.); CHU Lille, Pôle Pathologie Biologique, Service Anatomie Pathologique, Lille, France (C.-A.M.); CHU Nancy, Hôpital Central, Laboratoire d'Anatomie Pathologique, Nancy, France (J.-M.V.); AP-HP, Hôpital Lariboisière, Service d'Anatomie et Cytologie Pathologique, Paris, France (M.P.); CHU Caen, Hôpital de la Côte de Nacre, Service d'Anatomie Pathologique, Caen, France (E.L.-Z.); CNRS, UMR 6301 ISTCT, CERVOxy, GIP CYCERON, Caen, France (E.L.-Z.); CHU Bordeaux, Hôpital Pellegrin, Service de Pathologie - Neuropathologie, Bordeaux, France (S.E.); EA2406, Histologie et Pathologie Moléculaire des Tumeurs, Université Bordeaux Segalen, Bordeaux, France (S.E.); CHU Besançon, Hôpital Jean Minjoz, Service Anatomie et Cytologie Pathologiques, Besançon, France (G.V.); CHU Brest, Hôpital de la Cavale Blanche, Service Anatomie Pathologique, Brest, France (I.Q.-R.); CHU Dijon, Plateau Technique de Biologie G. Mack, Service Anatomie et
| | - Christo Christov
- APHM, Hôpital de la Timone, Service d'Anatomie Pathologique et de Neuropathologie, Marseille, France (D.F.-B.); Aix-Marseille Université, Inserm, CRO2 UMR_S 911, Marseille, France (D.F.-B., C.Co.); AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Service de Neuropathologie Raymond Escourolle, Paris, France (K.M., A.I.); Université Pierre et Marie Curie - Paris 6, Centre de Recherche de l'Institut du Cerveau et de la Moelle épinière (CRICM), UMRS 975, Paris, France (K.M., C.Ca., A.I.); Inserm U975, Paris, France (K.M., C.Ca., A.I.); AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Service de Neurologie 2 - Mazarin, Paris, France (C.D.); Centre de Pathologie et de Neuropathologie Est, Bron, France (A.J.); CHU Toulouse, Hôpital Rangueil, Service d'Anatomie Pathologique et Histologie-Cytologie, Toulouse, France (E.U.-C.); Inserm U1037, Centre de Recherche en Cancérologie de Toulouse, Université de Toulouse, France (E.U.-C.); CHU Saint-Etienne, Hôpital Nord, Service d'Anatomie et Cytologie Pathologiques, Saint-Etienne, France (F.F., M.P.); CHU Lille, Pôle Pathologie Biologique, Service Anatomie Pathologique, Lille, France (C.-A.M.); CHU Nancy, Hôpital Central, Laboratoire d'Anatomie Pathologique, Nancy, France (J.-M.V.); AP-HP, Hôpital Lariboisière, Service d'Anatomie et Cytologie Pathologique, Paris, France (M.P.); CHU Caen, Hôpital de la Côte de Nacre, Service d'Anatomie Pathologique, Caen, France (E.L.-Z.); CNRS, UMR 6301 ISTCT, CERVOxy, GIP CYCERON, Caen, France (E.L.-Z.); CHU Bordeaux, Hôpital Pellegrin, Service de Pathologie - Neuropathologie, Bordeaux, France (S.E.); EA2406, Histologie et Pathologie Moléculaire des Tumeurs, Université Bordeaux Segalen, Bordeaux, France (S.E.); CHU Besançon, Hôpital Jean Minjoz, Service Anatomie et Cytologie Pathologiques, Besançon, France (G.V.); CHU Brest, Hôpital de la Cavale Blanche, Service Anatomie Pathologique, Brest, France (I.Q.-R.); CHU Dijon, Plateau Technique de Biologie G. Mack, Service Anatomie et
| | - Jean-Louis Kemeny
- APHM, Hôpital de la Timone, Service d'Anatomie Pathologique et de Neuropathologie, Marseille, France (D.F.-B.); Aix-Marseille Université, Inserm, CRO2 UMR_S 911, Marseille, France (D.F.-B., C.Co.); AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Service de Neuropathologie Raymond Escourolle, Paris, France (K.M., A.I.); Université Pierre et Marie Curie - Paris 6, Centre de Recherche de l'Institut du Cerveau et de la Moelle épinière (CRICM), UMRS 975, Paris, France (K.M., C.Ca., A.I.); Inserm U975, Paris, France (K.M., C.Ca., A.I.); AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Service de Neurologie 2 - Mazarin, Paris, France (C.D.); Centre de Pathologie et de Neuropathologie Est, Bron, France (A.J.); CHU Toulouse, Hôpital Rangueil, Service d'Anatomie Pathologique et Histologie-Cytologie, Toulouse, France (E.U.-C.); Inserm U1037, Centre de Recherche en Cancérologie de Toulouse, Université de Toulouse, France (E.U.-C.); CHU Saint-Etienne, Hôpital Nord, Service d'Anatomie et Cytologie Pathologiques, Saint-Etienne, France (F.F., M.P.); CHU Lille, Pôle Pathologie Biologique, Service Anatomie Pathologique, Lille, France (C.-A.M.); CHU Nancy, Hôpital Central, Laboratoire d'Anatomie Pathologique, Nancy, France (J.-M.V.); AP-HP, Hôpital Lariboisière, Service d'Anatomie et Cytologie Pathologique, Paris, France (M.P.); CHU Caen, Hôpital de la Côte de Nacre, Service d'Anatomie Pathologique, Caen, France (E.L.-Z.); CNRS, UMR 6301 ISTCT, CERVOxy, GIP CYCERON, Caen, France (E.L.-Z.); CHU Bordeaux, Hôpital Pellegrin, Service de Pathologie - Neuropathologie, Bordeaux, France (S.E.); EA2406, Histologie et Pathologie Moléculaire des Tumeurs, Université Bordeaux Segalen, Bordeaux, France (S.E.); CHU Besançon, Hôpital Jean Minjoz, Service Anatomie et Cytologie Pathologiques, Besançon, France (G.V.); CHU Brest, Hôpital de la Cavale Blanche, Service Anatomie Pathologique, Brest, France (I.Q.-R.); CHU Dijon, Plateau Technique de Biologie G. Mack, Service Anatomie et
| | - Marie-Pierre Chenard
- APHM, Hôpital de la Timone, Service d'Anatomie Pathologique et de Neuropathologie, Marseille, France (D.F.-B.); Aix-Marseille Université, Inserm, CRO2 UMR_S 911, Marseille, France (D.F.-B., C.Co.); AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Service de Neuropathologie Raymond Escourolle, Paris, France (K.M., A.I.); Université Pierre et Marie Curie - Paris 6, Centre de Recherche de l'Institut du Cerveau et de la Moelle épinière (CRICM), UMRS 975, Paris, France (K.M., C.Ca., A.I.); Inserm U975, Paris, France (K.M., C.Ca., A.I.); AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Service de Neurologie 2 - Mazarin, Paris, France (C.D.); Centre de Pathologie et de Neuropathologie Est, Bron, France (A.J.); CHU Toulouse, Hôpital Rangueil, Service d'Anatomie Pathologique et Histologie-Cytologie, Toulouse, France (E.U.-C.); Inserm U1037, Centre de Recherche en Cancérologie de Toulouse, Université de Toulouse, France (E.U.-C.); CHU Saint-Etienne, Hôpital Nord, Service d'Anatomie et Cytologie Pathologiques, Saint-Etienne, France (F.F., M.P.); CHU Lille, Pôle Pathologie Biologique, Service Anatomie Pathologique, Lille, France (C.-A.M.); CHU Nancy, Hôpital Central, Laboratoire d'Anatomie Pathologique, Nancy, France (J.-M.V.); AP-HP, Hôpital Lariboisière, Service d'Anatomie et Cytologie Pathologique, Paris, France (M.P.); CHU Caen, Hôpital de la Côte de Nacre, Service d'Anatomie Pathologique, Caen, France (E.L.-Z.); CNRS, UMR 6301 ISTCT, CERVOxy, GIP CYCERON, Caen, France (E.L.-Z.); CHU Bordeaux, Hôpital Pellegrin, Service de Pathologie - Neuropathologie, Bordeaux, France (S.E.); EA2406, Histologie et Pathologie Moléculaire des Tumeurs, Université Bordeaux Segalen, Bordeaux, France (S.E.); CHU Besançon, Hôpital Jean Minjoz, Service Anatomie et Cytologie Pathologiques, Besançon, France (G.V.); CHU Brest, Hôpital de la Cavale Blanche, Service Anatomie Pathologique, Brest, France (I.Q.-R.); CHU Dijon, Plateau Technique de Biologie G. Mack, Service Anatomie et
| | - Danchristian Chiforeanu
- APHM, Hôpital de la Timone, Service d'Anatomie Pathologique et de Neuropathologie, Marseille, France (D.F.-B.); Aix-Marseille Université, Inserm, CRO2 UMR_S 911, Marseille, France (D.F.-B., C.Co.); AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Service de Neuropathologie Raymond Escourolle, Paris, France (K.M., A.I.); Université Pierre et Marie Curie - Paris 6, Centre de Recherche de l'Institut du Cerveau et de la Moelle épinière (CRICM), UMRS 975, Paris, France (K.M., C.Ca., A.I.); Inserm U975, Paris, France (K.M., C.Ca., A.I.); AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Service de Neurologie 2 - Mazarin, Paris, France (C.D.); Centre de Pathologie et de Neuropathologie Est, Bron, France (A.J.); CHU Toulouse, Hôpital Rangueil, Service d'Anatomie Pathologique et Histologie-Cytologie, Toulouse, France (E.U.-C.); Inserm U1037, Centre de Recherche en Cancérologie de Toulouse, Université de Toulouse, France (E.U.-C.); CHU Saint-Etienne, Hôpital Nord, Service d'Anatomie et Cytologie Pathologiques, Saint-Etienne, France (F.F., M.P.); CHU Lille, Pôle Pathologie Biologique, Service Anatomie Pathologique, Lille, France (C.-A.M.); CHU Nancy, Hôpital Central, Laboratoire d'Anatomie Pathologique, Nancy, France (J.-M.V.); AP-HP, Hôpital Lariboisière, Service d'Anatomie et Cytologie Pathologique, Paris, France (M.P.); CHU Caen, Hôpital de la Côte de Nacre, Service d'Anatomie Pathologique, Caen, France (E.L.-Z.); CNRS, UMR 6301 ISTCT, CERVOxy, GIP CYCERON, Caen, France (E.L.-Z.); CHU Bordeaux, Hôpital Pellegrin, Service de Pathologie - Neuropathologie, Bordeaux, France (S.E.); EA2406, Histologie et Pathologie Moléculaire des Tumeurs, Université Bordeaux Segalen, Bordeaux, France (S.E.); CHU Besançon, Hôpital Jean Minjoz, Service Anatomie et Cytologie Pathologiques, Besançon, France (G.V.); CHU Brest, Hôpital de la Cavale Blanche, Service Anatomie Pathologique, Brest, France (I.Q.-R.); CHU Dijon, Plateau Technique de Biologie G. Mack, Service Anatomie et
| | - François Ducray
- APHM, Hôpital de la Timone, Service d'Anatomie Pathologique et de Neuropathologie, Marseille, France (D.F.-B.); Aix-Marseille Université, Inserm, CRO2 UMR_S 911, Marseille, France (D.F.-B., C.Co.); AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Service de Neuropathologie Raymond Escourolle, Paris, France (K.M., A.I.); Université Pierre et Marie Curie - Paris 6, Centre de Recherche de l'Institut du Cerveau et de la Moelle épinière (CRICM), UMRS 975, Paris, France (K.M., C.Ca., A.I.); Inserm U975, Paris, France (K.M., C.Ca., A.I.); AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Service de Neurologie 2 - Mazarin, Paris, France (C.D.); Centre de Pathologie et de Neuropathologie Est, Bron, France (A.J.); CHU Toulouse, Hôpital Rangueil, Service d'Anatomie Pathologique et Histologie-Cytologie, Toulouse, France (E.U.-C.); Inserm U1037, Centre de Recherche en Cancérologie de Toulouse, Université de Toulouse, France (E.U.-C.); CHU Saint-Etienne, Hôpital Nord, Service d'Anatomie et Cytologie Pathologiques, Saint-Etienne, France (F.F., M.P.); CHU Lille, Pôle Pathologie Biologique, Service Anatomie Pathologique, Lille, France (C.-A.M.); CHU Nancy, Hôpital Central, Laboratoire d'Anatomie Pathologique, Nancy, France (J.-M.V.); AP-HP, Hôpital Lariboisière, Service d'Anatomie et Cytologie Pathologique, Paris, France (M.P.); CHU Caen, Hôpital de la Côte de Nacre, Service d'Anatomie Pathologique, Caen, France (E.L.-Z.); CNRS, UMR 6301 ISTCT, CERVOxy, GIP CYCERON, Caen, France (E.L.-Z.); CHU Bordeaux, Hôpital Pellegrin, Service de Pathologie - Neuropathologie, Bordeaux, France (S.E.); EA2406, Histologie et Pathologie Moléculaire des Tumeurs, Université Bordeaux Segalen, Bordeaux, France (S.E.); CHU Besançon, Hôpital Jean Minjoz, Service Anatomie et Cytologie Pathologiques, Besançon, France (G.V.); CHU Brest, Hôpital de la Cavale Blanche, Service Anatomie Pathologique, Brest, France (I.Q.-R.); CHU Dijon, Plateau Technique de Biologie G. Mack, Service Anatomie et
| | - Ahmed Idbaih
- APHM, Hôpital de la Timone, Service d'Anatomie Pathologique et de Neuropathologie, Marseille, France (D.F.-B.); Aix-Marseille Université, Inserm, CRO2 UMR_S 911, Marseille, France (D.F.-B., C.Co.); AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Service de Neuropathologie Raymond Escourolle, Paris, France (K.M., A.I.); Université Pierre et Marie Curie - Paris 6, Centre de Recherche de l'Institut du Cerveau et de la Moelle épinière (CRICM), UMRS 975, Paris, France (K.M., C.Ca., A.I.); Inserm U975, Paris, France (K.M., C.Ca., A.I.); AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Service de Neurologie 2 - Mazarin, Paris, France (C.D.); Centre de Pathologie et de Neuropathologie Est, Bron, France (A.J.); CHU Toulouse, Hôpital Rangueil, Service d'Anatomie Pathologique et Histologie-Cytologie, Toulouse, France (E.U.-C.); Inserm U1037, Centre de Recherche en Cancérologie de Toulouse, Université de Toulouse, France (E.U.-C.); CHU Saint-Etienne, Hôpital Nord, Service d'Anatomie et Cytologie Pathologiques, Saint-Etienne, France (F.F., M.P.); CHU Lille, Pôle Pathologie Biologique, Service Anatomie Pathologique, Lille, France (C.-A.M.); CHU Nancy, Hôpital Central, Laboratoire d'Anatomie Pathologique, Nancy, France (J.-M.V.); AP-HP, Hôpital Lariboisière, Service d'Anatomie et Cytologie Pathologique, Paris, France (M.P.); CHU Caen, Hôpital de la Côte de Nacre, Service d'Anatomie Pathologique, Caen, France (E.L.-Z.); CNRS, UMR 6301 ISTCT, CERVOxy, GIP CYCERON, Caen, France (E.L.-Z.); CHU Bordeaux, Hôpital Pellegrin, Service de Pathologie - Neuropathologie, Bordeaux, France (S.E.); EA2406, Histologie et Pathologie Moléculaire des Tumeurs, Université Bordeaux Segalen, Bordeaux, France (S.E.); CHU Besançon, Hôpital Jean Minjoz, Service Anatomie et Cytologie Pathologiques, Besançon, France (G.V.); CHU Brest, Hôpital de la Cavale Blanche, Service Anatomie Pathologique, Brest, France (I.Q.-R.); CHU Dijon, Plateau Technique de Biologie G. Mack, Service Anatomie et
| | | |
Collapse
|
44
|
Badaoui N, Meyronet D, Cartalat-Carel S, Guyotat J, Jouanneau E, d’Hombres A, Sunyach M, Jouvet A, Louis-Tisserand G, Archinet A, Frappaz D, Bauchet L, Honnorat J, Ducray F. Patterns of care and survival of glioblastoma patients: A comparative study between 2004 and 2008 in Lyon, France. Rev Neurol (Paris) 2014; 170:222-7. [DOI: 10.1016/j.neurol.2013.09.007] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/27/2013] [Revised: 08/21/2013] [Accepted: 09/13/2013] [Indexed: 11/28/2022]
|
45
|
Fèvre Montange M, Vasiljevic A, Champier J, Jouvet A. Papillary tumor of the pineal region: Histopathological characterization and review of the literature. Neurochirurgie 2014; 61:138-42. [PMID: 24556386 DOI: 10.1016/j.neuchi.2013.04.011] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/26/2013] [Accepted: 04/26/2013] [Indexed: 11/18/2022]
Abstract
BACKGROUND AND PURPOSE The papillary tumor of the pineal region (PTPR) was described as a distinct new entity for the first time in 2003 by our team and has been included in the last 2007 WHO classification of tumors of the Central Nervous System. We describe the histopathological characterization of PTPR and present a review of the literature. METHODS The description of the histological and immunological features of PTPR is based on the 2007 WHO classification. RESULTS PTPR affects both children and adults, and mostly young adults in the third decade. PTPR is a neuroepithelial tumor occurring in the vicinity of the pineal gland, and characterized by its papillary architecture. The papillae are lined by multi-layered cuboidal to columnar epithelioid tumoral cells arranged in perivascular pseudorosettes. Immunohistochemistry shows strong reactivity for cytokeratins, particularly for cytokeratin 18. On electron microscopy, PTPR reveals ultrastructural features indicative of ependymal differentiation, including abundant microvilli at the apical cell pole. The differential diagnosis includes a variety of other papillary tumors, most notably papillary ependymoma, choroid plexus papilloma, papillary meningioma, and metastatic papillary carcinoma in adults. On the basis of ultrastructural and immunohistochemical features, it has been suggested that a PTPR arises from specialized cytokeratin-positive and nestin-positive ependymal cells that are derived from the subcommissural organ. Although the precise histological grading criteria of PTPR remain to be defined, its biological behavior may correspond to WHO grade II or III.
Collapse
Affiliation(s)
- M Fèvre Montange
- Équipe neuro-oncologie et neuro-inflammation, Inserm U1028, CNRS UMR5292, centre de recherche en neurosciences de Lyon, université Lyon 1, rue Paradin, 69372 Lyon cedex 08, France.
| | - A Vasiljevic
- Service de pathologie et de neuropathologie, centre de biologie et pathologie Est, groupement hospitalier Est, hospices civils de Lyon, 59, boulevard Pinel, 69500 Bron, France
| | - J Champier
- Équipe neuro-oncologie et neuro-inflammation, Inserm U1028, CNRS UMR5292, centre de recherche en neurosciences de Lyon, université Lyon 1, rue Paradin, 69372 Lyon cedex 08, France
| | - A Jouvet
- Équipe neuro-oncologie et neuro-inflammation, Inserm U1028, CNRS UMR5292, centre de recherche en neurosciences de Lyon, université Lyon 1, rue Paradin, 69372 Lyon cedex 08, France; Service de pathologie et de neuropathologie, centre de biologie et pathologie Est, groupement hospitalier Est, hospices civils de Lyon, 59, boulevard Pinel, 69500 Bron, France
| |
Collapse
|
46
|
Shih DJH, Northcott PA, Remke M, Korshunov A, Ramaswamy V, Kool M, Luu B, Yao Y, Wang X, Dubuc AM, Garzia L, Peacock J, Mack SC, Wu X, Rolider A, Morrissy AS, Cavalli FMG, Jones DTW, Zitterbart K, Faria CC, Schüller U, Kren L, Kumabe T, Tominaga T, Shin Ra Y, Garami M, Hauser P, Chan JA, Robinson S, Bognár L, Klekner A, Saad AG, Liau LM, Albrecht S, Fontebasso A, Cinalli G, De Antonellis P, Zollo M, Cooper MK, Thompson RC, Bailey S, Lindsey JC, Di Rocco C, Massimi L, Michiels EMC, Scherer SW, Phillips JJ, Gupta N, Fan X, Muraszko KM, Vibhakar R, Eberhart CG, Fouladi M, Lach B, Jung S, Wechsler-Reya RJ, Fèvre-Montange M, Jouvet A, Jabado N, Pollack IF, Weiss WA, Lee JY, Cho BK, Kim SK, Wang KC, Leonard JR, Rubin JB, de Torres C, Lavarino C, Mora J, Cho YJ, Tabori U, Olson JM, Gajjar A, Packer RJ, Rutkowski S, Pomeroy SL, French PJ, Kloosterhof NK, Kros JM, Van Meir EG, Clifford SC, Bourdeaut F, Delattre O, Doz FF, Hawkins CE, Malkin D, Grajkowska WA, Perek-Polnik M, Bouffet E, Rutka JT, Pfister SM, Taylor MD. Cytogenetic prognostication within medulloblastoma subgroups. J Clin Oncol 2014; 32:886-96. [PMID: 24493713 DOI: 10.1200/jco.2013.50.9539] [Citation(s) in RCA: 211] [Impact Index Per Article: 21.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022] Open
Abstract
PURPOSE Medulloblastoma comprises four distinct molecular subgroups: WNT, SHH, Group 3, and Group 4. Current medulloblastoma protocols stratify patients based on clinical features: patient age, metastatic stage, extent of resection, and histologic variant. Stark prognostic and genetic differences among the four subgroups suggest that subgroup-specific molecular biomarkers could improve patient prognostication. PATIENTS AND METHODS Molecular biomarkers were identified from a discovery set of 673 medulloblastomas from 43 cities around the world. Combined risk stratification models were designed based on clinical and cytogenetic biomarkers identified by multivariable Cox proportional hazards analyses. Identified biomarkers were tested using fluorescent in situ hybridization (FISH) on a nonoverlapping medulloblastoma tissue microarray (n = 453), with subsequent validation of the risk stratification models. RESULTS Subgroup information improves the predictive accuracy of a multivariable survival model compared with clinical biomarkers alone. Most previously published cytogenetic biomarkers are only prognostic within a single medulloblastoma subgroup. Profiling six FISH biomarkers (GLI2, MYC, chromosome 11 [chr11], chr14, 17p, and 17q) on formalin-fixed paraffin-embedded tissues, we can reliably and reproducibly identify very low-risk and very high-risk patients within SHH, Group 3, and Group 4 medulloblastomas. CONCLUSION Combining subgroup and cytogenetic biomarkers with established clinical biomarkers substantially improves patient prognostication, even in the context of heterogeneous clinical therapies. The prognostic significance of most molecular biomarkers is restricted to a specific subgroup. We have identified a small panel of cytogenetic biomarkers that reliably identifies very high-risk and very low-risk groups of patients, making it an excellent tool for selecting patients for therapy intensification and therapy de-escalation in future clinical trials.
Collapse
Affiliation(s)
- David J H Shih
- David J.H. Shih, Marc Remke, Vijay Ramaswamy, Betty Luu, Yuan Yao, Xin Wang, Adrian M. Dubuc, Livia Garzia, John Peacock, Stephen C. Mack, Xiaochong Wu, Adi Rolider, A. Sorana Morrissy, Florence M.G. Cavalli, Claudia C. Faria, Stephen W. Scherer, Uri Tabori, Cynthia E. Hawkins, David Malkin, Eric Bouffet, James T. Rutka, and Michael D. Taylor, Hospital for Sick Children; David J.H. Shih, Marc Remke, Vijay Ramaswamy, Yuan Yao, Xin Wang, Adrian M. Dubuc, John Peacock, Stephen C. Mack, and Michael D. Taylor, University of Toronto, Toronto; Boleslaw Lach, McMaster University, Hamilton, Ontario; Jennifer A. Chan, University of Calgary, Calgary, Alberta; Steffen Albrecht, Adam Fontebasso, and Nada Jabado, McGill University, Montreal, Quebec, Canada; Paul A. Northcott, Andrey Korshunov, Marcel Kool, David T.W. Jones, and Stefan M. Pfister, German Cancer Research Center; Stefan M. Pfister, University Hospital Heidelberg, Heidelberg; Ulrich Schüller, Ludwig-Maximilians-University, Munich; Stefan Rutkowski, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Karel Zitterbart, Masaryk University School of Medicine; Karel Zitterbart and Leos Kren, University Hospital Brno, Brno, Czech Republic; Toshihiro Kumabe and Teiji Tominaga, Tohoku University Graduate School of Medicine, Sendai, Japan; Young Shin Ra, University of Ulsan, Asan Medical Center; Ji-Yeoun Lee, Byung-Kyu Cho, Seung-Ki Kim, and Kyu-Chang Wang, Seoul National University Children's Hospital, Seoul; Shin Jung, Chonnam National University Research Institute of Medical Sciences, Chonnam National University Hwasun Hospital and Medical School, Chonnam, South Korea; Peter Hauser and Miklós Garami, Semmelweis University, Budapest; László Bognár and Almos Klekner, University of Debrecen, Medical and Health Science Centre, Debrecen, Hungary; Shenandoah Robinson, Boston Children's Hospital; Scott L. Pomeroy, Harvard Medical School, Boston, MA; Ali G. Saad, University of Arkansas for Medical Sciences, Little
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
47
|
Meyronet D, Silva K, Figarella-Branger D, Godfraind C, Delisle MB, Maurage CA, Miquel C, Varlet P, Gentet JC, Salamon AIB, Vasiljevic A, Jouvet A. Réseau de relecture des tumeurs pédiatriques du système nerveux central par le Groupe d’étude de neuropathologie oncologique pédiatrique (GENOP). Ann Pathol 2014; 34:74-86. [DOI: 10.1016/j.annpat.2014.01.002] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/08/2014] [Accepted: 01/10/2014] [Indexed: 01/18/2023]
|
48
|
Remke M, Ramaswamy V, Peacock J, Shih DJH, Koelsche C, Northcott PA, Hill N, Cavalli FMG, Kool M, Wang X, Mack SC, Barszczyk M, Morrissy AS, Wu X, Agnihotri S, Luu B, Jones DTW, Garzia L, Dubuc AM, Zhukova N, Vanner R, Kros JM, French PJ, Van Meir EG, Vibhakar R, Zitterbart K, Chan JA, Bognár L, Klekner A, Lach B, Jung S, Saad AG, Liau LM, Albrecht S, Zollo M, Cooper MK, Thompson RC, Delattre OO, Bourdeaut F, Doz FF, Garami M, Hauser P, Carlotti CG, Van Meter TE, Massimi L, Fults D, Pomeroy SL, Kumabe T, Ra YS, Leonard JR, Elbabaa SK, Mora J, Rubin JB, Cho YJ, McLendon RE, Bigner DD, Eberhart CG, Fouladi M, Wechsler-Reya RJ, Faria CC, Croul SE, Huang A, Bouffet E, Hawkins CE, Dirks PB, Weiss WA, Schüller U, Pollack IF, Rutkowski S, Meyronet D, Jouvet A, Fèvre-Montange M, Jabado N, Perek-Polnik M, Grajkowska WA, Kim SK, Rutka JT, Malkin D, Tabori U, Pfister SM, Korshunov A, von Deimling A, Taylor MD. TERT promoter mutations are highly recurrent in SHH subgroup medulloblastoma. Acta Neuropathol 2013; 126:917-29. [PMID: 24174164 PMCID: PMC3830749 DOI: 10.1007/s00401-013-1198-2] [Citation(s) in RCA: 122] [Impact Index Per Article: 11.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/02/2013] [Accepted: 10/15/2013] [Indexed: 11/27/2022]
Abstract
Telomerase reverse transcriptase (TERT) promoter mutations were recently shown to drive telomerase activity in various cancer types, including medulloblastoma. However, the clinical and biological implications of TERT mutations in medulloblastoma have not been described. Hence, we sought to describe these mutations and their impact in a subgroup-specific manner. We analyzed the TERT promoter by direct sequencing and genotyping in 466 medulloblastomas. The mutational distributions were determined according to subgroup affiliation, demographics, and clinical, prognostic, and molecular features. Integrated genomics approaches were used to identify specific somatic copy number alterations in TERT promoter-mutated and wild-type tumors. Overall, TERT promoter mutations were identified in 21 % of medulloblastomas. Strikingly, the highest frequencies of TERT mutations were observed in SHH (83 %; 55/66) and WNT (31 %; 4/13) medulloblastomas derived from adult patients. Group 3 and Group 4 harbored this alteration in <5 % of cases and showed no association with increased patient age. The prognostic implications of these mutations were highly subgroup-specific. TERT mutations identified a subset with good and poor prognosis in SHH and Group 4 tumors, respectively. Monosomy 6 was mostly restricted to WNT tumors without TERT mutations. Hallmark SHH focal copy number aberrations and chromosome 10q deletion were mutually exclusive with TERT mutations within SHH tumors. TERT promoter mutations are the most common recurrent somatic point mutation in medulloblastoma, and are very highly enriched in adult SHH and WNT tumors. TERT mutations define a subset of SHH medulloblastoma with distinct demographics, cytogenetics, and outcomes.
Collapse
Affiliation(s)
- Marc Remke
- The Arthur and Sonia Labatt Brain Tumour Research Centre, The Hospital for Sick Children, Toronto, ON Canada
- Developmental and Stem Cell Biology Program, The Hospital for Sick Children, Toronto, ON Canada
- Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON Canada
| | - Vijay Ramaswamy
- The Arthur and Sonia Labatt Brain Tumour Research Centre, The Hospital for Sick Children, Toronto, ON Canada
- Developmental and Stem Cell Biology Program, The Hospital for Sick Children, Toronto, ON Canada
- Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON Canada
| | - John Peacock
- The Arthur and Sonia Labatt Brain Tumour Research Centre, The Hospital for Sick Children, Toronto, ON Canada
- Developmental and Stem Cell Biology Program, The Hospital for Sick Children, Toronto, ON Canada
- Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON Canada
| | - David J. H. Shih
- The Arthur and Sonia Labatt Brain Tumour Research Centre, The Hospital for Sick Children, Toronto, ON Canada
- Developmental and Stem Cell Biology Program, The Hospital for Sick Children, Toronto, ON Canada
- Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON Canada
| | - Christian Koelsche
- Department of Neuropathology, University Hospital Heidelberg, Heidelberg, Germany
- Clinical Cooperation Unit Neuropathology, German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - Paul A. Northcott
- Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - Nadia Hill
- The Arthur and Sonia Labatt Brain Tumour Research Centre, The Hospital for Sick Children, Toronto, ON Canada
- Developmental and Stem Cell Biology Program, The Hospital for Sick Children, Toronto, ON Canada
| | - Florence M. G. Cavalli
- The Arthur and Sonia Labatt Brain Tumour Research Centre, The Hospital for Sick Children, Toronto, ON Canada
- Developmental and Stem Cell Biology Program, The Hospital for Sick Children, Toronto, ON Canada
| | - Marcel Kool
- Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - Xin Wang
- The Arthur and Sonia Labatt Brain Tumour Research Centre, The Hospital for Sick Children, Toronto, ON Canada
- Developmental and Stem Cell Biology Program, The Hospital for Sick Children, Toronto, ON Canada
- Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON Canada
| | - Stephen C. Mack
- The Arthur and Sonia Labatt Brain Tumour Research Centre, The Hospital for Sick Children, Toronto, ON Canada
- Developmental and Stem Cell Biology Program, The Hospital for Sick Children, Toronto, ON Canada
- Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON Canada
| | - Mark Barszczyk
- The Arthur and Sonia Labatt Brain Tumour Research Centre, The Hospital for Sick Children, Toronto, ON Canada
| | - A. Sorana Morrissy
- The Arthur and Sonia Labatt Brain Tumour Research Centre, The Hospital for Sick Children, Toronto, ON Canada
- Developmental and Stem Cell Biology Program, The Hospital for Sick Children, Toronto, ON Canada
| | - Xiaochong Wu
- The Arthur and Sonia Labatt Brain Tumour Research Centre, The Hospital for Sick Children, Toronto, ON Canada
- Developmental and Stem Cell Biology Program, The Hospital for Sick Children, Toronto, ON Canada
| | - Sameer Agnihotri
- The Arthur and Sonia Labatt Brain Tumour Research Centre, The Hospital for Sick Children, Toronto, ON Canada
| | - Betty Luu
- The Arthur and Sonia Labatt Brain Tumour Research Centre, The Hospital for Sick Children, Toronto, ON Canada
- Developmental and Stem Cell Biology Program, The Hospital for Sick Children, Toronto, ON Canada
| | - David T. W. Jones
- Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - Livia Garzia
- The Arthur and Sonia Labatt Brain Tumour Research Centre, The Hospital for Sick Children, Toronto, ON Canada
- Developmental and Stem Cell Biology Program, The Hospital for Sick Children, Toronto, ON Canada
| | - Adrian M. Dubuc
- The Arthur and Sonia Labatt Brain Tumour Research Centre, The Hospital for Sick Children, Toronto, ON Canada
- Developmental and Stem Cell Biology Program, The Hospital for Sick Children, Toronto, ON Canada
- Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON Canada
| | - Nataliya Zhukova
- The Arthur and Sonia Labatt Brain Tumour Research Centre, The Hospital for Sick Children, Toronto, ON Canada
| | - Robert Vanner
- The Arthur and Sonia Labatt Brain Tumour Research Centre, The Hospital for Sick Children, Toronto, ON Canada
| | - Johan M. Kros
- Department of Pathology, Erasmus Medical Center, Rotterdam, The Netherlands
| | - Pim J. French
- Department of Neurology, Erasmus Medical Center, Rotterdam, The Netherlands
| | - Erwin G. Van Meir
- Departments of Neurosurgery and Hematology and Medical Oncology, School of Medicine and Winship Cancer Institute, Emory University, Atlanta, GA USA
| | - Rajeev Vibhakar
- Department of Pediatrics, University of Colorado Denver, Aurora, CO USA
| | - Karel Zitterbart
- Department of Pediatric Oncology, School of Medicine, Masaryk University and University Hospital Brno, Brno, Czech Republic
| | - Jennifer A. Chan
- Department of Pathology and Laboratory Medicine, University of Calgary, Calgary, AB Canada
| | - László Bognár
- Department of Neurosurgery, Medical and Health Science Centre, University of Debrecen, Debrecen, Hungary
| | - Almos Klekner
- Department of Neurosurgery, Medical and Health Science Centre, University of Debrecen, Debrecen, Hungary
| | - Boleslaw Lach
- Division of Anatomical Pathology, Department of Pathology and Molecular Medicine, McMaster University, Hamilton, ON Canada
| | - Shin Jung
- Department of Neurosurgery, Chonnam National University Research Institute of Medical Sciences, Chonnam National University Hwasun Hospital and Medical School, Chonnam, South Korea
| | - Ali G. Saad
- Department of Pathology, University of Arkansas for Medical Sciences, Little Rock, AR USA
| | - Linda M. Liau
- Department of Neurosurgery, David Geffen School of Medicine at UCLA, Los Angeles, CA USA
| | | | - Massimo Zollo
- Dipartimento di Medicina Molecolare e Biotecnologie Mediche, University of Naples, Naples, Italy
- CEINGE Biotecnologie Avanzate, Naples, Italy
| | - Michael K. Cooper
- Department of Neurology, Vanderbilt Medical Center, Nashville, TN USA
| | - Reid C. Thompson
- Department of Neurological Surgery, Vanderbilt Medical Center, Nashville, TN USA
| | - Oliver O. Delattre
- Laboratoire de Génétique et Biologie des Cancers, Institut Curie, Paris, France
| | - Franck Bourdeaut
- Laboratoire de Génétique et Biologie des Cancers, Institut Curie, Paris, France
| | - François F. Doz
- Department of Pediatric Oncology, Institut Curie and University Paris Descartes, Sorbonne Paris Cité, Paris, France
| | - Miklós Garami
- 2nd Department of Pediatrics, Semmelweis University, Budapest, Hungary
| | - Peter Hauser
- 2nd Department of Pediatrics, Semmelweis University, Budapest, Hungary
| | - Carlos G. Carlotti
- Department of Surgery and Anatomy, Faculty of Medicine of Ribeirão Preto, Universidade de São Paulo, São Paulo, Brazil
| | - Timothy E. Van Meter
- Pediatric Hematology-Oncology, School of Medicine, Virginia Commonwealth University, Richmond, VA USA
| | - Luca Massimi
- Pediatric Neurosurgery, Catholic University Medical School, Rome, Italy
| | - Daniel Fults
- Department of Neurosurgery, Clinical Neurosciences Center, University of Utah, Salt Lake City, UT USA
| | - Scott L. Pomeroy
- Department of Neurology, Harvard Medical School, Children’s Hospital Boston, Boston, ME USA
| | - Toshiro Kumabe
- Department of Neurosurgery, Tohoku University Graduate School of Medicine, Sendai, Japan
| | - Young Shin Ra
- Department of Neurosurgery, Asan Medical Center, University of Ulsan, Seoul, South Korea
| | - Jeffrey R. Leonard
- Division of Pediatric Neurosurgery, Department of Neurosurgery, Washington University School of Medicine, St. Louis Children’s Hospital, St. Louis, MO USA
| | - Samer K. Elbabaa
- Division of Pediatric Neurosurgery, Department of Neurological Surgery, Saint Louis University School of Medicine, Saint Louis, MO USA
| | - Jaume Mora
- Developmental Tumor Biology Laboratory, Hospital Sant Joan de Déu, Barcelona, Spain
| | - Joshua B. Rubin
- Departments of Pediatrics, Anatomy and Neurobiology, Washington University School of Medicine, St. Louis Children’s Hospital, St. Louis, MO USA
| | - Yoon-Jae Cho
- Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA USA
| | | | | | - Charles G. Eberhart
- Departments of Pathology, Ophthalmology and Oncology, John Hopkins University School of Medicine, Baltimore, MD USA
| | - Maryam Fouladi
- Division of Oncology, Cincinnati Children’s Hospital Medical Center, University of Cincinnati, Cincinnati, OH USA
| | | | - Claudia C. Faria
- Division of Neurosurgery, Department of Surgery, The Hospital for Sick Children and The Arthur and Sonia Labatt Brain Tumour Research Centre, Toronto, ON Canada
- Division of Neurosurgery, Hospital de Santa Maria, Centro Hospitalar Lisboa Norte EPE, Lisbon, Portugal
| | - Sidney E. Croul
- Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON Canada
| | - Annie Huang
- Division of Haematology and Oncology, Department of Pediatrics, The Hospital for Sick Children, University of Toronto, Toronto, ON Canada
| | - Eric Bouffet
- Division of Haematology and Oncology, Department of Pediatrics, The Hospital for Sick Children, University of Toronto, Toronto, ON Canada
| | - Cynthia E. Hawkins
- Department of Pathology, The Hospital for Sick Children, Toronto, ON Canada
| | - Peter B. Dirks
- Division of Neurosurgery, Department of Surgery, The Hospital for Sick Children and The Arthur and Sonia Labatt Brain Tumour Research Centre, Toronto, ON Canada
| | - William A. Weiss
- Department of Neurology, University of California, San Francisco, San Francisco, CA USA
| | - Ulrich Schüller
- Center for Neuropathology and Prion Research, University of Munich, Munich, Germany
| | - Ian F. Pollack
- Department of Neurological Surgery, School of Medicine, University of Pittsburgh, Pittsburgh, PA USA
| | - Stefan Rutkowski
- Department of Pediatric Hematology and Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - David Meyronet
- Neuro-oncology and Neuro-inflammation Team, Inserm U1028, CNRS UMR 5292, Neuroscience Center, University Lyon 1, 69000 Lyon, France
- Hospices Civils de Lyon, Centre de Pathologie et de Neuropathologie Est, Lyon, 69003 France
| | - Anne Jouvet
- Neuro-oncology and Neuro-inflammation Team, Inserm U1028, CNRS UMR 5292, Neuroscience Center, University Lyon 1, 69000 Lyon, France
- Hospices Civils de Lyon, Centre de Pathologie et de Neuropathologie Est, Lyon, 69003 France
| | - Michelle Fèvre-Montange
- Centre de Recherche en Neurosciences, INSERM U1028, CNRS UMR5292, Université de Lyon, Lyon, France
| | - Nada Jabado
- Division of Experimental Medicine, McGill University, Montreal, QC Canada
| | - Marta Perek-Polnik
- Department of Oncology, The Children’s Memorial Health Institute, Warsaw, Poland
| | | | - Seung-Ki Kim
- Division of Pediatric Neurosurgery, Department of Neurosurgery, Seoul National University Children’s Hospital, Seoul, Korea
| | - James T. Rutka
- Division of Neurosurgery, Department of Surgery, The Hospital for Sick Children and The Arthur and Sonia Labatt Brain Tumour Research Centre, Toronto, ON Canada
| | - David Malkin
- Division of Haematology and Oncology, Department of Pediatrics, The Hospital for Sick Children, University of Toronto, Toronto, ON Canada
| | - Uri Tabori
- Division of Haematology and Oncology, Department of Pediatrics, The Hospital for Sick Children, University of Toronto, Toronto, ON Canada
| | - Stefan M. Pfister
- Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ), Heidelberg, Germany
- Department of Pediatric Oncology, Hematology, Immunology and Pulmonology, University Hospital Heidelberg, Heidelberg, Germany
| | - Andrey Korshunov
- Department of Neuropathology, University Hospital Heidelberg, Heidelberg, Germany
- Clinical Cooperation Unit Neuropathology, German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - Andreas von Deimling
- Department of Neuropathology, University Hospital Heidelberg, Heidelberg, Germany
- Clinical Cooperation Unit Neuropathology, German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - Michael D. Taylor
- The Arthur and Sonia Labatt Brain Tumour Research Centre, The Hospital for Sick Children, Toronto, ON Canada
- Developmental and Stem Cell Biology Program, The Hospital for Sick Children, Toronto, ON Canada
- Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON Canada
- Division of Neurosurgery, Department of Surgery, The Hospital for Sick Children and The Arthur and Sonia Labatt Brain Tumour Research Centre, Toronto, ON Canada
| |
Collapse
|
49
|
Zhukova N, Ramaswamy V, Remke M, Pfaff E, Shih DJH, Martin DC, Castelo-Branco P, Baskin B, Ray PN, Bouffet E, von Bueren AO, Jones DTW, Northcott PA, Kool M, Sturm D, Pugh TJ, Pomeroy SL, Cho YJ, Pietsch T, Gessi M, Rutkowski S, Bognar L, Klekner A, Cho BK, Kim SK, Wang KC, Eberhart CG, Fevre-Montange M, Fouladi M, French PJ, Kros M, Grajkowska WA, Gupta N, Weiss WA, Hauser P, Jabado N, Jouvet A, Jung S, Kumabe T, Lach B, Leonard JR, Rubin JB, Liau LM, Massimi L, Pollack IF, Shin Ra Y, Van Meir EG, Zitterbart K, Schüller U, Hill RM, Lindsey JC, Schwalbe EC, Bailey S, Ellison DW, Hawkins C, Malkin D, Clifford SC, Korshunov A, Pfister S, Taylor MD, Tabori U. Subgroup-specific prognostic implications of TP53 mutation in medulloblastoma. J Clin Oncol 2013; 31:2927-35. [PMID: 23835706 DOI: 10.1200/jco.2012.48.5052] [Citation(s) in RCA: 310] [Impact Index Per Article: 28.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022] Open
Abstract
PURPOSE Reports detailing the prognostic impact of TP53 mutations in medulloblastoma offer conflicting conclusions. We resolve this issue through the inclusion of molecular subgroup profiles. PATIENTS AND METHODS We determined subgroup affiliation, TP53 mutation status, and clinical outcome in a discovery cohort of 397 medulloblastomas. We subsequently validated our results on an independent cohort of 156 medulloblastomas. RESULTS TP53 mutations are enriched in wingless (WNT; 16%) and sonic hedgehog (SHH; 21%) medulloblastomas and are virtually absent in subgroups 3 and 4 tumors (P < .001). Patients with SHH/TP53 mutant tumors are almost exclusively between ages 5 and 18 years, dramatically different from the general SHH distribution (P < .001). Children with SHH/TP53 mutant tumors harbor 56% germline TP53 mutations, which are not observed in children with WNT/TP53 mutant tumors. Five-year overall survival (OS; ± SE) was 41% ± 9% and 81% ± 5% for patients with SHH medulloblastomas with and without TP53 mutations, respectively (P < .001). Furthermore, TP53 mutations accounted for 72% of deaths in children older than 5 years with SHH medulloblastomas. In contrast, 5-year OS rates were 90% ± 9% and 97% ± 3% for patients with WNT tumors with and without TP53 mutations (P = .21). Multivariate analysis revealed that TP53 status was the most important risk factor for SHH medulloblastoma. Survival rates in the validation cohort mimicked the discovery results, revealing that poor survival of TP53 mutations is restricted to patients with SHH medulloblastomas (P = .012) and not WNT tumors. CONCLUSION Subgroup-specific analysis reconciles prior conflicting publications and confirms that TP53 mutations are enriched among SHH medulloblastomas, in which they portend poor outcome and account for a large proportion of treatment failures in these patients.
Collapse
|
50
|
Bouvier C, Bertucci F, Métellus P, Finetti P, de Paula AM, Forest F, Mokhtari K, Miquel C, Birnbaum D, Vasiljevic A, Jouvet A, Coindre JM, Loundou A, Figarella-Branger D. ALDH1 is an immunohistochemical diagnostic marker for solitary fibrous tumours and haemangiopericytomas of the meninges emerging from gene profiling study. Acta Neuropathol Commun 2013; 1:10. [PMID: 24252471 PMCID: PMC3893364 DOI: 10.1186/2051-5960-1-10] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/17/2013] [Accepted: 03/17/2013] [Indexed: 01/23/2023] Open
Abstract
Background Solitary Fibrous Tumours (SFT) and haemangiopericytomas (HPC) are rare meningeal tumours that have to be distinguished from meningiomas and more rarely from synovial sarcomas. We recently found that ALDH1A1 was overexpressed in SFT and HPC as compared to soft tissue sarcomas. Using whole-genome DNA microarrays, we defined the gene expression profiles of 16 SFT/HPC (9 HPC and 7 SFT). Expression profiles were compared to publicly available expression profiles of additional SFT or HPC, meningiomas and synovial sarcomas. We also performed an immunohistochemical (IHC) study with anti-ALDH1 and anti-CD34 antibodies on Tissue Micro-Arrays including 38 SFT (25 meningeal and 13 extrameningeal), 55 meningeal haemangiopericytomas (24 grade II, 31 grade III), 163 meningiomas (86 grade I, 62 grade II, 15 grade III) and 98 genetically confirmed synovial sarcomas. Results ALDH1A1 gene was overexpressed in SFT/HPC, as compared to meningiomas and synovial sarcomas. These findings were confirmed at the protein level. 84% of the SFT and 85.4% of the HPC were positive with anti-ALDH1 antibody, while only 7.1% of synovial sarcomas and 1.2% of meningiomas showed consistent expression. Positivity was usually more diffuse in SFT/HPC compared to other tumours with more than 50% of tumour cells immunostained in 32% of SFT and 50.8% of HPC. ALDH1 was a sensitive and specific marker for the diagnosis of SFT (SE = 84%, SP = 98.8%) and HPC (SE = 84.5%, SP = 98.7%) of the meninges. In association with CD34, ALDH1 expression had a specificity and positive predictive value of 100%. Conclusion We show that ALDH1, a stem cell marker, is an accurate diagnostic marker for SFT and HPC, which improves the diagnostic value of CD34. ALDH1 could also be a new therapeutic target for these tumours which are not sensitive to conventional chemotherapy.
Collapse
|